# Minozzi_2024_Psychosocial interventions for stimulant use disorder.

Cochrane
Library

Cochrane Database of Systematic Reviews

Psychosocial interventions for stimulant use disorder (Review)

Minozzi S, Saulle R, Amato L, Traccis F, Agabio R

Minozzi S, Saulle R, Amato L, Traccis F, Agabio R. 
Psychosocial interventions for stimulant use disorder. 
Cochrane Database of Systematic Reviews 2024, Issue 2. Art. No.: CD011866. 
DOI: 10.1002/14651858.CD011866.pub3.

www.cochranelibrary.com

Psychosocial interventions for stimulant use disorder (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

T A B L E   O F   C O N T E N T S

ABSTRACT.....................................................................................................................................................................................................
PLAIN LANGUAGE SUMMARY.......................................................................................................................................................................
SUMMARY OF FINDINGS..............................................................................................................................................................................
BACKGROUND..............................................................................................................................................................................................
OBJECTIVES..................................................................................................................................................................................................
METHODS.....................................................................................................................................................................................................
RESULTS........................................................................................................................................................................................................
Figure 1..................................................................................................................................................................................................
Figure 2..................................................................................................................................................................................................
Figure 3..................................................................................................................................................................................................
Figure 4..................................................................................................................................................................................................
Figure 5..................................................................................................................................................................................................
Figure 6..................................................................................................................................................................................................
Figure 7..................................................................................................................................................................................................
Figure 8..................................................................................................................................................................................................
DISCUSSION..................................................................................................................................................................................................
AUTHORS' CONCLUSIONS...........................................................................................................................................................................
ACKNOWLEDGEMENTS................................................................................................................................................................................
REFERENCES................................................................................................................................................................................................
CHARACTERISTICS OF STUDIES..................................................................................................................................................................
DATA AND ANALYSES....................................................................................................................................................................................
Analysis 1.1. Comparison 1: Any psychosocial treatment versus no intervention, Outcome 1: Dropouts.......................................
Analysis  1.2.  Comparison  1:  Any  psychosocial  treatment  versus  no  intervention,  Outcome  2:  Point  abstinence,  end  of
treatment...............................................................................................................................................................................................
Analysis 1.3. Comparison 1: Any psychosocial treatment versus no intervention, Outcome 3: Point abstinence, longest follow-
up...........................................................................................................................................................................................................
Analysis 1.4. Comparison 1: Any psychosocial treatment versus no intervention, Outcome 4: Continuous abstinence, end of
treatment...............................................................................................................................................................................................
Analysis 1.5. Comparison 1: Any psychosocial treatment versus no intervention, Outcome 5: Continuous abstinence, longest
follow-up................................................................................................................................................................................................
Analysis 1.6. Comparison 1: Any psychosocial treatment versus no intervention, Outcome 6: Frequency of drug intake, end of
treatment...............................................................................................................................................................................................
Analysis 1.7. Comparison 1: Any psychosocial treatment versus no intervention, Outcome 7: Longest period of abstinence.......
Analysis 1.8. Comparison 1: Any psychosocial treatment versus no intervention, Outcome 8: Craving.........................................
Analysis 1.9. Comparison 1: Any psychosocial treatment versus no intervention, Outcome 9: Severity of dependence...............
Analysis 1.10. Comparison 1: Any psychosocial treatment versus no intervention, Outcome 10: Depression................................
Analysis 2.1. Comparison 2: Any psychosocial treatment versus treatment as usual (TAU), Outcome 1: Dropouts........................
Analysis 2.2. Comparison 2: Any psychosocial treatment versus treatment as usual (TAU), Outcome 2: Point abstinence, end
of treatment..........................................................................................................................................................................................
Analysis 2.3. Comparison 2: Any psychosocial treatment versus treatment as usual (TAU), Outcome 3: Point abstinence, longest
follow up................................................................................................................................................................................................
Analysis 2.4. Comparison 2: Any psychosocial treatment versus treatment as usual (TAU), Outcome 4: Continuous abstinence,
end of treatment...................................................................................................................................................................................
Analysis 2.5. Comparison 2: Any psychosocial treatment versus treatment as usual (TAU), Outcome 5: Frequency of drug intake,
end of treatment...................................................................................................................................................................................
Analysis  2.6.  Comparison  2:  Any  psychosocial  treatment  versus  treatment  as  usual  (TAU),  Outcome  6:  Longest  period  of
abstinence..............................................................................................................................................................................................
Analysis 2.7. Comparison 2: Any psychosocial treatment versus treatment as usual (TAU), Outcome 7: Craving..........................
Analysis 2.8. Comparison 2: Any psychosocial treatment versus treatment as usual (TAU), Outcome 8: Severity of dependence
(ASI)........................................................................................................................................................................................................
Analysis 2.9. Comparison 2: Any psychosocial treatment versus treatment as usual (TAU), Outcome 9: Depression.....................
Analysis  3.1.  Comparison  3:  Contingency  management  (CM)  reinforcement  versus  non-contingency  management  (non-CM)
reinforcement, Outcome 1: Dropouts..................................................................................................................................................

Psychosocial interventions for stimulant use disorder (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

1
2
4
7
9
9
12
13
15
16
19
20
21
22
23
26
27
28
29
44
165
168
169

170

171

172

173

174
174
175
175
177
178

178

179

179

180

180
181

181
182

i

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis  3.2.  Comparison  3:  Contingency  management  (CM)  reinforcement  versus  non-contingency  management  (non-CM)
reinforcement, Outcome 2: Point abstinence, longest follow-up......................................................................................................
Analysis  3.3.  Comparison  3:  Contingency  management  (CM)  reinforcement  versus  non-contingency  management  (non-CM)
reinforcement, Outcome 3: Continuous abstinence, end of treatment............................................................................................
Analysis  3.4.  Comparison  3:  Contingency  management  (CM)  reinforcement  versus  non-contingency  management  (non-CM)
reinforcement, Outcome 4: Frequency of drug intake, end of treatment.........................................................................................
Analysis  3.5.  Comparison  3:  Contingency  management  (CM)  reinforcement  versus  non-contingency  management  (non-CM)
reinforcement, Outcome 5: Severity of dependence..........................................................................................................................
Analysis  4.1.  Comparison  4:  Cognitive  behavioural  therapy  (CBT)  versus  other  psychosocial  interventions,  Outcome  1:
Dropouts................................................................................................................................................................................................
Analysis 4.2. Comparison 4: Cognitive behavioural therapy (CBT) versus other psychosocial interventions, Outcome 2: Point
abstinence, end of treatment...............................................................................................................................................................
Analysis 4.3. Comparison 4: Cognitive behavioural therapy (CBT) versus other psychosocial interventions, Outcome 3: Point
abstinence, longest follow-up..............................................................................................................................................................
Analysis  4.4.  Comparison  4:  Cognitive  behavioural  therapy  (CBT)  versus  other  psychosocial  interventions,  Outcome  4:
Continuous abstinence, end of treatment..........................................................................................................................................
Analysis  4.5.  Comparison  4:  Cognitive  behavioural  therapy  (CBT)  versus  other  psychosocial  interventions,  Outcome  5:
Continuous abstinence, longest follow-up..........................................................................................................................................
Analysis  4.6.  Comparison  4:  Cognitive  behavioural  therapy  (CBT)  versus  other  psychosocial  interventions,  Outcome  6:
Frequency of drug intake, end of treatment.......................................................................................................................................
Analysis 4.7. Comparison 4: Cognitive behavioural therapy (CBT) versus other psychosocial interventions, Outcome 7: Longest
period of abstinence.............................................................................................................................................................................
Analysis 4.8. Comparison 4: Cognitive behavioural therapy (CBT) versus other psychosocial interventions, Outcome 8: Severity
of dependence.......................................................................................................................................................................................
Analysis  4.9.  Comparison  4:  Cognitive  behavioural  therapy  (CBT)  versus  other  psychosocial  interventions,  Outcome  9:
Depression.............................................................................................................................................................................................
APPENDICES.................................................................................................................................................................................................
WHAT'S NEW.................................................................................................................................................................................................
HISTORY........................................................................................................................................................................................................
CONTRIBUTIONS OF AUTHORS...................................................................................................................................................................
DECLARATIONS OF INTEREST.....................................................................................................................................................................
SOURCES OF SUPPORT...............................................................................................................................................................................
DIFFERENCES BETWEEN PROTOCOL AND REVIEW....................................................................................................................................
INDEX TERMS...............................................................................................................................................................................................

Psychosocial interventions for stimulant use disorder (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

182

182

183

183

185

186

186

187

187

187

188

188

188

188
197
197
197
198
198
198
199

ii

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

[Intervention Review]

Cochrane Database of Systematic Reviews

Psychosocial interventions for stimulant use disorder

Silvia Minozzi1, Rosella Saulle1, Laura Amato1, Francesco Traccis2, Roberta Agabio2

1Department of Epidemiology, Lazio Regional Health Service, Rome, Italy. 2Department of Biomedical Sciences, Section of Neuroscience
and Clinical Pharmacology, University of Cagliari, Cagliari, Italy

Contact: Silvia Minozzi, s.minozzi@deplazio.it.

Editorial group: Cochrane Drugs and Alcohol Group.
Publication status and date: New search for studies and content updated (no change to conclusions), published in Issue 2, 2024.

Citation: Minozzi S, Saulle R, Amato L, Traccis F, Agabio R. Psychosocial interventions for stimulant use disorder. Cochrane Database of
Systematic Reviews 2024, Issue 2. Art. No.: CD011866. DOI: 10.1002/14651858.CD011866.pub3.

Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Background

A B S T R A C T

Stimulant use disorder is a continuously growing medical and social burden without approved medications available for its treatment.
Psychosocial  interventions  could  be  a  valid  approach  to  help  people  reduce  or  cease  stimulant  consumption.  This  is  an  update  of  a
Cochrane review first published in 2016.

Objectives

To assess the efficacy and safety of psychosocial interventions for stimulant use disorder in adults.

Search methods

We  searched  the  Cochrane  Drugs  and  Alcohol  Group  Specialised  Register,  Cochrane  Central  Register  of  Controlled  Trials  (CENTRAL),
MEDLINE, Embase, three other databases, and two trials registers in September 2023. All searches included non-English language literature.
We handsearched the references of topic-related systematic reviews and the included studies.

Selection criteria

We included randomised controlled trials (RCTs) comparing any psychosocial intervention with no intervention, treatment as usual (TAU),
or a different intervention in adults with stimulant use disorder.

Data collection and analysis

We used the standard methodological procedures expected by Cochrane.

Main results

We included a total of 64 RCTs (8241 participants). Seventy-three percent of studies included participants with cocaine or crack cocaine use
disorder; 3.1% included participants with amphetamine use disorder; 10.9% included participants with methamphetamine use disorder;
and 12.5% included participants with any stimulant use disorder. In 18 studies, all participants were in methadone maintenance treatment.

In  our  primary  comparison  of  any  psychosocial  treatment  to  no  intervention,  we  included  studies  which  compared  a  psychosocial
intervention  plus  TAU  to  TAU  alone.  In  this  comparison,  12  studies  evaluated  cognitive  behavioural  therapy  (CBT),  27  contingency
management,  three  motivational  interviewing,  one  study  looked  at  psychodynamic  therapy,  and  one  study  evaluated  CBT  plus
contingency management. We also compared any psychosocial intervention to TAU. In this comparison, seven studies evaluated CBT,
two contingency management, two motivational interviewing, and one evaluated a combination of CBT plus motivational interviewing.
Seven studies compared contingency management reinforcement related to abstinence versus contingency management not related to
abstinence. Finally, seven studies compared two different psychosocial approaches.

Psychosocial interventions for stimulant use disorder (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

1

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

We judged 65.6% of the studies to be at low risk of bias for random sequence generation and 19% at low risk for allocation concealment.
Blinding of personnel and participants was not possible for the type of intervention, so we judged all the studies to be at high risk of
performance bias for subjective outcomes but at low risk for objective outcomes. We judged 22% of the studies to be at low risk of detection
bias for subjective outcomes. We judged most of the studies (69%) to be at low risk of attrition bias.

When compared to no intervention, we found that psychosocial treatments: reduce the dropout rate (risk ratio (RR) 0.82, 95% confidence
interval (CI) 0.74 to 0.91; 30 studies, 4078 participants; high-certainty evidence); make little to no difference to point abstinence at the
end of treatment (RR 1.15, 95% CI 0.94 to 1.41; 12 studies, 1293 participants; high-certainty evidence); make little to no difference to point
abstinence at the longest follow-up (RR 1.22, 95% CI 0.91 to 1.62; 9 studies, 1187 participants; high-certainty evidence); probably increase
continuous abstinence at the end of treatment (RR 1.89, 95% CI 1.20 to 2.97; 12 studies, 1770 participants; moderate-certainty evidence);
may make little to no difference in continuous abstinence at the longest follow-up (RR 1.14, 95% CI 0.89 to 1.46; 4 studies, 295 participants;
low-certainty evidence); reduce the frequency of drug intake at the end of treatment (standardised mean difference (SMD) −0.35, 95% CI
−0.50 to −0.19; 10 studies, 1215 participants; high-certainty evidence); and increase the longest period of abstinence (SMD 0.54, 95% CI 0.41
to 0.68; 17 studies, 2118 participants; high-certainty evidence).

When  compared  to  TAU,  we  found  that  psychosocial  treatments  reduce  the  dropout  rate  (RR  0.79,  95%  CI  0.65  to  0.97;  9  studies,  735
participants; high-certainty evidence) and may make little to no difference in point abstinence at the end of treatment (RR 1.67, 95% CI 0.64
to 4.31; 1 study, 128 participants; low-certainty evidence). We are uncertain whether they make any difference in point abstinence at the
longest follow-up (RR 1.31, 95% CI 0.86 to 1.99; 2 studies, 124 participants; very low-certainty evidence). Compared to TAU, psychosocial
treatments may make little to no difference in continuous abstinence at the end of treatment (RR 1.18, 95% CI 0.92 to 1.53; 1 study, 128
participants; low-certainty evidence); probably make little to no difference in the frequency of drug intake at the end of treatment (SMD
−1.17, 95% CI −2.81 to 0.47, 4 studies, 479 participants, moderate-certainty evidence); and may make little to no difference in the longest
period  of  abstinence  (SMD  −0.16,  95%  CI  −0.54  to  0.21;  1  study,  110  participants;  low-certainty  evidence).  None  of  the  studies  for  this
comparison assessed continuous abstinence at the longest follow-up.

Only five studies reported harms related to psychosocial interventions; four of them stated that no adverse events occurred.

Authors' conclusions

This review's findings indicate that psychosocial treatments can help people with stimulant use disorder by reducing dropout rates. This
conclusion is based on high-certainty evidence from comparisons of psychosocial interventions with both no treatment and TAU. This is an
important finding because many people with stimulant use disorders leave treatment prematurely. Stimulant use disorders are chronic,
lifelong, relapsing mental disorders, which require substantial therapeutic efforts to achieve abstinence. For those who are not yet able to
achieve complete abstinence, retention in treatment may help to reduce the risks associated with stimulant use. In addition, psychosocial
interventions reduce stimulant use compared to no treatment, but they may make little to no difference to stimulant use when compared
to TAU.

The  most  studied  and  promising  psychosocial  approach  is  contingency  management.  Relatively  few  studies  explored  the  other
approaches, so we cannot rule out the possibility that the results were imprecise due to small sample sizes.

P L A I N   L A N G U A G E   S U M M A R Y

Do psychosocial treatments help people with stimulant use disorder?

Key messages

• Psychosocial treatments reduce the number of participants with stimulant use disorder who leave treatment prematurely and probably
increase the length of time they abstain from stimulants, compared to no treatment.
• Compared to usual care, psychosocial treatments help people stay in treatment longer, but probably make little to no difference in the
frequency of drug intake.
• More studies are needed comparing different psychosocial approaches to increase our understanding of what treatments are best for
whom, when, and in what context.

What is stimulant use disorder?

Stimulant  use  disorder  is  a  mental  disorder  characterised  by  a  strong  urge  to  use  psychostimulants  and  the  inability  to  control  their
use.  Cocaine,  amphetamines,  crack,  and  MDMA  are  psychostimulants.  Psychostimulants  are  the  second-most  commonly  used  illicit
drug  worldwide,  after  cannabis.  Stimulant  use  disorder  is  associated  with  serious  medical  consequences,  including  delusions  and
hallucinations, cardiovascular diseases, AIDS, viral hepatitis, and sexually transmitted infections. People with stimulant use disorder are
at high risk of being involved in car accidents, crime, sexual abuse, and interpersonal violence.

How is stimulant use disorder treated?

Currently, no medicines are approved for treating stimulant use disorder. Consequently, psychosocial treatments are regarded as suitable
alternatives. Psychosocial treatments act on people's memory and learning, and aim to help them develop the skills to deal with stimulant

Psychosocial interventions for stimulant use disorder (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

2

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

use disorder. Many types of psychosocial therapy exist, and each has a theory to explain how it helps people change. The most widely-
used psychosocial treatments for stimulant use disorder are the following.

•  Cognitive  behavioural  therapy  tries  to  help  people  recognise  and  alter  their  dysfunctional  beliefs,  negative  thoughts,  and  unwanted
behaviours, through behavioural tasks and coping skills.
• Contingency management rewards or 'reinforces' people for positive behavioural change, giving them money, vouchers, or other rewards
when they abstain from using stimulants.
• Motivational interviewing aims to resolve people's contradictory feelings about their drug use and increase their readiness to change.
• Psychodynamic therapy uses the therapeutic relationship between a psychotherapist and a client to solve unconscious conflicts and
develop insight.
• Twelve-step facilitation are treatments that have adapted the methodology and concepts of Alcoholics Anonymous.

What did we want to find out?

We wanted to find out whether psychosocial treatments help people with stimulant use disorder to reduce or stop using psychostimulants.

What did we do?

We searched for studies where people were allocated at random to one of two or more treatment groups that compared any psychosocial
treatment with no treatment or usual care (counselling, education, or information about stimulant use). We summarised the results of the
studies and rated our confidence in the evidence, based on factors such as study methods and precision of the results.

What did we find?

We found 64 studies involving a total of 8241 people with stimulant use disorder. Nearly three-quarters of the studies involved people who
used cocaine or crack. Most studies were conducted in the USA, and there were 4 studies in Spain, 3 each in Australia and the UK, 2 each
in Switzerland, Brazil, and Iran, and 1 each in the Netherlands and South Africa. Overall, the studies offered treatment for an average of 4
months, but the study programmes varied from a single session to a 12-month programme. The studies examined the different types of
psychosocial treatments outlined above.

Most  studies  compared  psychosocial  treatment  with  no  treatment.  Twelve  studies  compared  psychosocial  treatment  with  usual  care.
Fourteen studies compared one type of psychosocial treatment to another type.

Main results

Compared to no treatment, psychosocial treatments reduce the number of people who leave the study prematurely and probably increase
the length of time that they stay off stimulants (i.e. they increase abstinence). They also reduce the frequency of drug intake. They probably
help people to have longer periods of abstinence during treatment but may make little to no difference in continuous abstinence in the
long term.

Compared to usual care, psychosocial treatments reduce the number of people who leave treatment prematurely. They may have little
to no effect on helping people have periods of continuous abstinence during treatment and in increasing the period of abstinence. They
probably have little to no effect on the frequency of drug intake.

Five  studies  assessed  whether  psychosocial  treatments  had  any  negative  effects.  Of  these,  4  studies  stated  that  no  negative  effects
occurred.

What are the limitations of the evidence?

Both the people delivering treatments and the participants knew which type of treatment they were receiving. Therefore, they could have
modified their behaviours in a way that would influence the outcomes. However, in most studies, the drug use outcomes reported by
participants were verified by urine analysis, so we believe that people's awareness did not influence the results substantially. We cannot
be sure that the allocation of participants to groups was done appropriately, as most studies provided insufficient information about this
process. Studies comparing psychosocial treatments with usual care were scarce and small, so we are uncertain about our results.

How up to date is this evidence?

The evidence is current to 26 September 2023.

Psychosocial interventions for stimulant use disorder (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

3

 
 
P
s
y
c
h
o
s
o
c
i
a
l

i

n
t
e
r
v
e
n
t
i
o
n
s
f
o
r
s
t
i

m
u
l
a
n
t
u
s
e
d
i
s
o
r
d
e
r

(
R
e
v
i
e
w

)

C
o
p
y
r
i
g
h
t

©
2
0
2
4
T
h
e
C
o
c
h
r
a
n
e
C
o

l
l
a
b
o
r
a
t
i
o
n

.

P
u
b

l
i
s
h
e
d
b
y
J
o
h
n
W

i
l
e
y
&
S
o
n
s
,
L
t
d

.

S U M M A R Y   O F   F I N D I N G S

Summary of findings 1.   Summary of findings table - Any psychosocial intervention compared to no intervention for adults with stimulant use
disorder

Any psychosocial intervention compared to no intervention for adults with stimulant use disorder

Patient or population: adults with stimulant use disorder
Setting: outpatients
Intervention: any psychosocial intervention
Comparison: no intervention

Outcomes

Anticipated absolute effects* (95% CI)

Risk with no
intervention

Risk with any psychosocial inter-
vention

Relative effect
(95% CI)

№ of partici-
pants
(studies)

Certainty of
the evidence
(GRADE)

Comments

Dropouts

356 per 1000

Point abstinence, end of treat-
ment

364 per 1000

Point abstinence, longest fol-
low-up

436 per 1000

Continuous abstinence, end of
treatment

131 per 1000

Continuous abstinence, longest
follow-up

479 per 1000

292 per 1000
(263 to 324)

418 per 1000
(342 to 513)

532 per 1000
(397 to 706)

247 per 1000
(157 to 388)

546 per 1000
(407 to 738)

Frequency of drug intake, end
of treatment

Longest period of abstinence

-

-

SMD 0.35 SD lower
(0.51 lower to 0.18 lower)

SMD 0.54 SD higher
(0.41 higher to 0.68 higher)

RR 0.82
(0.74 to 0.91)

RR 1.15
(0.94 to 1.41)

RR 1.22
(0.91 to 1.62)

RR 1.89
(1.20 to 2.97)

RR 1.14
(0.85 to 1.54)

-

-

4049
(29 RCTs)

1293
(12 RCTs)

1187
(9 RCTs)

1770
(12 RCTs)

266
(3 RCTs)

1186
(9 RCTs)

2118
(17 RCTs)

⊕⊕⊕⊕
High

⊕⊕⊕⊕
High

⊕⊕⊕⊕
High

⊕⊕⊕⊝
Moderatea

⊕⊕⊝⊝
Lowb,c

⊕⊕⊕⊕
High

⊕⊕⊕⊕
High

*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and
its 95% CI).

CI: confidence interval; RR: risk ratio; SMD: standardised mean difference

GRADE Working Group grades of evidence

4

L
i
b
r
a
r
y

C
o
c
h
r
a
n
e

B
e
t
t
e
r
h
e
a
l
t
h
.

T
r
u
s
t
e
d
e
v
i
d
e
n
c
e
.

I
n
f
o
r
m
e
d
d
e
c
i
s
i
o
n
s
.

C
o
c
h
r
a
n
e
D
a
t
a
b
a
s
e
o
f
S
y
s
t
e
m
a
t
i
c
R
e
v
i
e
w
s

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
High certainty: we are very confident that the true effect lies close to that of the estimate of the effect.
Moderate certainty: we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is
substantially different.
Low certainty: our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.
Very low certainty: we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect.

See interactive version of this table: https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_440467640937001406.

a Downgraded one level for suspicion of publication bias: asymmetrical funnel plot (Figure 6)
b Downgraded one level for high risk of selection and attrition bias in studies that contributed most to the overall estimate (weight 64%)
c Downgraded one level for imprecision: optimal information size not met

Summary of findings 2.   Summary of findings table - Any psychosocial intervention compared to treatment as usual (TAU) for adults with stimulant
use disorder

Any psychosocial intervention compared to treatment as usual (TAU) for adults with stimulant use disorder

Patient or population: adults with stimulant use disorder
Setting: outpatients
Intervention: any psychosocial intervention
Comparison: treatment as usual (TAU)

Outcomes

Anticipated absolute effects* (95% CI)

Relative effect
(95% CI)

№ of partici-
pants
(studies)

Certainty of
the evidence
(GRADE)

Comments

Dropouts

Risk with
treatment as
usual (TAU)

407 per 1000

Point abstinence, end of treatment

94 per 1000

Point abstinence, longest fol-
low-up

362 per 1000

Continuous abstinence, end of
treatment

594 per 1000

Risk with any psychosocial inter-
vention

322 per 1000
(265 to 395)

157 per 1000
(60 to 404)

474 per 1000
(311 to 721)

701 per 1000
(546 to 908)

RR 0.79
(0.65 to 0.97)

RR 1.67
(0.64 to 4.31)

RR 1.31
(0.86 to 1.99)

RR 1.18
(0.92 to 1.53)

Frequency of drug intake, end of
treatment

-

SMD 1.17 SD lower
(2.81 lower to 0.47 higher)

-

735
(9 RCTs)

128
(1 RCT)

124
(2 RCTs)

128
(1 RCT)

479
(4 RCTs)

⊕⊕⊕⊕
High

⊕⊕⊝⊝
Lowa

⊕⊝⊝⊝
Very lowb

⊕⊕⊝⊝
Lowb

⊕⊕⊕⊝
Moderatec

C
o
p
y
r
i
g
h
t

©
2
0
2
4
T
h
e
C
o
c
h
r
a
n
e
C
o

l
l
a
b
o
r
a
t
i
o
n

.

P
u
b

l
i
s
h
e
d
b
y
J
o
h
n
W

i
l
e
y
&
S
o
n
s
,
L
t
d

.

P
s
y
c
h
o
s
o
c
i
a
l

i

n
t
e
r
v
e
n
t
i
o
n
s
f
o
r
s
t
i

m
u
l
a
n
t
u
s
e
d
i
s
o
r
d
e
r

(
R
e
v
i
e
w

)

5

L
i
b
r
a
r
y

C
o
c
h
r
a
n
e

B
e
t
t
e
r
h
e
a
l
t
h
.

T
r
u
s
t
e
d
e
v
i
d
e
n
c
e
.

I
n
f
o
r
m
e
d
d
e
c
i
s
i
o
n
s
.

C
o
c
h
r
a
n
e
D
a
t
a
b
a
s
e
o
f
S
y
s
t
e
m
a
t
i
c
R
e
v
i
e
w
s

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
C
o
p
y
r
i
g
h
t

©
2
0
2
4
T
h
e
C
o
c
h
r
a
n
e
C
o

l
l
a
b
o
r
a
t
i
o
n

.

P
u
b

l
i
s
h
e
d
b
y
J
o
h
n
W

i
l
e
y
&
S
o
n
s
,
L
t
d

.

P
s
y
c
h
o
s
o
c
i
a
l

i

n
t
e
r
v
e
n
t
i
o
n
s
f
o
r
s
t
i

m
u
l
a
n
t
u
s
e
d
i
s
o
r
d
e
r

(
R
e
v
i
e
w

)

6

Longest period of abstinence

Continuous abstinence, longest
follow-up - not measured

-

-

SMD 0.16 lower
(0.54 lower to 0.21 higher)

-

-

-

110
(1 RCT)

-

⊕⊕⊝⊝
Lowd,e

-

*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and
its 95% CI).

CI: confidence interval; RR: risk ratio; SMD: standardised mean difference

GRADE Working Group grades of evidence
High certainty: we are very confident that the true effect lies close to that of the estimate of the effect.
Moderate certainty: we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is
substantially different.
Low certainty: our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.
Very low certainty: we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect.

See interactive version of this table: https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_440564295462044805.

a Downgraded two levels for imprecision: fewer than 100 events
b Downgraded one level fo high risk attrition bias
c Downgraded one level for inconsistency: I2 98%
d Downgraded one level for high risk of attrition bias
e Downgraded one level for imprecision: fewer than 400 participants

L
i
b
r
a
r
y

C
o
c
h
r
a
n
e

B
e
t
t
e
r
h
e
a
l
t
h
.

T
r
u
s
t
e
d
e
v
i
d
e
n
c
e
.

I
n
f
o
r
m
e
d
d
e
c
i
s
i
o
n
s
.

C
o
c
h
r
a
n
e
D
a
t
a
b
a
s
e
o
f
S
y
s
t
e
m
a
t
i
c
R
e
v
i
e
w
s

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

B A C K G R O U N D

Description of the condition

Cocaine and amphetamine-type stimulants

Cocaine  products  and  amphetamine-type  stimulants  are  the  two
main  recreational  classes  of  psychostimulants  (Farrell  2019).
Cocaine  products  comprise  coca  paste  and  cocaine  base,
hydrochloride  salt  of  cocaine,  and  freebase  cocaine  (a  form  of
cocaine  that  can  be  smoked)  (UNODC  2022).  Worldwide,  the
powder of hydrochloride salt is the most commonly-used product,
usually by insufflation or 'snorting' (UNODC 2022). In Europe and
North America, freebase 'crack' cocaine is also common, whereas in
South America and adjacent regions, coca paste and cocaine base
are more common products (UNODC 2022). Cocaine hydrochloride
and cocaine base can also be injected (UNODC 2022).

(MDMA  or 

(usually  named 

Amphetamine-type  stimulants  comprise  amphetamine  and
'amphetamines'),  3,4-
methamphetamine 
methylenedioxymethamphetamine 
'ecstasy'),  3,4-
methylenedioxyamphetamine (MDA), other psychostimulants such
as cathinone, ephedrine, pseudoephedrine, and some medications
when used for nonmedical aims, such as dexamphetamine, dextro-
amphetamine, methylphenidate, and phentermine (UNODC 2022).
Worldwide,  methamphetamine,  amphetamines,  and  ecstasy  are
the most commonly-used amphetamine-type stimulants (UNODC
2022).

According to the World Drug Report from the United Nations Office
on  Drugs  and  Crime,  in  2020,  approximately  21.5  million  people
used cocaine at least once in the previous year, equivalent to 0.4%
of  the  global  population  aged  15  to  64,  and  34  million  people
used amphetamines, equivalent to 0.7% of the global population
(UNODC 2022). The highest prevalence of cocaine use was observed
in  Australia  and  New  Zealand  (3.6%),  followed  by  North  America
(2.0%),  South  America  (1.6%),  and  Western  and  Central  Europe
(1.4%) (UNODC 2022). The highest prevalence rate of amphetamine
use  was  observed  in  North  America  (3.9%),  followed  by  Australia
and New Zealand (1.3%), and Western and Central Europe (0.7%)
(UNODC 2022).

Stimulant use disorder

According  to  the  most  recent  versions  of  the  Diagnostic  and
Statistical  Manual  of  Mental  Disorders  (DSM-5  and  DSM-5-Text
Revision), stimulant use disorder is a severe disorder, characterised
by the strong and irrepressible desire to use psychostimulants such
as amphetamine-type substances or cocaine, their compulsive use,
and  inability  to  control  their  use  despite  the  knowledge  of  their
negative consequences (DSM 5, American Psychiatric Association
2013;  American  Psychiatric  Association  2022).  Diagnosis  of
stimulant use disorder requires meeting at least two of 11 criteria
in a 12-month period, and its severity (mild, moderate, or severe)
is  based  on  the  number  of  criteria  met  (American  Psychiatric
Association  2013;  American  Psychiatric  Association  2022).  In  the
previous DSM editions, stimulant use disorder was classified into
two  independent  disorders,  labelled  'abuse'  and  'dependence'.
These  two  disorders,  and  their  diagnostic  criteria,  have  been
merged into the single category of 'stimulant use disorder' in DSM
5  (American  Psychiatric  Association  2013;  American  Psychiatric
Association 2022).

Cochrane Database of Systematic Reviews

is  considerable  diversity  amongst  people  who  use
There 
stimulants,  ranging  from  those  who  use  these  substances
occasionally,  those  who  use  them  regularly,  and  people  with  a
stimulant  use  disorder  (Farrell  2019).  Farrell  and  colleagues  also
point  out  that  cocaine  and  amphetamine  are  used  for  treating
certain  conditions:  cocaine  as  a  local  anaesthetic  agent  and
amphetamines  in  the  treatment  of  attention-deficit  hyperactivity
disorder, obesity, and narcolepsy (Farrell 2019). Some studies have
reported that people who smoke or inject stimulants have a higher
risk  of  developing  stimulant  use  disorder  than  those  who  use
stimulants intranasally (McKetin 2006; Volkow 2004).

Stimulant  use  disorder  has  a  chronic,  relapsing,  and  progressive
course 
(American  Psychiatric  Association  2013;  American
It  represents  a
Psychiatric  Association  2022;  Dackis  2001). 
significant public health problem and a treatment priority because
of  the  highly  addictive  properties  of  stimulant  agents  (American
Psychiatric  Association  2013).  This  disorder  may  cause  serious
somatic and psychiatric damage (American Psychiatric Association
2013; American Psychiatric Association 2022; Gawin 1988). These
include  an  increased  risk  of  death  by  suicide,  overdose,  acute
(e.g.  myocardial  infarction)  and  chronic  cardiovascular  diseases
(e.g. cardiomyopathy), car accidents, and homicides (Farrell 2019).
Some  of  the  frequent  medical  consequences  for  people  with
stimulant  use  disorder  include  a  wide  spectrum  of  psychiatric
symptoms, ranging from depressive symptoms (during withdrawal
from use of stimulants) to psychotic disorders and delusions during
intoxication  with  stimulants  (American  Psychiatric  Association
2013;  American  Psychiatric  Association  2022).  People  with
stimulant  use  disorder  are  at  high  risk  for  blood-borne  viral
infections  such  as  HIV  infection  (or  AIDS),  hepatitis  C  (HCV)  and
hepatitis  B  (HBV),  and  sexually  transmitted  infections  (Conner
2008;  Cornish  1996;  Cregler  1989;  Darke  2004;  Degenhardt  2005;
Degenhardt  2012;  Degenhardt  2017;  Falck  2003;  Farrell  2019;
Haasen  2005;  Kaye  2004;  Marzuk  1992;  Mathers  2008;  Mooney
2006;  Ribeiro  2006;  Roy  2001).  Several  studies  show  a  close  link
between  the  use  of  stimulants  (including  crack,  cocaine,  and
amphetamines)  and  violent  behaviours  such  as  crime,  sexual
abuse, and interpersonal violence (Atkinson 2014; Farrell 2019).

Stimulant use disorder is the most common illicit drug use disorder
after opioid use disorder (Degenhardt 2013; Degenhardt 2014; GBD
2018).  According  to  a  study  that  encompassed  195  countries,  in
2016, there were 5.8 million estimated cases of cocaine use disorder
(age-standardised  prevalence  of  77.6  cases  per  100,000  people,
95% uncertainty interval (UI) 70.7 to 85.9) and 5 million estimated
cases of amphetamine use disorder (age-standardised prevalence
of 64.7 cases per 100,000 people (95% UI 48.3 to 84.8)) (GBD 2018).
The  prevalence  was  higher  amongst  men  than  women,  for  both
cocaine use disorder (women: 49.4 cases per 100,000 people (95%
UI  44.7  to  54.9);  men:  105.5  cases  per  100,000  people  (95%  UI
96.3 to 116.3)) and amphetamine use disorder (women: 45.4 cases
per  100,000  people  (95%  UI  33.9  to  59.5);  men:  83.2  cases  per
100,000  people  (95%  UI  62.4  to  109.3))  (GBD  2018).  Prevalence
rates  of  cocaine  use  disorder  and  amphetamine  use  disorder
increased  from  1990  to  2016  by  39.7%  and  22.5%,  respectively
(GBD 2018). The estimated prevalence varied widely by region. The
highest  prevalence  of  cocaine  use  disorder  was  estimated  to  be
in  North  America  (524.1  cases  per  100,000  people  (95%  UI  484.6
to  567.0)),  followed  by  Southern  Latin  America  (259.6  cases  per
100,000 people (95% UI 227.7 to 295.8)), Australasia (234.9 cases per
100,000 people (95% UI 204.1 to 267.6)), and Western Europe (162.8

Psychosocial interventions for stimulant use disorder (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

7

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

cases per 100,000 people (95% UI 146.1 to 181.2)) (GBD 2018). The
highest prevalence of amphetamine use disorder was estimated to
be in Australasia (574.2 cases per 100,000 people (95% UI 483.7 to
664.7)), followed by North America (240.5 cases per 100,000 people
(95% UI 202.5 to 287.2)), Southern Latin America (179.3 cases per
100,000 people (95% UI 126.3 to 252.0)), Southeast Asia (126.4 cases
per  100,000  people  (95%  UI  84.3  to  177.9)),  and  Western  Europe
(110.2 cases per 100,000 people (95% UI 84.3 to 146.6)) (GBD 2018),
with the highest burden attributable to cocaine use disorder and
amphetamine use disorder observed in North America (GBD 2018).

In  2020,  although  all  indicators  suggested  an  increase  in  the
use of both cocaine products and amphetamine-type stimulants,
most  countries  reported  a  decrease  in  the  numbers  of  people
in  drug  treatment  (UNODC  2022).  This  reduction  mirrors  the
overall decrease in drug treatment observed during the COVID-19
pandemic  (UNODC  2022).  In  addition,  although  women  account
for approximately one in three people with stimulant use disorder
(GBD 2018), only one in five people in treatment for these disorders
is a woman (UNODC 2022).

Description of the intervention

At  the  present  time,  there  is  no  widely  accepted  treatment  for
stimulant use disorder. Regarding pharmacological treatment, no
medication has been specifically approved for this disorder (Chan
2019a; Chan 2019b; Knapp 2007; Farrell 2019; Paulus 2020). Several
medications  have  been  investigated,  including  bupropion  (Chan
2020; Siefried 2020), mirtazapine (Naji 2022), antipsychotics (Kishi
2013), anticonvulsants (Minozzi 2015), disulfiram (Pani 2010), and
psychostimulants  (Castells  2010;  Tardelli  2023).  However,  there
is  insufficient  evidence  to  support  their  use  in  the  treatment  of
stimulant  use  disorder  (Ronsley  2020).  Accordingly,  psychosocial
treatments are usually suggested as a suitable alternative approach
(Ronsley 2020).

interventions  that  we  considered  for 

We  included  in  this  systematic  review  only  textbook-recognised,
standardised  psychosocial  interventions  (De  Leon  1995;  NICE
inclusion
2007).  The 
were:  cognitive  behavioural  therapy,  contingency  management,
motivational interviewing, interpersonal therapy, psychodynamic
therapies,  and  12-step  facilitation.  We  did  not  consider  clinical
management, case management, or drug counselling.

Cognitive behavioural therapy

Cognitive behavioural therapy (CBT) is a structured psychotherapy
focused on resolving current problems and adjusting dysfunctional
cognitive  and  behavioural  patterns  (Beck  2011;  Magill  2023).  We
describe the various forms of CBT considered in this review below.

Cognitive therapy

Cognitive  therapy  is  based  on  the  assertion  that  stimulant  use
disorder  is  related  to  an  individual's  dysfunctional  beliefs  and
associated  cognitive  processes.  Cognitive  therapy  for  stimulant
use  disorder  consists  of  different  elements  alongside  the  use  of
cognitive and behavioural techniques, such as collaboration, case
conceptualisation,  structure,  and  socialisation  to  the  cognitive
model.  Amongst  the  cognitive  techniques  used  are  advantages-
disadvantages  analysis,  activity  monitoring  and  scheduling,
Socratic questioning, monitoring of drug-related beliefs, and role-
playing (Beck 2011).

Cochrane Database of Systematic Reviews

Coping skills training/relapse prevention

Coping  skills  training  and  relapse  prevention  interventions  are
focused  on  reducing  the  possibility  of  relapse  by  strengthening
the  individual's  ability  to  cope  with  high-risk  situations.  These
interventions  are  specifically  designed  to  identify  and  reduce
subjective craving for psychoactive substances. The aim is to help
people deal with high-risk situations for psychostimulant use and
develop  strategies  to  cope  with  and  control  the  urge.  In  this
approach, people are encouraged to reduce psychostimulant use,
to explore the consequences of stimulant use disorder, to recognise
high-risk situations for relapse, to develop strategies to deal with
craving, to be prepared for emergencies, and to identify alternative
activities to psychostimulant use (Carroll 2005).

Community reinforcement approach

reinforcement  approach 

Community 
is  a  multicomponent
approach  that  considers  that  environmental  events  influence
habitual  psychostimulant  use.  It  is  focused  on  providing  skills
training, improving relations, offering employment and vocational
counselling,  and  cultivating  new  activities  and  social  networks
(Bickel  1997;  Roozen  2004).  In  various  randomised  controlled
trials  (RCTs),  the  community  reinforcement  approach  has  been
associated with contingency management.

Contingency management

Contingency  management  provides  a  system  of 
incentives
designed  to  make  abstinence  more  attractive  than  continual
psychostimulant use (Hall 1977). Since its inception, contingency
management  has  been  widely  studied  for  stimulant  use  disorder
(NICE  2007),  and  it  now  comprises  different  methods  to  provide
reinforcement, which usually happens when individuals provide a
negative urine analysis for the tested drug. The reinforcement can
be money, vouchers, prizes, or even clinic privileges (Rawson 2002
arm 1; Shoptaw 2006).

Motivational interviewing

Motivational interviewing is a psychosocial intervention that aims
to evoke and strengthen personal motivation for change. It was first
developed for people with alcohol use disorder, and subsequently
applied to use disorders for other substances (Hettema 2005; Miller
1992; Miller 2003).

Interpersonal therapy

Interpersonal therapy is a supportive, time-limited psychotherapy,
originally  developed  for  the  treatment  of  depression.  It  is  based
on the assumption that psychiatric disorders are due to defective
interpersonal  relationships,  which  may  be  related  to  the  genesis
and protraction of the disorders (Van Schaik 2006).

Psychodynamic therapy

Psychodynamic therapies view substance use disorders in a broad
context considering the individual's interpersonal and intrapsychic
functioning.  The  unconscious,  core  conflictual  relationship
themes  and  defences  make  it  difficult  to  stop  stimulant  use.
Psychodynamic  psychotherapists  apply  supportive,  expressive,
and  interpretative  techniques  to  help  patients  explore  those
aspects of self that are not fully known, especially those which most
interfere  with  the  accomplishment  of  a  patient's  goals  (Shedler
2010).

Psychosocial interventions for stimulant use disorder (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

8

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Twelve-step facilitation

Twelve-step 
facilitation  consists  of  a  structured  and  brief
intervention  to  facilitate  early  recovery  from  alcohol  and  other
substance  use  disorders  (Chappel  1999).  It  is  based  on  cognitive,
behavioural,  and  spiritual  principles.  The  path  is  designed  in  12
steps, which are the core of the intervention, based on groups such
as Alcoholics Anonymous (AA) and Narcotics Anonymous (NA) (Ferri
2006).

How the intervention might work

Studies  using  functional  magnetic  resonance  imaging  suggest
that  psychosocial  treatments  can  influence  the  brain's  reward
system  by  inhibiting  activation  in  brain  regions  that  respond
to  satiety  (Feldstein  2011).  People  with  cocaine  use  disorder
present  with  poor  cognitive  control,  cue  reactivity  (which  results
in  them  having  physiological  and  psychological  reactions  when
they  are  exposed  to  drug  cues  or  stimuli),  and  craving  that
leads  them  through  appetitive  motivational  states  (Worhunsky
2013).  Psychosocial  interventions  act  on  all  of  these  domains
by  acting  on  memory  and  learning.  Memory  and  learning  bring
neuroadaptive  changes  and  neural  plasticity  (Koob  2010).  Neural
plasticity entails changes in the brain structure and circuitry, which
may  occur  as  a  result  of  experience  or  learning.  Indeed,  neural
plasticity  is  present  at  multiple  levels  and  facilitates  cognitive
control (Bryck 2012). This circle, starting from an at-risk condition
of  poor  cognitive  control,  and  arriving  at  neuroadaptive  changes
and neural plasticity (Koob 2010), shows us how psychotherapies
can change the brain structure and reminds us that mind and brain
are  intimately  correlated.  Under  this  assumption,  psychosocial
interventions  may  alleviate  stimulant  use  disorder,  reducing
craving and the risk of relapse. Although the various psychosocial
interventions start from very different theoretical assumptions and
the therapeutic techniques differ according to the model adopted,
all these interventions aim to counteract the addictive behaviours
underlying stimulant use disorder.

the  previous  section  has  already 

touched  on,  each
As 
psychosocial  intervention  considered  in  this  review  adopts  a
specific  theory  to  explain  its  psychological  and  behavioural
mechanisms  of  effect.  Briefly,  the  mechanisms  of  action  of
the  main  treatments  considered  here  are  the  following.  CBT
is  aimed  at  reducing  dysfunctional  beliefs,  negative  thoughts,
and unwanted behaviours, through behavioural tasks and coping
skills  training  (Klimas  2018).  Contingency  management  uses
reinforcing  and  punishing  consequences  to  alter  substance  use
(Witkiewitz 2011). Motivational interviewing is aimed at increasing
an individual's motivation and readiness to change (Foxcroft 2016).
Psychodynamic  therapy  employs  the  therapeutic  relationship
between psychotherapist and client to solve unconscious conflicts
and  develop  insight  (Klimas  2018).  Twelve-step  facilitations  are
clinical  interventions  that  have  adapted  the  methodology  and
concepts of Alcoholics Anonymous (Kelly 2020).

Why it is important to do this review

The  Cochrane  Drugs  and  Alcohol  Group  has  performed  various
reviews  of  psychosocial  treatments  for  different  substance  use
disorders  (e.g.  Amato  2011a;  Amato  2011b;  Gates  2016;  Hunt
2019;  Klimas  2014;  Klimas  2018;  McGovern  2021;  Minozzi  2014;
Smedslund  2011).  In  recent  years,  research  on  psychosocial
treatments  for  stimulant  use  disorder  has  rapidly  developed,  in
part  due to the relative inefficacy of pharmacological treatments

Cochrane Database of Systematic Reviews

(Dellazizzo 2023; Farrell 2019; Paulus 2020; Rawson 2023; Ronsley
2020;  Tran  2021).  High  dropout  rates  suggest  that  specific
approaches to compliance are important, and that some types of
psychosocial interventions may be promising treatments, helping
people  with  stimulant  use  disorder  to  have  realistic  beliefs  and
to  set  short-term  objectives.  This  may  keep  people  in  treatment
and  abstinent,  and  may  also  help  to  prevent  relapses  (Carroll
2005). However, evidence of the efficacy of psychosocial treatments
for  stimulant  use  disorder  is  still  unclear.  This  is  an  update  of  a
Cochrane review first published in 2016.

O B J E C T I V E S

To assess the efficacy and safety of psychosocial interventions for
stimulant use disorder in adults.

M E T H O D S

Criteria for considering studies for this review

Types of studies

We  included  parallel,  individually-randomised  controlled  trials
(RCTs) and cluster-randomised controlled trials (cluster-RCTs).

Types of participants

Adults  (18  years  and  older)  with  a  diagnosis  of  stimulant
dependence,  abuse,  or  stimulant  use  disorder  according  to  the
Diagnostic and Statistical Manual of Mental Disorders (DSM) III, IV,
or 5, or the ninth, tenth, or eleventh revision of the International
Classification  of  Diseases  (ICD-9,  ICD-10,  or  ICD-11;  see  https://
icd.who.int/en) criteria, irrespective of pattern of use, sex, age, or
nationality. We considered psychostimulants to be any substance
that activates, enhances, or increases neural activity (WHO 2006).
We included trials in people with additional diagnoses of substance
use  disorders  for  other  substances,  such  as  alcohol  or  cannabis,
and people with comorbid psychiatric disorders. We also included
trials  in  people  with  opiate  use  disorder,  those  in  methadone
maintenance  schemes,  or  both.  We  excluded  studies  aiming  to
prevent relapse in participants who were already detoxified.

Types of interventions

Experimental interventions

We considered any of the following psychosocial treatments:

• cognitive  behavioural  therapies  (CBT),  including:  cognitive
therapy,  community  reinforcement  approach,  coping  skills
training (CST), relapse prevention;
• contingency management approach;
• motivational interviewing approach (motivational interviewing,

motivational enhancement);
• interpersonal therapy approach;
• psychodynamic therapy and supportive expressive therapy;
• 12-step facilitation approach.

We included studies if they considered the above treatments alone
or in combination with other types of treatment.

We  did  not  include  other,  eclectic  approaches.  We  only  included
structured and standardised interventions.

Psychosocial interventions for stimulant use disorder (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

9

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Case  management  and  counselling  are  usually  provided  in
standard  care  (treatment  as  usual),  so  we  did  not  consider  them
amongst the experimental interventions.

We excluded studies that compared the same type of intervention
given in a different modality or at a different intensity (e.g. intensive
versus standard, group versus individual, long versus short).

Control interventions

• No treatment
• Treatment  as  usual  (TAU; 

individual  or  group
counselling,  case  management,  clinical  management,  or
educational/informative interventions)

including 

• Other psychosocial treatment
• Pharmacological treatment

Types of comparisons foreseen

• Any  psychosocial  approach  versus  no  treatment  (including
studies  where  any  psychosocial  intervention  was  given  in
addition  to  any  other  treatment,  including  TAU,  which  was
received by both groups), stratified for type of intervention
• Any  psychosocial  approach  versus  TAU,  stratified  for  type  of

intervention

• Single  psychosocial 
psychosocial approach

approach 

versus 

an 

alternative

Types of outcome measures

Primary outcomes

• Dropouts from treatment: number of participants who did not

complete the study protocol

• Use of the primary stimulant substance, measured as:

◦ Point  abstinence  at  the  end  of  treatment  (number  of
participants  who  self-reported  abstinence,  gave  negative
urine samples, or both)

◦ Point  abstinence  at  the  longest  follow-up  (number  of
participants  who  self-reported  abstinence,  gave  negative
urine samples, or both)

◦ Continuous abstinence at the end of treatment (number of
participants who self-reported continuous abstinence, gave
negative  urine  samples,  or  both,  for  at  least  half  of  the
duration of treatment)

◦ Continuous abstinence at the longest follow-up (number of
participants who self-reported continuous abstinence, gave
negative  urine  samples,  or  both,  for  at  least  half  of  the
duration of the longest follow-up)

◦ Frequency of drug intake at the end of treatment
◦ Longest period of abstinence at the end of treatment

Secondary outcomes

• Craving, as measured by validated scales (e.g. Brief Substance

Craving Scale (BSCS), visual analogue scale (VAS))

• Severity of dependence, as measured by validated scales (e.g.
Addiction Severity Index (ASI), Clinical Global Impression scale-
Severity of illness (CGI-S)

• Depression,  as  measured  by  validated  scales  (e.g.  Hamilton

Depression Rating Scale, Beck Depression Inventory)

• Adverse  events,  measured  by  number  of  participants  with  at

least one adverse event

Cochrane Database of Systematic Reviews

We assessed the secondary outcomes at the end of treatment.

Search methods for identification of studies

Electronic searches

We searched the following electronic databases.

• Cochrane Drugs and Alcohol Group (CDAG) Specialised Register
(inception to 26 April 2022), using the search strategy outlined in
Appendix 1.

• Cochrane Central Register of Controlled Trials (CENTRAL) (2023,

Issue 9), using the search strategy outlined in Appendix 2.

• MEDLINE (via OVID) (January 1966 to 26 September 2023), using

the search strategy outlined in Appendix 3.

• Embase (via OVID) (January 1974 to 26 September 2023), using

the search strategy outlined in Appendix 4.

• CINAHL  (Cumulative  Index  to  Nursing  and  Allied  Health
Literature; EBSCO HOST) (1982 to 26 September 2023), using the
search strategy outlined in Appendix 5.

• Web  of  Science  (Thomson  Reuters)  (January  2006  to  26
September 2023), using the search strategy outlined in Appendix
6.

• PsycINFO  (via  OVID)  (1800  to  26  September  2023),  using  the

search strategy outlined in Appendix 7.

We  searched  the  databases  using  medical  subject  headings
(MeSH) and text words relating to psychological interventions and
stimulant use disorder. We combined the MEDLINE search with the
Cochrane Highly Sensitive Search Strategy for identifying RCTs in
MEDLINE:  sensitivity-maximising  version  (2008  revision;  Lefebvre
2011). We revised this strategy appropriately for each database to
take  account  of  differences  in  controlled  vocabulary  and  syntax
rules.

We searched for ongoing clinical trials and unpublished trials via
Internet searches on the following websites.

• ClinicalTrials.gov (www.clinicaltrials.gov) (26 September 2023);
International  Clinical
• World  Health  Organization 
Trials Registry Platform (ICTRP) (apps.who.int/trialsearch/) (26
September 2023), using the search strategy outlined in Appendix
8.

(WHO) 

Searching other resources

We also used the following sources:

• references of the articles obtained by any means;
• conference  proceedings  likely  to  contain  trials  relevant  to  the
review.  These  included  proceedings  from  the  Society  for  the
Study of Addiction, International Harm Reduction Association,
and  the  American  Association  for  the  Treatment  of  Opioid
Dependence.

• contact  with  investigators  and  relevant  trial  authors,  seeking

information about unpublished or incomplete trials.

All  searches  included  non-English  language  literature,  and  we
assessed studies with non-English abstracts for inclusion. When we
considered that the studies likely met the inclusion criteria, we had
them translated.

Psychosocial interventions for stimulant use disorder (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

10

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Data collection and analysis

Selection of studies

Two  authors  (FT,  RA)  independently  screened  the  abstracts  of  all
publications  obtained  by  the  search  strategy.  Two  authors  (FT,
RA)  independently  assessed  the  full  texts  of  potentially  relevant
studies for inclusion. We resolved any disagreements by discussion
or consulting a third review author (SM).

Data extraction and management

Two  authors  (RS,  FT)  extracted  data.  SM  and  RA  checked  all
the  data  extraction  forms.  We  resolved  any  doubts  by  discussion
amongst  the  review  author  team.  We  extracted  the  following
information:  number  and  characteristics  of  participants,  setting,
type  of  experimental  and  control  intervention,  length  of  follow-
up, types of outcomes, country of origin, funding, and conflicts of
interest.

Assessment of risk of bias in included studies

Two  authors  (SM,  FT)  independently  assessed  the  risk  of  bias
of  the  included  studies.  We  used  the  criteria  recommended  by
the  Cochrane  Handbook  for  Systematic  Reviews  of  Interventions
(Higgins  2011).  The  recommended  approach  for  assessing  risk
of  bias  in  studies  included  in  Cochrane  reviews  is  a  two-
part  tool,  addressing  the  following  specific  domains:  sequence
generation  and  allocation  concealment  (selection  bias),  blinding
of  participants  and  personnel  (performance  bias),  blinding  of
outcome  assessors  (detection  bias),  incomplete  outcome  data
(attrition  bias),  and  selective  outcome  reporting  (reporting  bias).
The first part of the tool involves describing what was reported to
have  happened  in  the  study,  and  the  second  elicits  a  judgement
of  low,  high,  or  unclear  risk  of  bias  for  that  entry.  To  make
these judgements, we used the criteria indicated by the Cochrane
Handbook for Systematic Reviews of Interventions, adapted to the
addiction field. See Appendix 9 for details.

We  assessed  the  domains  sequence  generation  and  allocation
concealment  (avoidance  of  selection  bias)  at  a  study  level.  We
considered  blinding  of  participants,  personnel,  and  outcome
assessors  (avoidance  of  performance  bias  and  detection  bias)
separately  for  objective  outcomes  (e.g.  dropout,  use  of  primary
stimulant  substance  measured  by  urine  analysis,  participants
relapsed  at  the  end  of  follow-up)  and  subjective  outcomes  (e.g.
participant-reported use of substance, craving, severity of signs and
symptoms of withdrawal, depression, adverse events).

Measures of treatment effect

We  analysed  dichotomous  outcomes  by  calculating  the  risk  ratio
(RR)  for  each  trial  with  the  uncertainty  in  each  result  being
expressed  with  a  95%  confidence  interval  (CI).  We  planned  to
analyse continuous outcomes by calculating the mean difference
(MD)  with  95%  CI  when  the  studies  used  the  same  instrument
for assessing the outcome, and the standardised mean difference
(SMD)  when  the  studies  used  different  instruments.  In  the  event,
the  included  studies  used  different  instruments  for,  or  ways  of
measuring, the continuous outcomes. Therefore, we used SMDs for
all  the  continuous  outcomes.  We  also  used  the  SMD  for  the  very
few comparisons where only one study was included, to increase
the  comparability  of  outcomes  across  comparisons.  We  did  not
use data presented as the number of positive urine tests over the
total number of tests in the experimental and control groups as a

Cochrane Database of Systematic Reviews

measure  of  substance  use.  We  made  this  decision  because  using
the number of tests, instead of the number of participants who had
one (or more) positive test result, as the unit of the analysis violates
the hypothesis of independence amongst observations. In fact, the
results of tests done for each participant are not independent.

Unit of analysis issues

For  multi-arm  studies  that  compared  different  treatments  with
the  same  control  group,  we  divided  the  number  of  events  and
the  number  of  participants  of  the  control  group  by  the  number
of  experimental  arms  to  avoid  double-counting  participants  in
the  control  groups.  This  approach  only  partially  overcomes  the
unit-of-analysis  error  (because  the  resulting  comparisons  remain
correlated) (Higgins 2023). However, we determined that it was the
best  method  for  those  studies  that  compared  different  types  of
psychosocial treatments to a single control group, where we were
interested both in the overall estimate and in the stratified analysis
for each type of psychosocial intervention.

For  multi-arm  studies  that  compared  different  intensities  or
frequencies of the same experimental intervention with the same
control group, we combined the experimental arms into one arm to
create a single pair-wise comparison (Higgins 2023).

We  analysed  cluster-randomised  trials  according  to  methods
described  in  the  Cochrane  Handbook  for  Systematic  Reviews  of
Interventions (Higgins 2023). If studies did not control for clustering,
we  imputed  the  intracluster  correlation  coefficient  (ICC)  from
similar studies. We divided the effective sample size of each arm by
the "design effect" quantity (1 + (M-1) x ICC), where M is the average
cluster size.

Dealing with missing data

We included all randomised participants in the statistical analysis,
without  any  imputation  of  missing  data.  If  standard  deviations
(SDs) were missing, we used the mean of the available SDs of the
other included studies (Furukawa 2006)

Assessment of heterogeneity

We  analysed  heterogeneity  using  the 
I2  statistic  and  the
Chi2  test.  We  regarded  heterogeneity  as  substantial  if  the  I2
statistic  was  greater  than  50%  or  if  P  was  less  than  0.10
for  the  Chi2  test  for  heterogeneity.  Following  the  guidance  in
the  Cochrane  Handbook  for  Systematic  Reviews  of  Interventions
(Deeks  2022),  we  distinguished  the  following  values:  0%  to  40%
denoted  no  important  heterogeneity;  30%  to  60%  moderate
heterogeneity;  50%  to  90%  substantial  heterogeneity;  and  75%
to  100%  considerable  heterogeneity.  If  we  found  considerable
heterogeneity (i.e. 75% or above), we explored possible reasons by
visually inspecting the forest plot to identify studies that might be
contributing to heterogeneity.

Assessment of reporting biases

We  visually  inspected  funnel  plots  (plots  of  the  effect  estimate
from each study against the sample size or effect standard error)
to indicate possible publication bias. We acknowledge that funnel
plots  should  be  seen  as  a  generic  means  of  displaying  small-
study  effects  –  a  tendency  for  the  intervention  effects  estimated
in smaller studies to differ from those estimated in larger studies,
so  that  asymmetry  could  be  due  to  publication  bias  –  but  small-
study  effects  may  be  due  to  reasons  other  than  publication  bias,

Psychosocial interventions for stimulant use disorder (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

11

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

such as greater risk of bias in smaller studies, inclusion of a more
restricted and thus responsive population, or merely due to the role
of chance. We inspected funnel plot symmetry when there were at
least 10 studies included in the meta-analysis.

Data synthesis

We  combined  the  outcomes  from  the  individual  trials  through
meta-analysis  where  possible  (comparability  of  intervention  and
outcomes  between  trials)  using  a  random-effects  model  because
we expected a certain degree of heterogeneity amongst trials.

Subgroup analysis and investigation of heterogeneity

We  performed  subgroup  analyses  for  the  primary  outcomes
reported by at least 10 studies. We created three subgroups: trials
in  which  all  participants  had  comorbid  opiate  dependence  and
were in methadone treatment; trials with variable percentages of
participants with comorbid opiate dependence and in methadone
treatment; trials with no participants with opiate dependence and
in methadone treatment.

Sensitivity analysis

To incorporate our assessment of risk of bias in the review process,
we first plotted the intervention effect estimates, stratified by risk
of  bias  for  allocation  concealment  (selection  bias),  blinding  of
outcome assessors (detection bias), and attrition bias. If there were
differences  in  the  results  between  studies  with  different  risks  of
bias, we performed sensitivity analyses by excluding studies with a
high risk of bias from the analysis.

Summary of findings and assessment of the certainty of the
evidence

The Grading of Recommendation, Assessment, Development and
Evaluation (GRADE) Working Group developed a system for grading
the certainty of evidence that considers issues related to internal
validity  (i.e.  risk  of  bias),  consistency  of  the  results,  precision
of  estimate,  external  validity,  such  as  directness  of  results,  and
suspicion  of  publication  bias  (GRADE  2004;  Guyatt  2008;  Guyatt
2011;  Schünemann  2006).  Using  the  GRADE  system,  two  review
authors  (SM,  RA)  assessed  the  overall  certainty  of  the  evidence
for  the  primary  outcomes  of  the  two  main  comparisons:  (1)  any
psychosocial intervention versus no intervention (including studies
which  compared  any  psychosocial  treatment  plus  TAU  to  TAU
alone),  and  (2)  any  psychosocial  intervention  versus  TAU.  We
have  presented  summary  of  findings  tables  for  these  two  main
comparisons. This is a transparent and simple tabular format that
provides key information concerning the certainty of evidence, the

Cochrane Database of Systematic Reviews

magnitude of effect of the interventions examined, and the sum of
available data on the main outcomes.

The GRADE system uses the following criteria to assign a grade of
evidence certainty.

• High: we are very confident that the true effect lies close to that

of the estimate of the effect.

• Moderate: we are moderately confident in the effect estimate.
The true effect is likely to be close to the estimate of the effect,
but there is a possibility that it is substantially different.

• Low: our confidence in the effect estimate is limited. The true
effect  may  be  substantially  different  from  the  estimate  of  the
effect.

• Very low: we have very little confidence in the effect estimate.
The  true  effect  is  likely  to  be  substantially  different  from  the
estimate of effect.

The certainty of the evidence is downgraded by one (−1) or two (−2)
levels for the following reasons.

• Serious (−1) or very serious (−2) study limitations for risk of bias.
• Serious  (−1)  or  very  serious  (−2)  inconsistency  between  study

results.

• Some  (−1)  or  major  (−2)  uncertainty  about  directness  (the
correspondence  between  the  population,  the  intervention,  or
the outcomes measured in the studies actually found and those
under consideration in our systematic review).

• Serious  (−1)  or  very  serious  (−2)  imprecision  of  the  pooled

estimate.

• Strong suspicion of publication bias (−1).

We  used  GRADEpro  GDT  software  to  prepare  the  summary  of
findings tables (GRADEpro GDT).

R E S U L T S

Description of studies

Results of the search

For this update, after removing duplicates, we were left with 1799
unique references for screening. Of these, we excluded 1751 on the
basis  of  title  and  abstract.  We  retrieved  48  articles  in  full  text  for
more detailed evaluation, 19 of which we excluded for not meeting
the inclusion criteria, six were ongoing studies, and three had been
included in the previous version of the review. Finally, we included
12  new  studies  (20  records)  that  satisfied  all  criteria  required  for
inclusion in the review. See Figure 1.

Psychosocial interventions for stimulant use disorder (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

12

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Figure 1.   Study flow diagram

Cochrane Database of Systematic Reviews

52 studies included 
in previous version 
of review 

3369 records 
identified through 
database searching

0 additional 
records identified 
through other 
sources

1799 records after 
duplicates removed

1799 records 
screened

1752 records 
excluded

48 full-text records 
assessed for 
eligibility

19 full-text records 
excluded, with 
reasons

12 new studies 
included (20 
articles) 

6 ongoing

3 already included 
in the previous 
version

64 studies (96 
reports) included 
in qualitative 
synthesis

63 studies included 
in quantitative 
synthesis 
(meta-analysis)

Psychosocial interventions for stimulant use disorder (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

13

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Figure 1.   (Continued)

Cochrane Database of Systematic Reviews

For  substantive  descriptions  of  studies,  see  Characteristics
of  included  studies,  Characteristics  of  excluded  studies,  and
Characteristics of ongoing studies.

Included studies

Overall,  we  included  64  randomised  controlled  trials  (RCTs)  (52
included in the previous version and 12 in this update), involving a
total of 8241 participants (see Characteristics of included studies).
We  did  not  include  data  from  one  study  in  meta-analysis  as  it
did  not  report  the  number  of  clusters  and  their  sizes  (Mitcheson
2007), and therefore, it was not possible to adjust the data for the
“design  effect”.  Thus,  we  included  63  studies  in  the  quantitative
synthesis. We reclassified one RCT included in the previous version
(NCT01140880)  as  a  secondary  reference  of  an  already  included
RCT  (Landovitz  2015).  We  included  three  studies  with  multiple
experimental arms that were eligible for inclusion in the review. As
noted in Unit of analysis issues, our approach to these studies was
to divide the number of events and the number of participants of
the  control  group  by  the  number  of  experimental  arms  to  create
two  or  more  pair-wise  comparisons  per  study.  One  RCT  had  two
arms  (labelled  as  Crits-Christoph  1999  arm  1  and  Crits-Christoph
1999 arm 2 in the Characteristics of included studies table and the
analyses),  one  had  four  arms  (Rawson  2002  arm  1,  Rawson  2002
arm 2, Rawson 2002 arm 3, Rawson 2002 arm 4), and one had three
arms (Shoptaw 2005 arm 1, Shoptaw 2005 arm 2, Shoptaw 2005 arm
3).

Studies  ranged  in  size  from  19  (Petry  2013)  to  487  participants
(Crits-Christoph 1999 arm 1). Twenty-seven studies recruited fewer
than 100 participants. The mean age of participants was about 38
years, and there were more men (about 71%) than women. Forty-
six studies took place in the USA, four in Spain, three in Australia,
three in the UK, two in Switzerland, two in Brazil, two in Iran, and
one each in the Netherlands and South Africa.

Forty-seven  studies  (73.4%)  included  participants  with  cocaine
or  crack  cocaine  use  disorder;  two  (3.1%)  included  participants
with  amphetamine  use  disorder;  seven 
included
participants  with  methamphetamine  use  disorder;  and  eight
(12.5%) included participants with any stimulant use disorder by
any psychostimulant.

(10.9%) 

In  18  studies,  all  participants  were  in  methadone  maintenance
treatment  (Alammehrjerdi  2019;  Blanken  2016;  Carroll  2012;
Carroll 2014; Carroll 2018; Dursteler-MacFarland 2013; Ghitza 2007;
Knealing  2006;  Mitcheson  2007;  Peirce  2006;  Petry  2005b;  Petry
2007;  Petry  2012a;  Petry  2015;  Poling  2006;  Rawson  2002  arm  1;
Rawson  2002  arm  2;  Rawson  2002  arm  3;  Rawson  2002  arm  4;
Silverman  1996;  Silverman  1998).  In  four  studies,  the  proportion
of participants with comorbid opioid dependence and methadone
maintenance  ranged  from  36.4%  to  67%  (Baker  2001;  Marsden
2018; Petitjean 2014; Petry 2013).

In  19  studies,  participants  reported  also  having  alcohol  use
disorder, with percentages ranging from 17% (Peirce 2006) to 100%
(Carroll 1998). In eight studies, participants reported cannabis use

disorder,  and  in  three  studies,  participants  had  substance  use
disorder for multiple psychoactive substances.

In  23  studies,  participants  had  other  psychiatric  disorders,  such
as  mood  disorders,  anxiety,  psychotic  disorders,  or  antisocial
personality disorders.

The mean duration of the interventions was 3.7 months (or roughly
16  weeks),  with  the  number  of  sessions  offered  to  participants
ranging  from  one  session  (Marsden  2006;  Mitcheson  2007)  to
multiple sessions over 12 months (Parsons 2018).

The  included  studies  assessed  the  severity  of  craving  using  the
following  scales:  Cocaine  Craving  Questionnaire  (Tiffany  1993;  3
studies: Festinger 2014; Pirnia 2016; Silverman 1998); Penn craving
scale  (Flannery  1999;  one  study:  Sorsdahl  2021),  and  Craving
Experiences Questionnaire (CEQ-F) (May 2014; one study: Marsden
2006). The severity of stimulant use disorder was measured using
the following scales: Severity of Dependence Scale (SDS) (Gossop
1995;  two  studies:  Alammehrjerdi  2019;  Mitcheson  2007);  Leeds
Dependence Questionnaire (LDQ) (Raistrick 1994; one study: Smout
2010);  Clinical  Global  Impressions  Scale  (CGI)  (Busner  2007;  one
study, Sorsdahl 2021); and Addiction Severity Index (ASI) (Mclellan
1992; seven studies: Garcia-Fernandez 2011; Higgins 1994; Higgins
2000; Ingersoll 2011; Petry 2005b; Roll 2013; Sanchez-Hervas 2010).
Lastly,  studies  measured  the  presence  of  depressive  symptoms
using  the  Beck  Depression  Inventory  II  (BDI-II)  (Beck  1996;  two
studies:  Garcia-Fernandez  2011;  Smout  2010),  the  Montgomery-
Åsberg Depression Rating Scale (MADRS) (Montgomery 1979; one
study:  Mimiaga  2019),  and  the  Hamilton  Depression  Rating  Scale
(HAM-D) (Maier 1988; one study: Sorsdahl 2021).

Types of interventions and comparisons

The  included  studies  considered  the  following  psychosocial
interventions:  cognitive  behavioural  therapy  (CBT),  contingency
management, motivational interviewing, a combination of CBT and
contingency management, a combination of CBT and motivational
interviewing, interpersonal therapy, psychodynamic therapy, and
12-step facilitation.

Comparison 1: any psychosocial intervention versus no intervention

In  this  comparison,  we  also  included  any  studies  which  gave  a
psychosocial intervention plus TAU compared to TAU alone.

CBT  versus  no  intervention:  12  studies  (Baker  2001,  Baker  2005;
Carroll 2014; Carroll 2018; Crits-Christoph 1999 arm 1; Higgins 2003;
Marsden 2018; McKee 2007; Milby 2008; Mimiaga 2019; Rawson 2002
arm 1; Shoptaw 2005 arm 2)

Contingency  management  versus  no  intervention:  27  studies
(Blanken 2016; Carroll 2016;Festinger 2014; Garcia-Fernandez 2011;
Ghitza 2007; Hagedorn 2013; Higgins 1994; Kirby 1998; Ledgerwood
2006; Menza 2010; Miguel 2017; Miguel 2022; Peirce 2006; Petitjean
2014; Petry 2005a; Petry 2005b; Petry 2007; Petry 2013; Petry 2012a;
Petry 2012b; Petry 2015; Petry 2018; Pirnia 2016; Rawson 2002 arm
2; Roll 2013; Secades Villa 2013; Shoptaw 2005 arm 3)

Psychosocial interventions for stimulant use disorder (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

14

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Motivational  interviewing  versus  no  intervention:  three  studies
(Marsden  2006;  McKee  2007;  Stein  2009).  We  did  not  include
Mitcheson  2007,  a  cluster-RCT  with  a  total  sample  size  of  29
participants, in the meta-analyses as it did not report the number of
clusters and their sizes and, therefore, it was not possible to adjust
the data for the "design effect".

Psychodynamic  therapy  versus  no  intervention:  one  study  (Crits-
Christoph 1999 arm 2)

Combination  of  CBT  plus  contingency  management  versus  no
intervention: one study (Rawson 2002 arm 3)

Comparison 2: any psychosocial intervention versus TAU

CBT versus TAU: seven studies (Alammehrjerdi 2019; Carroll 1994;
Dursteler-MacFarland  2013;  Higgins  1993;  Rawson  2002  arm  1;
Sanchez-Hervas 2010; Shoptaw 2008)

Contingency  management  versus  TAU:  two  studies  (Garcia-
Rodriguez 2007; Knealing 2006)

Motivational interviewing versus TAU: two studies (Ingersoll 2011;
Sorsdahl 2021)

Combination of CBT plus motivational interviewing versus TAU: one
study (Parsons 2018)

Comparison 3: contingency management versus non-contingent
management (reinforcement related to abstinence versus
reinforcement not related to abstinence)

Seven studies (Higgins 2000; Landovitz 2015; McDonell 2013; Poling
2006; Schottenfeld 2011; Silverman 1996; Silverman 1998)

Cochrane Database of Systematic Reviews

Comparison 4: any psychosocial intervention versus an alternative
psychosocial intervention

CBT versus 12-step facilitation: two studies (Carroll 1998; Maude-
Griffin 1998)

CBT versus interpersonal therapy: two studies (Carroll 1991; Carroll
2004)

CBT versus contingency management: two studies (Rawson 2002
arm 4; Shoptaw 2005 arm 1)

CBT versus acceptance and commitment therapy (ACT): one study
(Smout 2010)

Excluded studies

We  excluded  85  studies  for  the  following  reasons:  ineligible
participants  (48  studies);  ineligible  interventions  (24  studies);
ineligible comparisons: this category included eight studies which
compared the same intervention delivered at different intensities,
frequencies,  or  modalities,  and  two  studies  for  an  otherwise
ineligible comparison (10 studies in total); ineligible study design
(three studies).

Risk of bias in included studies

See Figure 2 and Figure 3. For detailed descriptions of the reasons
supporting  our  judgements,  see  the  risk  of  bias  tables  in  the
Characteristics of included studies.

Figure 2.   Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages
across all included studies.

Random sequence generation (selection bias)
Allocation concealment (selection bias)
Blinding of participants and personnel (performance bias): Subjective outcomes
Blinding of participants and personnel (performance bias): Objective outcomes
Blinding of outcome assessment (detection bias): Subjective outcomes
Blinding of outcome assessment (detection bias): Objective outcomes
Incomplete outcome data (attrition bias): All outcomes except retention in treatment
Selective reporting (reporting bias)

Low risk of bias

Unclear risk of bias

High risk of bias

0%

25%

50%

75% 100%

Psychosocial interventions for stimulant use disorder (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

15

 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Figure 3.   Risk of bias summary: review authors' judgements about each risk of bias item for each included study.

s
e
m
o
c
t
u
o

e
v
i
t
c
e
j
b
u
S

:
)
s
a
i
b

e
c
n
a
m
r
o
f
r
e
p
(

l
e
n
n
o
s
r
e
p

d
n
a

s
t
n
a
p
i
c
i
t
r
a
p
f
o

g
n
i
d
n
i
l

B

−

−

−

−

−

−

−

−

−

−

−

−

−

−

s
e
m
o
c
t
u
o

e
v
i
t
c
e
j
b
O

:
)
s
a
i
b

e
c
n
a
m
r
o
f
r
e
p
(

l
e
n
n
o
s
r
e
p

d
n
a

s
t
n
a
p
i
c
i
t
r
a
p
f
o

g
n
i
d
n
i
l

B

+

+

+

+

+

+

+

+

+

+

+

+

+

+

s
e
m
o
c
t
u
o

e
v
i
t
c
e
j
b
u
S

:
)
s
a
i
b

n
o
i
t
c
e
t
e
d
(

t
n
e
m
s
s
e
s
s
a

e
m
o
c
t
u
o
f
o

g
n
i
d
n
i
l

B

?

+

+

?

?

+

+

?

?

?

?

?

+

+

s
e
m
o
c
t
u
o
e
v
i
t
c
e
j
b
O

:
)
s
a
i
b
n
o
i
t
c
e
t
e
d
(

t
n
e
m
s
s
e
s
s
a

e
m
o
c
t
u
o
f
o

g
n
i
d
n
i
l

B

+

+

+

+

+

+

+

+

+

+

+

+

+

+

t
n
e
m
t
a
e
r
t
n
i

n
o
i
t
n
e
t
e
r

t
p
e
c
x
e

s
e
m
o
c
t
u
o

l
l

A

:
)
s
a
i
b

n
o
i
t
i
r
t
t
a
(

a
t
a
d

e
m
o
c
t
u
o

e
t
e
l
p
m
o
c
n
I

+

+

+

+

−

−

+

−

+

+

+

+

+

+

)
s
a
i
b
g
n
i
t
r
o
p
e
r
(

g
n
i
t
r
o
p
e
r

e
v
i
t
c
e
l
e
S

?

?

?

+

?

?

?

?

?

+

+

+

+

+

)
s
a
i
b
n
o
i
t
c
e
l
e
s
(

n
o
i
t
a
r
e
n
e
g

e
c
n
e
u
q
e
s
m
o
d
n
a
R

+

?

+

+

?

?

?

?

+

+

+

+

+

+

)
s
a
i
b
n
o
i
t
c
e
l
e
s
(

t
n
e
m
l
a
e
c
n
o
c

n
o
i
t
a
c
o
l
l

A

+

?

+

?

?

?

?

?

?

?

?

?

+

+

Alammehrjerdi 2019

Baker 2001

Baker 2005

Blanken 2016

Carroll 1991

Carroll 1994

Carroll 1998

Carroll 2004

Carroll 2012

Carroll 2014

Carroll 2016

Carroll 2018

Crits-Christoph 1999 arm 1

Crits-Christoph 1999 arm 2

Psychosocial interventions for stimulant use disorder (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

16

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Figure 3.   (Continued)

Cochrane Database of Systematic Reviews

Crits-Christoph 1999 arm 2

Dursteler-MacFarland 2013

Festinger 2014

Garcia-Fernandez 2011

Garcia-Rodriguez 2007

Ghitza 2007

Hagedorn 2013

Higgins 1993

Higgins 1994

Higgins 2000

Higgins 2003

Ingersoll 2011

Kirby 1998

Knealing 2006

Landovitz 2015

Ledgerwood 2006

Marsden 2006

Marsden 2018

Maude-Griffin 1998

McDonell 2013

McKee 2007

Menza 2010

Miguel 2017

Miguel 2022

Milby 2008

Mimiaga 2019

Mitcheson 2007

Parsons 2018

Peirce 2006

Petitjean 2014

Petry 2005a

Petry 2005b

Petry 2007

Petry 2012a

Petry 2012b

Petry 2013

+

?

?

+

+

+

+

+

?

+

+

?

+

?

?

+

+

+

?

+

?

+

+

+

?

?

?

+

+

+

+

+

+

+

+

+

+

?

?

+

?

?

?

?

?

?

?

?

?

?

?

?

+

−

?

?

+

+

?

+

?

?

−

?

+

+

+

?

?

?

?

?

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

?

?

?

?

?

?

?

?

?

−

+

?

?

+

?

?

?

?

?

+

−

?

?

+

?

?

?

?

?

?

?

?

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

?

−

+

+

−

+

+

+

−

−

+

?

−

?

+

+

?

+

−

+

+

+

+

+

+

+

−

+

+

+

+

+

+

+

+

?

−

?

?

?

?

−

?

?

?

?

?

?

+

?

?

?

?

+

?

+

−

−

?

?

?

?

?

+

?

?

?

?

?

−

Psychosocial interventions for stimulant use disorder (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

17

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Figure 3.   (Continued)

Cochrane Database of Systematic Reviews

Petry 2012b

Petry 2013

Petry 2015

Petry 2018

Pirnia 2016

Poling 2006

Rawson 2002 arm 1

Rawson 2002 arm 2

Rawson 2002 arm 3

Rawson 2002 arm 4

Roll 2013

Sanchez-Hervas 2010

Schottenfeld 2011

Secades Villa 2013

Shoptaw 2005 arm 1

Shoptaw 2005 arm 2

Shoptaw 2005 arm 3

Shoptaw 2008

Silverman 1996

Silverman 1998

Smout 2010

Sorsdahl 2021

Stein 2009

+

+

+

+

?

+

?

?

?

?

?

+

+

+

+

+

+

?

+

?

+

+

?

?

?

?

?

?

+

?

?

?

?

−

?

?

?

?

?

?

?

?

?

−

?

?

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

?

?

?

+

?

?

?

?

?

?

?

?

?

?

?

?

?

?

?

+

?

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

?

?

−

+

+

+

+

+

−

−

−

+

+

+

+

+

?

+

+

+

?

−

?

?

?

?

?

?

?

?

?

?

+

?

?

?

?

?

?

?

?

?

?

Allocation

Random sequence generation

We  judged  42  studies  to  be  at  low  risk  of  bias.  We  rated  the
remaining 22 studies to have an unclear risk of bias, as authors did
not  report  any  information  about  methods  of  random  sequence
generation.

Allocation concealment

We  judged  all  objective  outcomes  to  be  at  low  risk  because  we
considered that the outcome was not likely to be influenced by lack
of blinding.

Detection bias

For subjective outcomes, we considered 14 studies to be at low risk
of bias and two studies to be at high risk of bias. The other studies
did not report enough information to make a judgement.

We judged 13 studies to be at low risk of bias and four studies to
be at high risk of bias; the other studies did not report methods of
allocation concealment.

We  judged  all  objective  outcomes  to  be  at  low  risk  because  we
considered that these outcomes were unlikely to be influenced by
lack of blinding.

Blinding

Performance bias

We judged all subjective outcomes to be at high risk of bias because
blinding of participants and personnel was impossible for the types
of intervention studied.

Incomplete outcome data

We deemed 43 studies to be at low risk of bias and 14 studies to
be at high risk of bias. For the remaining studies, authors did not
report information about numbers of and reasons for dropouts, or
missing data for each group.

Psychosocial interventions for stimulant use disorder (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

18

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Selective reporting

We judged 11 studies to be at low risk of bias and five studies to be
at high risk of bias. Authors of the other studies reported insufficient
information to judge the risk of bias.

Other potential sources of bias

We did not consider any other potential sources of bias.

Effects of interventions

See:  Summary  of  findings  1  Summary  of  findings  table  -  Any
psychosocial intervention compared to no intervention for adults
with  stimulant  use  disorder;  Summary  of  findings  2  Summary
of  findings  table  -  Any  psychosocial  intervention  compared  to
treatment as usual (TAU) for adults with stimulant use disorder

Comparison 1. Any psychosocial intervention versus no
treatment

Primary outcomes

See Summary of findings 1.

Dropouts from treatment

Cochrane Database of Systematic Reviews

The  subgroup  analysis  according  to  percentages  of  participants
in  methadone  treatment  did  not  show  significant  differences
amongst groups (test for subgroup differences: Chi2 = 4.93, degrees
of freedom (df) 2 (P = 0.08); data not shown).

Stratified  analysis  by  intervention  type  showed  evidence  of  a
difference in favour of contingency management.

• CBT  versus  no  intervention:  little  to  no  difference  in  dropouts
from  treatment  (RR  0.89,  95%  CI  0.68  to  1.17;  8  studies,  851
participants).

• Contingency  management  versus  no  intervention:  results  in
favour of contingency management (RR 0.76, 95% CI 0.67 to 0.87;
16 studies, 2287 participants).

• Motivational  interviewing  versus  no  intervention:  little  to  no
difference  (RR  0.92,  95%  CI  0.66  to  1.29;  3  studies,  614
participants).

• 12-step facilitation versus no intervention: little to no difference

(RR 1.58, 95% CI 0.85 to 2.94; 1 study, 112 participants).

• Psychodynamic  therapy  versus  no  intervention:  little  to  no
difference  (RR  0.87,  95%  CI  0.72  to  1.04;  1  study,  185
participants).

Based  on  data  from  29  studies  involving  4049  participants,
compared  to  no  treatment,  psychosocial  interventions  reduce
the  risk  of  dropout  (risk  ratio  (RR)  0.82,  95%  confidence  interval
(CI)  0.74  to  0.91;  I2  =  27%;  high-certainty  evidence;  Analysis  1.1).

For the above comparisons, see Analysis 1.1.

A visual inspection of the funnel plot did not suggest the presence
of publication bias (Figure 4).

Figure 4.   Any psychosocial intervention versus no treatment; outcome: dropout from treatment

0

SE(log[RR])

0.5

1

1.5

2
0.1

0.2

0.5

1

2

5

Psychosocial interventions for stimulant use disorder (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

RR

10

19

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Point abstinence at end of treatment

Psychosocial  interventions  make  little  to  no  difference  to  point
abstinence  at  the  end  of  treatment,  when  compared  to  no
treatment,  based  on  data  from  12  studies  in  1293  participants
(RR  1.15,  95%  CI  0.94  to  1.41;  I2  =  45%;  high-certainty  evidence;
Analysis 1.2). The subgroup analysis according to the percentages
of  participants  in  methadone  treatment  did  not  show  significant
differences amongst groups (test for subgroup differences: Chi2 =
0.38, df 1 (P = 0.54); data not shown).

Stratified analysis by intervention type showed evidence of little to
no difference for all intervention types.

• CBT versus no intervention: RR 1.05, 95% CI 0.88 to 1.25; 4 studies,

454 participants.

Cochrane Database of Systematic Reviews

• Contingency management versus no intervention: RR 1.75, 95%

CI 0.92 to 3.34; 5 studies, 507 participants.

• 12-step facilitation versus no intervention: RR 0.84, 95% CI 0.48 to

1.46; 1 study, 112 participants.

• Psychodynamic therapy versus no intervention: RR 1.05, 95% CI

0.77 to 1.44; 1 study, 185 participants.

• CBT  plus  contingency  management  versus  no  intervention:  RR

2.08, 95% CI 0.57 to 7.55; 1 study, 35 participants.

For the above comparisons, see Analysis 1.2.

A visual inspection of the funnel plot did not suggest the presence
of publication bias (Figure 5).

Figure 5.   Any psychosocial intervention versus no treatment; outcome: point abstinence at the end of treatment

0

SE(log[RR])

0.5

1

1.5

2
0.1

0.2

0.5

1

2

5

RR

10

Point abstinence at longest follow-up

• CBT versus no intervention: RR 1.78, 95% CI 0.98 to 3.24; 4 studies,

Psychosocial  interventions  make  little  to  no  difference  to  point
abstinence  at  the  longest  follow  up  when  compared  to  placebo,
based  on  data  from  nine  studies  involving  1187  participants  (RR
1.22,  95%  CI  0.91  to  1.62;  I2  =  73%;  high-certainty  evidence;
Analysis  1.3).  The  subgroup  analysis  according  to  percentages
of  participants  in  methadone  treatment  did  not  show  significant
differences amongst groups (test for subgroup differences: Chi2 =
0.63, df 1 (P = 0.43); data not shown).

Stratified analysis by intervention type showed evidence of little to
no difference for all intervention types.

484 participants.

• Contingency management versus no intervention: RR 1.06, 95%

CI 0.28 to 3.98; 2 studies, 141 participants.

• Psychodynamic therapy versus no intervention: RR 0.95, 95% CI

0.72 to 1.27; 1 study, 185 participants.

• Motivational interviewing versus no intervention: RR 1.17, 95% CI

0.94 to 1.46; 1 study, 342 participants.

• CBT  plus  contingency  management  versus  no  intervention:  RR

1.15, 95% CI 0.41 to 3.28; 1 study, 35 participants.

For the above comparisons, see Analysis 1.3.

Psychosocial interventions for stimulant use disorder (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

20

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Continuous abstinence at end of treatment

• CBT versus no intervention: little to no difference (RR 1.30, 95%

Psychosocial  interventions  probably  increase  the  likelihood  of
continuous  abstinence  based  on  data  from  12  studies  involving
1770 participants (RR 1.89, 95% CI 1.20 to 2.97; I2 = 76%; moderate-
certainty evidence; Analysis 1.4). The subgroup analysis according
to  percentages  of  participants  in  methadone  treatment  did  not
show  significant  differences  amongst  groups  (test  for  subgroup
differences: Chi2 = 6.18, df 2 (P = 0.05); data not shown).

Stratified  analysis  by  intervention  type  showed  evidence  of  a
difference in favour of contingency management.

CI 0.51 to 3.34; 2 studies, 282 participants).

• Contingency  management  versus  no  intervention:  results  in
favour of contingency management (RR 2.51, 95% CI 1.43 to 4.43;
9 studies, 1303 participants).

• Psychodynamic  therapy  versus  no  intervention:  little  to  no
difference  (RR  0.68,  95%  CI  0.38  to  1.19;  1  study,  185
participants).

For the above comparisons, see Analysis 1.4.

A  visual  inspection  of  the  funnel  plot  did  show  asymmetry,
suggesting the presence of publication bias (Figure 6).

Figure 6.   Any psychosocial intervention versus no treatment; outcome: continuous abstinence at the of treatment

0

SE(log[RR])

0.5

1

1.5

2
0.1

0.2

0.5

1

2

5

RR

10

Continuous abstinence at longest follow-up

• Contingency management versus no intervention: RR 1.88, 95%

Psychosocial  interventions  may  make  little  to  no  difference  to
continuous  abstinence  at  the  longest  follow-up,  based  on  data
from  three  studies  in  266  participants  (RR  1.14,  95%  CI  0.85  to
1.54; I2 = 36%; low-certainty evidence; Analysis 1.5). The subgroup
analysis  according  to  percentages  of  participants  in  methadone
treatment  did  not  show  significant  differences  amongst  groups
(test for subgroup differences: Chi2 = 0.321, df 1 (P = 0.57); data not
show).

Stratified analysis by intervention type provided evidence of little
to no difference for all intervention types.

• CBT versus no intervention: RR 1.16, 95% CI 0.93 to 1.46; 1 study,

85 participants.

CI 0.33 to 10.61; 2 studies, 181 participants.

For the above comparisons, see Analysis 1.5.

Frequency of drug intake at end of treatment

Psychosocial  interventions  reduce  the  frequency  of  stimulant
intake at the end of treatment, based on data from nine studies in
1186 participants (SMD −0.35, 95% CI −0.51 to −0.18; I2 = 38%; high-
certainty evidence; Analysis 1.6). The subgroup analysis according
to  percentages  of  participants  in  methadone  treatment  did  not
show  significant  differences  amongst  groups  (test  for  subgroup
differences: Chi2 = 3.19, df 2 (P = 0.20); data not shown).

Psychosocial interventions for stimulant use disorder (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

21

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Stratified  analysis  by  intervention  type  showed  evidence  of  a
difference in favour of contingency management.

• CBT versus no intervention: little to no difference (SMD −0.49, 95%

• Motivational  interviewing  versus  no  intervention:  little  to  no
difference  (SMD  −0.15,  95%  CI  −0.37  to  0.06;  1  study,  342
participants).

CI −1.06 to 0.08; 3 studies, 133 participants).

For the above comparisons, see Analysis 1.6.

• Contingency  management  versus  no  intervention:  results  in
favour of contingency management (SMD −0.39, 95% CI −0.56 to
−0.22; 5 studies, 711 participants).

A visual inspection of the funnel plot did not suggest the presence
of publication bias (Figure 7).

Figure 7.   Any psychosocial intervention versus no treatment; outcome: frequency of drug intake at the end of
treatment

0

SE(SMD)

0.1

0.2

0.3

0.4

0.5

-1

-0.5

0

0.5

1

SMD

Longest period of abstinence at end of treatment

Psychosocial  interventions  increase  abstinence  at  the  end  of
treatment,  based  on  data  from  17  studies  in  2018  participants
(SMD 0.54, 95% CI 0.41 to 0.68; I2 = 48%; high-certainty evidence;
Analysis  1.7).  The  subgroup  analysis  according  to  percentages
of  participants  in  methadone  treatment  did  not  show  significant
differences amongst groups (test for subgroup differences: Chi2 =
0.39, df 2 (P = 0.82); data not shown).

Stratified  analysis  by  intervention  type  showed  a  difference
favouring CBT and contingency management.

• CBT versus no intervention: results in favour of CBT (SMD 0.59,

95% CI 0.23 to 0.94; I2 =62%; 5 studies, 440 participants).

• Contingency  management  versus  no  intervention:  results  in
favour of contingency management (SMD 0.54, 95% CI 0.39 to
0.69; I2 = 45%; 12 studies, 1678 participants).

For the above comparisons, see Analysis 1.7.

A visual inspection of the funnel plot did not suggest the presence
of publication bias (Figure 8).

Psychosocial interventions for stimulant use disorder (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

22

 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Figure 8.   Any psychosocial intervention versus no treatment; outcome: longest period of abstinence

0

SE(SMD)

0.2

0.4

0.6

0.8

1

-1

-0.5

0

0.5

1

SMD

Secondary outcomes

Craving

Compared  to  no  intervention,  psychosocial  interventions  reduce
craving, based on data from only three studies with 272 participants
(SMD −0.85, 95% CI −1.67 to −0.03; I2 = 85%; Analysis 1.8).

Stratified  analysis  by  intervention  type  showed  a  difference
favouring CBT.

• CBT  versus  no  treatment:  results  in  favour  of  CBT  (SMD  −1.63,

95% CI −2.47 to −0.79; 1 study, 30 participants).

• Contingency  management  versus  no  intervention:  little  to  no
difference  (SMD  −0.52,  95%  CI  −1.26  to  0.22;  2  studies,  242
participants).

For the above comparisons, see Analysis 1.8.

Severity of dependence

Compared  to  no 
intervention,  we  found  that  psychosocial
interventions  make  little  to  no  difference  to  the  severity  of
participants'  dependence,  based  on  data  from  four  studies
comparing  contingency  management  to  no  intervention  in  223
participants (SMD −0.83, 95% CI −1.96 to 0.30; I2 = 92%; Analysis 1.9).

For the above comparisons, see Analysis 1.9.

Depression

Compared  to  no 
intervention,  we  found  that  psychosocial
interventions make little to no difference to depression, based on
data from two studies with 78 participants (SMD −0.41, 95% CI −0.86
to 0.04; Analysis 1.10).

Stratified analysis by intervention type provided evidence of little to
no difference for both intervention types (i.e. CBT and contingency
management).

• CBT versus no intervention: SMD −0.28, 95% CI −0.90 to 0.34; 1

study, 41 participants.

• Contingency  management  versus  no  intervention:  SMD  −0.56,

95% CI −1.22 to 0.10; 1 study, 37 participants.

For the above comparisons, see Analysis 1.10.

Number of participants with at least one adverse event

Four  studies  assessed  this  outcome  (Marsden  2018;  Petry  2007;
Petry  2012b;  Petry  2018).  Marsden  2018  reported  that  five  of  16
participants in the psychosocial intervention group and one of 14 in
the no intervention group had at least one adverse event. The other
studies reported that no adverse events occurred.

Psychosocial interventions for stimulant use disorder (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

23

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Comparison 2. Any psychosocial intervention versus
treatment as usual (TAU)

Primary outcomes

See Summary of findings 2. We did not perform subgroup analyses
according  to  the  percentages  of  participants  in  methadone
treatment due to the paucity of studies.

Dropouts from treatment

Compared  to  TAU,  psychosocial  interventions  reduce  the  risk  of
dropout, based on data from nine studies involving 735 participants
(RR  0.79,  95%  CI  0.65  to  0.97;  I2  =  23%;  high-certainty  evidence;
Analysis 2.1).

Stratified  analysis  by  intervention  type  provided  evidence  of  a
difference favouring CBT.

• CBT versus TAU: results favour CBT (RR 0.76, 95% CI 0.61 to 0.95;

6 studies, 540 participants).

• Contingency management versus TAU: little to no difference (RR

0.74, 95% CI 0.49 to 1.13; 1 study, 82 participants).

Frequency of drug intake at end of treatment

Compared to TAU, psychosocial interventions probably make little
to no difference to the frequency of drug intake, based on data from
four studies with 479 participants (SMD −1.17, 95% CI −2.81 to 0.47;
I2 = 98%; moderate-certainty evidence; Analysis 2.5).

Stratified  analysis  by  intervention  type  provided  evidence  of  a
difference favouring CBT.

• CBT versus TAU: results favour CBT (SMD −4.76, 95% CI −5.47 to

−4.05; 1 study, 120 participants).

• Motivational interviewing versus TAU: little to no difference (SMD

−0.25, 95% CI −0.89 to 0.38; 1 study, 39 participants).

• Motivational  interviewing  plus  CBT  versus  TAU:  little  to  no
difference  (SMD  0.07,  95%  CI  −0.20  to  0.34;  1  study,  210
participants).

• Interpersonal  therapy  versus  TAU:  little  to  no  difference  (SMD

0.15, 95% CI −0.22 to 0.53; 1 study, 110 participants).

For the above comparisons, see Analysis 2.5.

• Motivational interviewing versus TAU: little to no difference (RR

Longest period of abstinence

1.46, 95% CI 0.73 to 2.91; 2 studies, 113 participants).

For the above comparisons, see Analysis 2.1.

Point abstinence at end of treatment

Psychosocial  interventions  may  make  little  to  no  difference
compared to TAU in point abstinence at end of treatment, based
on data from only one study comparing CBT to TAU (RR 1.67, 95%
CI  0.64  to  4.31;  1  study,  128  participants;  low-certainty  evidence;
Analysis 2.2).

Point abstinence at longest follow-up

We  are  uncertain  whether  psychosocial  interventions  make  any
difference  compared  to  TAU  in  point  abstinence  at  the  longest
follow-up as the certainty of the evidence was very low (RR 1.31,
95% CI 0.86 to 1.99; I2 = 0%; 2 studies, 124 participants; Analysis 2.3).

Stratified analysis by intervention type provided evidence of little to
no difference for both intervention types (i.e. CBT and motivational
interviewing).

• CBT  versus  TAU:  RR  1.65,  95%  CI  0.86  to  3.18;  1  study,  82

participants.

Psychosocial  interventions  may  make  little  to  no  difference
compared to TAU in the longest period of abstinence at the end of
treatment, based on data from only one study comparing CBT to
TAU (SMD −0.16, 95% CI −0.54 to 0.21; 1 study, 110 participants; low-
certainty evidence; Analysis 2.6).

Secondary outcomes

Craving

We found little to no differences in craving between psychosocial
interventions and TAU, based on data from one study comparing
motivational interviewing to TAU (SMD −0.18, 95% CI −0.81 to 0.46;
1 study, 39 participants; Analysis 2.7).

Severity of dependence

Compared  to  no 
intervention,  we  found  that  psychosocial
interventions  make  little  to  no  difference  to  the  severity  of
participants' dependence, based on data from six studies with 509
participants (SMD −0.42, 95% CI −1.15 to 0.32; I2 = 93%; Analysis 2.8).

Stratified analysis by intervention type provided evidence of little
to no difference for all intervention types.

• Motivational interviewing versus TAU: RR 1.11, 95% CI 0.64 to 1.92;

• CBT versus TAU:SMD  −0.89,  95%  CI  −2.10  to  0.32;  3studies,  312

1 study, 42 participants.

participants.

For the above comparisons, see Analysis 2.3.

Continuous abstinence at end of treatment

Psychosocial  interventions  may  make  little  to  no  difference
compared to TAU in continuous abstinence at the end of treatment,
based  on  data  from  only  one  study  comparing  CBT  to  TAU  (RR
1.18,  95%  CI  0.92  to  1.53;  1  study,  128  participants;  low-certainty
evidence; Analysis 2.4).

Continuous abstinence at longest follow-up

None  of  the  studies  included  in  this  comparison  assessed  this
outcome.

• Motivational interviewing versus TAU: SMD 0.02, 95% CI −0.63 to

0.67; 2 studies, 79 participants.

• Contingency management versus TAU: SMD 0.18, 95% CI −0.24 to

0.60; 1 study, 118 participants.

For the above comparisons, see Analysis 2.8.

Depression

We found no differences between psychosocial interventions and
TAU, based on data from one study on motivational interviewing
with 39 participants (SMD −0.16, 95% CI −0.80 to 0.47; Analysis 2.9).

Number of participants with at least one adverse event

One study reported no adverse events (Sorsdahl 2021).

Psychosocial interventions for stimulant use disorder (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

24

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Comparison 3. Contingency management (reinforcement
related to abstinence) versus non-contingent management
(reinforcement not related to abstinence)

Primary outcomes

Dropouts from treatment

We  did  not  perform  subgroup  analyses  according  to  percentages
of  participants  in  methadone  treatment  due  to  the  paucity  of
studies. None of the studies in this comparison reported on three
of the review's primary outcomes (i.e. point abstinence at end of
treatment, continuous abstinence at longest follow-up, and longest
period  of  abstinence  at  end  of  treatment)  and  three  secondary
outcomes (i.e. craving, depression, and number of participants with
at least one adverse event).

Primary outcomes

Dropouts from treatment

little 

found 

We 
to  no  differences  between  contingency
management  and  non-contingent  management  for  the  risk  of
dropout, based on data from six studies involving 704 participants
(RR 0.86, 95% CI 0.56 to 1.32; I2 = 78%; Analysis 3.1).

Point abstinence at longest follow-up

We found no differences in the risk of dropouts between CBT and
other interventions (see Analysis 4.1).

• CBT versus interpersonal therapy:RR 0.54, 95% CI 0.27 to 1.08; 1

study, 42 participants.

• CBT versus psychodynamic therapy: RR 0.99, 95% CI 0.83 to 1.18;

1 study, 243 participants.

• CBT  versus  12-step  facilitation:  RR  0.87,  95%  CI  0.62  to  1.24;  1

study, 145 participants.

• CBT versus acceptance and commitment therapy (ACT): RR 0.94,

95% CI 0.73 to 1.2; 1 study, 104 participants.

Point abstinence at end of treatment

We found no differences in point abstinence at the end of treatment
between CBT and other interventions (see Analysis 4.2).

• CBT versus interpersonal therapy:RR 1.71, 95% CI 0.84 to 3.48; 1

study, 42 participants.

Compared  to  non-contingency  management,  we  found  that
contingency  management  increased  the  number  of  participants
with point abstinence at the longest follow-up, based on data from
two studies in 246 participants (RR 1.43, 95% CI 1.00 to 2.04; I2 =
30%; Analysis 3.2).

• CBT versus psychodynamic therapy: RR 0.87, 95% CI 0.66 to 1.15;

1 study, 243 participants.

• CBT  versus  contingency  management:  RR  0.66,  95%  CI  0.38  to

1.16; 1 study, 55 participants.

• CBT  versus  ACT:  RR  1.29,  95%  CI  0.47  to  3.51;  1  study,  26

Continuous abstinence at end of treatment

Compared  to  non-contingency  management,  we  found  that
contingency  management  increased  the  number  of  participants
with continuous abstinence at the end of treatment, based on data
from two studies in 96 participants (RR 8.11, 95% CI 1.62 to 40.55;
I2 = 0%; Analysis 3.3).

Frequency of drug intake at longest follow-up

Compared  to  non-contingency  management,  we  found  that
contingency  management  reduced  the  frequency  of  drug  intake,
based on data from one study in 176 participants (SMD −0.67, 95%
CI −0.97 to −0.36; Analysis 3.4).

Secondary outcomes

Severity of dependence

little 

found 

We 
to  no  differences  between  contingency
management  and  non-contingent  management,based  on  data
from one study in 70 participants (SMD 0.16, 95% CI −0.30 to 0.63;
Analysis 3.5).

Comparison 4. Single psychosocial intervention versus
alternative psychosocial intervention: CBT versus another
intervention

We  did  not  perform  subgroup  analyses  for  these  comparisons
according to percentages of participants in methadone treatment
due to the paucity of studies. None of the studies in this comparison
reported on two of the review's secondary outcomes (i.e. craving
and number of participants with at least one adverse event).

participants.

Point abstinence at longest follow-up

We found no differences in point abstinence at the longest follow-
up between CBT and other interventions (see Analysis 4.3).

• CBT versus psychodynamic therapy: RR 1.04, 95% CI 0.82 to 1.32;

1 study, 243 participants.

• CBT  versus  contingency  management:  RR  1.17,  95%  CI  0.73  to

1.87; 1 study, 55 participants.

• CBT  versus  ACT:  RR  0.73,  95%  CI  0.26  to  2.07;  1  study,  19

participants.

Continuous abstinence at end of treatment

We  found  no  differences  in  continuous  abstinence  at  the  end  of
treatment between CBT and other interventions (see Analysis 4.4).

• CBT versus interpersonal therapy: RR 2.25, 95% CI 0.82 to 6.18; 1

study, 42 participants.

• CBT versus 12-step facilitation: RR 1.23, 95% CI 0.89 to 1.70; I2 =

0%; 2 studies, 225 participants.

Continuous abstinence at longest follow-up

Compared  to  12-step  facilitation,  we  found  that  CBT  increased
the number of participants with continuous abstinence at longest
follow  up  (RR  1.97,  95%  CI  1.00  to  3.86;  1  study,  51  participants;
Analysis 4.5).

Frequency of drug intake at longest follow-up

We  found  no  differences  in  the  frequency  of  drug  intake  at  the
longest  follow-up  between  CBT  and  contingency  management
(SMD −0.09, 95% CI −0.53 to 0.34; 1 study, 82 participants; Analysis
4.6).

Psychosocial interventions for stimulant use disorder (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

25

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Longest period of abstinence

Compared  to  CBT,  we  found  that  contingency  management
increased the longest period of abstinence, based on one study with
82 participants (SMD −0.79, 95% CI −1.24 to −0.34; Analysis 4.7).

Secondary outcomes

Severity of dependence

We found no differences in the severity of participants' dependence
between CBT and ACT (SMD −0.02, 95% CI −0.40 to 0.37; 1 study, 104
participants; Analysis 4.8).

Depression

We found no differences in participants' depression between CBT
and ACT (SMD 0.18, 95% CI −0.21 to 0.56; 1 study, 104 participants).

Sensitivity analysis

We did not perform sensitivity analysis by excluding studies at high
risk  of  selection,  detection,  or  attrition  bias,  because  our  visual
inspections of the forest plots indicated that studies at high risk of
bias were few and had a low weight in the overall estimates.

D I S C U S S I O N

Summary of main results

We 
included  64  trials  (8241  participants)  that  considered
cognitive  behavioural  therapy  (CBT),  contingency  management,
motivational interviewing, a combination of CBT and contingency
management, a combination of CBT and motivational interviewing,
interpersonal  therapy,  psychodynamic  therapy,  and  12-step
facilitation.  Most  of  the  studies  either  compared  psychosocial
intervention,  or  compared  psychosocial
treatments  to  no 
treatment  plus  treatment  as  usual 
(TAU)  to  TAU  alone.
The  psychosocial  intervention  most  studied  was  contingency
management, followed by CBT.

When  compared  to  no  intervention,  we  found  that  psychosocial
treatments  reduce  participants'  risk  of 
leaving  the  study
prematurely, increase the longest period of abstinence, and reduce
the  frequency  of  drug  intake  (high-certainty  evidence).  We  also
found  that  they  probably  increase  continuous  abstinence  at  the
end  of  treatment  (moderate-certainty  evidence),  but  that  these
results  may  not  be  maintained  at  the  longest  follow-up  (low-
certainty evidence). Results in the subgroup analyses according to
percentages of participants in methadone treatment did not show
significant  differences  in  any  of  the  primary  outcomes.  It  should
be  noted  that  most  of  the  studies  in  this  comparison  assessed
the  efficacy  of  a  specific  psychosocial  treatment  added  to  TAU
or to another specific psychosocial or pharmacological treatment
received  by  both  groups.  Thus,  in  this  comparison,  many  of  the
control  participants  were  not  really  untreated.  Receiving  some
amount of treatment is not the same as receiving no intervention.
Thus,  it  is  possible  that  the  overall  effect  of  an  experimental
psychosocial  treatment  is  smaller  when  the  intervention  is  given
as  an  add-on  to  TAU  or  to  another  intervention  than  when  it
is  given  to  participants  not  receiving  any  intervention.  For  this
reason,  the  effect  of  the  psychosocial  interventions  could  be  of
a  smaller  magnitude  when  given  as  an  add-on,  underestimating
the true effect of psychosocial interventions. The same is not true
for motivational interviewing, which was almost always compared
with informative handouts only.

Cochrane Database of Systematic Reviews

When  compared  to  TAU,  we  found  that  psychosocial  treatments
reduce  participants'  risk  of  leaving  the  study  prematurely  (high-
certainty evidence), but that they may make little to no difference
in continuous abstinence at the end of treatment and to the longest
period of abstinence (low-certainty evidence). They also probably
make little to no difference in the frequency of drug intake at the
end of treatment (moderate-certainty evidence).

Considering different psychosocial interventions, the most studied
and effective approach when compared to no intervention or TAU
was  contingency  management.  However,  the  other  approaches
were analysed only by a few small studies, so we cannot rule out
the possibility that the results were imprecise due to small sample
sizes.

We  grouped  the  studies  that  compared  two  different  types  of
psychosocial approaches to each other into two comparisons: (1)
contingency  management  (reinforcement  related  to  abstinence)
versus not contingency management (reinforcements not related
to  abstinence);  and  (2)  single  psychosocial  intervention  versus
an  alternative  psychosocial  intervention.  In  the  first  comparison,
reinforcement  related  to  abstinence  (contingency  management)
was  found  to  be  effective  in  reducing  psychostimulant  use
compared  to  reinforcement  not  contingent  on  abstinence  (not
contingency  management).  In  the  second  comparison,  CBT  was
compared  to  different  psychosocial  approaches,  and  we  found
differences  in  only  two  outcomes,  both  based  on  single-study
comparisons.

Overall completeness and applicability of evidence

There 
is  no  widely  accepted  definition  of  psychosocial
interventions  (Committee  2015).  In  this  update,  we  considered
in  the  previous
only  the 
version.  Accordingly,  our  conclusions  cannot  be  applied  to  other
interventions not assessed in this review.

interventions  that  were 

included 

Contingency  management  is  the  most  studied  treatment  and  –
perhaps  for  this  reason  –  the  one  with  the  greatest  evidence  of
efficacy.  It  is  a  widely  used  treatment  in  the  USA  but  is  difficult
to implement in some European countries, especially those with a
public national health service, mainly for organisational and ethical
reasons.

Most studies took place in the USA. This geographic concentration
could  limit  the  generalisability  of  the  results  as  the  effects  of
psychosocial treatments could be influenced by the social context
and ethnicity.

We  found  few  studies  directly  comparing  two  different  types  of
psychosocial  approaches;  the  comparisons  were  heterogeneous;
and the sample sizes were small. Therefore, our results cannot be
considered conclusive.

One criticism by frontline healthcare workers might be that people
under  the  acute  effect  of  stimulants  may  not  be  in  a  position  to
sustain any conversation, thus limiting the (potential) effectiveness
of  psychosocial  interventions.  Nevertheless,  the  results  of  the
present systematic review show that psychosocial treatments can
help  people  with  stimulant  use  disorder  by  reducing  the  risk  of
dropout. In other words, they can help people with stimulant use
disorder while they are not under the acute effect of these drugs.

Psychosocial interventions for stimulant use disorder (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

26

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Finally,  we  did  not  assess  treatment  fidelity  in  this  review.
Therefore, it is possible that the small or null effects observed in
some outcomes could be ascribed to the fact that the psychosocial
interventions were inadequately delivered.

Certainty of the evidence

The studies could not blind participants and personnel delivering
the intervention; therefore, they are all at high risk of performance
bias. However, all the primary outcomes concerning drug use were
verified  by  urine  analysis  in  most  of  the  studies.  An  important
limitation of the studies was the poor reporting on methods, which
limited the assessment of risk of bias. We judged about 75% of the
studies to have an unclear risk of bias for allocation concealment
and  blinding  of  outcome  assessor.  In  addition,  for  about  75%  of
the  studies,  the  protocol  was  not  available.  Another  important
limitation is the imprecision of the estimates in the comparison of
any psychosocial intervention versus TAU.

Potential biases in the review process

We  assessed  the  risk  of  publication  bias  by  inspecting  the
funnel  plots  for  five  primary  outcomes  in  the  comparison  of  any
psychosocial  intervention  to  no  intervention  only.  In  the  other
comparisons,  there  were  too  few  studies  to  make  the  funnel
plot informative. We found evidence suggesting the possibility of
publication bias only for the outcome of continuous abstinence at
the end of treatment.

We  searched  several  databases  and  performed  a  systematic
search  of  ongoing  clinical  trials  and  unpublished  trials  on  the
websites ClinicalTrials.gov (clinicaltrials.gov), and the World Health
Organization (WHO) International Clinical Trials Registry Platform
(ICTRP) (apps.who.int/trialsearch/). Therefore, we believe the risk
of having missed negative studies is small.

Agreements and disagreements with other studies or
reviews

Results  from  the  present  review  expand  previous  findings
supporting the use of psychosocial interventions for the treatment
of people with stimulant use disorder. National Institute for Health
and  Care  Excellence  (NICE)  guidelines  recommend  considering
psychosocial interventions, such as CBT, psychodynamic therapy,
and contingency management (NICE 2007). A review in individuals
with  substance  use  disorder  highlighted  the  effectiveness  of
contingency  management  in  people  with  cocaine  use  disorder
(Secades Villa 2015).

Two systematic reviews published in 2021 assessed the efficacy of
psychosocial interventions for the treatment of adults with cocaine
use  disorder  and  amphetamine-type  stimulant  use  disorder,
respectively  (Bentzley  2021;  Tran  2021).  The  Bentzley  2021
review considered psychotherapy, contingency management, and
pharmacological treatments. The primary outcome of the review
was the reduction of urinalysis-confirmed cocaine use at the end of
the treatment compared to baseline. All types of psychotherapies
were  considered  together,  apart  from  contingency  management,
which  was  analysed  separately.  Only  contingency  management
programmes  were  found  to  be  associated  with  a  significant
increase  in  the  likelihood  of  negative  urine  analyses  at  the
end  of  treatment  compared  to  baseline.  However,  the  review’s
authors obtained this result by performing an intra-group analysis
comparing urinalysis results at baseline and at the end of treatment

Cochrane Database of Systematic Reviews

within  each  treatment  arm,  including  placebo,  and  not  across
groups.  Furthermore,  the  authors  did  not  assess  the  risk  of  bias
of  the  included  studies  and  included  any  clinical  trials,  not  only
RCTs.  Nevertheless,  their  finding  of  a  positive  effect  induced  by
contingency management in increasing the likelihood of negative
urine  analyses  for  cocaine  use  is  in  agreement  with  our  finding
that contingency management reduces the frequency of stimulant
intake.

The  Tran  2021  review,  an  overview  of  systematic  reviews  using
a  meta-analytic  approach,  found  that  psychosocial  interventions
decreased the proportion of participants who used amphetamine-
type  stimulants  at  the  end  of  treatment  compared  to  no
treatment  or  TAU.  In  this  analysis,  psychosocial  interventions
comprised  contingency  management,  CBT,  and  combinations
of  different  psychosocial  therapies.  This  review  also  found
that  psychosocial  interventions  decreased  the  number  of  days
using  amphetamine-type  stimulants  compared  to  no  treatment
or  TAU,  in  the  month  following  the  end  of  treatment.  In
this  analysis,  the  psychosocial  interventions  included  different
combinations  compared  to  CBT  and  CBT  compared  to  no
treatment.  Globally,  these  findings  are  in  agreement  with  our
finding  that  psychosocial  interventions  increase  the  continuous
abstinence at the end of treatment. Finally, this review found that
psychosocial  interventions  increase  compliance  with  treatment.
In  this  analysis,  contingency  management  was  compared  to  no
contingency  management  and  CBT  to  TAU.  This  finding  is  in
agreement with our finding that psychosocial interventions reduce
the  risk  of  leaving  treatment  before  its  end.  However,  in  our
systematic  review,  we  included  participants  with  stimulant  use
disorder by any psychostimulants, and we compared the efficacy
of  psychosocial  interventions  to  no  treatment  and  TAU  in  two
different analyses.

A  network  meta-analysis  comparing  the  efficacy  of  different
psychosocial  treatments  for  cocaine  and  amphetamine  use
disorders  published  in  2018  concluded  that  the  most  effective
approach, when compared to TAU, was contingency management
combined  with  a  community  reinforcement  approach 
(De
Crescenzo  2018).  A  2023  meta-review  evaluated  the  efficacy
of  psychosocial  therapies  for  the  treatment  of  substance  use
disorders, and concluded that contingency management and CBT
show  small  effects  for  the  treatment  of  stimulant  use  disorder
(Dellazizzo 2023). These results are in agreement with the results
derived from our analyses, stratified by type of treatment, showing
that contingency management appears to be the most promising
approach.

A U T H O R S '   C O N C L U S I O N S

Implications for practice

This  review's  findings  indicate  that  psychosocial  treatments  can
help  people  with  stimulant  use  disorder  by  reducing  dropout
rates.  This  conclusion  is  based  on  high-certainty  evidence  from
comparisons of psychosocial interventions with both no treatment
and TAU. This is an important finding because many people with
stimulant  use  disorders  leave  treatment  prematurely.  Stimulant
use  disorders  are  chronic,  lifelong,  relapsing  mental  disorders,
which require substantial therapeutic efforts to achieve abstinence.
For  those  who  are  not  yet  able  to  achieve  complete  abstinence,
retention  in  treatment  may  help  to  reduce  the  risks  associated
with stimulant use. In addition, psychosocial interventions reduce

Psychosocial interventions for stimulant use disorder (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

27

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

stimulant use compared to no treatment, but they may make little
to no difference to stimulant use when compared to TAU.

A C K N O W L E D G E M E N T S

The  most  studied  and  promising  psychosocial  approach 
is
contingency  management.  Relatively  few  studies  explored  the
other  approaches,  so  we  cannot  rule  out  the  possibility  that  the
results were imprecise due to small sample sizes.

Implications for research

This field would benefit from future research that:

• compares  two  different  types  of  psychosocial  intervention,  as
few existing studies do this, the comparisons are heterogeneous,
and the samples size small;

• focuses  on  psychosocial  interventions  besides  contingency

management, which is the most studied approach;

• is  conducted  outside  the  USA  to  explore  the  applicability  of

these results, derived mainly from American studies;

• explores  the  effect  of  the  different  psychosocial  approaches
in  key  subgroups:  people  of  all  genders;  consumers  of  single
stimulants; people with additional diagnoses of other substance
use disorders; and those with comorbid psychiatric disorders.

In  future  updates  of  this  review,  we  will  consider  expanding  the
review’s scope in the following ways:

• including  other  psychosocial  treatments  used 

in  clinical

practice;

• analysing factors that potentially influence treatment efficacy;

and

• considering the question of tailoring treatment to the needs of

different subgroups of people who use stimulants.

We want to thank Zuzana Mitrova, the trial search co-ordinator, for
her help in performing the bibliographic searches and retrieving the
articles for the review.

Editorial and peer-reviewer contributions

Cochrane  Drugs  and  Alcohol  supported  the  authors  in  the
development of this review update.

The  following  people  conducted  the  editorial  process  for  this
article.

• Sign-off  Editor  (provided  editorial  guidance  to  authors,  final
editorial decision): Marica Ferri, MSc, PhD, European Monitoring
Centre for Drugs and Drug Addiction (EMCDDA), Praça Europa,
Lisbon, Portugal

• Managing  Editor  (selected  peer  reviewers,  collated  peer-
reviewer  comments):  Zuzana  Mitrova,  Cochrane  Drugs  and
Alcohol

• Copy  Editor  (copy  editing  and  production):  Faith  Armitage,

Cochrane Central Production Service

• Peer  reviewers  (provided  comments  and  recommended  an
editorial decision): Dr Alison K. Beck, Clinical Psychologist and
Postdoctoral  Research  Fellow  School  of  Psychology  Faculty
of  the  Arts,  Social  Sciences  and  Humanities  University  of
Wollongong, NSW, Australia (clinical/content review); Takayuki
Harada,  Faculty  of  Human  Sciences,  University  of  Tsukuba,
Tokyo, Japan (clinical/content review)

Psychosocial interventions for stimulant use disorder (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

28

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

References to studies included in this review

Carroll 1998 {published data only}

R E F E R E N C E S

Alammehrjerdi 2019 {published data only}

Alammehrjerdi Z, Briggs NE, Biglarian A, Mokri A, Dolan K.
A randomized controlled trial of brief cognitive behavioral
therapy for regular methamphetamine use in methadone
treatment. Journal of Psychoactive Drugs 2019;51(3):280-9.

IRCT2015091424012N1. The effects of cognitive-behavioral
therapy on methamphetamine use among women in
methadone treatment in Tehran. en.search.irct.ir/view/25615 8
March 2016.

Baker 2001 {published data only}

*  Baker A, Boggs TG, Lewin TJ. Randomized controlled trial of
brief cognitive-behavioural interventions among regular users
of amphetamine. Addiction 2001;96(9):1279-87.

Baker 2005 {published data only}

ACTRN12611000355976. Cognitive behavioural therapy for the
reduction of methamphetamine use among people who are
regular users of methamphetamines. www.anzctr.org.au/Trial/
Registration/TrialReview.aspx?id=336758&isReview=true (first
received 9 November 2015).

Baker A, Lee NK, Claire M, Lewin TJ, Grant T, Pohlman S,
et al. Brief cognitive behavioural interventions for regular
amphetamine users: a step in the right direction. Addiction
2005;100(3):367–78.

Blanken 2016 {published data only}

Blanken P, Hendriks VM, Huijsman IA, van Ree JM, van den
Brink W. Efficacy of cocaine contingency management in
heroin-assisted treatment: results of a randomized controlled
trial. Drugs and Alcohol Dependence 2016;164:55-63.

Carroll 1991 {published data only}

*  Carrol KM, Rounsaville BJ, Gawin FH. A comparative trial
of psychotherapies for ambulatory cocaine abusers: relapse
prevention and interpersonal psychotherapy. American Journal
of Drug and Alcohol Abuse 1991;17(3):229-47.

Carroll 1994 {published data only}

Carrol KM, Nich C, Rounsaville BJ. Differential symptom
reduction in depressed cocaine abusers treated with
psychotherapy and pharmacotherapy. The Journal of Nervous
and Mental Disease 1995;183(4):251-9.

*  Carroll KM, Rounsaville BJ, Gordon LT, Nich C, Jatlow P,
Bisighini RM, et al. Psychotherapy and pharmacotherapy for
ambulatory cocaine abusers. Archives of General Psychiatry
1994;51(3):177-87.

Carroll KM, Rounsaville BJ, Nich C, Gordon LT, Wirtz PW,
Gawin F, et al. One-year follow-up of psychotherapy and
pharmacotherapy for cocaine dependence: delayed emergence
of psychotherapy effects. Archives of General Psychiatry
1994;51(12):989-97.

*  Carroll KM, Nich C, Ball SA, McCance E, Frankforter TL,
Rounsaville BJ. One-year follow-up of disulphiram and
psychotherapy for cocaine-alcohol users: sustained effects of
treatment. Addiction 2000;95(9):1335-49.

Carroll KM, Nich C, Ball SA, McCance E, Rounsavile BJ.
Treatment of cocaine and alcohol dependence with
psychotherapy and disulphiram. Addiction 1998;93(5):713-28.

Carroll 2004 {published data only}

Carroll KM, Fenton LR, Ball SA, Nich C, Frankforter TL,
Shi J, et al. Efficacy of disulfiram and cognitive behavior
therapy in cocaine-dependent outpatients: a randomized
placebo-controlled trial. Archives of General Psychiatry
2004;61(3):264-72.

Carroll 2012 {published data only}

Carroll KM, Nich C, Shi JM, Eagan D, Ball SA. Efficacy of
disulfiram and twelve step facilitation in cocaine-dependent
individuals maintained on methadone: a randomized
placebo-controlled trial. Drug and Alcohol Dependence
2012;126(1-2):224-31.

Carroll 2014 {published data only}

Carroll KM, Ball SA, Martino S, Nich C, Babuscio TA, Nuro KF, et
al. Computer-assisted delivery of cognitive-behavioral therapy
for addiction: A randomized trial of CBT4CBT. American Journal
of Psychiatry 2008;165(7):881-8.

Carroll KM, Ball SA, Martino S, Nich C, Babuscio TA,
Rounsaville BJ. Enduring effects of a computer-assisted
training program for cognitive behavioral therapy: a 6-
month follow-up of CBT4CBT. Drug and Alcohol Dependence
2009;100(1-2):178-81.

*  Carroll KM, Kiluk BD, Nich C, Gordon MA, Portnoy GA,
Marino DR, et al. Computer-assisted delivery of cognitive-
behavioral therapy: efficacy and durability of CBT4CBT among
cocaine-dependent individuals maintained on methadone. The
American Journal of Psychiatry 2014;171(4):436-44.

Kiluk BD, Serafini K, Frankforter T, Nich C, Carroll KM. Only
connect: the working alliance in computer-based cognitive
behavioral therapy. Behaviour Research and Therapy
2014;63:139-46.

Carroll 2016 {published data only}

Carroll KM, Nich C, Petry NM, Eagan DA, Shi JM, Ball SA. A
randomized factorial trial of disulfiram and contingency
management to enhance cognitive behavioral therapy
for cocaine dependence. Drug and Alcohol Dependence
2016;160:135-42.

Carroll 2018 {published data only}

Carroll KM, Nich C, DeVito EE, Shi JM, Sofuoglu M. Galantamine
and computerized cognitive behavioral therapy for cocaine
dependence: a randomized clinical trial. Journal of Clinical
Psychiatry 2018;79(1):17m11669.

Psychosocial interventions for stimulant use disorder (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

29

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Crits-Christoph 1999 arm 1 {published data only}

Garcia-Fernandez 2011 {published data only}

Barber JP, Foltz C, Crits-Christoph P, Chittams J. Therapists'
adherence and competence and treatment discrimination in
the NIDA Collaborative Cocaine Treatment Study. Journal of
Clinical Psychology 2004;60(1):29-41.

*  Crits-Christoph P, Siqueland L, Blaine J, Frank A, Luborsky L,
Onken LS, et al. Psychosocial treatments for cocaine
dependence: National Institute of Drug Abuse Collaborative
Cocaine Treatment Study. Archives of General Psychiatry
1999;56(6):493-502.

Crits-Christoph P, Siqueland L, Blaine J, Frank A, Luborsky L,
Onken LS, et al. The national institute on drug abuse
collaborative cocaine treatment study. Rationale and methods.
Archives of General Psychiatry 1997;54(8):721-6.

Najavits LM, Harned MS, Gallop RJ, Butler SF, Barber JP,
Thase ME, et al. Six-month treatment outcomes of cocaine-
dependent patients with and without PTSD in a multisite
national trial. Journal of Studies on Alcohol and Drugs
2007;68(3):353-61.

Siqueland L, Crits-Christoph P, Frank A, Daley D, Weiss R,
Chittams J, et al. Predictors of dropout from psychosocial
treatment of cocaine dependence. Drug and Alcohol
Dependence 1998;52(1):1-13.

Weiss RD, Griffin ML, Gallop RJ, Najavits LM, Frank A, Crits-
Christoph P, et al. The effect of 12-step self-help group
attendance and participation on drug use outcomes among
cocaine-dependent patients. Drug and Alcohol Dependence
2005;77(2):177-84.

Worley M, Gallop R, Gibbons MB, Ring-Kurtz S, Present J,
Weiss RD, et al. Additional treatment services in a cocaine
treatment study: level of services obtained and impact on
outcome. American Journal on Addictions/American Academy of
Psychiatrists in Alcoholism and Addictions 2008;17(3):209-17.

Crits-Christoph 1999 arm 2 {published data only}

Crits-Christoph P, Siqueland L, Blaine J, Frank A, Luborsky L,
Onken LS, et al. Psychosocial treatments for cocaine
dependence: National Institute of Drug Abuse Collaborative
Cocaine Treatment Study. Archives of General Psychiatry
1999;56(6):493-502.

Dursteler-MacFarland 2013 {published data only}

Dursteler-MacFarland KM, Farronato NS, Strasser J, Boss J,
Kuntze MF, Petitjean SA, et al. A randomized, controlled, pilot
trial of methylphenidate and cognitive-behavioral group
therapy for cocaine dependence in heroin prescription. Journal
of Clinical Pharmacology 2013;33(1):104-8.

Festinger 2014 {published data only}

Festinger DS, Dugosh KL, Kirby KC, Seymour BL. Contingency
management for cocaine treatment: cash vs. vouchers. Journal
of Substance Abuse Treatment 2014;47(2):168-74.

NCT01366716. Contingency management for cocaine
dependence: cash versus vouchers. clinicaltrials.gov/show/
NCT01366716 (first received 6 June 2011).

Garcia-Fernandez G, Secades-Villa R, Garcia-Rodriguez O,
Alvarez-Lopez H, Fernandez-Hermida JR, Fernandez-
Artamendi S, et al. Long-term benefits of adding incentives
to the community reinforcement approach for cocaine
dependence. European Addiction Research 2011;17(3):139-45.

*  García-Fernández G, Secades-Villa R, García-Rodríguez O,
Sánchez-Hervás E, Fernández-Hermida JR, Higgins ST. Adding
voucher-based incentives to community reinforcement
approach improves outcomes during treatment for
cocaine dependence. The American Journal on Addictions
2011;20(5):456-61.

Garcia-Rodriguez 2007 {published data only}

Garcia-Rodriguez O, Secades-Villa R, Alvarez Rodriguez H, Rio
Rodriguez A, Fernandez-Hermida JR, Carballo JL, et al. [Effect of
incentives on retention in an outpatient treatment for cocaine
addicts] [Efecto de los incentivos sobre la retención en un
tratamiento ambulatorio para adictos a la cocaína]. Psicothema
2007;19(1):134-9.

Garcia-Rodriguez O, Secades-Villa R, Higgins ST, Fernandez-
Hermida JR, Carballo JL, Errasti Perez JM, et al. Effects of
voucher-based intervention on abstinence and retention in
an outpatient treatment for cocaine addiction: a randomized
controlled trial. Experimental and Clinical Psychopharmacology
2009;17(3):131-8.

Secades-Villa R, Garcia-Rodriguez O, Higgins ST, Fernandez-
Hermida JR, Carballo JL. Community reinforcement approach
plus vouchers for cocaine dependence in a community setting
in Spain: six-month outcomes. Journal of Substance Abuse
Treatment 2008;34(2):202-7.

Ghitza 2007 {published data only}

Ghitza UE, Epstein DH, Preston KL. Contingency management
reduces injection-related HIV risk behaviors in heroin
and cocaine using outpatients. Addictive Behaviors
2008;33(4):593-604.

Ghitza UE, Epstein DH, Schmittner J, Vahabzadeh M, Lin JL,
Preston KL. Effect of reinforcement probability and prize
size on cocaine and heroin abstinence in prize-based
contingency management. Journal of Applied Behavior Analysis
2008;41(4):539-49.

*  Ghitza UE, Epstein DH, Schmittner J, Vahabzadeh M, Lin JL,
Preston KL. Randomized trial of prize-based reinforcement
density for simultaneous abstinence from cocaine and heroin.
Journal of Consulting and Clinical Psychology 2007;75(5):765-74.

Hagedorn 2013 {published data only}

Hagedorn HJ, Noorbaloochi S, Simon AB, Bangerter A,
Stitzer ML, Stetler CB, et al. Rewarding early abstinence in
Veterans Health Administration addiction clinics. Journal of
Substance Abuse treatment 2013;45(1):109-17.

Higgins 1993 {published data only}

Higgins ST, Budney AJ, Bickel WK, Badger GJ, Foerg FE,
Ogden D. Outpatient behavioral treatment for cocaine

Psychosocial interventions for stimulant use disorder (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

30

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

dependence one-year outcome. Experimental and Clinical
Psychopharmacology 1995;3(2):205-12.

*  Higgins ST, Budney AJ, Bickel WK, Hughes JR, Foerg FE,
Badger GJ. Achieving cocaine abstinence with a behavioral
approach. American Journal of Psychiatry 1993;150(5):763-9.

Higgins 1994 {published data only}

Higgins ST, Budney AJ, Bickel WK, Badger GJ, Foerg FE,
Ogden D. Outpatient behavioral treatment for cocaine
dependence. one-year outcome. Experimental and Clinical
Psychopharmacology 1995;3(2):205-12.

*  Higgins ST, Budney AJ, Bickel WK, Foerg FE, Donham R,
Badger GJ. Incentives improve outcome in outpatient
behavioral treatment of cocaine dependence. Archives of
General Psychiatry 1994;51(July):568-76.

Higgins 2000 {published data only}

*  Higgins ST, Wong CJ, Badger GJ, Ogden DEH, Dantona RL.
Contingent reinforcement increases cocaine abstinence during
outpatient treatment and 1 year of follow-up. Journal of
Consulting and Clinical Psychology 2000;68(1):64-72.

Higgins 2003 {published data only}

*  Higgins ST, Sigmon SC, Wong CJ, Heil SH, Badger GJ,
Donham R, et al. Community reinforcement therapy for
cocaine-dependent outpatients. Archives of General Psychiatry
2003;60(10):1043-52.

Ingersoll 2011 {published data only}

Ingersoll KS, Farrell-Carnahan L, Cohen-Filipic J, Heckman CJ,
Ceperich SD, Hettema J, et al. A pilot randomized clinical trial
of two medication adherence and drug use interventions for
HIV plus crack cocaine users. Drug and Alcohol Dependence
2011;116(1-3):177-87.

Kirby 1998 {published data only}

Cochrane Database of Systematic Reviews

Ledgerwood 2006 {published data only}

Ledgerwood DM, Petry NM. Does contingency management
affect motivation to change substance use? Drug and Alcohol
Dependence 2006;83(1):65-72.

Marsden 2006 {published data only}

Marsden J, Stillwell G, Barlow H, Boys A, Taylor C, Hunt N, et al.
An evaluation of a brief motivational intervention among young
ecstasy and cocaine users: no effect on substance and alcohol
use outcomes. Addiction 2006;101:1014-26.

Marsden 2018 {published data only}

Marsden J, Goetz C, Meynen T, Mitcheson L, Stillwell G,
Eastwood B, et al. Memory-focused cognitive therapy for
cocaine use disorder: rationale, design and protocol for an
external pilot randomised controlled trial. Contemporary
Clinical Trials 2017;8:264-73.

Marsden J, Goetz C, Meynen T, Mitcheson L, Stillwell G,
Eastwood B, et al. Memory-focused cognitive therapy for
cocaine use disorder: theory, procedures and preliminary
evidence from an external pilot randomised controlled trial.
EBioMedicine 2018;29:177-89.

Maude-Griffin 1998 {published data only}

*  Maude-Griffin PM, Hohenstein JM, Humfleet GL, Reilly PM,
Tusel DJ, Hall SM. Superior efficacy of cognitive-behavioral
therapy for urban crack cocaine abusers: main and matching
effects. Journal of Consulting and Clinical Psychology
1998;66(5):832-7.

McDonell 2013 {published data only}

McDonell M G, Srebnik D, Angelo F, McPherson S, Lowe J M,
Sugar A, et al. Randomized controlled trial of contingency
management for stimulant use in community mental health
patients with serious mental illness. American Journal of
Psychiatry 2013;170:94-101.

*  Kirby KC, Marlowe DB, Lamb RJ, Platt JJ. Schedule of voucher
delivery influences initiation of cocaine abstinence. Journal of
Consulting and Clinical Psychology 1998;66(5):761-7.

NCT00809770. Contingency management of psychostimulant
abuse in the severely mentally ill. clinicaltrials.gov/study/
NCT00809770 (first received 17 December 2008).

Knealing 2006 {published data only}

McKee 2007 {published data only}

Knealing TW, Wong CJ, Diemer KN, Hampton J, Silverman K.
A randomized controlled trial of the therapeutic workplace
for community methadone patients: a partial failure to
engage. Experimental and Clinical Psychopharmacology
2006;14(3):350-60.

Landovitz 2015 {published data only}

Landovitz RJ, Fletcher JB, Shoptaw S, Reback CJ. Contingency
management facilitates the use of postexposure prophylaxis
among stimulant-using men who have sex with men. Open
Forum Infectious Diseases 2015;2(1):1-9. [DOI: 10.1093/ofid/
ofu114.]

NCT01140880. Biobehavioral Interventions for HIV-negative,
stimulant using men who have sex with men. clinicaltrials.gov/
show/NCT01140880 (first received 10 June 2010).

McKee SA, Carroll KM, Sinha R, Robinson JE, Nich C, Cavallo D,
et al. Enhancing brief cognitive-behavioral therapy with
motivational enhancement techniques in cocaine users. Drug
and Alcohol Dependence 2007;91(1):97-101.

Menza 2010 {published data only}

Menza TW, Jameson DR, Hughes JP, Colfax GN, Shoptaw S,
Golden MR. Contingency management to reduce
methamphetamine use and sexual risk among men who have
sex with men: a randomized controlled trial. BMC Public Health
2010;10:774.

Miguel 2017 {published data only}

Miguel AQ, Madruga CS, Cogo-Moreira H, Yamauchi R, Simões V,
da Silva CJ, et al. Contingency management is effective in
promoting abstinence and retention in treatment among
crack cocaine users in Brazil: a randomized controlled trial.
Psychology of Addictive Behaviors 2016;30(5):536-43.

Psychosocial interventions for stimulant use disorder (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

31

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Miguel AQC, Madruga CS, Cogo-Moreira H, Yamauchi R,
Simões V, Ribeiro A, et al. Contingency management
targeting abstinence is effective in reducing depressive
and anxiety symptoms among crack cocaine-dependent
individuals. Experimental and Clinical Psychopharmacology
2017;25(6):466-72.

NCT01815645. Contingency management treatment for crack
addiction - study with brazilian population. clinicaltrials.gov/
show/NCT01401270NCT01815645 ( first received 21 March
2013).

Miguel 2022 {published data only}

Effectiveness of contingency management in the treatment of
crack addiction for individuals living in the "Crackland" region.
A single-blind randomized controlled trial. clinicaltrials.gov/
study/NCT03345394 (first received 17 November 2017).

Miguel AQC, McPherson SM, Simões V, Yamauchi R, Madruga CS,
Smith CL, et al. Effectiveness of incorporating contingency
management into a public treatment program for people
who use crack cocaine in Brazil. A single-blind randomized
controlled trial. International Journal of Drug Policy
2022;99:103464.

Milby 2008 {published data only}

*  Milby JB, Schumacher JE, Vuchinich RE, Freedman MJ,
Kertesz S, Wallace D. Toward cost-effective initial care for
substance-abusing homeless. Journal of Substance Abuse
Treatment 2008;32(2):180-91.

Milby JB, Schumacher JE, Wallace D, Vuchinich R,
Mennemeyer ST, Kertesz SG. Effects of sustained abstinence
among treated substance-abusing homeless persons on
housing and employment. American Journal of Public Health
2010;100(5):913-8.

Mimiaga 2019 {published data only}

Mimiaga MJ, Pantalone DW, Biello KB, Glynn TR,
Santostefano CM, Olson J, et al. A randomized controlled
efficacy trial of behavioral activation for concurrent stimulant
use and sexual risk for HIV acquisition among MSM: project
IMPACT study protocol. BMC Public Health 2018;18(1):914.

*  Mimiaga MJ, Pantalone DW, Biello KB, Hughto JMW, Frank J,
O'Cleirigh C, et al. An initial randomized controlled trial of
behavioral activation for treatment of concurrent crystal
methamphetamine dependence and sexual risk for HIV
acquisition among men who have sex with men. AIDS Care
2019;31(9):1083.

NCT03175159. Integrated BA and HIV RR Counseling for MSM
With Stimulant Abuse. clinicaltrials.gov/study/NCT03175159
(first received 1 June 2017).

Mitcheson 2007 {published data only}

Mitcheson L, McCambridge J, Byrne S. Pilot cluster-randomised
trial of adjunctive motivational interviewing to reduce crack
cocaine use in clients on methadone maintenance. European
Addiction Research 2007;13(1):6-10.

Cochrane Database of Systematic Reviews

Parsons 2018 {published data only}

Parsons JT, John SA, Millar BM, Starks TJ. Testing the efficacy of
combined motivational interviewing and cognitive behavioral
skills training to reduce methamphetamine use and improve
HIV medication adherence among HIV-positive gay and bisexual
men. AIDS and Behavior 2018;22(8):2674-86.

Peirce 2006 {published data only}

*  Peirce JM, Petry NM, Stitzer ML, Blaine J, Kellogg S,
Satterfield F, et al. Effects of lower-cost incentives on stimulant
abstinence in methadone maintenance treatment: a National
Drug AbuseTreatment Clinical Trials Network study. Archives of
General Psychiatry 2006;63(2):201-8.

Petitjean 2014 {published data only}

NCT00877435. Prize reinforcement contingency management
for cocaine dependence: a 24-week randomized controlled
trial. clinicaltrials.gov/show/NCT00877435 (first received 7 April
2009).

Petitjean SA, Dürsteler-MacFarland KM, Krokar MC, Strasser J,
Mueller SE, Degen B, et al. A randomized, controlled trial of
combined cognitive-behavioral therapy plus prize-based
contingency management for cocaine dependence. Drug and
Alcohol Dependence 2014;145:94-100.

Petry 2005a {published data only}

Peirce JM, Petry NM, Roll JM, Kolodner K, Krasnansky J,
Stabile PQ, et al. Correlates of stimulant treatment outcome
across treatment modalities. American Journal of Drug and
Alcohol Abuse 2009;35(1):48-53.

*  Petry NM, Peirce JM, Stitzer ML, Blaine J, Roll JM, Cohen A, et
al. Effect of prize-based incentives on outcomes in stimulant
abusers in outpatient psychosocial treatment programs: a
national drug abuse treatment clinical trials network study.
Archives of General Psychiatry 2005;62(10):1148-56.

Petry 2005b {published data only}

*  Petry NM, Martin B, Simcic F. Prize reinforcement contingency
management for cocaine dependence: integration with group
therapy in a methadone clinic. Journal of Consulting and Clinical
Psychology 2005;73(2):354-9.

Petry 2007 {published data only}

Petry NM, Alessi S M, Hanson T, Sierra S. Randomized trial of
contingent prizes versus vouchers in cocaine-using methadone
patients. Journal of Consulting and Clinical Psychology
2007;75(6):983-91.

Petry 2012a {published data only}

Petry NM, Alessi SM, Ledgerwood DM. A randomized trial of
contingency management delivered by community therapists.
Journal of Consulting and Clinical Psychology 2012;80(2):286-98.

Petry 2012b {published data only}

Petry NM, Barry D, Alessi SM, Rounsaville BJ, Carroll KM. A
randomized trial adapting contingency management targets
based on initial abstinence status of cocaine-dependent
patients. Journal of Consulting and Clinical Psychology
2012;80(2):276-85.

Psychosocial interventions for stimulant use disorder (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

32

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Petry 2013 {published data only}

Roll 2013 {published data only}

Petry NM, Alessi SM, Rash CJ. A randomized study of
contingency management in cocaine-dependent patients with
severe and persistent mental health disorders. Drug and Alcohol
Dependence 2013;130(1-3):234-7.

Roll JM, Chudzynski J, Cameron JM, Howell DN, McPherson S.
Duration effects in contingency management treatment
of methamphetamine disorders. Addictive Behaviors
2013;38(9):2455-62.

Petry 2015 {published data only}

Sanchez-Hervas 2010 {published data only}

Petry NM, Alessi SM, Barry D, Carroll KM. Standard magnitude
prize reinforcers can be as efficacious as larger magnitude
reinforcers in cocaine-dependent methadone patients. Journal
of Consulting and Clinical Psychology 2015;83(3):464-72.

Petry 2018 {published data only}

Petry NM, Alessi SM, Rash CJ, Barry D, Carroll KM. A randomized
trial of contingency management reinforcing attendance
at treatment: do duration and timing of reinforcement
matter? Journal of Consulting and Clinical Psychology
2018;86(10):799-809.

Pirnia 2016 {published data only}

Pirnia B, Tabatabaei SK, Tavallaii A, Soleimani AA, Pirnia K.
The efficacy of contingency management on cocaine craving,
using prize-based reinforcement of abstinence in cocaine users.
Electronic Physician 2016;8(11):3214-21.

Poling 2006 {published data only}

Poling J, Oliveto A, Petry N, Sofuoglu M, Gonsai K, Gonzalez G, et
al. Six-month trial of bupropion with contingency management
for cocaine dependence in a methadone-maintained
population. Archives of General Psychiatry 2006;63:219-28.

Rawson 2002 arm 1 {published data only}

Farabee D, Rawson R, McCann M. Adoption of drug avoidance
activities among patients in contingency management and
cognitive-behavioral treatments. Journal of Substance Abuse
Treatment 2002;23(4):343-50.

*  Rawson RA, Huber A, McCann M, Shoptaw S, Farabee D,
Reiber C, et al. A comparison of contingency management
and cognitive-behavioral approaches during methadone
maintenance treatment for cocaine dependence. Archives of
General Psychiatry 2002;59(9):817-24.

Rawson 2002 arm 2 {published data only}

Farabee D, Rawson R, McCann M. Adoption of drug avoidance
activities among patients in contingency management and
cognitive-behavioral treatments. Journal of Substance Abuse
Treatment 2002;23(4):343-50.

Rawson 2002 arm 3 {published data only}

Farabee D, Rawson R, McCann M. Adoption of drug avoidance
activities among patients in contingency management and
cognitive-behavioral treatments. Journal of Substance Abuse
Treatment 2002;23(4):343-50.

Rawson 2002 arm 4 {published data only}

Farabee D, Rawson R, McCann M. Adoption of drug avoidance
activities among patients in contingency management and
cognitive-behavioral treatments. Journal of Substance Abuse
Treatment 2002;23(4):343-50.

Sanchez-Hervas E, Secades-Villa R, Zacares Romaguera F,
Garcia-Rodriguez O, Fernandez-Hermida JR, Santonja
Gomez FJ. Psychological treatment for cocaine addicts in public
health services [Tratamiento psicologico para dependientes
a la cocaina en la red sanitaria publica]. Trastornos adictivos
2008;10(4):275-83.

Sanchez-Hervas E, Zacares-Romaguera F, Garcia-Rodriguez O,
Secades-Villa R, Fernandez-Hermida JR. Community
reinforcement approach (CRA) for cocaine addicts:
establishment in a public health setting. Anales de Psiquiatria
2008;24(4):153-8.

*  Secades-Villa R, Sanchez-Hervas E, Zacares-Romaguera F,
Garcia-Rodriguez O, Santonja-Gomez FJ, Garcia-Fernandez G.
Community Reinforcement Approach (CRA) for cocaine
dependence in the Spanish public health system: 1 year
outcome. Drug and Alcohol Review 2011;30(6):606-12.

Schottenfeld 2011 {published data only}

NCT00914381. Behavioral treatment for cocaine dependent
women. clinicaltrials.gov/show/NCT00914381 (first received 5
June 2009).

*  Schottenfeld RS, Moore B, Pantalon MV. Contingency
management with community reinforcement approach or
twelve-step facilitation drug counseling for cocaine dependent
pregnant women or women with young children. Drug and
Alcohol Dependence 2011;118:48-55.

Secades Villa 2013 {published data only}

Secades-Villa R, Garcia-Fernandez G, Pena-Suarez E, Garcia-
Rodriguez O, Sanchez-Hervas E, Fernandez-Hermida JR.
Contingency management is effective across cocaine-
dependent outpatients with different socioeconomic status.
Journal of Substance Abuse Treatment 2013;44(3):349-54.

Shoptaw 2005 arm 1 {published data only}

Jaffe A, Shoptaw S, Stein J, Reback CJ, Rotheram-Fuller E.
Depression ratings, reported sexual risk behaviors, and
methamphetamine use: latent growth curve models
of positive change among gay and bisexual men in an
outpatient treatment program. Experimental and Clinical
Psychopharmacology 2007;15(3):301-7.

*  Shoptaw S, Reback CJ, Peck JA, Yang X, Rotheram-Fuller E,
Larkins S, et al. Behavioral treatment approaches for
methamphetamine dependence and HIV-related sexual risk
behaviors among urban gay and bisexual men. Drug and Alcohol
Dependence 2005;78(2):125-34.

Shoptaw 2005 arm 2 {published data only}

Shoptaw S, Reback CJ, Peck JA, Yang X, Rotheram-Fuller E,
Larkins S, et al. Behavioral treatment approaches for
methamphetamine dependence and HIV-related sexual risk

Psychosocial interventions for stimulant use disorder (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

33

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

behaviors among urban gay and bisexual men. Drug and Alcohol
Dependence 2005;78(2):125-34.

Shoptaw 2005 arm 3 {published data only}

Shoptaw S, Reback CJ, Peck JA, Yang X, Rotheram-Fuller E,
Larkins S, et al. Behavioral treatment approaches for
methamphetamine dependence and HIV-related sexual risk
behaviors among urban gay and bisexual men.. Drug and
Alcohol Dependence 2005;78(2):125-34.

Shoptaw 2008 {published data only}

Shoptaw S, Reback CJ, Larkins S, Wang PC, Rotheram-
Fuller E, Dang J, et al. Outcomes using two tailored behavioral
treatments for substance abuse in urban gay and bisexual men.
Journal of Substance Abuse Treatment 2008;35(3):285-93.

Silverman 1996 {published data only}

*  Silverman K, Higgins ST, Brooner RK, Montoya ID, Cone EJ,
Schuster CR, et al. Sustained cocaine abstinence in methadone
maintenance patients through voucher-based reinforcement
therapy. Archives of General Psychiatry 1996;53(5):409-15.

Silverman 1998 {published data only}

*  Silverman K, Wong CJ, Umbricht-Schneiter A, Montoya ID,
Schuster CR, Preston KL. Broad beneficial effects of cocaine
abstinence reinforcement among methadone patients. Journal
of Consulting and Clinical Psychology 1998;66(5):811-24.

Smout 2010 {published data only}

Smout MF, Longo M, Harrison S, Minniti R, Wickes W, White JM.
Psychosocial treatment for methamphetamine use disorders:
a preliminary randomized controlled trial of cognitive behavior
therapy and Acceptance and Commitment Therapy. Substance
Abuse 2010;31(2):98-107.

Sorsdahl 2021 {published data only}

Sorsdahl K, Stein DJ, Pasche S, Jacobs Y, Kader R, Odlaug B, et
al. A novel brief treatment for methamphetamine use disorders
in South Africa: a randomised feasibility trial. Addict Sci Clin
Pract 2021;16(1):3.

Stein 2009 {published data only}

Stein MD, Herman DS, Anderson BJ. A motivational intervention
trial to reduce cocaine use. Journal of Substance Abuse
Treatment 2009;36:118-25.

References to studies excluded from this review

Aharonovich 2017 {published data only}

Aharonovich E, Hasin DS, Stohl M. HealthCall: technology use
to reduce non-injection drug use in HIV primary care. Drug and
Alcohol Dependence 2015;156:e3. 24154245

*  Aharonovich E, Sarvet A, Stohl M, DesJarlais D, Tross S,
Hurst T, et al. Reducing non-injection drug use in HIV primary
care: a randomized trial of brief motivational interviewing, with
and without HealthCall, a technology-based enhancement.
Journal of Substance Abuse Treatment 2017;74:71-9.

Cochrane Database of Systematic Reviews

Alessi 2007 {published data only}

Alessi SM, Hanson T, Wieners M, Petry NM. Low-cost contingency
management in community clinics: delivering incentives
partially in group therapy. Experimental and Clinical
Psychopharmacology 2007;15(3):293-300.

Alim 1995 {published data only}

Alim TN, Rosse RB, Vocci FJ Jr, Lindquist T, Deutsch SI.
Dethylpropion pharmacotherapeutic adjuvant therapy for
inpatient treatment of cocaine dependence: a test of the
cocaine-agonist hypothesis. Clinical Neuropharmacology
1995;18(2):183-95.

Azrin 1994 {published data only}

Azrin NH, McMahon PT, Donouhe B, Besalel VA, Lapinski KJ,
Kogan ES, et al. Behavior therapy for drug abuse: a controlled
treatment outcome study. Behaviour Research & Therapy
1994;32(8):857-66.

Azrin 1996 {published data only}

Azrin NH, Acierno R, Kogan ES, Donouhe B, Besalel VA,
McMahon PT. Follow-up results of Supportive versus Behavioral
Therapy for illicit drug use. Behaviour Research & Therapy
1996;34(1):41-6.

Bahrami 2017 {published data only}

Bahrami S, Asghari F. A controlled trial of acceptance
and commitment therapy for addiction severity in
methamphetamine users: preliminary study. Archives of
Psychiatry and Psychotherapy 2017;2:49–55.

Barrowclough 2009 {published data only}

Barrowclough C, Haddock G, Beardmore R, Conrod P, Craig T,
Davies L, et al. Evaluating integrated MI and CBT for people with
psychosis and substance misuse: recruitment, retention and
sample characteristics of the MIDAS trial. Addictive Behaviors
2009;34(10):859-66.

Bellack 2006 {published data only}

Bellack AS, Bennett ME, Gearon JS, Brown CH, Yang Y. A
randomized clinical trial of a new behavioral treatment for
drug abuse in people with severe and persistent mental illness.
Archives of General Psychiatry 2006;63(4):426-32.

Bickel 2008 {published data only}

Bickel WK, Marsch LA, Buchhalter AR, Badger GJ. Computerized
behavior therapy for opioid-dependent outpatients: a
randomized controlled trial. Experimental and Clinical
Psychopharmacology 2008;16(2):132-43.

Brewer 2009 {published data only}

Brewer JA, Sinha R, Chen JA, Michalsen RN, Babuscio TA, Nich C,
et al. Mindfulness training and stress reactivity in substance
abuse: results from a randomized, controlled stage I pilot study.
Substance Abuse 2009;30(4):306-17.

Brooner 1998 {published data only}

Brooner RK, Kidorf M, King VL, Stoller K. Preliminary evidence of
good treatment response in antisocial drug abusers. Drug and
Alcohol Dependence 1998;49:249-60.

Psychosocial interventions for stimulant use disorder (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

34

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Burduli 2018 {published data only}

Burduli E, Skalisky J, Hirchak K, Orr MF, Foote A, Granbois A,
et al. Contingency management intervention targeting co-
addiction of alcohol and drugs among American Indian
adults: design, methodology, and baseline data. Clinical Trials
2018;15(6):587-99.

Campbell 2014 {published data only}

Campbell ANC, Nunes EV, Matthews AG, Stitzer M, Miele GM,
Polsky D, et al. Internet-delivered treatment for substance
abuse: a multisite randomized controlled trial. American Journal
of Psychiatry 2014;171(6):683-90.

Carrico 2018 {published data only}

Carrico AW, Gόmez W, Jain J, Shoptaw S, Discepola MV,
Olem D, et al. Randomized controlled trial of a positive affect
intervention for methamphetamine users. Drug and Alcohol
Dependence 2018;192:8-15.

Carrico AW, Jain J, Discepola MV, Olem D, Andrews R, Woods WJ,
et al. A community-engaged randomized controlled trial of an
integrative intervention with HIV-positive, methamphetamine-
using men who have sex with men. BMC Public Health
2016;16:673.

Carrico AW, Neilands TB, Dilworth SE, Evans JL, Gόmez W,
Jain JP, et al. Randomized controlled trial of a positive affect
intervention to reduce HIV viral load among sexual minority
men who use methamphetamine. Journal of the International
AIDS Society 2019;22(12):e25436.

NCT01926184. clinicaltrials.gov/study/NCT01926184 (first
received 20 August 2013).

Chen 2013 {published data only}

Chen KW, Berger CC, Gandhi D, Weintraub E, Lejuez CW. Adding
integrative meditation with ear acupressure to outpatient
treatment of cocaine addiction: a randomized controlled pilot
study. Journal of Alternative and Complementary Medicine
2013;19(3):204-10.

Covi 2002 {published data only}

Covi L, Hess JM, Schroeder JR, Preston KL. A dose response
study of cognitive behavioral therapy in cocaine abusers.
Journal of Substance Abuse Treatment 2002;23(3):191-7.

Dansereau 1996 {published data only}

Dansereau DF, Joe GW, Dees SM, Simpson DD. Ethnicity and the
effects of mapping-enhance drug abuse counseling. Addictive
Behaviors 1996;21(3):363-76.

Dees 1997 {published data only}

Dees SM, Dansereau DF, Simpson DD. Mapping-enhanced
drug abuse counseling: urinalysis results in the first year of
methadone treatment. Journal of Substance Abuse Treatment
1997;14(1):45-54.

DeFulio 2009 {published data only}

DeFulio A, Donlin WD, Wong CJ, Silverman K. Employment-
based abstinence reinforcement as a maintenance intervention
for the treatment of cocaine dependence: a randomized
controlled trial. Addiction 2009;104(9):1530-8.

*  DeFulio A, Silverman K. Employment-based abstinence
reinforcement as a maintenance intervention for the treatment
of cocaine dependence: post-intervention outcomes. Addiction
2011;106(5):960-7.

Donovan 2013 {published data only}

Donovan DM, Daley DC, Brigham GS, Hodgkins CC, Perl HI,
Garrett SB, et al. Stimulant abuser groups to engage in 12-
Step: a multisite trial in the National Institute on Drug Abuse
Clinical Trials Network. Journal of Substance Abuse Treatment
2013;44(1):103–14.

Gawin 1984 {published data only}

Gawin FH, Kleber HD. Cocaine abuse treatment. Open pilot trial
with desipramine and lithium carbonate. Archives of General
Psychiatry 1984;41(9):903-9.

Gawin 1989 {published data only}

Gawin FH, Kleber HD, Byck R, Rounsaville BJ, Kosten TR,
Jatlow PI, et al. Desipramine facilitation of initial cocaine
abstinence. Archives of General Psychiatry 1989;46(2):117-21.

Glasner 2022 {published data only}

Glasner S, Patrick K, Ybarra M, Reback CJ, Ang A, Kalichman S,
et al. Promising outcomes from a cognitive behavioral therapy
text-messaging intervention targeting drug use, antiretroviral
therapy adherence, and HIV risk behaviors among adults
living with HIV and substance use disorders. Drug and Alcohol
Dependence 2022;231:109229.

Glasner-Edwards 2007 {published data only}

Glasner-Edwards S, Tate SR, McQuaid JR, Cummins K,
Granholm E, Brown SA. Mechanisms of action in integrated
cognitive-behavioral treatment versus twelve-step facilitation
for substance-dependent adults with comorbid major
depression. Journal of Studies on Alcohol and Drugs
2007;68(5):663-72.

Gonçalves 2014 {published data only}

Gonçalves PD, Ometto M, Bechara A, Malbergier A, Amaral R,
Nicastri S, et al. Motivational interviewing combined with chess
accelerates improvement in executive functions in cocaine
dependent patients: A one-month prospective study. Drug and
Alcohol Dependence 2014;141:79-84.

Gottheil 1998 {published data only}

*  Gottheil E, Weinstein SP, Sterling RC, Lundy A, Serota RD. A
randomised controlled study of the effectiveness of intensive
outpatient treatment for cocaine dependence. Psychiatric
Services 1998;49(6):782-7.

Weinstein SP, Gottheil E, Sterling RC. Randomized comparison
of intensive outpatient vs individual therapy for cocaine
abusers. Journal of Addictive Disorders 1997;16:41-56.

Gross 2006 {published data only}

Gross A, Marsch LA, Badger GJ, Bickel WK. A comparison
between low-magnitude voucher and buprenorphine
medication contingencies in promoting abstinence
from opioids and cocaine. Experimental and Clinical
Psychopharmacology 2006;14(2):148-56.

Psychosocial interventions for stimulant use disorder (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

35

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Hall 1994 {published data only}

Keoleian 2013 {published data only}

*  Hall SM, Tunis S, Triffleman E, Banys P, Clark HW, Tusel D,
et al. Continuity of care and desipramine in primary
cocaine abusers. The Journal of Nervous and Mental Disease
1994;182(10):570-5.

Keoleian V, Stalcup SA, Polcin DL, Brown M, Galloway G. A
cognitive behavioral therapy-based text messaging intervention
for methamphetamine dependence. Journal of Psychoactive
Drugs 2013;45(5):434-42.

Hawkins 1989 {published data only}

Kidorf 2013 {published data only}

*  Hawkins DJ, Catalano RF, Gillmore MR, Wells EA. Skills training
for drug abusers: generalization, maintenance, and effects
on drug use. Journal of Consulting and Clinical Psychology
1989;57(4):559-63.

Kidorf M, Brooner RK, Gandotra N, Antoine D, King VL, Peirce J,
et al. Reinforcing integrated psychiatric service attendance in
an opioid-agonist program: A randomized and controlled trial.
Drug and Alcohol Dependence 2013;133(1):30-6.

Hoffman 1994 {published data only}

Kiluk 2010 {published data only}

*  Hoffman JA, Caudill BD, Koman JJ, Luckey JW, Flynn PM,
Hubbard RL. Comparative cocaine abuse treatment strategies:
enhancing client retention and treatment exposure. Journal of
Addictive Diseases 1994;13(4):115-28.

Kiluk BD, Nich C, Babuscio T, Carroll KM. Quality versus
quantity: acquisition of coping skills following computerized
cognitive behavioral therapy for substance use disorders.
Addiction 2010;105(12):2120-7.

Hoffman JA, Caudill BD, Koman JJ, Luckey JW, Flynn PM,
Mayo DW. Psychosocial treatments for cocaine abuse: 12-month
treatment outcomes. Journal of Substance Abuse Treatment
1996;13(1):3-11.

Knight 1994 {published data only}

Knight DK, Dansereau DF, Joe GW, Simpson DD. The role
of node-link mapping in individual and group counseling.
American Journal of Drug and Alcohol Abuse 1994;20(4):517-27.

Holtyn 2020 {published data only}

Kouri 1995 {published data only}

Holtyn AF, Toegel F, Subramaniam S, Jarvis BP, Leoutsakos JM,
Fingerhood M, et al. Abstinence-contingent wage supplements
to promote drug abstinence and employment: a randomised
controlled trial. Journal of Epidemiology and Community Health
2020;74(5):445-52.

Islam 2014 {published data only}

Islam LZ. Using behavioral incentives to promote exercise
compliance in women with cocaine dependence [Dissertation
Abstracts International: Section B: The Sciences and
Engineering]. In: ProQuest Information & Learning. 2014.

Jones 2005 {published data only}

*  Jones HE, Wong CJ, Tuten M, Stitzer ML. Reinforcement-
based therapy: 12-month evaluation of an outpatient drug-free
treatment for heroin abusers. Drug and Alcohol Dependence
2005;79(2):119-28.

Kalapatapu 2021 {published data only}

Kalapatapu R. Cognitive rehabilitation for cocaine use
disorder. Dissertation submitted in partial satisfaction of the
requirements for degree of Doctor of Philosophy 2021.

Kang 1991 {published data only}

Kang SY, Kleinman PH, Woody GE, Millman RB, Todd TC,
Kemp J, et al. Outcomes for cocaine abusers after once-a-
week psychosocial therapy. American Journal of Psychiatry
1991;148(5):630-5.

Kelpin 2022 {published data only}

Kelpin SS, Parlier-Ahmad AB, Jallo N, Carroll K, Svikis DS. A
pilot randomized trial of CBT4CBT for women in residential
treatment for substance use disorders. Journal of Substance
Abuse Treatment 2022;132:108622.

Kouri EM, Lukas SE, Mendelson JH. P300 Assessment of opiate
and cocaine users: effects of detoxification and buprenorphine
treatment. Biological Psychiatry 1996;40(7):617-28.

Magura 1994 {published data only}

*  Magura S, Rosenblum A, Lovejoy M, Handelsman L, Foote J,
Stimmel B. Neurobehavioral treatment for cocaine-using
methadone patients: a preliminary report. Journal of Addictive
Diseases 1994;13(4):143-60.

Marcus 2009 {published data only}

Marcus MT, Schmitz J, Moeller G, Liehr P, Cron SG, Swank P, et al.
Mindfulness-based stress reduction in therapeutic community
treatment: a stage 1 trial. American Journal of Drug and Alcohol
Abuse 2009;35(2):103-8.

Martino 2006 {published data only}

Martino S, Carroll KM, Nich C, Rounsaville BJ. A randomized
controlled pilot study of motivational interviewing for
patients with psychotic and drug use disorders. Addiction
2006;101(10):1479-92.

Martino 2016 {published data only}

Martino S, Paris M Jr, Añez L, Nich C, Canning-Ball M, Hunkele K,
et al. The effectiveness and cost of clinical supervision for
motivational interviewing: a randomized controlled trial.
Journal of Substance Abuse Treatment 2016;68:11-23.

McKay 1997 {published data only}

McKay JR, Alterman AI, Cacciola JS, O'Brien CP,
Koppenhaver JM, Shepard DS. Continuing care for cocaine
dependence comprehensive 2-year outcomes. Journal of
Consulting and Clinical Psychology 1999;67(3):420-7.

*  McKay JR, Alterman AI, Cacciola JS, Rutherford MJ,
O'Brien CP, Koppenhaver J. Group counseling versus
individualized relapse prevention aftercare following intensive

Psychosocial interventions for stimulant use disorder (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

36

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

outpatient treatmentfor cocaine dependence: initial results.
Journal of Consulting and Clinical Psychology 1997;65(5):778-88.

McKay 1998 {published data only}

McKay JR, McLellan T, Alterman AI, Cacciola JS, Rutherford MJ,
O'Brien CP. Predictors of participation in aftercare sessions and
self-help groups following completion of intensive outpatient
treatment for substance abuse. Journal of Studies on Alcohol
1998;59(2):152-62.

McKay 2004 {published data only}

McKay JR, Lynch KG, Shepard DS, Ratichek S, Morrison R,
Koppenhaver J, et al. The effectiveness of telephone-based
continuing care in the clinical management of alcohol and
cocaine use disorders: 12-month outcomes. Journal of
Consulting and Clinical Psychology 2004;72(6):967-79.

McKay 2005 {published data only}

McKay JR, Lynch KG, Shepard DS, Pettinati HM. The
effectiveness of telephone-based continuing care for alcohol
and cocaine dependence: 24-month outcomes. Archives of
General Psychiatry 2005;62(2):199-207.

McKay 2010 {published data only}

McKay JR, Lynch KG, Coviello D, Morrison R, Cary MS, Skalina L,
et al. Randomized trial of continuing care enhancements for
cocaine-dependent patients following initial engagement.
Journal of Consulting and Clinical Psychology 2010;78(1):111-20.

McKay 2013a {published data only}

McKay JR, Van Horn HA, Lynch KG, Ivey M, Carry MS, Drapkin ML,
et al. An adaptive approach for identifying cocaine dependent
patients who benefit from extended continuing care. Journal of
Consulting and Clinical Psychology 2013;81(6):1063-73.

McKay 2013b {published data only}

Rohsenow DJ, Monti PM, Martin RA, Michalec E, Abrams DB.
Brief coping skills treatment for cocaine abuse: 12-month
substance use outcomes. Journal of Consulting and Clinical
Psychology 2000;68(3):515-20.

Mueser 2009 {published data only}

Mueser KT, Glynn SM, Cather C, Zarate R, Fox L, Feldman J,
et al. Family intervention for co-occurring substance use
and severe psychiatric disorders: participant characteristics
and correlates of initial engagement and more extended
exposure in a randomized controlled trial. Addictive Behaviors
2009;34(10):867-77.

Najavits 2018 {published data only}

Najavits LM, Enggasser J, Brief D, Federman E. A randomized
controlled trial of a gender-focused addiction model versus
12-step facilitation for women veterans. American Journal on
Addictions 2018;27(3):210-216.

Norberg 2014 {published data only}

Norberg MM, Hides L, Olivier J, Khawar L, McKetin R,
Copeland J. Brief interventions to reduce ecstasy use: a
multi-site randomized controlled trial. Behavior Therapy
2014;45(6):745–59.

Ollo 1996 {published data only}

Ollo C, Alim TN, Rosse RB, Lindquist T, Green T, Gillis T, et al.
Lack of neurotoxic effect of diethylpropion in crack-cocaine
abusers. Clinical Neuropharmacology 1996;19(1):52-8.

Petry 2010 {published data only}

Petry NM, Weinstock J, Alessi SM, Lewis MW, Dieckhaus K.
Group-based randomized trial of contingencies for health and
abstinence in HIV patients. Journal of Consulting and Clinical
Psychology 2010;78(1):89-97.

McKay JR, Van Horn D, Ivey M, Drapkin ML, Rennert L, Lynch KG.
Enhanced continuing care provided in parallel to intensive
outpatient treatment does not improve outcomes for patients
with cocaine dependence. Journal of Studies on Alcohol and
Drugs 2013;74(4):642-51.

Petry 2011 {published data only}

Petry NM, Weinstock J, Alessi SM. A randomized trial of
contingency management delivered in the context of group
counseling. Journal of Consulting and Clinical Psychology
2011;79(5):686-96.

McKay JR, Van Horn DH, Lynch KG, Ivey M, Cary MS, Drapkin M,
et al. Who benefits from extended continuing care for cocaine
dependence? Adaptive Behavior 2014;39(3):660-8.

Metsch 2018 {published data only}

Metsch L, Feaster D, Gooden L, Root C, Castellon PC, Colasanti J,
et al. Integrated cocaine & mental health treatment with
navigation RCT for HIV+ outpatients.. In: Topics in Antiviral
Medicine. 2018:494S.

Miller 1983 {published data only}

Miller L, Griffith J. A comparison of bupropion,
dextroamphetamine, and placebo in mixed-substance abusers.
Psychopharmacology 1983;80(3):199-205.

Monti 1997 {published data only}

*  Monti PM, Rohsenow DJ, Michalec E, Martin RA, Abrams DB.
Brief coping skills treatment for cocaine abuse: substance use
outcomes at three months. Addiction 1997;99(12):1717-28.

Pirnia 2017 {published data only}

Pirnia B, Moradi AR, Pirnia K, Kolahi P, Roshan R. A novel therapy
for cocaine dependence during abstinence: a randomized
clinical trial. Electronic Physician 2017;9(7):4862-71.

Polcin 2014 {published data only}

Polcin DL, Bond J, Korcha R, Nayak MB, Galloway GP, Evans K.
Randomized trial of intensive motivational interviewing for
methamphetamine dependence. Journal of Addictive Diseases
2014;33(33):253-65.

Preston 2008 {published data only}

Preston KL, Ghitza UE, Schmittner JP, Schroeder JR, Epstein DH.
Randomized trial comparing two treatment strategies using
prize-based reinforcement of abstinence in cocaine and opiate
users. Journal of Applied Behavior Analysis 2008;41(4):551-63.

Psychosocial interventions for stimulant use disorder (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

37

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Rash 2008 {published data only}

Silverman 2001 {published data only}

Rash CJ, Alessi SM, Petry NM. Contingency management
is efficacious for cocaine abusers with prior treatment
attempts. Experimental and Clinical Psychopharmacology
2008;16(6):547-54.

*  Silverman K, Svikis D, Robles E, Stitzer ML, Bigelow GE. A
reinforcement-based therapeutic workplace for the treatment
of drug abuse. Six-month abstinence outcomes. Experimental
and Clinical Psychopharmacology 2001;9(1):14-23.

Rawson 2021 {published data only}

Stitzer 2010 {published data only}

Rawson R, Glasner S, Brecht ML, Farabee D. A randomized
comparison of 4 vs. 16 weeks of psychosocial treatment
for stimulant users. Journal of Substance Abuse Treatment
2021;124:108274.

Rogers 2008 {published data only}

Rogers RE, Higgins ST, Silverman K, Thomas CS, Badger GJ,
Bigelow G, et al. Abstinence-contingent reinforcement and
engagement in non-drug-related activities among illicit drug
abusers. Psychology of Addictive Behaviors 2008;22(4):544-50.

Rosen 2009 {published data only}

Rosen MI, Carroll KM, Stefanovics E, Rosenheck RA. A
randomized controlled trial of a money management-
based substance use intervention. Psychiatric Services
2009;60(4):498-504.

Stitzer ML, Polk T, Bowles S, Kosten T. Drug users' adherence
to a 6-month vaccination protocol: effects of motivational
incentives. Drug and Alcohol Dependence 2010;107(1):76-9.

Van Horn 2011 {published data only}

Van Horn DH, Drapkin M, Ivey M, Thomas T, Domis SW,
Abdalla O, et al. Voucher incentives increase treatment
participation in telephone-based continuing care for cocaine
dependence. Drug and Alcohol Dependence 2011;114(2-3):225-8.

Wardle 2015 {published data only}

Wardle M, Vincent J, Suchting R, Green C, Lane S,
Schmitz J. Anhedonia predicts poorer outcomes in
contingency management for cocaine use disorder, with
or without levodopa enhancement of treatment. In:
Neuropsychopharmacology. Vol. 40. 2015:S436.

Rosenblum 2005 {published data only}

Wechsberg 2007 {published data only}

*  Rosenblum A, Magura S, Kayman DJ, Fong C. Motivationally
enhanced group counselling for substance users in a soup
kitchen: a randomised clinical trial. Drug and Alcohol
Dependence 2005;80(1):91-103.

Wechsberg WM, Zule WA, Riehman KS, Luseno WK, Lam WK.
African-American crack abusers and drug treatment initiation:
barriers and effects of a pretreatment intervention. Substance
Abuse Treatment, Prevention, and Policy 2007;2:10.

Ruger 2012 {published data only}

Weddington 1991 {published data only}

Ruger JP, Abdallah AB, Luekens C, Cottler L. Cost-effectiveness
of peer-delivered interventions for cocaine and alcohol abuse
among women: a randomized controlled trial. PLoS One
2012;7(3):e33594.

Santisteban 2011 {published data only}

Santisteban DA, Mena MP, McCabe BE. Preliminary results for
an adaptive family treatment for drug abuse in Hispanic youth.
Journal of Family Psychology 2011;25(4):610-4.

Saxon 1996 {published data only}

Saxon AJ, Wells EA, Fleming C, Jackson TR, Calsyn DA. pre-
treatment characteristics, program philosophy and level of
ancillary services as predictors of methadone maintenance
treatment outcome. Addiction 1996;91(8):1197-209.

Schaub 2019 {published data only}

Schaub MP, Castro RP, Wenger A, Baumgartner C, Stark L,
Ebert DD, et al. Web-based self-help with and without chat
counseling to reduce cocaine use in cocaine misusers: results
of a three-arm randomized controlled trial. Internet Interv.
Internet Interventions 2019;17:100251.

Schmitz 1997 {published data only}

*  Schmitz JM, Oswald LM, Jacks SD, Rustin T, Rhoades HM,
Grabowski J. Relapse prevention treatment for cocaine
dependence: group vs individual format. Addictive Behaviors
1997;22(3):405-18.

Weddington WW, Brown BS, Haertzen CA, Hess JM, Mahaffey JR,
Kolar AF, et al. Comparison of amantadine and desipramine
combined with psychotherapy for treatment of cocaine
dependence. American Journal of Drug and Alcohol Abuse
1991;17(2):137-52.

Weiss 2007 {published data only}

Weiss RD, Griffin ML, Kolodziej ME, Greenfield SF, Najavits LM,
Daley DC, et al. A randomized trial of integrated group therapy
versus group drug counseling for patients with bipolar disorder
and substance dependence. American Journal of Psychiatry
2007;164(1):100-7.

Winters 2000 {published data only}

*  Winters KC, Stinchfield RD, Opland E, Weller C, Latimer WW.
The effectiveness of the Minnesota Model approach in
the treatment of adolescent drug abusers. Addiction
2000;95(4):601-12.

Xu 2021 {published data only}

Xu X, Ding X, Chen L, Chen T, Su H, Li X, et al. The transcranial
direct current stimulation over prefrontal cortex combined
with the cognitive training reduced the cue-induced craving
in female individuals with methamphetamine use disorder:
a randomized controlled trial. Journal of Psychiatric Research
2021;134:102-10.

Zhu 2018 {published data only}

Zhu Y, Jiang H, Su H, Zhong N, Li R, Li X, et al. A newly designed
mobile-based computerized cognitive addiction therapy app for

Psychosocial interventions for stimulant use disorder (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

38

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

the improvement of cognition impairments and risk decision
making in methamphetamine use disorder: randomized
controlled trial. JMIR Mhealth Uhealth 2018;6(6):e10292.

NCT04982796 {published data only}

Ongoing study. 7 July 2022. Contact author for more
information.

Zlotnick 2009 {published data only}

Zlotnick C, Johnson J, Najavits LM. Randomized controlled
pilot study of cognitive-behavioral therapy in a sample of
Incarcerated women with substance use disorder and PTSD.
Behavior Therapy 2009;40(4):325-36.

NCT05207228 {published data only}

*  NCT05207228. Improvement of cocaine use disorder
treatment through cognitive behavioral therapy web-
based treatment (CBT4CBT). classic.clinicaltrials.gov/show/
NCT05207228 ( first received 26 January 2022).

References to ongoing studies

IRCT20221018056234N1 {published data only}

IRCT20221018056234N1. The effects of motivational
interviewing on beliefs related to substances, craving and
desire for treatment in methamphetamine-dependent
psychotic patients. https:/trialsearch.who.int/Trial2.aspx?
TrialID=IRCT20221018056234N1 (first received 17 December
2022).

NCT05593796 {published data only}

*  NCT05593796. Cognitive behavioral therapy(CBT) in
treatment of methamphetamine use disorder. clinicaltrials.gov/
study/NCT05593796 (first received 25 October 2022).

NCT05854667 {published data only}

NCT05854667. Clinical Trial of High Dose Lisdexamfetamine and
Contingency Management in MA Users. clinicaltrials.gov/show/
NCT05854667 (first posted 11 May 2023).

Mallorquí-Bagué 2023 {published data only}

Shaub 2015 {published data only}

*  Mallorquí-Bagué N, Palazón-Llecha A, Madre M, Batlle F,
Duran-Sindreu S, Trujols J. CBT4CBT web-based add-
on treatment for cocaine use disorder: Study protocol
for a randomized controlled trial. Frontiers in Psychiatry
2023;14:1051528. [PMID: 36937712]

NCT00292110 {published data only}

NCT00292110. Treatment of heroin and cocaine with
methadone maintenance and contingency management.
clinicaltrials.gov/show/NCT00292110 (first received 15 February
2006).

NCT01401270 {published data only}

NCT01401270. Prize contingency management for cocaine-
dependent methadone patients. clinicaltrials.gov/show/
NCT01401270 ( first received 25 July 2011).

Schaub MP, Maier L, Wenger A, Stark L, Berg O, Beck T, et al.
Evaluating the efficacy of a web-based self-help intervention
with and without chat counselling in reducing the cocaine use
of problematic cocaine users: the study protocol of a pragmatic
three-arm randomised controlled trial. BMC Psychiatry
2015;15:156. [ISRCTN12205466]

Additional references

Amato 2011a

Amato L, Minozzi S, Davoli M, Vecchi S. Psychosocial
combined with agonist maintenance treatments versus
agonist maintenance treatments alone for treatment of
opioid dependence. Cochrane Database of Systematic
Reviews 2011, Issue 10. Art. No: CD004147. [DOI:
10.1002/14651858.CD004147.pub4]

NCT01899313 {published data only}

Amato 2011b

NCT01899313. A cognitive behavioral therapy-based text
message intervention for methamphetamine dependence.
clinicaltrials.gov/show/NCT01899313 ( first received 15 July
2013).

NCT01926184 {published data only}

NCT01926184. RCT of an integrative intervention for non-
treatment-seeking meth users. clinicaltrials.gov/show/
NCT01926184 ( first posted 20 August 2013).

NCT01986075 {published data only}

Blevins D, Carpenter KM, Martinez D, Mariani JJ, Levin FR. An
adaptive clinical trial design for cocaine use disorder: extended-
release amphetamine salts for early behavioral intervention
non-responders. Contemporary Clinical Trials 2020;98:106187.

NCT01986075. A sequenced behavioral and medication
intervention for cocaine dependence. clinicaltrials.gov/show/
NCT01986075 ( first received 18 November 2013).

Amato L, Minozzi S, Davoli M, Vecchi S. Psychosocial and
pharmacological treatments versus pharmacological
treatments for opioid detoxification. Cochrane Database of
Systematic Reviews 2011, Issue 9. Art. No: CD005031. [DOI:
10.1002/14651858.CD005031.pub4]

American Psychiatric Association 2013

American Psychiatric Association. Diagnostic and Statistical
Manual of Mental Disorders (DSM 5). Fifth edition. Arlington (VA):
American Psychiatric Association, 2013.

American Psychiatric Association 2022

American Psychiatric Association. Diagnostic and Statistical
Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5-
TR). American Psychiatric Association, 2022. [DOI: 10.1176/
appi.books.9780890425787]

Atkinson 2014

Atkinson A, Anderson Z, Hughes K, Bellis MA, Sumnall H,
Syed Q. Interpersonal violence and illicit drugs; June 2009.

Psychosocial interventions for stimulant use disorder (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

39

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

www.who.int/publications/m/item/interpersonal-violence-and-
illicit-drugs (accessed 18 November 2014).

disorders. Drug and Alcohol Dependence 2020;216:108193. [DOI:
doi: 10.1016/j.drugalcdep.2020.108193]

Beck 1996

Chappel 1999

Beck AT, Steer RA, Brown GK. Manual for the Beck Depression
Inventory-II. San Antonio (TX): Psychological Corporation, 1996.

Beck 2011

Beck JS. Cognitive Behavior Therapy: Basics and Beyond. 2nd
edition. New York: Guilford Press, 2011.

Bentzley 2021

Bentzley BS, Han SS, Neuner S, Humphreys K, Kampman KM,
Halpern CH. Comparison of treatments for cocaine use disorder
among adults: a systematic review and meta-analysis. JAMA
Network Open 2021;4(5):e218049.

Chappel JN, DuPont RL. Twelve-step and mutual-help programs
for addictive disorders. Psychiatric Clinics of North America
1999;22(2):425-46.

Committee 2015

Committee on developing evidence-based standards for
psychosocial interventions for Mental Disorders, Board on
Health Sciences Policy, Institute of Medicine. Psychosocial
interventions for mental and substance use disorders: a
framework for establishing evidence-based standards.
Washington (DC): National Academies Press (US), 2015. [PMID:
26203478]

Bickel 1997

Conner 2008

Bickel WK, Amass L, Higgins ST, Badger GJ, Esch RA. Effects
of adding behavioral treatment to opioid detoxification with
buprenorphine. Journal of Consulting and Clinical Psychology
1997;65(5):803-10.

Bryck 2012

Bryck RL, Fisher PA. Training the brain: practical applications
of neural plasticity from the intersection of cognitive
neuroscience, developmental psychology, and prevention
science. American Psychologist 2012;67(2):87-100.

Busner 2007

Busner J, Targum SD. The clinical global impressions scale:
applying a research tool in clinical practice. Psychiatry
2007;4(7):28-37.

Carroll 2005

Conner KR, Pinquart M, Holbrook AP. Meta-analysis of
depression and substance use and impairment among cocaine
users. Drug and Alcohol Dependence 2008;98(1-2):13-23.

Cornish 1996

Cornish JW, O'Brien CP. Crack cocaine abuse: an epidemic with
many public health consequences. Annual Review of Public
Health 1996;17:2559-73.

Cregler 1989

Cregler LL. Adverse health consequences of cocaine abuse.
Journal of the National Medical Association 1989;81(1):27-38.

Dackis 2001

Dackis CA, O'Brien CP. Cocaine dependence: a disease of the
brain's reward centers. Journal of Substance Abuse Treatment
2001;21(3):111-7.

Carroll KM, Onken LS. Behavioral therapies for drug abuse.
American Journal of Psychiatry 2005;162(8):1452-60.

Darke 2004

Castells 2010

Castells X, Casas M, Pérez-Mañá C, Roncero C, Vidal X, Capellà D.
Efficacy of psychostimulant drugs for cocaine dependence.
Cochrane Database of Systematic Reviews 2010, Issue 2. Art. No:
CD007380. [DOI: 10.1002/14651858.CD007380.pub3]

Chan 2019a

Chan B, Freeman M, Kondo K, Ayers C, Montgomery J, Paynter R,
et al. Pharmacotherapy for methamphetamine/amphetamine
use disorder-a systematic review and meta-analysis. Addiction
2019;114(12):2122-36. [DOI: doi: 10.1111/add.14755]

Chan 2019b

Chan B, Kondo K, Freeman M, Ayers C, Montgomery J,
Kansagara D. Pharmacotherapy for cocaine use disorder-
a systematic review and meta-analysis. Journal of General
Internal Medicine 2019;34(12):2858-73. [DOI: doi: 10.1007/
s11606-019-05074-8]

Chan 2020

Chan B, Freeman M, Ayers C, Korthuis PT, Paynter R, Kondo K,
et al. A systematic review and meta-analysis of medications for
stimulant use disorders in patients with co-occurring opioid use

Darke S, Kaye S. Attempted suicide among injecting and non
injecting cocaine users in Sydney, Australia. Journal of Urban
Health 2004;81(3):505-15.

De Crescenzo 2018

De Crescenzo F, Ciabattini M, D'Alò GL, De Giorgi R, Del
Giovane C, Cassar C, Janiri L, Claret al. Comparative efficacy and
acceptability of psychosocial interventions for individuals with
cocaine and amphetamine addiction: a systematic review and
network meta-analysis. PLOS Medicine 2018;15(12):e1002715.

De Leon 1995

De Leon G. Therapeutic communities for addictions: a
theoretical framework. International Journal of the Addictions
1995;30(12):1603-45.

Deeks 2022

Deeks JJ, Higgins JP, Altman DG, on behalf of the Cochrane
Statistical Methods Group. Chapter 10: Analysing data and
undertaking meta-analyses. In: Higgins JP, Thomas J, Chandler
J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane
Handbook for Systematic Reviews of Interventions version 6.3
(updated February 2022). Cochrane, 2022. Available from
www.training.cochrane.org/handbook.

Psychosocial interventions for stimulant use disorder (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

40

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Degenhardt 2005

Flannery 1999

Degenhardt L, Day C, Hall W, Conroy E, Gilmour S. Was an
increase in cocaine use among injecting drug users in New
South Wales, Australia, accompanied by an increase in violent
crime? BMC Public Health 2005;5:40.

Degenhardt 2012

Degenhardt L, Hall W. Extent of illicit drug use and dependence,
and their contribution to the global burden of disease. Lancet
2012;379(9810):55-70.

Degenhardt 2013

Degenhardt L, Whiteford H, Ferrari AJ, Baxter A, Charlson F,
Hall W, et al. The global burden of disease attributable to illicit
drug use and dependence: results from the GBD 2010 study.
Lancet 2013;382(9904):1564-74.

Degenhardt 2014

Degenhardt L, Baxter AJ, Lee YY, Halle W, Grant E, Sarad GE, et
al. The global epidemiology and burden of psychostimulant
dependence: findings from the Global Burden of Disease Study
2010. Drug and Alcohol Dependence 2014;137:36-47.

Degenhardt  2017

Degenhardt L, Peacock A, Colledge S, Leung J, Grebely J,
Vickerman P, et al. Global prevalence of injecting drug use and
sociodemographic characteristics and prevalence of HIV, HBV,
and HCV in people who inject drugs: a multistage systematic
review. Lancet Global Health 2017;5(12):e1192-207. [DOI:
10.1016/S2214-109X(17)30375-3]

Dellazizzo 2023

Dellazizzo L, Potvin S, Giguère S, Landry C, Léveillé N, Dumais A.
Meta-review on the efficacy of psychological therapies for the
treatment of substance use disorders. Psychiatry Research
2023;326:115318. [DOI: 10.1016/j.psychres.2023.115318]

Falck 2003

Falck RS, Wang J, Siegal HA, Carlson RG. Current physical health
problems and their predictors among a community sample of
crack-cocaine smokers in Ohio. Journal of Psychoactive Drugs
2003;35(4):471-8.

Flannery BA, Volpicelli JR, Pettinati HM. Psychometric
properties of the Penn Alcohol Craving Scale. Alcoholism:
Clinical and Experimental Research 1999;23(8):1289–95.

Foxcroft 2016

Foxcroft DR, Coombes L, Wood S, Allen D, Almeida
Santimano NM, Moreira MT. Motivational interviewing for
the prevention of alcohol misuse in young adults. Cochrane
Database of Systematic Reviews 2016, Issue 7. Art. No:
CD007025. [DOI: 10.1002/14651858.CD007025] [PMID: 27426026]

Furukawa 2006

Furukawa TA, Barbui C, Cipriani A, Brambilla P, Watanabe N.
Imputing missing standard deviations in meta-analyses can
provide accurate results. Journal of Clinical Epidemiology
2006;59:7-10.

Gates 2016

Gates PJ, Sabioni P, Copeland J, Le Foll B, Gowing L.
Psychosocial interventions for cannabis use disorder. Cochrane
Database of Systematic Reviews 2016, Issue 5. Art. No:
CD005336. [DOI: 10.1002/14651858.CD005336.pub4]

Gawin 1988

Gawin FH, Ellinwood EHJ. Cocaine and other stimulants.
Actions, abuse, and treatment. New England Journal of Medicine
1988;318(18):1173-82.

GBD 2018

GBD 2016 Alcohol and Drug Use Collaborators. The global
burden of disease attributable to alcohol and drug use in 195
countries and territories, 1990-2016: a systematic analysis for
the Global Burden of Disease Study 2016. Lancet Psychiatry
2018;5(12):987-1012. [DOI: 10.1016/S2215-0366(18)30337-7]

Gossop 1995

Gossop M, Darke S, Griffiths P, Hando J, Powis B, Hall W, et
al. The Severity of Dependence Scale (SDS):psychometric
properties of the SDS in English and Australiansamples
of heroin, cocaine and amphetamine users. Addiction
1995;90:607–14.

Farrell 2019

GRADE 2004

Farrell M, Martin NK, Stockings E, Bórquez A, Cepeda JA,
Degenhardt L, et al. Responding to global stimulant use:
challenges and opportunities. Lancet 2019;394(10209):1652-67.
[DOI: 10.1016/S0140-6736(19)32230-5]

Feldstein 2011

Feldstein Ewing SW, Filbey FM, Sabbineni A, Chandler LD,
Hutchison KE. How psychosocial alcohol interventions work: a
preliminary look at what FMRI can tell us. Alcoholism, Clinical
and Experimental Research 2011;35(4):643-51.

Ferri 2006

Ferri M, Amato L, Davoli M. Alcoholics Anonymous and other 12-
step programmes for alcohol dependence. Cochrane Database
of Systematic Reviews 2006, Issue 3. Art. No: CD005032. [DOI:
10.1002/14651858.CD005032.pub2]

Oxman AD, GRADE Working Group. Grading quality of evidence
and strength of recommendations. BMJ 2004;328(19):1490-4.

GRADEpro GDT [Computer program]

GRADEpro GDT. Version accessed 15 April 2023. Hamilton (ON):
McMaster University (developed by Evidence Prime), 2015.
Available at gradepro.org.

Guyatt 2008

Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-
Coello P, et al. GRADE: an emerging consensus on rating
quality of evidence and strength of recommendations. BMJ
2008;336(7560):924-6.

Guyatt 2011

Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J, et al.
GRADE guidelines 1. Introduction-GRADE evidence profiles and

Psychosocial interventions for stimulant use disorder (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

41

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

summary of findings tables. Journal of Clinical Epidemiology
2011;64(4):383-94.

Haasen 2005

Haasen C, Prinzleve M, Gossop M, Fischer G, Casas M, the CEU-T.
Relationship between cocaine use and mental health problems
in a sample of European cocaine powder or crack users. World
Psychiatry 2005;4(3):173-6.

Hall 1977

Hall SM, Cooper JL, Burmaster S, Polk A. Contingency
contracting as a therapeutic tool with methadone maintenance
clients: six single subject studies. Behaviour Research and
Therapy 1977;15(5):438-41.

Hettema 2005

Hettema J, Steele J, Miller WR. Motivational interviewing.
Annual Review of Clinical Psychology 2005;1:91-111.

Higgins 2011

Higgins JPT, Green S (editors). Cochrane Handbook for
Systematic Reviews of Interventions Version 5.1.0 [updated
March 2011]. The Cochrane Collaboration, 2011. Available from
www.cochrane-handbook.org.

Klimas 2014

Klimas J, Tobin H, Field CA, O'Gorman CS, Glynn LG, Keenan E,
et al. Psychosocial interventions to reduce alcohol consumption
in concurrent problem alcohol and illicit drug users. Cochrane
Database of Systematic Reviews 2014, Issue 12. Art. No:
CD009269. [DOI: 10.1002/14651858.CD009269.pub3]

Klimas 2018

Klimas J, Fairgrieve C, Tobin H, Field CA, O'Gorman CS,
Glynn LG, et al. Psychosocial interventions to reduce alcohol
consumption in concurrent problem alcohol and illicit drug
users. Cochrane Database of Systematic Reviews 2018, Issue 12.
Art. No: CD009269. [DOI: 10.1002/14651858.CD009269.pub4]

Knapp 2007

Knapp WP, Soares BG, Farrel M, Lima MS. Psychosocial
interventions for cocaine and psychostimulant
amphetamines related disorders. Cochrane Database of
Systematic Reviews 2007, Issue 3. Art. No: CD003023. [DOI:
10.1002/14651858.CD003023.pub3]

Koob 2010

Koob GF, Volkow ND. Neurocircuitry of addiction.
Neuropsychopharmacology 2010;35(1):217-38.

Higgins 2023

Lefebvre 2011

Higgins JPT, Eldridge S, Li T (editors). Chapter 23: Including
variants on randomized trials. In: Higgins JP, Thomas J,
Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors).
Cochrane Handbook for Systematic Reviews of Interventions
version 6.4 (updated August 2023). Cochrane, 2023. Available
from www.training.cochrane.org/handbook.

Hunt 2019

Hunt GE, Siegfried N, Morley K, Brooke-Sumner C, Cleary M.
Psychosocial interventions for people with both severe
mental illness and substance misuse. Cochrane Database of
Systematic Reviews 2019, Issue 12. Art. No: CD001088. [DOI:
10.1002/14651858.CD001088.pub4]

Kaye 2004

Kaye S, Darke S. Injecting and non-injecting cocaine use in
Sydney, Australia: physical and psychological morbidity. Drug
and Alcohol Review 2004;23(4):391-8.

Lefebvre C, Manheimer E, Glanville J. Chapter 6: Searching for
studies. In: Higgins JPT, Green S (editors). Cochrane Handbook
for Systematic Reviews of Interventions Version 5.1.0 (updated
March 2011). The Cochrane Collaboration, 2011. Available from
www.cochrane-handbook.org.

Magill 2023

Magill M, Kiluk BD, Ray LA. Efficacy of cognitive behavioral
therapy for alcohol and other drug use disorders: is a one-
size-fits-all approach appropriate? Substance Abuse and
Rehabilitation 2023;14:1-11. [DOI: 10.2147/SAR.S362864] [PMID:
36844999]

Maier 1988

Maier W, Buller R, Philipp M, Heuser I. The Hamilton Anxiety
Scale: reliability,validity and sensitivity to change in anxiety
and depressive disorders. Journal of Affective Disorders
1988;14(1):61-8.

Kelly 2020

Marzuk 1992

Kelly JF, Humphreys K, Ferri M. Alcoholics Anonymous and
other 12-step programs for alcohol use disorder. Cochrane
Database of Systematic Reviews 2020, Issue 3. Art. No:
CD012880. [DOI: 10.1002/14651858.CD012880.pub2] [PMID:
32159228]

Kishi 2013

Kishi T, Matsuda Y, Iwata N, Correll CU. Antipsychotics for
cocaine or psychostimulant dependence: systematic review and
meta-analysis of randomized, placebo-controlled trials. Journal
of Clinical Psychiatry 2013;74(12):e1169-80. [DOI: doi: 10.4088/
JCP.13r08525]

Marzuk PM, Tardiff K, Leon AC, Stajic M, Morgan EB, Mann JJ.
Prevalence of cocaine use among residents of New York City
who committed suicide during a one-year period. American
Journal of Psychiatry 1992;149(3):371-5.

Mathers 2008

Mathers B, Degenhardt M, Phillips L, Wiessing B, Hickman L,
Strathdee M, et al. Global epidemiology of injecting drug use
and HIV among people who inject drugs: a systematic review.
The Lancet 2008;371(9651):1733-45.

May 2014

May J, Andrade J, Kavanagh DJ, Feeney GF, Gullo MJ,
Statham DJ, et al. The craving experience questionnaire: a brief,

Psychosocial interventions for stimulant use disorder (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

42

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

theory-basedmeasure of consummatory desire and craving.
Addiction 2014;109:728–35.

McGovern 2021

McGovern R, Newham JJ, Addison MT, Hickman M,
Kaner EF. Effectiveness of psychosocial interventions for
reducing parental substance misuse. Cochrane Database of
Systematic Reviews 2021, Issue 3. Art. No: CD012823. [DOI:
10.1002/14651858.CD012823.pub2]

McKetin 2006

McKetin R, Kelly E, McLaren J. The relationship between
crystalline methamphetamine use and methamphetamine
dependence. Drug and Alcohol Dependence 2006;85(3):198-204.

Mclellan 1992

McLellan AT, Kushner H, Metzger D, Peters R, Smith I, Grissom G,
et al. The fifth edition of the Addiction Severity Index. journal of
Substance Abuse Treatment 1992;9(3):199-213.

Miller 1992

Miller WR, Zweben A, DiClemente CC, Rychtarik RG. Motivational
enhancement therapy manual: a clinical research guide
for therapists treating individuals with alcohol abuse and
dependence. Volume 2, Project MATCH Monograph Series
edition. Rockville, MD: National Institute on Alcohol Abuse and
Alcoholism, 1992.

Miller 2003

Miller WR, Yahne CE, Tonigan JS. Motivational interviewing in
drug abuse services: a randomized trial. Journal of Consulting
and Clinical Psychology 2003;71(4):754-63.

Minozzi 2014

Minozzi S, Amato L, Bellisario C, Davoli M. Detoxification
treatments for opiate dependent adolescents. Cochrane
Database of Systematic Reviews 2014 Apr 29, Issue 4. Art. No:
CD006749. [DOI: 10.1002/14651858.CD006749.pub3]

Minozzi 2015

Minozzi S, Cinquini M, Amato L, Davoli M, Farrell MF, Pani PP, et
al. Anticonvulsants for cocaine dependence. Cochrane Database
of Systematic Reviews 2015, Issue 4. Art. No: CD006754. [DOI:
10.1002/14651858.CD006754.pub4]

Montgomery 1979

Montgomery SA, Asberg M. A new depression scale designed
to be sensitive to change. The British Journal of Psychiatry
1979;134:382–9.

Mooney 2006

Mooney M, Sofuoglu M, Dudish-Poulsen S, Hatsukami DK.
Preliminary observations of paranoia in a human laboratory
study of cocaine. Addictive Behaviors 2006;31:1245-54.

Naji 2022

Naji L, Dennis B, Rosic T, Wiercioch W, Paul J, Worster A,
et al. Mirtazapine for the treatment of amphetamine and
methamphetamine use disorder: A systematic review and meta-
analysis. Drug and Alcohol Dependence 2022;232:109295. [DOI:
doi: 10.1016/j.drugalcdep.2022.109295]

Cochrane Database of Systematic Reviews

NICE 2007

NICE. Drug Misuse: Psychosocial Interventions. NICE clinical
guideline 51. 2007. Available from www.nice.org.uk/CG51 [NICE
guideline].

Pani 2010

Pani PP, Trogu E, Vacca R, Amato L, Vecchi S, Davoli M.
Disulfiram for the treatment of cocaine dependence. Cochrane
Database of Systematic Reviews 2010, Issue 1. Art. No:
CD007024. [DOI: 10.1002/14651858.CD007024.pub2]

Paulus 2020

Paulus MP, Stewart JL. Neurobiology, clinical presentation,
and treatment of methamphetamine use disorder: a
review. JAMA Psychiatry 2020;77(9):959-66. [DOI: 10.1001/
jamapsychiatry.2020.0246]

Raistrick 1994

Raistrick D, Bradshaw J, Tober G, Weiner J, Allison J.
Development of the Leeds Dependence Questionnaire (LDQ):
a questionnaire to measure alcohol and opiate dependence
in the context of a treatment evaluation package. Addiction
1994;89(5):563-72.

Rawson 2023

Rawson RA, Erath TG, Chalk M, Clark HW, McDaid C,
Wattenberg SA, et al. Contingency management for stimulant
use disorder: progress, challenges, and recommendations.
Journal of Ambulatory Care Management 2023;46(2):152-9. [DOI:
10.1097/JAC.0000000000000450]

Ribeiro 2006

Ribeiro M, Dunn J, Sesso R, Dias AC, Laranjeira R. Causes
of death among crack cocaine users. Revista Brasileira de
Psiquiatria 2006;28:196-202.

Ronsley 2020

Ronsley C, Nolan S, Knight R, Hayashi K, Klimas J, Walley A, et
al. Treatment of stimulant use disorder: a systematic review
of reviews. PLoS One 2020;15(6):e0234809. [DOI: doi: 10.1371/
journal.pone.0234809]

Roozen 2004

Roozen HG, Boulogne JJ, Van Tulder MW, Van den Brink W, De
Jong CA, Kerkhof AJ. A systematic review of the effectiveness of
the community reinforcement approach in alcohol, cocaine and
opioid addiction. Drug and Alcohol Dependence 2004;74(1):1-13.

Roy 2001

Roy A. Characteristics of cocaine-dependent patients
who attempt suicide. American Journal of Psychiatry
2001;158(8):1215-9.

Schünemann 2006

Schünemann HJ, Jaeschke R, Cook D, Bria W, El-Solh A, Ernst A,
et al. An official ATS statement: grading the quality of evidence
and strength of recommendations in ATS guidelines and
recommendations. American Journal of Respiratory and Critical
Care Medicine 2006;174(5):605-14.

Psychosocial interventions for stimulant use disorder (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

43

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Secades Villa 2015

UNODC 2022

Secades-Villa R, García-Rodríguez O, Fernández-Hermida JR.
Contingency management for substance use disorders in Spain:
Implications for research and practice. Preventive Medicine
2015;80:82-8.

Shedler 2010

Shedler J. The efficacy of psychodynamic psychotherapy.
American Psychologist 2010;65(2):98-109.

United Nations Office on Drugs and Crime. World Drug Report.
Vienna: United Nations publication, Sales No. E.15.XI.6, 2022.

Van Schaik 2006

Van Schaik A, Van Marwijk H, Adèr H, Van Dyck R, De Haan M,
Penninx B, et al. Interpersonal psychotherapy for elderly
patients in primary care. American Journal of Geriatric
Psychiatry 2006;14(9):777-86.

Shoptaw 2006

Volkow 2004

Volkow N, Fowler J, Wang GJ, Swanson J. Dopamine in
drug abuse and addiction: results from imaging studies and
treatment implications. Molecular Psychiatry 2004;9(6):557-69.

WHO 2006

World Health Orgnization. Lexicon of alcohol and drug
terms published by the World Health Organization. 2006.
Available from: www.who.int/substance_abuse/terminology/
who_lexicon/en/ (accessed 8 March 2016).

Witkiewitz 2011

Witkiewitz K, Marlatt A. Behavioral therapy across the spectrum.
Alcohol Research & Health 2011;33(4):313-9. [PMID: 23580016]

Worhunsky 2013

Worhunsky PD, Stevens MC, Carroll KM, Rounsaville BJ,
Calhoun VD, Pearlson GD, et al. Functional brain networks
associated with cognitive control, cocaine dependence,
and treatment outcome. Psychology of Addictive Behaviors
2013;27(2):477-88.

References to other published versions of this review

Minozzi 2015a

Minozzi S, Saulle R, De Crescenzo F, Amato L. Psychosocial
interventions for psychostimulant misuse. Cochrane Database
of Systematic Reviews 2015, Issue 11. Art. No: CD011866. [DOI:
10.1002/14651858.CD011866]

Minozzi 2016

Minozzi S, Saulle R, De Crescenzo F, Amato L. Psychosocial
interventions for psychostimulant misuse. Cochrane Database
of Systematic Reviews 2016, Issue 9. Art. No: CD011866. [DOI:
10.1002/14651858.CD011866.pub2]

* Indicates the major publication for the study

Shoptaw S, Klausner JD, Reback CJ, Tierney S,
Stansell J, Hare CB, et al. A public health response to the
methamphetamine epidemic: the implementation of
contingency management to treat methamphetamine
dependence. BMC Public Health 2006;6:214.

Siefried 2020

Siefried KJ, Acheson LS, Lintzeris N, Ezard N. Pharmacological
treatment of methamphetamine/amphetamine dependence:
a systematic review. CNS Drugs 2020;34(4):337-65. [DOI: doi:
10.1007/s40263-020-00711-x]

Smedslund 2011

Smedslund G, Berg RC, Hammerstrøm KT, Steiro A, Leiknes KA,
Dahl HM, et al. Motivational interviewing for substance abuse.
Cochrane Database of Systematic Reviews 2011, Issue 5. Art. No:
CD008063. [DOI: 10.1002/14651858.CD008063.pub2]

Tardelli 2023

Tardelli VS, Berro LF, Gerra G, Tadonio L, Bisaga A, Fidalgo TM.
Prescription psychostimulants for cocaine use disorder: a
review from molecular basis to clinical approach. Addiction
Biology 2023;28(4):e13271. [DOI: doi: 10.1111/adb.13271]

Tiffany 1993

Tiffany ST, Singleton E, Haertzen CA, Henningfield JE. The
development of a cocaine cravingquestionnaire.. Drug and
Alcohol Dependence 1993;34(1):19-28.

Tran 2021

Tran MTN, Luong QH, Le Minh G, Dunne MP, Baker P.
Psychosocial interventions for amphetamine type stimulant
use disorder: an overview of systematic reviews. Frontiers in
Psychiatry 2021;12:512076. [DOI: 10.3389/fpsyt.2021.512076]

C H A R A C T E R I S T I C S   O F   S T U D I E S

Characteristics of included studies [ordered by study ID]

Alammehrjerdi 2019 

Study characteristics

Methods

Randomised controlled trial

Participants

Country: Iran

Psychosocial interventions for stimulant use disorder (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

44

 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Alammehrjerdi 2019  (Continued)

Participants: Iranian methadone-maintained women

N = 120 women

Age: not reported

Sex: females (100%)

Ethnicity: not reported

Marital status: not reported

Education level: not reported

Employment: not reported

Setting: outpatients (four methadone treatment services located in Tehran, Iran)

History:

• Route: not reported
• Psychostimulant use: regular methamphetamine use; baseline methamphetamine items of the Opi-

ate Treatment Index (OTI; mean (SD) BCBT = 1.3 (0.47); Control = 1.2 (0.44)

• Other drugs: 100% methadone-maintained women
• Psychiatric comorbidity: not reported

Interventions

1. Brief cognitive behavioural therapy condition (BCBT, n = 60),
2. Non-BCBT control condition (control, n = 60)

Duration of intervention: 4 weeks; four weekly sessions

Duration of follow-up: three-month follow-up (week 12)

Outcomes

• Dropout
• Abstinence
• Frequency of drug intake
• Severity of dependence

Notes

Funding source: the authors thank the National Drug and Alcohol Research Centre

Conflict of interest: not reported

Risk of bias

Bias

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Low risk

Quote: "a statistician conducted block randomization by using STATA soft-
ware. The random allocation sequence was generated and stratified by study
site."

Allocation concealment
(selection bias)

Low risk

Quote: "The statistician who conducted the randomization placed the print-
ed codes in envelopes and gave them to the principal investigator (PI). The PI
gave sequentially numbered, opaque, sealed envelopes to a clinical psycholo-
gist for group allocation at each study site. The clinical psychologist was blind
to the codes inside the envelopes before opening them."

Blinding of participants
and personnel (perfor-
mance bias)
Subjective outcomes

High risk

Blinding of participants and personnel impossible for the types of intervention

Psychosocial interventions for stimulant use disorder (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

45

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Alammehrjerdi 2019  (Continued)

Blinding of participants
and personnel (perfor-
mance bias)
Objective outcomes

Low risk

No blinding or incomplete blinding, but the review authors judge that the out-
come is not likely to be influenced by lack of blinding.

Blinding of outcome as-
sessment (detection bias)
Subjective outcomes

Unclear risk

Blinding of outcome as-
sessment (detection bias)
Objective outcomes

Low risk

Quote: "One clinical psychologist conducted the treatment sessions and an-
other conducted the control sessions. One psychologist completed the study
assessments at baseline and post-treatment, and one psychologist complet-
ed assessments at follow-up. Before conducting the study, the research staff
were trained and participants were reminded by the psychologists not to dis-
cuss the sessions with other patients and methadone staff."

Unclear information, but the review authors judge that the outcome is not
likely to be influenced by lack of blinding.

Low risk

No dropout from the study

Unclear risk

N° of protocol provided not found in the Iranian Registry of Clinical Trials

Incomplete outcome data
(attrition bias)
All outcomes except reten-
tion in treatment

Selective reporting (re-
porting bias)

Baker 2001 

Study characteristics

Methods

Randomised controlled trial

Participants

Country: Australia

Participants: Regular users of amphetamines
N = 64
Age: 32 years old (mean age)
Sex: Males 62%
Ethnicity: Not reported

Marital status: Not reported

Education level: 10.5 years (mean)
Employment: Not reported

Setting: Outpatients

History:

• Route: not reported
• Psychostimulant use: mean daily level of amphetamine use (OTI score): control: 0.83 (SD 1.03); inter-

vention group: 1.20 (SD 1.65).

• Other drugs: reported use of cannabis, tobacco, and unspecified polydrug. 36.5% in methadone main-

tenance

• Psychiatric comorbidity: not reported

Interventions

1. CBT (RP Brief) (2 or 4 sessions) + self-help booklet on reducing amphetamine use and related harms

(n = 32)

2. Self-help booklet only (n = 32)

Psychosocial interventions for stimulant use disorder (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

46

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Baker 2001  (Continued)

Duration of intervention: Not reported

Duration of follow-up: 6 months

Outcomes

• Dropouts
• Use of cocaine at 6-month follow-up

Cochrane Database of Systematic Reviews

Notes

Funding source: Research Management Committee (RMC) grant from the University of Newcastle

Conflict of interest: Not stated

RP: individual sessions guided by a therapist

Risk of bias

Bias

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Unclear risk

Information not reported

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias)
Subjective outcomes

Blinding of participants
and personnel (perfor-
mance bias)
Objective outcomes

Blinding of outcome as-
sessment (detection bias)
Subjective outcomes

Blinding of outcome as-
sessment (detection bias)
Objective outcomes

Incomplete outcome data
(attrition bias)
All outcomes except reten-
tion in treatment

Unclear risk

Information not reported

High risk

Blinding of participants and personnel impossible for the types of intervention

Low risk

Low risk

Low risk

Low risk

No blinding or incomplete blinding, but the review authors judge that the out-
come is not likely to be influenced by lack of blinding

Quote: "Follow-up assessments were conducted by an interviewer blind to the
subject’s group allocation"

Quote: "Follow-up assessments were conducted by an interviewer blind to the
subject’s group allocation"

18.7% withdrew from the study; no significant difference in retention rates
across groups. Analysis of data on the same key prognostic variables above in-
dicated that there were no significant differences between participants who
were followed up (n = 52) and participants who were not followed up (n = 12).

Selective reporting (re-
porting bias)

Unclear risk

Information about protocol not reported; outcomes not clearly described in
the Methods section; raw data not reported for the majority of the outcomes

Baker 2005 

Study characteristics

Methods

Randomised controlled trial

Participants

Country: Australia

Psychosocial interventions for stimulant use disorder (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

47

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Baker 2005  (Continued)

Cochrane Database of Systematic Reviews

Participants: 214 regular users of amphetamines recruited from the Newcastle region (n = 98) of New
South Wales and from the Greater Brisbane Region of South-East Queensland (n = 116), Australia
N = 214
Age: 30.22 years old (mean age)

Sex: males 62.6%
Ethnicity: not reported
Marital status: not reported

Education level: not reported
Employment: not reported

Setting: outpatients

History

• Route: not reported
• Psychostimulant use: mean duration of regular use was 8.98 years (SD 6.99); OTI drug use score for

amphetamines: 1.55 (SD 1.61) pre-treatment (n = 214); polydrug use: 4.31 (SD 1.46)

• Psychiatric comorbidity: mental health % ever diagnosed/treated: 47.7% (n = 102); currently taking

medication for mental health: 41.6% (n = 89)

Interventions

The primary study had the following arms:

1. 2-session CBT (n = 74) + self-help booklet
2. 4-session CBT (n = 66) + self-help booklet
3. Control (n = 74) self-help booklet

In this review, we compared the combination of groups 1 and 2 (intervention) versus group 3 (control).

Duration of intervention: 5 weeks following pre-treatment assessment

Duration of follow-up: 6 months following the post-treatment assessment

Outcomes

• Changes in amphetamine use
• Abstinence rates

Notes

Funding source: Commonwealth Department of Health and Ageing

Conflict of interest: not stated

Risk of bias

Bias

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Low risk

Quote: "A nine-block randomization schedule was used, which was coordinat-
ed by an independent clinical trials researcher. The sample was stratified by
location, gender and maintenance pharmacotherapy status for heroin depen-
dence"

Allocation concealment
(selection bias)

Low risk

Quote: "randomization schedule was used, which was coordinated by an inde-
pendent clinical trials"

Blinding of participants
and personnel (perfor-
mance bias)
Subjective outcomes

Blinding of participants
and personnel (perfor-
mance bias)

High risk

Blinding of participants and personnel impossible for the types of intervention

Low risk

No blinding or incomplete blinding, but the review authors judge that the out-
come is not likely to be influenced by lack of blinding

Psychosocial interventions for stimulant use disorder (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

48

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Low risk

Low risk

Quote: "Assessments were conducted by trained interviewers who were blind
to participants' treatment allocation"

Quote: "Assessments were conducted by trained interviewers who were blind
to participants' treatment allocation"

Low risk

ITT analysis performed. Missing outcome data coded non-abstinent

Unclear risk

Protocol of the study was not available

Baker 2005  (Continued)
Objective outcomes

Blinding of outcome as-
sessment (detection bias)
Subjective outcomes

Blinding of outcome as-
sessment (detection bias)
Objective outcomes

Incomplete outcome data
(attrition bias)
All outcomes except reten-
tion in treatment

Selective reporting (re-
porting bias)

Blanken 2016 

Study characteristics

Methods

Multicenter, open-label, parallel-group, randomised controlled trial

Participants

Country: the Netherlands

Participants: treatment-refractory heroin-dependent who started heroin-assisted treatment (HAT)
with frequent cocaine use

N = 214

Age: 44.1 (mean age)

Sex: males 85.1%

Ethnicity: Dutch/western 69.5%

Marital status: not reported

Education level: not reported

Employment: source of income: welfare/public assistance 73.1%

Setting: outpatients

History:

• Route: not reported
• Psychostimulant use: a long history of regular heroin (20.6 years) and cocaine (16.6 years) use
• Other drugs: amphetamines, benzodiazepines, and alcohol
• Mental health problems assessed by the Symptom Check-list 90 items (SCL-90): 74.3% of the included
participants exhibited a score on SCL-90 greater than or equal to 60 in males and greater than or equal
to 40 in females

Interventions

Routine, daily supervised (injectable or inhalable) diacetylmorphine treatment, co-prescribed with oral
methadone (HAT), with and without 6 months of contingency management (CM) for cocaine use as an
add-on intervention

1. HAT + CM (n = 107)

Psychosocial interventions for stimulant use disorder (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

49

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Blanken 2016  (Continued)

Cochrane Database of Systematic Reviews

Outcomes

Notes

2. HAT-only (n = 107)

Duration of intervention: 6 months

Duration of Follow-up: 6 months naturalistic follow-up phase

• Dropout
• Frequency of drug intake
• Longest period of abstinence
• Cocaine craving

Funding source: "The trial was commissioned and funded by the Ministry of Health, Welfare and
Sports of the Netherlands. The funder was not involved in the design of the study, the implementation
of the study, the analyses of the results, nor in writing the manuscript."

Conflict of interest: "All authors were part of the research team of the Central Committee on the Treat-
ment of Heroin Addicts (CCBH), that designed, conducted and reported on the heroin trials in The
Netherlands. All authors have completed the ICMJE uniform disclosure format www.icmje.org/coi dis-
closure.pdf (available on request from the corresponding author) and all authors report grants from
Netherlands Ministry of Health, Welfare and Sports, during the conduct of the study. VMH reports per-
sonal fees from Lundbeck, outside the submitted work. WvdB reports personal fees from Lundbeck,
Merck Serono, Reckitt Benckiser, Eli Lilly, Pfizer, and Schering Plough, and grants from Alkermes, out-
side the submitted work. All authors report no relationships or activities that could appear to have in-
fluenced the submitted work."

Risk of bias

Bias

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Low risk

Quote: "computer generated block-assignment, with a 1:1 ratio in blocks of 2
per stratum. Randomization was stratified by treatment center and, to ensure
a similar distribution of patients with low and high frequency cocaine use in
both treatment conditions, randomization was pre-stratified by the level of re-
cent cocaine use (≤ 26 versus > 26 days in the month before randomization;
the 70th percentile)."

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias)
Subjective outcomes

Blinding of participants
and personnel (perfor-
mance bias)
Objective outcomes

Blinding of outcome as-
sessment (detection bias)
Subjective outcomes

Unclear risk

No information provided

High risk

Blinding of participants and personnel impossible for the types of intervention

Low risk

No blinding or incomplete blinding, but the review authors judge that the out-
come is unlikely to be influenced by lack of blinding

Unclear risk

Information not reported

Blinding of outcome as-
sessment (detection bias)
Objective outcomes

Low risk

Information not reported; however, objective outcomes unlikely to be biased
by lack of blinding

Incomplete outcome data
(attrition bias)

Low risk

ITT analysis performed. Missing outcome data coded non-abstinent

Psychosocial interventions for stimulant use disorder (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

50

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Blanken 2016  (Continued)

All outcomes except reten-
tion in treatment

Cochrane Database of Systematic Reviews

Selective reporting (re-
porting bias)

Low risk

Protocol available. All the outcomes listed in the study protocol were also re-
ported in the results section of the article

Carroll 1991 

Study characteristics

Methods

Randomised controlled trial

Participants

Country: USA

Participants: cocaine abusers (DSM-III)

N = 42

Age: 27 years old (mean age)

Sex: males 74%

Ethnicity: white 76.2%

Marital status: married 17.5%

Education level: 13 years (mean)

Employment: employed 65%

Setting: outpatients

History:

• Route: 33.3% freebase, 50% intranasal
• Psychostimulant use: ~ 4 g per week, for approximately 40 months
• Other drugs: 31% of participants also report regular use of other substances (alcohol 87.5%, marijuana

37.5%)

• Psychiatric comorbidity: depressive disorders (19%), antisocial personality disorders (26%)

Interventions

1. CBT (RP) (n = 21)
2. Interpersonal therapy (IPT) (n = 21)

Duration of intervention: both interventions consisted of individual sessions of 50 to 60 minutes once
a week for 3 months

Duration of follow-up: 3 months

Outcomes

• Dropouts
• Use of cocaine for at least 3 consecutive weeks at any point of treatment
• Use of cocaine for at least 3 consecutive weeks at endpoint of study

Notes

Funding source: National Institute on Drug Abuse Grant DA 04299

Conflict of interest: not stated

Risk of bias

Psychosocial interventions for stimulant use disorder (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

51

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Carroll 1991  (Continued)

Bias

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Unclear risk

Information not reported

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias)
Subjective outcomes

Blinding of participants
and personnel (perfor-
mance bias)
Objective outcomes

Blinding of outcome as-
sessment (detection bias)
Subjective outcomes

Unclear risk

Information not reported

High risk

Blinding of participants and personnel impossible for the types of intervention

Low risk

No blinding or incomplete blinding, but the review authors judge that the out-
come is unlikely to be influenced by lack of blinding

Unclear risk

No information reported

Blinding of outcome as-
sessment (detection bias)
Objective outcomes

Low risk

No blinding or incomplete blinding, but the review authors judge that the out-
come is unlikely to be influenced by lack of blinding

High risk

45% of participants dropped out from the study. Imbalance between groups:
33% RP, 62% IPT

Unclear risk

Protocol not available

Incomplete outcome data
(attrition bias)
All outcomes except reten-
tion in treatment

Selective reporting (re-
porting bias)

Carroll 1994 

Study characteristics

Methods

Randomised controlled trial

Participants

Country: USA

Participants: cocaine use/dependence (DSM-III-R)
N = 110 (139 randomised; 121 initiated treatment but only 110 analysed)
Sex: males 63%
Age: 28.8 years old (mean age)
Ethnicity: "minority" 54%
Marital status: married 29%
Education level: at least 12 years of education 76%

Employment: employed 53%

Setting: outpatients

History:

• Route: 62% freebase, 29% intranasal, 9% intravenous

Psychosocial interventions for stimulant use disorder (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

52

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Carroll 1994  (Continued)

Cochrane Database of Systematic Reviews

• Psychostimulant use: 4.4 (SD 3.3) g of cocaine use per week; years of use: mean of 4.2 years; previous

treatments: 30% of participants

• Other drugs: 48% lifetime alcohol dependence
• Psychiatric comorbidity: 20% lifetime affective disorder, 13% lifetime anxiety disorder, 49% antisocial

personality disorder, 65% any other personality disorder

Interventions

Pharmacotherapy (desipramine hydrochloride or placebo) and psychotherapy in a 2 x 2 design

1. CBT (n = 58)
2. Clinical management (n = 52)

Duration of intervention: psychosocial interventions were manual-guided and provided weekly in in-
dividual sessions over 3 months

Outcomes

Duration of follow-up: 3 months

• Dropouts
• Mean percent of abstinence days
• Mean number of sessions attended by depressed cocaine abusers
• Mean number of sessions attended by euthymic cocaine abusers

Notes

Funding source: National Institute on Drug Abuse. Bethesda, MD

Conflict of interest: not stated

Risk of bias

Bias

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Unclear risk

Information not reported

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias)
Subjective outcomes

Blinding of participants
and personnel (perfor-
mance bias)
Objective outcomes

Unclear risk

Information not reported

High risk

Blinding of participants and personnel impossible for the types of intervention

Low risk

No blinding or incomplete blinding, but the review authors judge that the out-
come is unlikely to be influenced by lack of blinding

Blinding of outcome as-
sessment (detection bias)
Subjective outcomes

Low risk

Blinding of outcome as-
sessment (detection bias)
Objective outcomes

Low risk

Quote: "to maintain a single blind for psychotherapy, the clinical evaluator
saw subjects in an office physically separated from the office in which therapy
was conducted and instructed subjects not to disclose details of their therapist
or treatment"

Quote: "to maintain a single blind for psychotherapy, the clinical evaluator
saw subjects in an office physically separated from the office in which therapy
was conducted and instructed subjects not to disclose details of their therapist
or treatment"

Incomplete outcome data
(attrition bias)

High risk

139 randomised (the initial allocation to each group not reported); 121 initiat-
ed treatment but only 110 analysed. 33% dropout at 3 months (12 weeks), bal-
anced across groups (34 CBT and 32 clinical management)

Psychosocial interventions for stimulant use disorder (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

53

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Carroll 1994  (Continued)

All outcomes except reten-
tion in treatment

Selective reporting (re-
porting bias)

Carroll 1998 

Study characteristics

Unclear risk

Protocol not available

Methods

Randomised controlled trial

Participants

Country: USA

Participants: cocaine dependence with comorbid alcohol dependence or abuse (DSM-III-R)

N = 122

Sex: males 73%

Age: 30.8 years old (mean age)

Ethnicity: African American 56%, white 39%, Latino 3%, other 2%

Marital status: married 41%

Education level: completed some college 23% (47% high school, 30% did not complete high school)

Employment: employed 43%

Setting: outpatient

History:

• Route: 77% freebase, 20% intranasal, 3% intravenous
• Psychostimulant use:

◦ Mean 4.0 (SD 5.1) g of cocaine per week
◦ Days of use: mean of 14.1 (SD 8.1) days of the past 30 days of cocaine use
◦ Years of cocaine dependence: 7.5 (4.4) years.
◦ Previous exposure to treatment: 53%

• Other drugs: alcohol use: mean of 17.2 days of the past 30 days, with a mean of 11.6 (SD 8.1) standard

drinks (SDU) per drinking occasion; years of alcohol abuse: 7.3 (SD 6.2)

• Psychiatric comorbidity: excluded participants currently physically dependent on opiates or barbitu-

rates, or whose principal drug of dependence was not cocaine

Interventions

The primary study had the following arms:

1. CBT (relapse prevention coping skills training) alone (n = 18)
2. CBT plus disulfiram (n = 24)
3. TSF, adapted from Project MATCH alone (n = 23)
4. TSF plus disulfiram (n = 25)
5. Clinical management plus disulfiram (n = 27)

In this review, we compared the combination of groups 1 and 2 versus the combination of groups 3 and
4. We did not consider group 5.

Treatments: each of the study treatments was manual-guided and delivered in weekly individual ses-
sions.

Psychosocial interventions for stimulant use disorder (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

54

 
 
 
 
Cochrane Database of Systematic Reviews

Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Carroll 1998  (Continued)

Duration of intervention: 3 months

Disulphiram: 250 to 500 mg/day. Modal dose 261.5 mg/day

Duration of follow-up: 3 months

Outcomes

• Abstinence from cocaine for at least 3 consecutive weeks
• Abstinence from cocaine and alcohol for 3 consecutive weeks

Notes

Funding source: National Institute on Drug Abuse

Conflict of interest: not stated

Weekly individual sessions

Risk of bias

Bias

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Unclear risk

Information not reported

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias)
Subjective outcomes

Blinding of participants
and personnel (perfor-
mance bias)
Objective outcomes

Unclear risk

Information not reported

High risk

Blinding of participants and personnel impossible for the types of intervention

Low risk

No blinding or incomplete blinding, but the review authors judge that the out-
come is not likely to be influenced by lack of blinding

Blinding of outcome as-
sessment (detection bias)
Subjective outcomes

Low risk

Blinding of outcome as-
sessment (detection bias)
Objective outcomes

Low risk

Quote: "to maintain a single blind for psychotherapy, the clinical evaluator
saw subjects in an office physically separated from the office in which therapy
was conducted and instructed subjects not to disclose details of their therapist
or treatment"

Quote: "to maintain a single blind for psychotherapy, the clinical evaluator
saw subjects in an office physically separated from the office in which therapy
was conducted and instructed subjects not to disclose details of their therapist
or treatment"

Low risk

4% dropout

Unclear risk

Protocol not available

Incomplete outcome data
(attrition bias)
All outcomes except reten-
tion in treatment

Selective reporting (re-
porting bias)

Carroll 2004 

Study characteristics

Psychosocial interventions for stimulant use disorder (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

55

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Carroll 2004  (Continued)

Methods

Randomised controlled trial

Participants

Country: USA

Cochrane Database of Systematic Reviews

Participants: individuals who met DSM-IV criteria for current cocaine dependence

N = 121

Sex: males 74%

Age: 34.6 years old (mean age)

Ethnicity: white 63%, African American 31%, Latino 6%

Marital status: single or divorced 77%

Education level: less than high school 25%, high school graduate 40%, some education after high
school 56%

Employment: working full- or part-time 55%

Setting: outpatient

History:

• Route: not reported
• Psychostimulant use: mean monthly cocaine use at baseline was 16.6 g, and participants reported

using cocaine a mean of 13.0 days in the previous 28 days

• Other drugs: participants reported drinking alcohol a mean of 9.4 days in the previous 28 days. 54% of
the participants met DSM-IV criteria for a lifetime diagnosis of alcohol dependence, and 26% met the
criteria for a lifetime diagnosis of alcohol abuse. 52% of the patients met DSM-IV criteria for current
alcohol abuse or dependence.

• Psychiatric comorbidity:

◦ N (%) psychiatric diagnoses meeting lifetime DSM-IV criteria: any affective disorder: 44 (36); any
anxiety disorder: 23 (19); antisocial personality disorder: 48 (41); other axis II disorder: 63 (52)
◦ N (%) psychiatric diagnoses meeting current DSM-IV criteria: any affective disorder: 30 (25); any

anxiety disorder: 14 (12)

Interventions

The primary study had the following four arms:

1. CBT + disulphiram (n = 30)
2. IPT (interpersonal therapy) + disulphiram (n = 30)
3. CBT + placebo (n = 30)
4. IPT + placebo (n = 31)

In this review, we compared the combination of groups 1 and 3 versus the combination of groups 2 and
4.

Duration of intervention: 3 months

Duration of follow-up: 3 months

Outcomes

• Self-reported frequency of cocaine use
• Results of urine toxicology screens

Notes

Funding source: National Institute on Drug Abuse

Conflict of interest: not stated

No useful data for meta-analysis

Psychosocial interventions for stimulant use disorder (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

56

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Carroll 2004  (Continued)

Risk of bias

Bias

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Unclear risk

Information not reported

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias)
Subjective outcomes

Blinding of participants
and personnel (perfor-
mance bias)
Objective outcomes

Blinding of outcome as-
sessment (detection bias)
Subjective outcomes

Unclear risk

Information not reported

High risk

Blinding of personnel impossible for the types of intervention; participants
blinded to the intervention

Low risk

Incomplete blinding, but the review authors judge that the outcome is unlikely
to be influenced by lack of blinding

Unclear risk

Information not reported

Blinding of outcome as-
sessment (detection bias)
Objective outcomes

Low risk

Information not reported, but the review authors judge that the outcome is
unlikely to be influenced by lack of blinding

High risk

16% of participants dropped out before the end of treatment; balanced be-
tween groups

Unclear risk

Protocol not available

Incomplete outcome data
(attrition bias)
All outcomes except reten-
tion in treatment

Selective reporting (re-
porting bias)

Carroll 2012 

Study characteristics

Methods

Randomised controlled trial

Participants

Country: USA

Participants: self-referred or referred by clinician on detection of positive urine tests for cocaine;
methadone maintenance patients were included as participants if they met DSM-IV criteria for current
cocaine dependence
N = 112
Age: 38.3 years old (mean age)

Sex: males 59%
Ethnicity: African American 22%,Latino 14%, white 64%
Marital status: never been married or were living alone 65%

Education level: completed some college-level worK 34% (70% had not completed high school; 43%
were high school graduates)
Employment: unemployed 45%

Psychosocial interventions for stimulant use disorder (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

57

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Carroll 2012  (Continued)

Setting: outpatients

History:

Cochrane Database of Systematic Reviews

• Route: not reported
• Psychostimulant use: cocaine an average of 15.4 days (SD 8.9)
• Other  drugs:  alcohol  an  average  of  4.6  days  (SD  7.7)  in  the  past  28  days.  100%  of  participants  in
methadone maintenance; 37% met DSM-IV criteria for a current alcohol use disorder (62% lifetime)
• Psychiatric comorbidity; 35% met criteria for a lifetime diagnosis of a depressive disorder, and 17%

met criteria for a lifetime anxiety disorder

Interventions

1. Disulphiram (n = 30) or placebo (n = 26)
2. 12-step facilitation (TSF) with disulphiram (n = 29) or with placebo (n = 27)

Duration of intervention: 3 months

Duration of follow-up: 3 months

Outcomes

Frequency of self-reported cocaine use and results of urine toxicology screens

Notes

Funding source: NIDA grants R01-DA10679 and P50-DA09241

Conflict of interest: "All authors have no conflicts to declare"

On average, participants had been enroled in the methadone programme for 14.8 months (SD 50.9) at
the time of the baseline assessment and their mean methadone dose was 87 mg (SD 19.0). The partici-
pants reported an average of 8 previous arrests and 20 months of incarceration during their lifetimes.

Risk of bias

Bias

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Low risk

Quote: "A computerized urn randomization . . . program used in several previ-
ous multicenter trials. . . was used to balance groups with respect to baseline
severity of cocaine dependence, alcohol use, gender and race."

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias)
Subjective outcomes

Blinding of participants
and personnel (perfor-
mance bias)
Objective outcomes

Blinding of outcome as-
sessment (detection bias)
Subjective outcomes

Unclear risk

Information not reported

High risk

Blinding of participants and personnel impossible for the types of intervention

Low risk

No blinding or incomplete blinding, but the review authors judge that the out-
come is unlikely to be influenced by lack of blinding

Unclear risk

No information reported

Blinding of outcome as-
sessment (detection bias)
Objective outcomes

Low risk

No blinding or incomplete blinding, but the review authors judge that the out-
come is unlikely to be influenced by lack of blinding

Incomplete outcome data
(attrition bias)

Low risk

1.7% dropout at the end of treatment; 3% at follow-up, balanced across
groups

Psychosocial interventions for stimulant use disorder (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

58

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Carroll 2012  (Continued)

All outcomes except reten-
tion in treatment

Selective reporting (re-
porting bias)

Carroll 2014 

Study characteristics

Unclear risk

Protocol not available

Methods

Randomised controlled trial

Participants

Country: USA

Participants: DSM-IV criteria for current (within the past 30 days) cocaine dependence. Participants re-
cruited from methadone maintenance programmes

N = 101

Age: 42 years old (mean of mean)

Sex: males 40%

Ethnicity: African American 30%, white 60%, Latino 8%

Marital status: single or divorced 88%

Education level: completed high school 71%

Employment: unemployed:89%

Setting: outpatients

History:

• Route: not reported
• Psychostimulant use: participants used cocaine an average of 15 days per month and had been using

cocaine for approximately 11 years.

• Other drugs: they reported using marijuana for about 2.5 days per month and alcohol less than 1 day
per month. 100% of participants in methadone maintenance; current alcohol use disorder: 2.2% in
experimental and 5.7% in the control group.

• Psychiatric comorbidity: major depression, lifetime 31.9% in experimental treatment and 25.9% in
the control group; anxiety disorder, lifetime: 34% in experimental treatment, 29.6% in control group

Interventions

1. Standard methadone maintenance (treatment as usual) (n = 54)
2. Treatment as usual plus CBT4CBT (computer-based training for CBT) (n = 47)

Duration of intervention: 2 months

Duration of follow-up: 12 months

Outcomes

Primary outcomes:

• Change in self-reported drug use over time verified by urine analysis (days of cocaine use by week)
• Results of urine toxicology screens (operationalised as the percentage of drug-negative urine samples

collected during treatment)

• Attainment of 3 or more weeks of continuous abstinence

Secondary outcomes: included reductions in self-reported HIV risk behaviours

Psychosocial interventions for stimulant use disorder (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

59

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Carroll 2014  (Continued)

Cochrane Database of Systematic Reviews

Notes

Funding source: National Institute on Drug Abuse grants R37-DA 015969 and P50-DA09241

Conflict of interest: "Dr. Carroll works with Yale University to manage any potential conflicts of inter-
est. The other authors report no financial relationships with commercial interests."

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias)
Subjective outcomes

Blinding of participants
and personnel (perfor-
mance bias)
Objective outcomes

Blinding of outcome as-
sessment (detection bias)
Subjective outcomes

Authors' judgement

Support for judgement

Low risk

Quote "We used a computerized urn randomization program"

Unclear risk

Information not reported

High risk

Blinding of participants and personnel impossible for the types of intervention

Low risk

No blinding or incomplete blinding, but the review authors judge that the out-
come is unlikely to be influenced by lack of blinding

Unclear risk

No information reported

Blinding of outcome as-
sessment (detection bias)
Objective outcomes

Low risk

No blinding or incomplete blinding, but the review authors judge that the out-
come is unlikely to be influenced by lack of blinding

Low risk

8% dropout, balanced across groups

Low risk

All the outcomes listed in the study protocol were also reported in the study.

Incomplete outcome data
(attrition bias)
All outcomes except reten-
tion in treatment

Selective reporting (re-
porting bias)

Carroll 2016 

Study characteristics

Methods

Randomized controlled trial

Participants

Country: USA

Participants: meet DSM-IV diagnostic criteria for current cocaine dependence

N = 99

Age: 39.3 (7.5), mean age (SD)

Sex: females 27.3%

Psychosocial interventions for stimulant use disorder (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

60

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Carroll 2016  (Continued)

Ethnicity: white 39.4%, African American 49.5%, Latino/a 7.1%, other 7.1%

Marital status: single 71.7%

Education level: high school education 85.9%

Employment: unemployed 66.7%

Setting: outpatients

History:

• Route: not reported
• Psychostimulant use: cocaine dependence
• Other drugs: individuals were excluded if they were currently dependent on another drug (except to-

bacco) or whose principal drug use was not cocaine

• Psychiatric comorbidity: major depression 18.2%, anxiety 5.1%

Interventions

In the primary study, participants were divided into the following 4 groups: (1) Disulfiram (DIS) + CBT/
CM n = 23; (2) DIS + CBT/no CM n = 28; (3) Placebo + CBT/no CM n = 26; (4) Placebo + CBT/CM n = 22

In the present systematic review, participants were combined into the two following groups:

1. CM group (n = 45): (DIS + CBT/CM n = 23) + (Placebo + CBT/CM n = 22)
2. No CM group (n = 54): (DIS + CBT/no CM n = 28) + (Placebo + CBT/no CM n = 26)

Duration of intervention:12 weeks

Duration of follow-up: 3 months

• Dropout
• Abstinence
• Frequency of drug intake

Funding source: Support provided by National Institute on Drug Abuse grants R01 DA019078, P50-
DA09241, K12 DA00167 and K05-DA00457

Conflict of interest: "None of the authors have other relevant financial disclosures or conflicts of inter-
est."

Authors' judgement

Support for judgement

Outcomes

Notes

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Low risk

Quote: "A computerized urn randomization program used in several previous
trials (Ball et al., 2007; Carroll et al., 2004a, 2009; Stout et al., 1994) was used
to produce equivalent group size and balance groups with respect to baseline
level of cocaine use (more or less than 11 days per month), presence of alcohol
dependence (yes/no), gender and ethnicity (ethnic minority/non-minority)"

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias)
Subjective outcomes

Blinding of participants
and personnel (perfor-
mance bias)

Unclear risk

No information

High risk

Blinding of participants and personnel impossible for the types of intervention

Low risk

No blinding or incomplete blinding, but the review authors judge that the out-
come is unlikely to be influenced by lack of blinding

Psychosocial interventions for stimulant use disorder (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

61

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Carroll 2016  (Continued)
Objective outcomes

Blinding of outcome as-
sessment (detection bias)
Subjective outcomes

Unclear risk

No information reported

Blinding of outcome as-
sessment (detection bias)
Objective outcomes

Low risk

No blinding or incomplete blinding, but the review authors judge that the out-
come is unlikely to be influenced by lack of blinding

Low risk

ITT analysis

Low risk

Protocol available; all the declared outcomes reported in the final publication

Incomplete outcome data
(attrition bias)
All outcomes except reten-
tion in treatment

Selective reporting (re-
porting bias)

Carroll 2018 

Study characteristics

Methods

Randomised factorial trial

Participants

Country: USA

Participants: individuals stabilised on methadone maintenance who met DSM-IV-R criteria for current
cocaine dependence

N = 120

Age: 38.2 years

Sex: females 34%

Ethnicity: white 52%

Marital status: not reported

Education level: completed high school: 71.5%

Employment: unemployed: 72.5%

Setting: outpatients

History:

• Route: not reported
• Psychostimulant use: days of cocaine use, past 28 days: 14.5
• Other drugs: marijuana, cigarettes, opiates, benzodiazepines, alcohol use disorder 55%
• Psychiatric  comorbidity:  major  depression  8.75%,  anxiety  13.5%,  antisocial  personality  disorder

13.5%

Interventions

All participants received standard methadone treatment, consisting of daily methadone and weekly in-
dividual or group counselling, with access to other program services (treatment as usual, TAU)

"Participants assigned to galantamine (GAL) were prescribed a maximum dose of 8 mg galantamine
extended release (ER) and control group received placebo (PLA). Computer based training in CBT
(CBT4CBT) was a direct-to-patient computer based version of a CBT manual that makes extensive use

Psychosocial interventions for stimulant use disorder (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

62

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Carroll 2018  (Continued)

Cochrane Database of Systematic Reviews

of video examples to each cognitive and behavioral control skills in 7 modules, each requiring about
30–40 minutes to complete. The CBT4CBT program uses video vignettes, quizzes, and interactive ex-
ercises to model effective use of skills and strategies. The vignettes present connected scenes of en-
gaging characters portrayed by professional actors, who first experience a common risky situation or
problem and then, after the skill is taught, demonstrate using the targeted skill to successfully negoti-
ate that situation without resorting to drug use. Participants assigned to CBT4CBT worked with the pro-
gram in a private area at the clinic on a weekly basis, usually at the time they completed study assess-
ments."

In the primary study, participants were divided into the following 4 groups:

Groups: (1) GAL plus TAU; (2) PLA plus TAU; (3) GAL plus CBT4CBT plus TAU; (4) PLA plus CBT4CBT+TAU

In the present systematic review, participants were combined into the following 2 groups:

1. no CBT4CBT (n = 54): (GAL plus TAU n = 27) + (PLA plus TAU n = 27)
2. CBT4CBT (n = 66): (GAL plus CBT4CBT plus TAU n = 28) + (PLA plus CBT4CBT+TAU n = 38).

Duration of intervention: 12 weeks

Duration of follow-up: not reported

• Dropout
• Abstinence
• Frequency of drug intake

Funding source: the work was supported by grants P50-DA09241 from the National Institute on Drug
Abuse.

Trial registration: clinicaltrials.gov NCT0080935.

Conflict of interest: "Dr. Carroll was a member in trust of CBT4CBT LLC, which made CBT4CBT avail-
able to qualified clinical providers and organizations on a commercial basis. Dr. Carroll worked with
Yale University to manage any potential conflicts of interest. The other authors had no conflicts to dis-
close."

Authors' judgement

Support for judgement

Outcomes

Notes

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Low risk

Quote: "A masked, computerized urn randomization program used in previous
trials... was used to produce equivalent group size and balance groups with re-
spect to baseline level of cocaine use (more or less than 11 days per month),
gender, ethnicity (ethnic minority/non-minority), age (over/under 40), and
baseline Shipley estimated IQ score."

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias)
Subjective outcomes

Blinding of participants
and personnel (perfor-
mance bias)
Objective outcomes

Blinding of outcome as-
sessment (detection bias)

Unclear risk

No information available

High risk

Blinding of participants and personnel impossible for the types of intervention

Low risk

No blinding or incomplete blinding, but the review authors judge that the out-
come is unlikely to be influenced by lack of blinding

Unclear risk

No information reported

Psychosocial interventions for stimulant use disorder (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

63

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Low risk

Low risk

No blinding or incomplete blinding, but the review authors judge that the out-
come is unlikely to be influenced by lack of blinding

Quote: "Recruitment fell short of this target (averaging 30 per condition), but
high rates of data availability permitted analysis of the full intention to treat
sample"

Low risk

All the outcomes listed in the protocol reported in the final publication

Carroll 2018  (Continued)
Subjective outcomes

Blinding of outcome as-
sessment (detection bias)
Objective outcomes

Incomplete outcome data
(attrition bias)
All outcomes except reten-
tion in treatment

Selective reporting (re-
porting bias)

Crits-Christoph 1999 arm 1 

Study characteristics

Methods

Randomised controlled trial

Participants

Country: USA

Participants: cocaine dependence (DSM-IV)

N = 487

Age: 33.9 years old (mean age)

Sex: males 76.8%

Ethnicity: white 57.9%, African American 39.8%, Latino 2.2%

Marital status: living alone 69.6%

Employment: unemployed 39.6%

Education level: completed a mean of 13 years of school (SD 2.0)

Setting: outpatients; 5 different sites

History:

• Route: 79.0% crack smoking, 18.9% intranasal, 2.1% intravenous
• Psychostimulant use: 10.4 (SD 7.8) days of use in previous 30 days; years of use: 6.9 (SD 4.8)
• Other drugs: 33% alcohol dependence, 4.5% cannabis dependence, 17.0% cannabis abuse
• Psychiatric comorbidity: 28% cocaine-induced mood disorder, 4.9% cocaine-induced anxiety disor-
der, 14% antisocial personality disorder, and 31.8% APD as an adult with no history of a childhood
conduct disorder

Interventions

In the original study, there were 4 arms:

1. CBT (CT) + group counselling (n = 119)
2. Supportive expressive (SE) therapy (psychodynamic approach) + group drug counselling (GDC) (n =

124)

3. Individual counselling (IDC) + group drug counselling (n = 121)
4. Group counselling (control) (n = 123)

For this review, we did not consider group 3.

Psychosocial interventions for stimulant use disorder (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

64

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Crits-Christoph 1999 arm 1  (Continued)

Cochrane Database of Systematic Reviews

In Crits-Christoph 1999 arm 1, we compared group 1 (CBT (CT) + group counselling) versus group 4
(control).

In Crits-Christoph 1999 arm 2, we compared group 2 (Supportive expressive (SE) therapy (psychody-
namic approach) + group drug counselling (GDC) versus group 4 (control).

CT, SE, and IDC: 50-minute individual sessions held twice per week during the first 3 months, then once
per week for the next 3 months, and once per month during a 3-month booster phase. All 3 individual
interventions also had 90-minute group drug counselling sessions held once a week for the 6-month ac-
tive phase.
GDC: in booster phase, participants met with group counsellor individually, 30-minute visit once a
month.

Group 3 (individual drug counselling + group drug counselling) was not considered in this review.

Duration of intervention: 6 months

Duration of follow-up: 6 months

Outcomes

• Dropouts
• Use of cocaine in previous month, measured at 6 months
• Use of cocaine in previous month, measured at endpoint

Notes

Funding source: National Institute on Drug Abuse, Rockville, MD

Conflict of interest: not stated

Drug counselling was based on the 12-step addiction and psycho-educational model, as well as provid-
ing group support and teaching problem-solving skills.

Risk of bias

Bias

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Low risk

Quote: "random assignment uses a special technique known as adaptive or
urn randomization"

Allocation concealment
(selection bias)

Low risk

Quote: "patients were centrally randomly assigned using a computerized 'urn'
randomisation procedure"

Blinding of participants
and personnel (perfor-
mance bias)
Subjective outcomes

Blinding of participants
and personnel (perfor-
mance bias)
Objective outcomes

Blinding of outcome as-
sessment (detection bias)
Subjective outcomes

High risk

Blinding of participants and personnel impossible for the types of intervention

Low risk

No blinding or incomplete blinding, but the review authors judge that the out-
come is unlikely to be influenced by lack of blinding

Low risk

The ASI interviewer was blind to the treatment condition

Blinding of outcome as-
sessment (detection bias)
Objective outcomes

Low risk

No blinding or incomplete blinding, but the review authors judge that the out-
come is unlikely to be influenced by lack of blinding

Incomplete outcome data
(attrition bias)

Low risk

23% dropout at the end of treatment, 21% at the end of follow-up, balanced
across groups

Psychosocial interventions for stimulant use disorder (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

65

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Crits-Christoph 1999 arm 1  (Continued)

All outcomes except reten-
tion in treatment

Cochrane Database of Systematic Reviews

Selective reporting (re-
porting bias)

Low risk

All the declared outcomes in the procotol were reported in the Results.

Crits-Christoph 1999 arm 2 

Study characteristics

Methods

Randomised controlled trial

Participants

Country: USA

Participants: cocaine dependence (DSM-IV)

N = 487

Age: 33.9 years old (mean age)

Sex: males 76.8%

Ethnicity: white 57.9%, African American 39.8%, Latino 2.2%

Marital status: living alone 69.6%

Employment: unemployed 39.6%

Education level: completed a mean of 13 years of school (SD 2.0)

Setting: outpatients; 5 different sites

History:

• Route: 79.0% crack smoking, 18.9% intranasal, 2.1% intravenous
• Psychostimulant use: 10.4 (SD 7.8) days of use in previous 30 days; years of use: 6.9 (SD 4.8)
• Other drugs: 33% alcohol dependence, 4.5% cannabis dependence, 17.0% cannabis abuse
• Psychiatric comorbidity: 28% cocaine-induced mood disorder, 4.9% cocaine-induced anxiety disor-
der, 14% antisocial personality disorder and 31.8% APD as an adult with no history of a childhood
conduct disorder

Interventions

In the original study, there were 4 arms:

1. CBT (CT) + group drug counselling (n = 119)
2. Supportive expressive (SE) therapy (psychodynamic approach) + group drug counselling (GDC) (n =

124)

3. Individual drug counselling (IDC) + group drug counselling (n = 121)
4. Group drug counselling (control) (n = 123)

For this review, we did not consider group 3.

In Crits-Christoph 1999 arm 1, we compared group 1 (CBT (CT) + group counselling) versus group 4
(control).

In Crits-Christoph 1999 arm 2, we compared group 2 (Supportive expressive (SE) therapy (psychody-
namic approach) + group drug counselling (GDC) versus group 4 (control).

CT, SE, and IDC: 50-minute individual sessions held twice per week during the first 3 months, then once
per week for the next 3 months, and once per month during a 3-month booster phase. All 3 individual

Psychosocial interventions for stimulant use disorder (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

66

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Crits-Christoph 1999 arm 2  (Continued)

Cochrane Database of Systematic Reviews

interventions also had 90-minute group drug counselling sessions held once a week for the 6-month ac-
tive phase.
GDC: in booster phase, participants met with group counsellor individually, 30-minute visit once a
month.

Group 3 (individual drug counselling + group drug counselling) was not considered in this review.

Duration of intervention: 6 months

Duration of follow-up: 6 months

Outcomes

• Dropouts
• Use of cocaine in previous month, measured at 6 months
• Use of cocaine in previous month, measured at endpoint

Notes

Funding source: National Institute on Drug Abuse, Rockville, MD

Conflict of interest: not stated

Drug counselling was based on the 12-step addiction and psycho-educational model, as well as provid-
ing group support and teaching problem-solving skills.

Risk of bias

Bias

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Low risk

Quote: "random assignment uses a special technique known as adaptive or
urn randomization"

Allocation concealment
(selection bias)

Low risk

Quote: "patients were centrally randomly assigned using a computerized 'urn'
randomisation procedure"

Blinding of participants
and personnel (perfor-
mance bias)
Subjective outcomes

Blinding of participants
and personnel (perfor-
mance bias)
Objective outcomes

Blinding of outcome as-
sessment (detection bias)
Subjective outcomes

Blinding of outcome as-
sessment (detection bias)
Objective outcomes

Incomplete outcome data
(attrition bias)
All outcomes except reten-
tion in treatment

Selective reporting (re-
porting bias)

High risk

Blinding of participants and personnel impossible for the types of intervention

Low risk

No blinding or incomplete blinding, but the review authors judge that the out-
come is unlikely to be influenced by lack of blinding

Low risk

The ASI interviewer was blind to the treatment condition

Low risk

Low risk

No blinding or incomplete blinding, but the review authors judge that the out-
come is unlikely to be influenced by lack of blinding

23% dropout at the end of treatment, 21% at the end of follow-up, balanced
across groups

Low risk

All the declared outcomes in the procotol were reported in the Results.

Psychosocial interventions for stimulant use disorder (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

67

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Dursteler-MacFarland 2013 

Study characteristics

Methods

Randomised controlled trial

Participants

Country: Switzerland

Participants: cocaine dependent diacetylmorphine (DAM) maintained patients (heroin dependence ac-
cording to DSM-IV)

N = 62

Age: 36 years old (mean of mean)

Sex: males 64.5%

Ethnicity: not reported

Marital status: unmarried 84%

Education level: high school graduate 93.5%

Employment: unemployed 38.7%

Setting: outpatients

History:

• Route: not reported
• Psychostimulant use: years of cocaine use in the past 30 days: about 11; 100% of participants DAM

maintained

• Other drugs: not reported
• Psychiatric comorbidity: not reported

Interventions

1. CBGT: cognitive behavioural group therapy (n = 32)
2. TAU: treatment as usual (n = 30)

Pharmacotherapy (methylphenidate or placebo) and psychotherapy

Duration of intervention: 3 months for a total of 36 appointments

Outcomes

Duration of follow-up: 3 months

• Retention in treatment
• Cocaine-free urine screens
• Self-reported cocaine use
• Adverse effects

Notes

Funding source: Swiss Federal Office of Public Health

Conflict of interest: "Durstteler holds a grant from the voluntary Academy Society of Basel. Petitjean,
Dursteler and Wiesbeck are currently receiving a grant from Swiss National Research Foundation. The
remaining authors declare no conflicts of interest."

Risk of bias

Bias

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Unclear risk

Information not reported

Psychosocial interventions for stimulant use disorder (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

68

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Dursteler-MacFarland 2013  (Continued)

Cochrane Database of Systematic Reviews

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias)
Subjective outcomes

Blinding of participants
and personnel (perfor-
mance bias)
Objective outcomes

Blinding of outcome as-
sessment (detection bias)
Subjective outcomes

Unclear risk

Information not reported

High risk

Blinding of participants and personnel impossible for the types of intervention

Low risk

No blinding or incomplete blinding, but the review authors judge that the out-
come is unlikely to be influenced by lack of blinding

Unclear risk

No information reported

Blinding of outcome as-
sessment (detection bias)
Objective outcomes

Low risk

No blinding or incomplete blinding, but the review authors judge that the out-
come is unlikely to be influenced by lack of blinding

Low risk

ITT analysis

Unclear risk

No protocol available

Incomplete outcome data
(attrition bias)
All outcomes except reten-
tion in treatment

Selective reporting (re-
porting bias)

Festinger 2014 

Study characteristics

Methods

Randomised controlled trial

Participants

Country: USA

Participants: meet DSM-IV diagnostic criteria for current cocaine dependence as assessed by the Sub-
stance Use Disorders section of the Structured Clinical Interview for DSM-IV (SCID-I)

N = 222

Age: 37.20 (mean age)

Sex: males 69%

Ethnicity: white 58%

Marital status: not reported

Education level: majority of participants were high school-educated (57%)

Employment: not paid for working in the past 30 days (98%)

Setting: outpatients

History:

• Route: not reported

Psychosocial interventions for stimulant use disorder (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

69

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Festinger 2014  (Continued)

Cochrane Database of Systematic Reviews

• Psychostimulant use: not reported:
• Other  drugs:  alcohol  to  intoxication  (past  month):  CBRT,  16.44%;  VBRT,  11.27%;  non-CM  control,

11.54%; 100% of participants in methadone maintenance

• Psychiatric comorbidity: not reported

Interventions

1. Voucher-based contingency management condition (VBRT, n = 71), + TAU
2. Cash-based contingency management condition (CBRT, n = 73), + TAU
3. Control condition (TAU, n = 78)

Outcomes

Duration of intervention: 3 months

Duration of follow-up: 3 months

• Abstinence
• Attendance
• Cocaine craving
• Engagement in high-risk behaviour

Notes

We combined the results of the voucher-based contingent management and cash-based contingent
management groups for comparison to the control condition.

Funding source: National Institute on Drug Abuse R01-DA021621

Conflict of interest: "None of the authors represent any interests that could be interpreted as influen-
tial"

Risk of bias

Bias

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Unclear risk

Information not reported

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias)
Subjective outcomes

Blinding of participants
and personnel (perfor-
mance bias)
Objective outcomes

Blinding of outcome as-
sessment (detection bias)
Subjective outcomes

Unclear risk

Information not reported

High risk

Blinding of participants and personnel impossible for the types of intervention

Low risk

No blinding or incomplete blinding, but the review authors judge that the out-
come is unlikely to be influenced by lack of blinding

Unclear risk

No information reported

Blinding of outcome as-
sessment (detection bias)
Objective outcomes

Low risk

Incomplete outcome data
(attrition bias)
All outcomes except reten-
tion in treatment

Unclear risk

No blinding or incomplete blinding, but the review authors judge that the out-
come is unlikely to be influenced by lack of blinding

Information on percentage of dropouts is not reported. Quote: "the cash (M =
28.49, SD = 9.05) and voucher (M = 28.28, SD = 9.78) groups to attend more re-
search appointments than participants in the control group (M = 24.83, SD =

Psychosocial interventions for stimulant use disorder (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

70

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Festinger 2014  (Continued)

Cochrane Database of Systematic Reviews

Selective reporting (re-
porting bias)

High risk

Some outcomes described in the protocol are not reported in the results of the
study.

10.79; ds = .37 and.33, respectively). Attendance rates for both CM groups were
approximately equal (d = .02)."

Garcia-Fernandez 2011 

Study characteristics

Methods

Randomised controlled trial

Participants

Country: Spain

Participants: patients meeting DSM-IV-TR criteria for active cocaine dependence and not presenting
serious psychopathological disorders or active opioid dependence

N = 58

Age: 30 years old (mean age)

Sex: males 87.9%

Ethnicity: not reported

Marital status: never married 48.2%

Education level: 10 years of education (mean of mean)

Employment: employed full-time 67.2%

Setting: outpatients

History:

• Route: cocaine use: intranasal route 92.6 % in CRA + voucher and 93.1% in CRA
• Psychostimulant use: years of regular cocaine use: 5.89 (SD 4.0) in CRA + voucher and 8.41 (SD 4.5)

in CRA

• Other drugs: lifetime abuse: alcohol 86.2% in CRA + voucher, 79.3% in CRA; cannabis 51.7% in CRA +

voucher, 58.6% in CRA, amphetamines 24.1% in CRA + voucher, 10.3% in CRA

• Psychiatric comorbidity: not reported

Interventions

1. CRA plus vouchers condition
2. CRA (Community Reinforcement Approach)

Outcomes

Notes

Duration of intervention: 6 months

Duration of follow-up: 6 months

• Cocaine abstinence
• Treatment retention
• Psychosocial functioning

Funding source: Spanish National Plan on Drugs (PNsD), Madrid, (Ref. MSC-06–01) and supported by a
predoctoral grant from the University of Oviedo, Oviedo (Ref. UNOV-08-BECDOC).

Conflict of interest: "The authors report no conflicts of interest. The authors alone are responsible for
the content and writing of the paper."

Psychosocial interventions for stimulant use disorder (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

71

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Garcia-Fernandez 2011  (Continued)

Risk of bias

Bias

Authors' judgement

Support for judgement

Cochrane Database of Systematic Reviews

Random sequence genera-
tion (selection bias)

Low risk

Quote: "58 patients were randomly assigned to the CRA or CRA plus vouchers
condition."

Allocation concealment
(selection bias)

Low risk

Quote: "In accordance with a computer-generated randomization list, patients
were assigned to the CRA plus vouchers group (N = 29) or to the CRA group (N =
29)."

Blinding of participants
and personnel (perfor-
mance bias)
Subjective outcomes

Blinding of participants
and personnel (perfor-
mance bias)
Objective outcomes

Blinding of outcome as-
sessment (detection bias)
Subjective outcomes

High risk

Blinding of participants and personnel impossible for the types of intervention

Low risk

No blinding or incomplete blinding, but the review authors judge that the out-
come is unlikely to be influenced by lack of blinding

Unclear risk

No information reported

Blinding of outcome as-
sessment (detection bias)
Objective outcomes

Low risk

No blinding or incomplete blinding, but the review authors judge that the out-
come is unlikely to be influenced by lack of blinding

High risk

36.2%, balanced across groups

Unclear risk

Protocol not available

Incomplete outcome data
(attrition bias)
All outcomes except reten-
tion in treatment

Selective reporting (re-
porting bias)

Garcia-Rodriguez 2007 

Study characteristics

Methods

Randomised controlled trial

Participants

Country: Spain

Participants: cocaine dependents according to DSM-IV (APA 2002)

N = 96

Age: 29 years old (mean age)

Sex: males 90%

Ethnicity: not reported

Marital status: never married 66.4%

Education level: average years of education 10 years

Psychosocial interventions for stimulant use disorder (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

72

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Garcia-Rodriguez 2007  (Continued)

Employment: employed full-time 77.5%

Setting: outpatients

History:

• Route: intranasal: 97.3%
• Psychostimulant use:

◦ Average years of consumption 6.7 years
◦ Weekly intake: 5 g

• Psychiatric comorbidity: exclusion criteria for severe psychopathology (e.g. psychosis or dementia)

Interventions

1. CRA + low voucher (CM) (n = 15)
2. CRA + high voucher (CM) (n = 29)
3. Standard therapy (TAU) outpatient programme, drug-free, cognitive behavioural approach (n = 52)

Duration of intervention: 6 months

Duration of follow-up: 6 months

• Cocaine abstinence
• Retention

Funding source: Spanish National Plan on Drugs (PNsD), Madrid, (Ref. MINT-03-01) and supported by
a predoctoral grant from the Asturian Foundation for Promoting Technology and Applied Scientific Re-
search (FICYT) (Ref. BP05-002) and a predoctoral grant from the University of Oviedo (Ref. UNIOVI-04-
BECDOC-05). Authors also acknowledge the Foundation Proyecto Hombre of Asturias and Madrid

Conflict of interest: not stated

Authors' judgement

Support for judgement

Low risk

Quote: "randomisation according to a computer random list"

Unclear risk

Information not reported

High risk

Blinding of participants and personnel impossible for the types of intervention

Low risk

No blinding or incomplete blinding, but the review authors judge that the out-
come is unlikely to be influenced by lack of blinding

Unclear risk

No information reported

Outcomes

Notes

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias)
Subjective outcomes

Blinding of participants
and personnel (perfor-
mance bias)
Objective outcomes

Blinding of outcome as-
sessment (detection bias)
Subjective outcomes

Blinding of outcome as-
sessment (detection bias)
Objective outcomes

Low risk

No blinding or incomplete blinding, but the review authors judge that the out-
come is unlikely to be influenced by lack of blinding

Psychosocial interventions for stimulant use disorder (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

73

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Garcia-Rodriguez 2007  (Continued)

Cochrane Database of Systematic Reviews

Low risk

ITT analyses, missing data imputed

Unclear risk

Protocol of the study not available

Incomplete outcome data
(attrition bias)
All outcomes except reten-
tion in treatment

Selective reporting (re-
porting bias)

Ghitza 2007 

Study characteristics

Methods

Randomised controlled trial

Participants

Country: USA

Participants: heroin and cocaine users in methadone maintenance

N = 116

Age: 37 years old (mean age)

Sex: males 56%

Ethnicity: African American 46%, white 52%, Latino 1%, and Asian 1%

Marital status: not reported

Education level: years of education 11.4 years (mean of mean)

Employment: monthly income USD 453

Setting: outpatients

History:

• Route: not reported
• Psychostimulant use: years cocaine use: 9.4 (SD 7.4); days cocaine use in the last 30 days before ad-

mission: 17.4 (SD 10.2)

• Other drugs: years heroin use: 10.3 (SD 7.5); days heroin use in the last 30 days before admission: 29.0

(SD 4.3); 100% of participants in methadone maintenance.

• Psychiatric comorbidity: current psychotic, bipolar, or major depressive disorders; current physical
dependence on alcohol or sedatives; unstable serious medical illness were criteria for exclusion

1. Contingent group (n = 76)
2. Non-contingent controls (n = 40)

Duration of intervention: 3 months

Duration of follow-up: 6 months

Outcome measures were qualitative urinalysis: cocaine-negative urine or opiate-negative urine during
the urine-collection day after prize-drawing days

Funding source: Relapse prevention of the National Institutes of Health, National Institute on Drug
Abuse

Conflict of interest: not stated

Interventions

Outcomes

Notes

Psychosocial interventions for stimulant use disorder (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

74

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Ghitza 2007  (Continued)

Risk of bias

Bias

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Low risk

Allocation concealment
(selection bias)

Unclear risk

Each participant was randomly assigned to one of three contingent condi-
tions (manual/standard, n = 20; computerised/standard, n = 36; or comput-
erised/high prize density, n = 20) or to a non-contingent (yoked) control group
(n = 40); the disparate group sizes resulted from an error in a computerised
randomisation algorithm.

Participants were randomised to the conditions by a study technician who
used a Microsoft Excel macro that stratified randomisations by ethnicity,
sex, employment status, probation status, and frequency of opiate- and co-
caine-positive urine specimens at baseline.

Blinding of participants
and personnel (perfor-
mance bias)
Subjective outcomes

Blinding of participants
and personnel (perfor-
mance bias)
Objective outcomes

Blinding of outcome as-
sessment (detection bias)
Subjective outcomes

High risk

Blinding of participants and personnel impossible for the types of intervention

Low risk

No blinding or incomplete blinding, but the review authors judge that the out-
come is unlikely to be influenced by lack of blinding

Unclear risk

No information reported

Blinding of outcome as-
sessment (detection bias)
Objective outcomes

Low risk

No blinding or incomplete blinding, but the review authors judge that the out-
come is unlikely to be influenced by lack of blinding

Low risk

ITT analysis

Unclear risk

Protocol of the study not available

Incomplete outcome data
(attrition bias)
All outcomes except reten-
tion in treatment

Selective reporting (re-
porting bias)

Hagedorn 2013 

Study characteristics

Methods

Randomised controlled trial

Participants

Country: USA

Participants: veterans diagnosed with alcohol dependence only (n = 191) or stimulant dependence
(cocaine, amphetamine, methamphetamine) (n = 139); only data of stimulant dependents reported
N = 139
Age: 50 years old (mean age)
Sex: males 98.59%
Ethnicity: white 58.1%, African American 35.1%, other non-white 6.9%

Marital status: married or cohabiting 18.8%

Psychosocial interventions for stimulant use disorder (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

75

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Hagedorn 2013  (Continued)

Education level: high school diploma or less 36.15%

Employment: unemployed 65%

Setting: outpatients

History:

Interventions

• Route: not reported
• Psychostimulant use: total sample of participants using stimulants on 18.5% of days (approximately 6
days) out of the past 30 days at baseline. Participants in the stimulant dependence subgroup reported
using stimulants on 40.5% of days out of the past 30 days (approximately 12 days)

• Other drugs: about 60% with a diagnosis of alcohol dependence; about 10% with other substance use
• Psychiatric comorbidity: within the stimulant dependence subgroup, participants in usual care were
significantly more likely to have a diagnosis of depression than participants in the CM intervention
(44.12%  versus  28.17%;  p.05).  Psychiatric  diagnoses:  post-traumatic  stress  disorder  (PTSD)  12.9%;
other anxiety, mood, or psychotic diagnosis, 14.35%

1. CM plus usual care: CM intervention participants received the standard programme services offered
by the clinic at each site. In addition, they earned chances to win vouchers when their urine and breath
test results were negative for all the targeted substances (cocaine, amphetamine, methamphetamine,
and alcohol) (n = 71)

2. Usual care: standard programme services offered by the SUD clinic at each site (n = 68)

Duration of intervention: 2 months

Duration of follow-up: 12 months

Outcomes

• Primary outcome: total number of urine and breath samples out of the possible 16 samples that were

negative for all targeted drugs (alcohol, cocaine, amphetamines, and methamphetamines)

• Secondary outcome: intervention retention and longest duration of abstinence

Notes

Funding source:Department of Veterans Affairs, Veterans Health Administration, Office of Research &
Development, Health Services Research & Development

Conflict of interest: not stated

Risk of bias

Bias

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Low risk

Quote: "Randomization was conducted by a computer program, separately for
participants within each site and drug dependence diagnosis with 90 partici-
pants planned per block. Randomization in running blocks of six ensured bal-
anced assignment over time."

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias)
Subjective outcomes

Blinding of participants
and personnel (perfor-
mance bias)
Objective outcomes

Unclear risk

Information not reported

High risk

Blinding of participants and personnel impossible for the types of intervention

Low risk

No blinding or incomplete blinding, but the review authors judge that the out-
come is unlikely to be influenced by lack of blinding

Psychosocial interventions for stimulant use disorder (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

76

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Hagedorn 2013  (Continued)

Blinding of outcome as-
sessment (detection bias)
Subjective outcomes

Unclear risk

No information reported

Blinding of outcome as-
sessment (detection bias)
Objective outcomes

Low risk

No blinding or incomplete blinding, but the review authors judge that the out-
come is unlikely to be influenced by lack of blinding

High risk

End of treatment: dropout CM 27.8%, usual care 25%; 6-month follow-up: CM
25.4%, usual care 29.4%; 12-month follow-up: CM 27.9%, usual care 31%.

Unclear risk

Protocol of the study not available

Incomplete outcome data
(attrition bias)
All outcomes except reten-
tion in treatment

Selective reporting (re-
porting bias)

Higgins 1993 

Study characteristics

Methods

Randomised controlled trial

Participants

Country: USA

Participants: cocaine dependence (DSM-III-R)

N = 38

Age: 29.3 years old (mean age)

Sex: males: 89%

Ethnicity: white: 100%

Marital status: married 29.7%

Education level: at least 12 years of education 60.5%

Employment: employed 42%

Setting: outpatient

History:

• Route: 52.5% intranasal, 29% intravenous, 16% free-base, no crack users
• Psychostimulant use: 4.37 g/week
• Other drugs: 55% alcohol; 42% cannabis
• Psychiatric comorbidity (Addiction Severity Index): 0.35 mean (SD 0.20) (unspecified psychiatric co-

morbidity)

Interventions

1. CBT (CRA) + CM (n = 19)
2. Drug counselling (n = 19) (TAU)

Participants who also met criteria for alcohol dependence/abuse were offered disulphiram (~250 mg/
day): 42% in CBT and 5.3% in drug counselling received it.

Duration of intervention: 6 months

Duration of follow-up: 6 months

Psychosocial interventions for stimulant use disorder (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

77

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Higgins 1993  (Continued)

Outcomes

• Dropouts (12 weeks)
• Dropouts (24 weeks)
• Failing to attend more than 1 therapy session
• Use of cocaine for at least 4 consecutive weeks
• Use of cocaine for at least 8 consecutive weeks
• Use of cocaine for at least 16 consecutive weeks

Notes

Risk of bias

Bias

Community Reinforcement Approach is a multicomponent behavioural treatment, with family and
friends' participation; it also provided skills training (e.g. drug refusal, problem-solving, and assertive-
ness), counselling for AIDS prevention, employment and new recreational activities, plus contingency
management procedures. Drug abuse counselling consisted of group and individual sessions based on
12-step model of drug abuse treatment.

Funding source: National Institute on Drug Abuse: treatment research demonstration Grant DA -06113.
First independent Research and transition Award DA-04545, Research Grant DA-06526, National Re-
search Service Award (Institutional Training Award)DA-07242, and Research Scientist Development
Award DA-00109

Conflict of interest: not stated

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Low risk

Quote: "minimum likelihood allocation was used to randomly assign patients
sequentially to the two treatments."

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias)
Subjective outcomes

Blinding of participants
and personnel (perfor-
mance bias)
Objective outcomes

Blinding of outcome as-
sessment (detection bias)
Subjective outcomes

Unclear risk

Information not reported

High risk

Blinding of participants and personnel impossible for the types of intervention

Low risk

No blinding or incomplete blinding, but the review authors judge that the out-
come is unlikely to be influenced by lack of blinding

Unclear risk

Information not reported

Blinding of outcome as-
sessment (detection bias)
Objective outcomes

Low risk

No blinding or incomplete blinding, but the review authors judge that the out-
come is unlikely to be influenced by lack of blinding

Incomplete outcome data
(attrition bias)
All outcomes except reten-
tion in treatment

Selective reporting (re-
porting bias)

Low risk

ITT analysis, missing urine tests counted as positives

High risk

Results not reported for entire treatment period

Psychosocial interventions for stimulant use disorder (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

78

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Higgins 1994 

Study characteristics

Methods

Randomised controlled trial

Participants

Country: USA

Participants: cocaine dependence (DSM-III-R)
N = 40
Age: 31.35 years old (mean age)
Sex: males 67.5%

Ethnicity: white 85%

Marital status: married 60%

Education level: at least 12 years of education 77.5%

Employment: employed 45%

Setting: outpatients.

• Route: 50% intranasal, 25% intravenous, 25% freebase
• Psychostimulant use: median 2.55 (IQR 1.5 to 5.2) g/week
• Other drugs: alcohol dependence 45% in the voucher group (VG) and 65% in the non-voucher group
(NVG); marijuana 10% in the VG and 15% in the NVG; alcohol and marijuana 10% in the VG and 5% in
the NVG. Opioid-dependent participants were excluded from study.

• Psychiatric comorbidity: 0.35 (SD 0.25) in the VG and 0.38 (SD 0.25) in the NVG (pathology not specified)

Interventions

1. CBT (CRA) + CM (n = 20)
2. CBT (CRA) (n = 20)

Participants who also met criteria for alcohol dependence/abuse (41%) were offered disulphiram
(~ 250 mg/day)

Duration of intervention: 3 months

Duration of follow-up: 6 months

• Dropouts (12 weeks)
• Dropouts (24 weeks)
• Average duration of weeks in treatment
• Use of cocaine for at least 5 consecutive weeks
• Use of cocaine for at least 10 consecutive weeks
• Use of cocaine for at least 20 consecutive weeks
• Average duration of continuous abstinence across the 24 weeks treatment

Community Reinforcement Approach (CRA) is a multicomponent behavioural treatment, with fami-
ly and friends' participation; also provided skills training (e.g. drug refusal, problem-solving, and as-
sertiveness), counselling for AIDS prevention, employment and new recreational activities.
Participants in the contingent reinforcement group received vouchers to purchase retail items in the
community for each urine specimen negative for benzoylecgonine.

Funding source: treatments research demonstration grants DA-06113 and DA-06969, research Grant
DA-08076 and National Research Service

Conflict of interest: not stated

Outcomes

Notes

Risk of bias

Psychosocial interventions for stimulant use disorder (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

79

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Higgins 1994  (Continued)

Bias

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Unclear risk

Quote: "minimum likelihood allocation was used to randomly assign the pa-
tients sequentially to the two treatments."

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias)
Subjective outcomes

Blinding of participants
and personnel (perfor-
mance bias)
Objective outcomes

Blinding of outcome as-
sessment (detection bias)
Subjective outcomes

Unclear risk

Information not reported

High risk

Blinding of participants and personnel impossible for the types of intervention

Low risk

No blinding or incomplete blinding, but the review authors judge that the out-
come is unlikely to be influenced by lack of blinding

Unclear risk

No information reported

Blinding of outcome as-
sessment (detection bias)
Objective outcomes

Low risk

No blinding or incomplete blinding, but the review authors judge that the out-
come is unlikely to be influenced by lack of blinding

Low risk

2 participants lost at follow-up, 1 per group

Unclear risk

Protocol of the study not available

Incomplete outcome data
(attrition bias)
All outcomes except reten-
tion in treatment

Selective reporting (re-
porting bias)

Higgins 2000 

Study characteristics

Methods

Randomised controlled trial

Participants

Country: USA

Participants: cocaine dependence (DSM-III-R)

N = 70

Age: 30.4 years (mean age)

Sex: males 73%

Ethnicity: white 94%

Marital status: married 18.5%

Educational level: at least 12 years of education 23%

Employment status: employed 57%

Psychosocial interventions for stimulant use disorder (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

80

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Higgins 2000  (Continued)

Setting: outpatient

History:

Cochrane Database of Systematic Reviews

• Route: 48.5% smoking, 37% intranasal, 14.5% intravenous
• Psychostimulant use:

◦ Years of regular use: 7.4 (SD 4.3)
◦ Days of use in past 30 days: 13.7 (SD 8.0)
◦ Grams used per week: 3.3 (IQR 1.8-9.1)
◦ Age of first cocaine use: 19.1 (SD 4.7) years

• Other drug dependence: 57% alcohol, 23% marijuana, 17% both
• Psychiatric comorbidity: 0.35 in voucher group; 0.38 in non-voucher group (illness psychiatric type

not specified)

1. CBT (CRA) + CM (n = 36)
2. CBT (CRA) (n = 34)

Duration of intervention: 6 months

Duration of follow-up: 12 months of post-treatment follow-up

• Dropouts (12 and 24 weeks)
• Use of cocaine
• Use of marijuana

Community Reinforcement Approach (CRA) is a multicomponent behavioural treatment, with fami-
ly and friends' participation; also provided skills training (e.g. drug refusal, problem-solving, and as-
sertiveness), counselling for AIDS prevention, employment and new recreational activities.
Both interventions had incentives, contingent or non-contingent on urinalysis negative results.

Funding source: National Institute of Drug Abuse

Conflict of interest: not stated

Authors' judgement

Support for judgement

Interventions

Outcomes

Notes

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Low risk

Quote on minimum likelihood allocation: "the aim of this type of randomiza-
tion was to achieve balance between the treatment groups for the following
baseline characteristics: gender, age. . ."

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias)
Subjective outcomes

Blinding of participants
and personnel (perfor-
mance bias)
Objective outcomes

Blinding of outcome as-
sessment (detection bias)
Subjective outcomes

Unclear risk

Information not reported

High risk

Blinding of participants and personnel impossible for the types of intervention

Low risk

No blinding or incomplete blinding, but the review authors judge that the out-
come is unlikely to be influenced by lack of blinding

Unclear risk

No information reported

Psychosocial interventions for stimulant use disorder (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

81

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Low risk

No blinding or incomplete blinding, but the review authors judge that the out-
come is unlikely to be influenced by lack of blinding

Low risk

ITT analysis

Unclear risk

Protocol of the study not available

Higgins 2000  (Continued)

Blinding of outcome as-
sessment (detection bias)
Objective outcomes

Incomplete outcome data
(attrition bias)
All outcomes except reten-
tion in treatment

Selective reporting (re-
porting bias)

Higgins 2003 

Study characteristics

Methods

Randomised controlled trial

Participants

Country: USA

Participants: cocaine dependence (DSM-III-R)

N = 100

Age: 34 years old (mean age)

Sex: males 59%

Ethnicity: white 95%

Marital status: married 20%

Employment: full-time employment 63%

Setting: outpatient

History:

• Route: 59% smoking, 34% intranasal, 7% intravenous
• Psychostimulant use: 4 g used per week: ~3.4 (IQR 1.2-7.0)
• Other drug dependence: 61% alcohol, 21% marijuana
• Psychiatric comorbidity (Addiction Severity Index): 0.30 in CRA + voucher and 0.41 in voucher only

Interventions

1. CBT (CRA) + CM, n = 49
2. CM, n = 51

Outcomes

Duration of intervention:6 months

Duration of follow-up: 36 months

• Dropouts (12 and 24 weeks)
• Use of cocaine (12 weeks)
• Use of marijuana (24 weeks)

Notes

Funding source: research grant DA-06113 and DA 08076 and training award DA

Conflict of interest: not stated

Psychosocial interventions for stimulant use disorder (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

82

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Higgins 2003  (Continued)

Risk of bias

Bias

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Low risk

Quote: "Minimum Likely Allocation was used to randomly assign patients
while achieving balance between conditions for the following baseline charac-
teristics: sex, primary route of cocaine administration, etc"

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias)
Subjective outcomes

Blinding of participants
and personnel (perfor-
mance bias)
Objective outcomes

Unclear risk

Information not reported

High risk

Blinding of participants and personnel impossible for the types of intervention

Low risk

No blinding or incomplete blinding, but the review authors judge that the out-
come is unlikely to be influenced by lack of blinding

Blinding of outcome as-
sessment (detection bias)
Subjective outcomes

High risk

Blinding of outcome as-
sessment (detection bias)
Objective outcomes

Low risk

Quote: "formal assessment performed by a trained bachelor's level research
assistant who were [sic] aware of patient treatment condition"

No blinding or incomplete blinding, but the review authors judge that the out-
come is unlikely to be influenced by lack of blinding

High risk

Loss at follow-up (12 and 24 weeks) was 14% and 2% in the experimental
group and between 27% and 8% in the control group; unbalanced

Unclear risk

Protocol of the study not available

Incomplete outcome data
(attrition bias)
All outcomes except reten-
tion in treatment

Selective reporting (re-
porting bias)

Ingersoll 2011 

Study characteristics

Methods

Randomised controlled trial

Participants

Country: USA

Participants: adults with crack cocaine use or crack cocaine use disorder and with a less than 90% self-
reported adherence to a current prescription for HAART over the preceding 14 days were eligible to par-
ticipate in the study.

N = 54 people on HAART participated in the study
Age: 45 years old (mean age)
Sex: more than half of this sample (32/54) was heterosexual (of n = 28 women, n = 25 men, and n = 1
transgendered individual)
Ethnicity: African American 82%
Marital status: not reported
Education level: some college education: 31.5%; high school education: 37%
Employment: unemployed 82%

Psychosocial interventions for stimulant use disorder (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

83

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Ingersoll 2011  (Continued)

Setting: outpatients
History:

Cochrane Database of Systematic Reviews

• Route: 100% smoking
• Psychostimulant use: most were classified as crack cocaine dependent on the MINI
• Other drugs: 38.5% classified with alcohol use disorders
• Psychiatric comorbidity: DSM-IV Psychiatric Disorders at baseline: current major depressive disorder
(MDD), n = 25 (48.1%); recurrent MDD, n = 19 (36.5%); current dysthymia, n = 11 (21.2%); current panic
D/O, n = 3 (5.8%); lifetime panic D/O, n = 8 (15.4%); current agoraphobia, n = 12 (23.1%); current social
phobia, n = 8 (15.4%); current OCD, n = 10 (19.2%); current gen. anxiety, n = 16 (30.8%); current PTSD,
n = 6 (11.5%); Ideation: suicidal, n = 18 (35.3%); homicidal, n = 7 (13.5%)

Interventions

1. Motivational interviewing plus feedback and skills building (MI +)
2. Video information plus debriefing (Video +)

Duration of intervention: 6 sessions over 2 months

Duration of follow-up: 6 months

Outcomes

Primary outcomes

• 14-day HAART adherence
• ASI Drug Composite Scores

Secondary outcomes

• HIV log VL
• Percent days using crack cocaine

Notes

Risk of bias

Bias

Other information: on average, participants had been diagnosed with HIV 11.3 years ago (SD 6.5); the
most recent diagnosis was 4 months before, and the most distant diagnosis was 22 years before. On av-
erage, participants took 58.27% (SD 27.5) of their prescribed HAART pills in the two weeks prior to en-
rolment.

Funding source: not stated

Conflict of interest: not stated

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Unclear risk

Information not reported

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias)
Subjective outcomes

Blinding of participants
and personnel (perfor-
mance bias)
Objective outcomes

Unclear risk

No information reported

High risk

Blinding of participants and personnel impossible for the types of intervention

Low risk

No blinding or incomplete blinding, but the review authors judge that the out-
come is unlikely to be influenced by lack of blinding

Blinding of outcome as-
sessment (detection bias)

Low risk

Quote: "Researchers blinded to participants' assigned conditions adminis-
tered the ASI, the HIV Medication Chart and Adherence Questions and the

Psychosocial interventions for stimulant use disorder (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

84

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Ingersoll 2011  (Continued)
Subjective outcomes

Blinding of outcome as-
sessment (detection bias)
Objective outcomes

Low risk

Cochrane Database of Systematic Reviews

TLFB for HAART adherence and crack cocaine use, and treatment satisfaction
forms"

Quote: "Researchers blinded to participants' assigned conditions adminis-
tered the ASI, the HIV Medication Chart and Adherence Questions and the
TLFB for HAART adherence and crack cocaine use, and treatment satisfaction
forms"

High risk

25% dropout, unbalanced across group (32% and 18%)

Unclear risk

Protocol of the study not available

Incomplete outcome data
(attrition bias)
All outcomes except reten-
tion in treatment

Selective reporting (re-
porting bias)

Kirby 1998 

Study characteristics

Methods

Randomised controlled trial

Participants

Country: USA

Participants: cocaine dependence (DSM-III-R)
N = 90
Sex: males 67%
Age: 31.7 years old (mean age)
Ethnicity: African American 92%, white 8%

Marital status: not reported

Education level: not reported
Employment: employed 11%
Setting: outpatients
History:

• Route: 88% crack smokers, 7% intranasal, 5% intravenous
• Psychostimulant use: cocaine dependence, 1% amphetamines
• Other drugs: 90% alcohol; 48% marijuana; 10% heroin; 9% benzodiazepines
• Psychiatric comorbidity: "absent of active psychosis or intellectual deficits"

Interventions

1. CM + CBT (n = 44)
2. CBT (n = 46)

Both groups received 26 individualised sessions plus 10 one-hour group sessions training in interper-
sonal problem-solving.
Vouchers were delivered on a weekly basis.

Duration of intervention: 3 months

Duration of follow-up: 3 months

Outcomes

• Treatment retention
• Weeks of continuous cocaine abstinence

Notes

Manual-guided cognitive-behavioural treatment sessions

Psychosocial interventions for stimulant use disorder (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

85

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Kirby 1998  (Continued)

Risk of bias

Bias

Funding source: Grant DA06986 from the National Institute on Drug Abuse

Conflict of interest: not stated

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Low risk

Quote: "dependent adults were randomly assigned to behavioral counseling
or counseling plus vouchers
for cocaine-free urine sample"

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias)
Subjective outcomes

Blinding of participants
and personnel (perfor-
mance bias)
Objective outcomes

Blinding of outcome as-
sessment (detection bias)
Subjective outcomes

Blinding of outcome as-
sessment (detection bias)
Objective outcomes

Incomplete outcome data
(attrition bias)
All outcomes except reten-
tion in treatment

Selective reporting (re-
porting bias)

Unclear risk

No information provided on allocation concealment

High risk

Blinding of participants and personnel impossible for the types of intervention

Low risk

No blinding or incomplete blinding, but the review authors judge that the out-
come is unlikely to be influenced by lack of blinding

Unclear risk

No information reported

Low risk

Low risk

No information reported but the review authors judge that the outcome is un-
likely to be influenced by lack of blinding

80% of participants did not complete the treatment. A worst-case analysis was
performed, assuming that "if a patient failed to provide a specimen, we con-
servatively assumed the end of continuous abstinence."

Unclear risk

Protocol of the study not available

Knealing 2006 

Study characteristics

Methods

Randomised controlled trial

Participants

Country: USA

Participants: cocaine dependence (DSM-IV)
N = 47
Age: 36.6 (mean of mean)
Sex: males 10.6%
Ethnicity: African American 85.1%, white 14.9%
Marital status: married 10.6%
Education level: completed 12 years of education 56.5%
Employment: employed full-time (at intake) 0%

Psychosocial interventions for stimulant use disorder (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

86

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Knealing 2006  (Continued)

Setting: outpatient

History:

Cochrane Database of Systematic Reviews

• Route: not reported
• Psychostimulant use: DSM–IV diagnosis, current dependence; cocaine TAU: 84%; TW: 95%;
• Other drugs: alcohol TAU: 16%; TW: 14%; 100% of participants in methadone maintenance
• Psychiatric comorbidity: individuals were excluded on the basis of responses to the ASI and the BDI
if they were considered at imminent risk of suicide or had a psychiatric disorder that could disrupt
workplace functioning or limit their ability to give informed consent (e.g. schizophrenia)

Interventions

1. Usual care + abstinent-contingent access to therapeutic workplace (CM) (n = 22)
2. Treatment as usual control group (n = 25)

All participants were offered 9 months of case management and HIV risk counselling.

Duration of intervention: 9 months

Duration of follow-up: 15 months

Outcomes

Use of cocaine assessed by urine analysis

Notes

Funding source: National Institute on Drug Abuse Grant R01 DA13107

Conflict of interest: not stated

Risk of bias

Bias

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Unclear risk

Method for random sequence generation not reported. For stratification, each
participant was given a binary score (0 or 1) for each of 2 stratification vari-
ables: opiate positive at intake (yes 1, no 0) and alcohol dependent (yes 1, no
0; using DSM–IV checklist criteria). Quote: "By combining the 2 scores, we as-
signed each participant a 2-digit binary code. Participants were randomly as-
signed to one of the two study groups unless there was an imbalance in the
number of participants with a particular 2-digit code across the groups. If a
group had more participants with that 2-digit code than the other group, the
next participant with that code was assigned to the other group."

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias)
Subjective outcomes

Blinding of participants
and personnel (perfor-
mance bias)
Objective outcomes

Blinding of outcome as-
sessment (detection bias)
Subjective outcomes

Unclear risk

Information not reported

High risk

Blinding of participants and personnel impossible for the types of intervention

Low risk

No blinding or incomplete blinding, but the review authors judge that the out-
come is unlikely to be influenced by lack of blinding

Unclear risk

No information reported

Blinding of outcome as-
sessment (detection bias)

Low risk

No blinding or incomplete blinding, but the review authors judge that the out-
come is unlikely to be influenced by lack of blinding

Psychosocial interventions for stimulant use disorder (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

87

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Unclear risk

Information not reported for the total sample. Quote: "Four participants (S1,
S2, S3, and S4) did not return to the Therapeutic Workplace following 'the
sample left at intake.'"

Unclear risk

Protocol of the study not available

Knealing 2006  (Continued)
Objective outcomes

Incomplete outcome data
(attrition bias)
All outcomes except reten-
tion in treatment

Selective reporting (re-
porting bias)

Landovitz 2015 

Study characteristics

Methods

Randomised controlled trial

Participants

Country: USA

Participants: stimulant-using methamphetamine, amphetamine, and/or powder or crack cocaine;
men who have sex with men (MSM) and are at high risk of human immunodeficiency virus (HIV) acquisi-
tion
N = 140
Age: 36.8 mean age (SD 10.2)
Sex: males 10.6%
Ethnicity: white 37%, African American 37%, Latino 18%
Sexual orientation: gay, n = 65 (46.4%); bisexual, n = 70 (50.0%); heterosexual, n = 2 (1.4%); other, n = 3
(2.1%)
Education level: 63% had high school education or less
Employment: not reported; 92% reported an annual income ≤ USD 30 000

Interventions

Outcomes

Notes

Setting: outpatients

History:

• Route: not reported
• Psychostimulant use: not reported
• Other drugs: not reported
• Psychiatric comorbidity: not reported

1. Contingency management
2. Non-contingent yoked condition

Duration of intervention: 2 months

Duration of follow-up: 6 months

• Adherence and completion
• Stimulant use

Funding source: Financial support. "This study was supported by the California HIV Research Program,
grant number MC08-LA-710. RJL acknowledges additional support from the National Institute of Drug
Abuse at the National Institutes of Health (grant K23DA026308), and RJL, SS, and CJR acknowledge ad-
ditional support from the National Institute of Mental Health at the National Institutes of Health (grant
5P30AI028697)."

Conflict of interest: "All authors have submitted the ICMJE form for disclosure of potential conflicts
of interest. Conflicts that the editors consider relevant to the content of the manuscript have been dis-
closed."

Psychosocial interventions for stimulant use disorder (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

88

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Landovitz 2015  (Continued)

No useful data for inclusion in meta-analysis

Risk of bias

Bias

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Unclear risk

Information not reported

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias)
Subjective outcomes

Blinding of participants
and personnel (perfor-
mance bias)
Objective outcomes

Unclear risk

Information not reported

High risk

Blinding of participants and personnel impossible for the types of intervention

Low risk

No blinding or incomplete blinding, but the review authors judge that the out-
come is unlikely to be influenced by lack of blinding

Blinding of outcome as-
sessment (detection bias)
Subjective outcomes

Blinding of outcome as-
sessment (detection bias)
Objective outcomes

Incomplete outcome data
(attrition bias)
All outcomes except reten-
tion in treatment

Low risk

Low risk

High risk

Quote: "Participants were assessed before treatment, weekly during treat-
ment, and at the 12-week treatment termination point by an independent clin-
ical evaluator who was masked to treatment condition"

Quote: "Participants were assessed before treatment, weekly during treat-
ment, and at the 12-week treatment termination point by an independent clin-
ical evaluator who was masked to treatment condition"

30% of participants dropped out from the study; reasons not reported for the
experimental group

Selective reporting (re-
porting bias)

Low risk

All the declared outcomes in the protocol were reported in the results of the
study.

Ledgerwood 2006 

Study characteristics

Methods

Randomised controlled trial

Participants

Country: USA

Participants: cocaine or opioid dependence, DSM-IV

N = 142

Age: 37 years old (mean age)

Sex: males 45.7%

Ethnicity: white 27.1%; African American 60%, Latino 12.9%

Marital status: information not reported

Psychosocial interventions for stimulant use disorder (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

89

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Ledgerwood 2006  (Continued)

Cochrane Database of Systematic Reviews

Education level: information not reported

Employment: employed 15.5%

Setting: outpatients

History:

• Route: not reported
• Psychostimulant use: 7.7% positive urine at baseline
• Other drugs: 50% alcohol abuse; 33% opioids abuse
• Psychiatric comorbidity: not reported

Interventions

1. TAU, n = 38
2. TAU + CM, n = 104

Duration of intervention: 3 months

Duration of follow-up: 12 months

• 8 weeks of continuous abstinence
• University of Rhode Island Change Assessment (URICA)
• Addiction severity index (ASI)

Funding source: "National Institutes of Health Grants R01-DA013444, R01-DA013444-suppl, R01-
DA016855, R01-DA014618, P50-DA09241, P50-AA03510, and General Clinical Research Center Grant
M01-RR06192".

Conflict of interest: not stated

Authors' judgement

Support for judgement

Outcomes

Notes

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Low risk

Quote: "Patients were randomised to one of three treatment conditions (stan-
dard treatment, voucher CM or prize CM) using an urn randomisation proce-
dure"

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias)
Subjective outcomes

Blinding of participants
and personnel (perfor-
mance bias)
Objective outcomes

Blinding of outcome as-
sessment (detection bias)
Subjective outcomes

Unclear risk

Information not reported

High risk

Blinding not possible for this type of trial

Low risk

Not likely to be influenced by lack of blinding

Unclear risk

Information not reported

Blinding of outcome as-
sessment (detection bias)
Objective outcomes

Low risk

Information not reported but outcomes not likely to be influenced by lack of
blinding

Psychosocial interventions for stimulant use disorder (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

90

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Unclear risk

19% dropouts, not known if balanced between groups

Unclear risk

Protocol of the study not available

Ledgerwood 2006  (Continued)

Incomplete outcome data
(attrition bias)
All outcomes except reten-
tion in treatment

Selective reporting (re-
porting bias)

Marsden 2006 

Study characteristics

Methods

Randomised controlled trial

Participants

Country: UK

Participants: psychostimulant abusers (ecstasy, cocaine powder, crack cocaine)
N = 342

Age: 18.4 years old (mean age)
Sex: males 66.3 %
Ethnicity: white 75.9%, black 11.3%, Asian 8.6%, other 4.2%
Marital status: information not reported

Education level: full-time students 35%

Employment: in full-time employment 11.1%

Setting: outpatients

History:

• Route: information not reported
• Psychostimulant use: mean 77.7% used 2.2 tablets of ecstasy for 18 days in previous 90 days; mean
61.9% used 0.5 g of cocaine powder for 9.5 days in previous 90 days; mean 33.3% used 0.25 g of crack
cocaine for 10.6 days in previous 90 days

• Other drugs: 89.7% cannabis abuse, 83% alcohol abuse
• Psychiatric comorbidity: information not reported

Interventions

1. Brief motivational interviewing + written health risk information (n = 166)
2. Written health risk information (n = 176)

Duration of intervention: single session of motivational intervention

Duration of follow-up: 6 months

Outcomes

• Self-reported use of substance in the previous 90 days
• Dropouts
• Oral mucosal transudate toxicology on a random sample of 45 participants in each arm (30% of the

sample followed-up)

Notes

Funding source: Department of Health for England and Wales (No 1217195).

Conflict of interest: not stated

Risk of bias

Psychosocial interventions for stimulant use disorder (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

91

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Marsden 2006  (Continued)

Bias

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Low risk

Quote: "allocation of participants to the experimental and control condition
was controlled and balanced by random permuted blocks"

Allocation concealment
(selection bias)

Low risk

Quote: "The randomisation and concealment procedure was overseen by the
trial's statistician"

Blinding of participants
and personnel (perfor-
mance bias)
Subjective outcomes

Blinding of participants
and personnel (perfor-
mance bias)
Objective outcomes

High risk

Blinding not possible for this type of trial

Low risk

No blinding or incomplete blinding, but the review authors judge that the out-
come is unlikely to be influenced by lack of blinding

Blinding of outcome as-
sessment (detection bias)
Subjective outcomes

Unclear risk

Quote: "To guard against bias, all follow-up interviews were conducted by a
different worker from the one who had administered the participant's recruit-
ment protocol". Not specified whether assessor was blinded to treatment con-
dition

Blinding of outcome as-
sessment (detection bias)
Objective outcomes

Low risk

Not likely to be influenced by lack of blinding

Incomplete outcome data
(attrition bias)
All outcomes except reten-
tion in treatment

Low risk

12.5% dropout at 6-month follow-up. Balanced between treatment arms (13%
brief MI; 12% written health risk information). ITT analysis; baseline scores
were substituted for cases lost to follow-up.

Selective reporting (re-
porting bias)

Unclear risk

Protocol of the study not available

Marsden 2018 

Study characteristics

Methods

Randomised controlled trial

Participants

Country: UK

Participants: meet DSM-5 diagnostic criteria for moderate-to-severe cocaine use disorder (CUD) using
the Structured Clinical Interview for DSM5

N = 30

Age: 44.1 (6.6) years

Sex: males (66.7%)

Ethnicity: White British/White Other 19/30; Black British/Black Other/Mixed11/30

Marital status: not reported

Education level: not reported

Psychosocial interventions for stimulant use disorder (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

92

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Marsden 2018  (Continued)

Employment: (e.g. full-time, part-time, unemployed) not reported

Setting: outpatients

History:

• Route: crack cocaine, smocking, injecting and powder cocaine
• Psychostimulant use: cocaine had been regularly used for a median of 96 months (IQR 60.0–123.0);

current (any) use of cocaine in past 28 days (verified by clinical record)

• Other drugs: current non-abstinent alcohol use disorder was an exclusion criterion. 20 of 30 partici-

pants had concurrent OUD and all of this group were stabilised on oral opioid agonist therapy.

• Psychiatric comorbidity co-occurring CUD and PTSD was an exclusion criterion; Prescribed anti-de-

pressant medication 9/30; Prescribed anxiolytic/sedative medication 3/30

Interventions

1. MFCT group (n = 16)
2. TAU group (n = 14)

Outcomes

Notes

The study evaluated the efficacy of an adjunctive psychosocial intervention for CUD, called ‘memo-
ry-focused cognitive therapy’ (MFCT) versus general counselling (treatment as usual; TAU). Partici-
pants were individually randomised (1:1) to a control group (ongoing TAU; 3 × 90-minute CUD cognitive
conceptualisation assessments; 2 × 30-minute cocaine-related cue-induction procedures; and 3 × 30-
minute research follow-ups); or to an intervention group (ongoing TAU; 3 × 90-minute cognitive con-
ceptualisation assessments; 2 × 30-minute cocaine-related cue-induction procedures; 5 × 120-minute,
one-to-one) MFCT sessions [in 1 week]; and 3 × 60-minute research follow-ups and MFCT-relapse pre-
vention).

Duration of intervention: 15 weeks

Duration of follow-up: 3 months

• Dropout
• Abstinence
• Frequency of drug intake a ‘timeline follow-back’ structured interview to record each day of cocaine
use in past 28 days), and the frequency version of the Craving Experiences Questionnaire (CEQ-F) (re-
call period, past two weeks; item response: ‘not at all’ to ‘constantly’ [0 to 10]; item scores summed
as a total score [percentage] for tabulation.

Funding source: "This paper represents independent research funded by the National Institute for
Health Research (NIHR) Biomedical Research Centre at South London and Maudsley NHS Foundation
Trust and King’s College London. South London and Maudsley NHS Trust and King’s College London
were the joint sponsors. They had no role in study design, data collection, analysis, interpretation, or
report writing. The views expressed are those of the authors and not necessarily those of the NHS, the
NIHR or the Department of Health. The corresponding author (J.M.) had full access to all study data and
took the decision to submit for publication."

Trial registration: The study is registered with the International Standard Randomised Controlled Tri-
al registry (ISRCTN164627831).

Conflict of interest: "The authors declare that they have no financial investment or relationship with
any organisation that could inappropriately influence or benefit this research. J.M. declares investiga-
tor-led, educational grant funding from Indivior (administered by Action-on-Addiction) for a study of
personalised psychosocial intervention for non-response to opioid agonist treatment (ARC Trial), and
support from NIHR (HTA) for a trial of extended-release naltrexone. He acknowledges part-time em-
ployment as Senior Academic Advisor for the Alcohol, Drugs and Tobacco Division, Health Improve-
ment, Public Health England and consultancy for the US National Institute on Drug Abuse, Centre for
Clinical Trials Network. In the past 3 years, he received honoraria from Merck Serono (2015; clinical
oncology training); Martindale (2017; expert meeting on OUD); and Indivior (via PCM Scientific) as co-
chair (2015, 2016) and chair (2017) for the conference on Improving Outcomes in Treatment of Opioid
Dependence. L.M. declares grant funding for an investigator-led, educational grant from Indivior (ad-
ministered by Action- on-Addiction) for the ARC Trial. He holds no stocks in any company. C.G. is sup-
ported by a PhD studentship award from the National Institute for Health Research (NIHR) Biomed-

Psychosocial interventions for stimulant use disorder (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

93

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Marsden 2018  (Continued)

Cochrane Database of Systematic Reviews

ical Research Centre at South London and Maudsley NHS Foundation Trust and King’s College London.
J.S. is a researcher and clinician who has worked with a range of types of treatment and rehabilitation
service-providers. He is supported by the NIHR BRC for Mental Health at S La Mand KCL. He has also
worked with a range of governmental and non-governmental organisations, and with pharmaceutical
companies to seek to identify new or improved treatments from whom he and his employer (KCL) have
received honoraria, travel costs and/or consultancy payments. This includes work with, during past 3
years, Martindale, Reckitt-Benckiser/Indivior, MundiPharma, Braeburn/Camrus (none of these activities
relate to the study being reported here). N.G. is part supported by a research grant from theWellcome
Foundation (grant held by Professors Anke Ehlers and David Clark at the University of Oxford). All other
authors declare no competing interests."

Risk of bias

Bias

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Low risk

Quote: "web-accessed, computer-generated random sequence (with random
varying blocks, and no stratification factors) independently managed by the
King's College London Clinical Trials Unit"

Allocation concealment
(selection bias)

High risk

Quote: "It was not feasible to mask group allocation. The participant was im-
mediately informed of their allocation."

High risk

Blinding not possible for this type of trial

Low risk

No blinding or incomplete blinding, but the review authors judge that the out-
come is unlikely to be influenced by lack of blinding

Unclear risk

No information

Low risk

Not likely to be influenced by lack of blinding

Low risk

No dropout from the study

Unclear risk

No protocol available

Blinding of participants
and personnel (perfor-
mance bias)
Subjective outcomes

Blinding of participants
and personnel (perfor-
mance bias)
Objective outcomes

Blinding of outcome as-
sessment (detection bias)
Subjective outcomes

Blinding of outcome as-
sessment (detection bias)
Objective outcomes

Incomplete outcome data
(attrition bias)
All outcomes except reten-
tion in treatment

Selective reporting (re-
porting bias)

Maude-Griffin 1998 

Study characteristics

Methods

Randomised controlled trial

Participants

Country: USA

Participants: cocaine dependence (DSM-III-R)

Psychosocial interventions for stimulant use disorder (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

94

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Maude-Griffin 1998  (Continued)

Cochrane Database of Systematic Reviews

N = 128
Sex: males 98.4%
Age: information not reported
Ethnicity: African American 80%
Marital status: married 14%

Education level: not reported

Employment: employed 16%

Setting: outpatients

History:

• Route: 100% crack smokers
• Psychostimulant use: years of use: mean 19 years; days of use: 14 days in the last month; money spent:

mean USD 110 a day on cocaine

• Other drugs: not reported
• Psychiatric comorbidity: excluded patients with diagnosis of schizophrenia; 82% of the participants
had at least 1 of the 3 psychiatric disorders assessed at baseline: major depressive disorder, post-
traumatic stress disorder or antisocial personality disorder

Interventions

1. CBT (CT) (n = 59)
2. 12-step approach (n = 69)

In each treatment condition, participants attended 3 group therapy sessions and 1 individual coun-
selling session each week for 12 weeks.
Group therapy sessions were considered to be the primary intervention, individual sessions being ad-
junctive.

Duration of intervention: 3 months

Duration of follow-up: 6 months

• 4 consecutive weeks of abstinence from cocaine
• Point prevalence abstinence of cocaine by treatment condition

Funding source: Department of Veterans Affairs health service research and development merit review
grants and National Institute of Drug Abuse

Conflict of interest: not stated

Authors' judgement

Support for judgement

Outcomes

Notes

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Unclear risk

No information reported

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias)
Subjective outcomes

Blinding of participants
and personnel (perfor-
mance bias)

Unclear risk

No information provided on allocation concealment

High risk

Blinding of participants and personnel impossible for the types of intervention

Low risk

No blinding or incomplete blinding, but the review authors judge that the out-
come is unlikely to be influenced by lack of blinding

Psychosocial interventions for stimulant use disorder (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

95

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Maude-Griffin 1998  (Continued)

Objective outcomes

Blinding of outcome as-
sessment (detection bias)
Subjective outcomes

Unclear risk

No information reported

Blinding of outcome as-
sessment (detection bias)
Objective outcomes

Low risk

No blinding or incomplete blinding, but the review authors judge that the out-
come is unlikely to be influenced by lack of blinding

Unclear risk

92% completed the 12-week assessment; 84% completed the 24-week fol-
low-up assessment. Information on percentage of dropout for each group not
reported, but authors stated that there was no significant difference

Unclear risk

Protocol of the study not available

Incomplete outcome data
(attrition bias)
All outcomes except reten-
tion in treatment

Selective reporting (re-
porting bias)

McDonell 2013 

Study characteristics

Methods

Randomised controlled trial

Participants

Country: USA

Participants: cocaine, amphetamine or methamphetamine dependence (MINI) and schizophrenia,
schizoaffective disorder, bipolar disorder, or recurrent major depressive disorder

N = 176

Age: 42.7 years old (mean age)

Sex: males 34.6%

Ethnicity: white 53.9%; African American 30.1%; others 16%

Marital status: information not reported

Education level: information not reported

Employment: information not reported

Setting: outpatients

History:

• Route: information not reported
• Psychostimulant use: mean 6 days use of cocaine and 0.7 days use of amphetamines in the 30 days

prior to study entry; 95% cocaine, 38.6% amphetamines abuse or dependence

• Other drugs: 45.4% alcohol abuse or dependence; 63% non-stimulant drug abuse or dependence
• Psychiatric  comorbidity:  26%  major  depressive  disorder,  34%  bipolar  disorder,  40%  schizoaffec-

tive-spectrum disorder

Interventions

1. Standard treatment + CM (n = 91)
2. Standard treatment + non-contingent reinforcement (n = 85)

Duration of intervention: 3 months

Psychosocial interventions for stimulant use disorder (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

96

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

McDonell 2013  (Continued)

Outcomes

Duration of follow-up: 3 months

• Days of stimulant use
• Days of alcohol use
• Injection drug use
• Brief Symptom Inventory Score
• Positive and Negative Symptom Scale Excitement Factor Score
• Dropout
• Urine toxicology

Notes

Funding source: "Drs Roll and McPherson have received research funding in the past 12 months from
Bristol-Myers Squibb"

Conflict of interest: "Dr Ries has been on the speaker bureaus of Lilly, Bristol-Myers Squibb, Pfizer,
Janssen, Astra-Zeneca and Suboxone in the past five years. All authors have no disclosure to report"

Risk of bias

Bias

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Low risk

Quote: "Randomization was conducted using the urn-randomization proce-
dure"

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias)
Subjective outcomes

Blinding of participants
and personnel (perfor-
mance bias)
Objective outcomes

Blinding of outcome as-
sessment (detection bias)
Subjective outcomes

Blinding of outcome as-
sessment (detection bias)
Objective outcomes

Unclear risk

Information not reported

High risk

Blinding not possible for this type of trial

Low risk

Not likely to be influenced by lack of blinding

Unclear risk

Information not reported

Low risk

Not likely to be influenced by lack of blinding

Incomplete outcome data
(attrition bias)
All outcomes except reten-
tion in treatment

Low risk

ITT analysis. Quote: "multiple imputation procedures were used to handle
missing data; multiple imputation requires the assumption of missing at ran-
dom. Preliminary analysis identified 12 variables that predicted missingness
due to treatment drop out. We used these variables to help ensure that our
missing at random was tenable"

Selective reporting (re-
porting bias)

Low risk

All the declared outcomes in the protocol were reported in the results of the
study.

Psychosocial interventions for stimulant use disorder (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

97

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

McKee 2007 

Study characteristics

Methods

Randomised controlled trial

Participants

Country: USA

Cochrane Database of Systematic Reviews

Participants: cocaine abuse or dependence (DSM-IV)
N = 74

Age: 35 years old (mean age)
Sex: males 73%
Ethnicity: white 44.6%, African American 48.6%, Latino 6.7%
Marital status: never married 52.7%, married or cohabitating 31%, divorced or separated 16.2%

Education level: college graduate 4%, partial college 25.6%, high school graduate 32.4%, less than
high school 37.8%

Employment: full-time employment 37.8%, part-time employment 10%, unemployed 51.3%

Setting: inpatients and outpatients

History:

• Route: not reported
• Psychostimulant use: mean 7.1 days of cocaine abuse in past 30 days
• Other drugs: mean 3.1 days of cannabis abuse, mean 8.7 days of alcohol abuse in past 30 days
• Psychiatric comorbidity: not reported

Interventions

1. Brief CBT + motivational enhancement techniques (MET) (n = 38)
2. Brief cognitive behavioural therapy (CBT) (n = 36)

Outcomes

Duration of intervention: 3 sessions within 2 months

Duration of follow-up: 4 months

• Retention
• Urine toxicology (cocaine, marijuana, opiates, benzodiazepines)
• Thoughts about abstinence scale (TAAS)
• Client satisfaction scale (CSQ)
• Patient therapy session report (PTSR)

Notes

Funding source: not stated

Conflict of interest: not stated

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Authors' judgement

Support for judgement

Unclear risk

Quote: "eligible individuals were randomised to therapy condition"

Allocation concealment
(selection bias)

Low risk

Quote: "Therapists, participants and staff were unaware of the therapy assign-
ment until the patient showed for session one"

Blinding of participants
and personnel (perfor-
mance bias)
Subjective outcomes

High risk

Blinding not possible for this type of trial

Psychosocial interventions for stimulant use disorder (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

98

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

McKee 2007  (Continued)

Blinding of participants
and personnel (perfor-
mance bias)
Objective outcomes

Low risk

No blinding or incomplete blinding, but the review authors judge that the out-
come is unlikely to be influenced by lack of blinding

Blinding of outcome as-
sessment (detection bias)
Subjective outcomes

Low risk

Quote: "Assessments were collected by research staff blind to the therapy con-
dition"

Low risk

Not likely to be influenced by lack of blinding

High risk

35.1% dropout. Unbalanced between treatment arms (38.8% CBT; 31.5% CBT
+ MET)

Unclear risk

Protocol of the study not available

Blinding of outcome as-
sessment (detection bias)
Objective outcomes

Incomplete outcome data
(attrition bias)
All outcomes except reten-
tion in treatment

Selective reporting (re-
porting bias)

Menza 2010 

Study characteristics

Methods

Randomised controlled trial

Participants

Country: USA

Participants: men who have sex with men (MSM), with methamphetamine abuse

N = 127

Age: 39 years old (mean age)

Sex: males 34.6%

Ethnicity: white 60%, African American 8%, Native American or Alaska Native 6%, Latino 13%, others
13%

Marital status: information not reported

Education level: college or greater 10%, partial college training 47%, high school 24%, less than high
school 15%

Employment: employed 30%

Setting: outpatients

History:

• Route: 54% injection of methamphetamines
• Psychostimulant use: 65% weekly or daily use for prior 6 weeks: 46% inhaled nitrates, 31% erectile

dysfunction medications, 28% cocaine, 42% crack, 15% ecstasy, 20% gamma-hydroxybutyrate

• Psychiatric comorbidity: information not reported

Interventions

1. Standard treatment and CM (n = 70)
2. Standard treatment (n = 57)

Psychosocial interventions for stimulant use disorder (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

99

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Menza 2010  (Continued)

Outcomes

Duration of intervention: 3 months

Duration of follow-up: 3 months

• Non-concordant unprotected anal intercourse (UAI)
• Number of non-concordant UAI partners
• Self-reported methamphetamine use
• Self-reported use of more than 2 g of methamphetamine
• Retention
• Urine toxicology

Notes

Funding source: not stated

Conflict of interest: the authors declare that they have no competing interests

Risk of bias

Bias

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Low risk

Quote: "The study randomised participants using a block of two, four and
eight varied randomly with a pseudo-random number generator"

Allocation concealment
(selection bias)

Low risk

Quote: "The randomizations list was used to assemble sequentially numbered,
sealed, opaque envelopes containing intervention arm assignment "

Blinding of participants
and personnel (perfor-
mance bias)
Subjective outcomes

Blinding of participants
and personnel (perfor-
mance bias)
Objective outcomes

Blinding of outcome as-
sessment (detection bias)
Subjective outcomes

Blinding of outcome as-
sessment (detection bias)
Objective outcomes

Incomplete outcome data
(attrition bias)
All outcomes except reten-
tion in treatment

High risk

Blinding not possible for this type of trial

Low risk

Not likely to be influenced by lack of blinding

High risk

Self-reported outcomes possibly influenced by lack of blinding

Low risk

Not likely to be influenced by lack of blinding

Low risk

19.6% dropouts, balanced between groups (20% CM, 19% TAU only)

Selective reporting (re-
porting bias)

Low risk

All the declared outcomes in the protocol were reported in the results of the
study.

Miguel 2017 

Study characteristics

Psychosocial interventions for stimulant use disorder (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

100

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Miguel 2017  (Continued)

Methods

Randomised controlled trial

Participants

Country: Brazil

Cochrane Database of Systematic Reviews

Participants: treatment-seeking, crack cocaine-dependent individuals with a diagnosis of crack co-
caine dependence according to the DSM-IV

N = 65

Age in years (SD): standard treatment alone (STA) 35.4 (8.5); standard treatment plus contingency man-
agement (STCM) 35.3 (8.7)

Males: STA 81.3%; STCM 90%

Ethnicity: not reported

Marital status: not reported

Education level (SD): STA 9.774 (3.747); STCM 8.911 (3.441) years

Employment: STA 84.4%; STCM 84.8%

Setting: outpatients

History:

• Route: crack cocaine
• Psychostimulant use: crack cocaine. The average length of crack cocaine use was over 12 years, with

an average age of onset of approximately 22 years

• Other drugs: those whose drug of choice was not crack cocaine were excluded; 75% had more than

one substance use disorder (THC; alcohol)

• Psychiatric comorbidity: those with a DSM-IV diagnosis of schizophrenia were excluded. Proportions

of samples testing negative for marijuana and alcohol were an outcome measure

Interventions

1. Standard treatment plus contingency management (STCM; n = 33)
2. Standard treatment alone (STA; n = 32).

Participants in the STCM group (n = 33) received the exact same treatment as those in the STA group ex-
cept that they could earn vouchers (monetary incentives) for being abstinent. No form of monetary in-
centive was offered to the STA group participants.

• Longest duration of confirmed crack cocaine abstinence (LDA)
• Proportion of samples testing negative for crack cocaine
• Proportions of samples testing negative for marijuana and alcohol

Funding source: "This study was supported by grants from Fundação de Amparo a Pesquisa de Sao
Paulo (FAPESP) during the design, conduct and stages of data analyses and interpretation (Regular Re-
search award number 2011/01469-7 and Ph.D. Scholarship award number 2013/04138-7). This study
was also supported by a grant from the Clinical Trials Network Pacific Northwest Node (award number
5 U10 DA013714-10) from the National Institute on Drug Abuse (NIDA)."

Trial registration: This study was registered at ClinicalTrials.gov under the identifier number
NCT01815645.

Conflict of interest: "All authors report no real or potential conflict(s) of interest, including financial,
personal, or other relationships with other organizations or pharmaceutical/biomedical companies
that may inappropriately impact or influence the research and interpretation of the findings."

Authors' judgement

Support for judgement

Outcomes

Notes

Risk of bias

Bias

Psychosocial interventions for stimulant use disorder (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

101

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Miguel 2017  (Continued)

Cochrane Database of Systematic Reviews

Random sequence genera-
tion (selection bias)

Low risk

Quote: "permuted block randomization; Participants were stratified by the
concurrent diagnosis of alcohol dependence."

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias)
Subjective outcomes

Blinding of participants
and personnel (perfor-
mance bias)
Objective outcomes

Blinding of outcome as-
sessment (detection bias)
Subjective outcomes

Unclear risk

No information

High risk

Blinding of participants and personnel impossible for the types of intervention

Low risk

No blinding or incomplete blinding, but the review authors judge that the out-
come is unlikely to be influenced by lack of blinding

Unclear risk

No information reported

Blinding of outcome as-
sessment (detection bias)
Objective outcomes

Low risk

No blinding or incomplete blinding, but the review authors judged that the
outcome is unlikely to be influenced by lack of blinding

Incomplete outcome data
(attrition bias)
All outcomes except reten-
tion in treatment

Low risk

No dropout from study

Selective reporting (re-
porting bias)

High risk

Protocol available. Primary and secondary outcomes changed at the time of
publication. Several original secondary outcomes (craving, anxiety, depres-
sion) not assessed

Miguel 2022 

Study characteristics

Methods

Single-blind randomised controlled trial

Participants

Country: Brazil

Participants: treatment-seeking individuals who use crack

N = 98

Age (SD): 38.7 (9.5) years

Sex: 83 males (84.7%)

Ethnicity: black 53 (54.1%), white 43 (43.9%), Asian 2 (2%)

Marital status: single 86 (87.8%), married 5 (5.1%), divorced 7 (7.1%)

Education level: 8.7 years of schooling (SD 2.7)

Employment: unemployed 60 (61.2%)

Setting: outpatients

Psychosocial interventions for stimulant use disorder (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

102

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Miguel 2022  (Continued)

History:

Cochrane Database of Systematic Reviews

Interventions

• Route: crack use
• Psychostimulant use: cocaine mean age of first use of crack use was 20.6 years old (SD 6.9), with an

average duration of continuous crack use of 15 years (SD 9.7)

• Other drugs: multiple substance use disorders (73.5%), alcohol use disorders (87.8%) and tobacco use

disorder (68.4%)

1. Control condition (n = 48): 12 weeks of the standard treatment: public ambulatory treatment program
for persons who use crack and live in the “Crackland” region in downtown São Paulo (Unidade Re-
começo Helvétia - URH)

2. Experimental condition (n = 50): same treatment + contingency management (URH + CM)

In URH + CM, participants were provided with vouchers with monetary value for submission of negative
cocaine urinalysis twice weekly.

Duration of intervention: 12 weeks

Duration of follow-up: 3 months follow-up

Outcomes

Primary outcome: objective verification of crack cocaine abstinence during the course of treatment
assessed as negative cocaine urinalysis tested twice weekly for 12 weeks.

Notes

Secondary outcomes included "three within-treatment cocaine use outcome measures (longest du-
ration of abstinence; percent of negative cocaine urinalysis submitted; achievement of three or more
weeks of continuous abstinence) that have previously shown to predict better long-term treatment
outcomes for cocaine and other stimulant use disorders treatment trials. All three cocaine use out-
come measures were computed based exclusively on urine toxicological results. Finally, treatment re-
tention, defined as the number of weeks elapsed between treatment intake and dropout (i.e., last ap-
pearance at treatment), was also analyzed as a secondary outcome."

Funding source: "This study was supported by the Research and Innovation grant for Prevention
of Mental Disorders and Abuse of Alcohol and Other Drugs (Pesquisas e Inovações em Prevenção de
Transtornos Mentais e Uso de Álcool e Outras Drogas) funded by the Brazilian Ministry of Health ( TED
#176/2017 ). Dr. Miguel was supported by Fundação de Amparo àPesquisa do Estado de São Paulo
(FAPESP) with the postdoctoral fellowship processes n°2017-05371-8 and n°2017-22004-9. The Ministry
of Health and FAPESP had no further role in the study design; the col- lection, analysis, and interpreta-
tion of data; the writing of the report; or the decision to submit the paper for publication."

Conflict of interest: "McPherson and Roll have received research funding from the Bristol- Myers
Squibb Foundation, Managed Health Connections, LLC, Ringful Health, LLC, and Pillsy, Inc. McPherson
has also received research funding from the Orthopedic Specialty Institute and consulted for Consis-
tent Care, LLC, and the United States Department of Justice. These funds are in no way related to the
investigation reported here. Miguel, Simões, Yamauchi, Madruga, Smith, da Silva, Laranjeira, McDonell,
and Mari have no financial relationships with commercial interests."

Risk of bias

Bias

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Low risk

Quote: "permuted block randomization with the inclusion of two binary co-
variates for stratification to balance the two groups (i.e., baseline urinalysis re-
sult and sex)."

Allocation concealment
(selection bias)

Low risk

Quote: "Researchers responsible for the randomization had no contact with
the participants and were responsible only for informing treatment providers
of each participant’s group allocation"

Psychosocial interventions for stimulant use disorder (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

103

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Miguel 2022  (Continued)

Blinding of participants
and personnel (perfor-
mance bias)
Subjective outcomes

Blinding of participants
and personnel (perfor-
mance bias)
Objective outcomes

Blinding of outcome as-
sessment (detection bias)
Subjective outcomes

High risk

Blinding of participants and personnel impossible for the types of intervention

Low risk

No blinding or incomplete blinding, but the review authors judge that the out-
come is unlikely to be influenced by lack of blinding

Unclear risk

Study stated it was single blinded ("blind researchers"). However, no further
information was provided.

Blinding of outcome as-
sessment (detection bias)
Objective outcomes

Low risk

Study stated it was single blinded ("blind researchers"). However, no further
information was provided. Review authors judged that the outcome was not
likely to be influenced by lack of blinding.

Incomplete outcome data
(attrition bias)
All outcomes except reten-
tion in treatment

Low risk

ITT analysis with missing data imputation using adequate procedure

Selective reporting (re-
porting bias)

High risk

Protocol available. Primary and secondary outcomes changed at the time of
publication. Two original secondary outcomes (anxiety, depression) not as-
sessed

Milby 2008 

Study characteristics

Methods

Randomised controlled trial

Participants

Country: USA

Participants: cocaine dependence (DSM-IV), homeless

N = 206

Age: 40 years old (mean age)

Sex: males 74.5%

Ethnicity: white 5.5%, African American 94.5%

Marital status: information not reported

Education level: 12 years (mean)

Employment: employed: 7%

Setting: outpatients

History:

• Route: not reported
• Psychostimulant use: cocaine abused for a mean period of 12 years.
• Other drugs: alcohol abused for a mean period of 18 years, cannabis used for a mean period of 10.6

years.

Psychosocial interventions for stimulant use disorder (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

104

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Milby 2008  (Continued)

Cochrane Database of Systematic Reviews

• Psychiatric comorbidity: significant psychological distress, as indicated by a score of 70 (2 SDs above

the mean) on one or more Brief Symptom Inventory (BSI) scales

Interventions

1. Abstinence-contingent housing, vocational training, and work (CM) (n = 103)
2. Same intervention (CM) plus CBT day treatment (n = 103)

Outcomes

Duration of intervention: 6 months

Duration of follow-up: 18 months

• Housing and employment
• Consecutive weeks of abstinence
• Missing information on urine toxicology

Notes

Funding source: this research was supported by NIDA grant 3R01 DAD 11788-0451

Conflict of interest: not stated

Risk of bias

Bias

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Unclear risk

Information not reported

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias)
Subjective outcomes

Blinding of participants
and personnel (perfor-
mance bias)
Objective outcomes

Unclear risk

Information not reported

High risk

Blinding not possible for the types of interventions

Low risk

Not likely to be influenced by lack of blinding

Blinding of outcome as-
sessment (detection bias)
Subjective outcomes

Low risk

Quote: "interviewers who did not know participants' treatment assignment as-
sessed housing and employment outcomes".

Blinding of outcome as-
sessment (detection bias)
Objective outcomes

Incomplete outcome data
(attrition bias)
All outcomes except reten-
tion in treatment

Low risk

Not likely to be influenced by lack of blinding

Low risk

ITT analysis

Selective reporting (re-
porting bias)

Unclear risk

The primary outcome reported in the protocol has been included in the study
results. However, the secondary outcomes are not clearly expressed in the
study protocol.

Psychosocial interventions for stimulant use disorder (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

105

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Mimiaga 2019 

Study characteristics

Methods

Randomised controlled trial

Participants

Country: USA

Cochrane Database of Systematic Reviews

Participants: men who have sex with men who met DSM-IV diagnostic criteria for crystal methamphet-
amine dependence

N = 41 after randomization (46 enroled)

Age: 39.8 (11.6)

Sex: men (100%)

Ethnicity: white 32 (78%); racial/ethnic minorities 9 (22%)

Marital status: single 29 (70.7%)

Education level: college degree or more 23 (56.1%)

Employment: employed full- or part-time 18 (43.9%); unemployed/disabled 23 (56.1%)

Setting: outpatients

History:

• Route: smoked, snorted, IDU (“slam”), and rectally inserted
• Psychostimulant use: crystal methamphetamine addiction
• Other  drugs:  "The  frequency  of  other  substances  used  in  the  prior  three  months  in  the  context  of
sex (using a few hours prior to or during sex) was also queried, including poppers, non-prescribed
erectile dysfunction drugs, marijuana, GHB [gamma-hydroxybutyric acid], crack, cocaine, downers,
painkillers, ecstasy, and alcohol. A summary score was created of the number of substances used dur-
ing sex in the prior three months by dichotomizing each substance used during sex at least once in
prior three months (yes/no) and summing across the binary variables, with possible values ranging
from 0 to 15. Number drugs used during sex, past 3 months at baseline SRR+BA [sexual risk reduction
counseling + behavioural activation] = 5.7 (2.1); SRR = 6.1 (2.6)"

• SRR: 3/20 at 3 months
• Psychiatric comorbidity: depression symptom scores (MADRS) SRR+BA = 19.8 (9.7); SRR = 17.6 (8.9)

Interventions

1. Control condition (n = 20) participants were assigned to a control condition (two sessions of sexual

risk reduction counseling (SRR))

2. Experimental condition (n = 21): 2 sessions of SRR + 10 sessions of BA (behavioral activation, including
3 sessions of cognitive behavior therapy) with SRR (sexual risk reduction counseling), and 1 session
of relapse prevention (13 sessions total)

Outcomes

Duration of intervention: 3 months

Duration of follow-up: 6 months

• Number of condomless anal sex acts
• Reduction in crystal meth use
• Retention in treatment

Notes

Funding source: not reported

Trial registration: ClinicalTrials.gov number NCT03175159

Conflict of interest: not reported

Risk of bias

Psychosocial interventions for stimulant use disorder (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

106

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Mimiaga 2019  (Continued)

Bias

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Unclear risk

No information

Unclear risk

No information

High risk

Blinding of participants and personnel impossible for the types of intervention

Low risk

No blinding or incomplete blinding, but the review authors judge that the out-
come is unlikely to be influenced by lack of blinding

Unclear risk

No information reported

Low risk

Low risk

No blinding or incomplete blinding, but the review authors judged that the
outcome is unlikely to be influenced by lack of blinding

Few dropouts (3/21), balanced between groups post intervention. No dropouts
at follow-up assessment

Unclear risk

No protocol available

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias)
Subjective outcomes

Blinding of participants
and personnel (perfor-
mance bias)
Objective outcomes

Blinding of outcome as-
sessment (detection bias)
Subjective outcomes

Blinding of outcome as-
sessment (detection bias)
Objective outcomes

Incomplete outcome data
(attrition bias)
All outcomes except reten-
tion in treatment

Selective reporting (re-
porting bias)

Mitcheson 2007 

Study characteristics

Methods

Cluster-randomised controlled trial

Participants

Country: UK

Participants: crack cocaine abuse or dependence in a methadone maintenance population
N = 29

Age: 40 years old (mean age)
Sex: males 65.5%
Ethnicity: not reported
Marital status: not reported

Education level: not reported

Employment: employed 89.6%

Setting: outpatients

History:

Psychosocial interventions for stimulant use disorder (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

107

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Mitcheson 2007  (Continued)

Cochrane Database of Systematic Reviews

• Route: not reported
• Psychostimulant use: mean 2.5 daily 'rocks'; 17% powder cocaine, 20% speedball
• Other drugs: use within previous 30 days: 72% alcohol, 60% heroin, 51% benzodiazepines, 100% in a

methadone maintenance programme

• Psychiatric comorbidity: information not reported

Interventions

1. Motivational interviewing (MI) plus TAU (poster display in the reception area and the ready provision
of a series of in-house-produced information leaflets describing various aspects and consequences of
crack cocaine use (n = 17)

Outcomes

2. TAU (n = 12)

Duration of intervention: single session

Duration of follow-up: 3 months

• Amount of drug use, self reported
• Maudsley Addiction Profile (MAP)
• Severity of dependence scale (SDS)
• Hospital Anxiety and Depression Scale

Notes

Funding source: not stated

Conflict of interest: not stated

Risk of bias

Bias

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Unclear risk

Allocation concealment
(selection bias)

High risk

Quote: "consenting crack-using clients of the staff member who received MI
training at the outset of the study were the clusters which were randomized
and who were thus eligible to receive the intervention. Consenting crack-using
clients of the staff who did not receive the initial training were assigned to the
control group". Methods for sequence generation not described

Quote: "consenting crack-using clients of the staff member who received MI
training at the outset of the study were the clusters which were randomized
and who were thus eligible to receive the intervention. Consenting crack-using
clients of the staff who did not receive the initial training were assigned to the
control group". Allocation not concealed

Blinding of participants
and personnel (perfor-
mance bias)
Subjective outcomes

Blinding of participants
and personnel (perfor-
mance bias)
Objective outcomes

Blinding of outcome as-
sessment (detection bias)
Subjective outcomes

Blinding of outcome as-
sessment (detection bias)
Objective outcomes

High risk

Blinding not possible for this type of trial

Low risk

No objective outcome presented in this cluster-RCT

Unclear risk

Information not reported

Low risk

No objective outcome presented in this cluster-RCT

Psychosocial interventions for stimulant use disorder (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

108

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Low risk

0% dropout at follow-up

Unclear risk

Protocol of the study not available

Mitcheson 2007  (Continued)

Incomplete outcome data
(attrition bias)
All outcomes except reten-
tion in treatment

Selective reporting (re-
porting bias)

Parsons 2018 

Study characteristics

Methods

Randomised controlled trial

Participants

Country: NYC metropolitan area, USA

Participants: HIV-positive men with methamphetamine use

N = 210

Age: 40.8

Sex: men

Ethnicity: white 70 (33.3%), black 72 (34.3%), Latino 54 (25.7%), other 14 (6.7%)

Marital status: not reported

Education level: college graduate or more 82 (39.1%)

Employment: working 48 (22.9%), not working 162 (77.1%)

Setting: outpatients

History:

• Psychostimulant use: at baseline, 5.76 days (SD = 5.69) of methamphetamine use in the past 30 days

Interventions

1. Experimental condition (n = 109): 8 sessions of motivational interview (MI) + cognitive behavioural

therapy (CBT)

2. Control condition (n = 107): 1 session of attention-matched education control

Outcomes

Notes

Duration of intervention: 12 months

Duration of follow-up: 3, 6, 9 and 12-month follow-up

Self-reported measures of methamphetamine use, HIV medication adherence, and condomless anal
sex

Funding source: "Funding support was provided by the National Institute on Drug Abuse (R01-
DA023395; Jeffrey T. Parsons, Principal Investigator). The content is solely the responsibility of the au-
thors and does not necessarily represent the official views of the National Institutes of Health. The au-
thors acknowledge the contributions of the ACE Project Team—Kristi Gamarel, Sarit Golub, Chris Hi-
etikko, Catherine Holder, William Kowalczyk, John Pachankis, Gregory Payton, H. Jonathon Rendi-
na, Kevin Robin, Julia Tomassilli, and the CHEST recruitment team. We also gratefully acknowledge
Shoshana Kahana for her support of the project, and Pamela Goodlow."

Trial registration: not reported

Psychosocial interventions for stimulant use disorder (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

109

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Parsons 2018  (Continued)

Risk of bias

Bias

Conflict of interest: "The authors declare that they have no conflict of interest."

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Low risk

Quote: "urn randomization procedures [47], which enabled stratification on
race/ethnicity, years on HIV medication, viral load, number of days that partic-
ipant missed their HIV medications in the last 30 days, and number of days of
methamphetamine use in the last 90 days."

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias)
Subjective outcomes

Blinding of participants
and personnel (perfor-
mance bias)
Objective outcomes

Blinding of outcome as-
sessment (detection bias)
Subjective outcomes

Blinding of outcome as-
sessment (detection bias)
Objective outcomes

Incomplete outcome data
(attrition bias)
All outcomes except reten-
tion in treatment

Selective reporting (re-
porting bias)

Unclear risk

No information

High risk

Blinding not possible for this type of trial

Low risk

Not likely to be influenced by lack of blinding

Unclear risk

Information not reported

Low risk

Not likely to be influenced by lack of blinding

Low risk

ITT analysis

Unclear risk

No protocol available

Peirce 2006 

Study characteristics

Methods

Randomised controlled trial

Participants

Country: USA

Participants: psychostimulants (cocaine, amphetamine, and methamphetamine) dependence in
methadone maintenance programme

N = 402

Age: 42 years old (mean age)

Sex: males 55.8%

Ethnicity: African American 50.4%, white 26%, Latino 16.5%, other 7%

Psychosocial interventions for stimulant use disorder (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

110

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Peirce 2006  (Continued)

Cochrane Database of Systematic Reviews

Marital status: married or cohabitating 13.6%; separated, divorced or widowed 35.2%; never married
51.1%

Education level: 11.7 years (mean)

Employment: full-time 15.4%, part-time 16.5%, unemployed 68.1%

Setting: outpatients

History:

• Route: not reported
• Psychostimulant use: 82.4% with psychostimulant dependence
• Other drugs: 17.1% alcohol dependence, 8.3% cannabis dependence, 80% opioid dependence.
• Psychiatric comorbidity: not reported

Interventions

1. Usual care + CM-abstinence-incentive condition (n = 204, analysed n = 198; 6 participants excluded

after randomisation due to ineligibility)

2. Usual care condition (n = 198, analysed n = 190; 8 participants excluded after randomisation due to

ineligibility)

Duration of intervention: 3 months

Duration of follow-up: 6 months

• Retention
• Urine toxicology
• Longest duration of abstinence

Funding source: supported by grants U10DA13034 and K23DA015739 from the National Institute on
Drug Abuse, Bethesda, MD

Conflict of interest: not stated

Authors' judgement

Support for judgement

Outcomes

Notes

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Low risk

Quote: "Stratification and random assignment were conducted independent-
ly at each site and accomplished by a computer program using a dynamic bal-
anced randomization procedure".

Allocation concealment
(selection bias)

Low risk

Quote: "Research staff did not know the randomisation sequence, but were
aware of individual group assignment".

Blinding of participants
and personnel (perfor-
mance bias)
Subjective outcomes

Blinding of participants
and personnel (perfor-
mance bias)
Objective outcomes

Blinding of outcome as-
sessment (detection bias)
Subjective outcomes

High risk

Blinding not possible for the types of interventions

Low risk

Not likely to be influenced by lack of blinding

Unclear risk

Information not reported

Psychosocial interventions for stimulant use disorder (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

111

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Low risk

Not likely to be influenced by lack of blinding

High risk

34% dropout, balanced between groups (32.9 % dropouts in CM group, 35.2%
in TAU)

Unclear risk

Protocol of the study not available

Peirce 2006  (Continued)

Blinding of outcome as-
sessment (detection bias)
Objective outcomes

Incomplete outcome data
(attrition bias)
All outcomes except reten-
tion in treatment

Selective reporting (re-
porting bias)

Petitjean 2014 

Study characteristics

Methods

Randomised controlled trial

Participants

Country: Switzerland

Participants: cocaine dependence (DSM-IV)
N = 60
Age: 34.5 years old (mean age)
Sex: males 80.1%
Ethnicity: not reported
Marital status: married 11.7%, unmarried 76.6%, divorced/separated 11.6%
Education level: university: 10%, college (≥ 12 years) 13%, job training after school 47%, standard
school (9 years) 29%, no school degree 1%

Employment: employed 56%

Setting: outpatients

History:

• Route: 60% intranasal, 25% injection, 15% smoking
• Psychostimulant use: mean 8.9 years of consumption, mean 1.8 days of cocaine use in the past 7 days
• Other drugs: 80.1% with another SUD, 36.4% on opioid maintenance treatment
• Psychiatric comorbidity: patients with current psychotic disorders excluded; 46.3% with a comorbid

axis I disorder, 23.1% with a comorbid personality disorder

Interventions

1. CBT + CM (n = 29)
2. CBT only (n = 31)

Duration of intervention: 6 months (18 CBT individual sessions, plus twice-weekly urine samples)

Outcomes

Duration of follow-up: 6 months

• Addiction Severity Index (ASI)
• Severity of Dependence Scale (SDS)
• Self-reported cocaine use (frequency and amount)
• Beck Depression Inventory (BDI)
• Retention
• Urine toxicology

Notes

Funding source: not stated

Psychosocial interventions for stimulant use disorder (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

112

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Petitjean 2014  (Continued)

Risk of bias

Bias

Conflict of interest: Dursteler holds a grant from the Voluntary Academic Society of Basel. The remain-
ing authors declare no conflicts of interest.

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Low risk

Quote: "Patients were randomly assigned to one of the two treatment arms us-
ing computerized randomization"

Allocation concealment
(selection bias)

Low risk

Quote: "The allocation sequence was provided in sealed envelopes and thus
blinded to the researchers and patients"

Blinding of participants
and personnel (perfor-
mance bias)
Subjective outcomes

Blinding of participants
and personnel (perfor-
mance bias)
Objective outcomes

Blinding of outcome as-
sessment (detection bias)
Subjective outcomes

Blinding of outcome as-
sessment (detection bias)
Objective outcomes

Incomplete outcome data
(attrition bias)
All outcomes except reten-
tion in treatment

High risk

Blinding not possible for this type of trial

Low risk

No blinding or incomplete blinding, but the review authors judge that the out-
come is unlikely to be influenced by lack of blinding

Unclear risk

Information not reported

Low risk

Not likely to be influenced by lack of blinding

Low risk

ITT analysis; missed urine test counted as positive

Selective reporting (re-
porting bias)

Low risk

All the declared outcomes in the protocol were reported in the results of the
study.

Petry 2005a 

Study characteristics

Methods

Randomised controlled trial

Participants

Country: USA

Participants: stimulant (cocaine or methamphetamine) dependence (79.3%) and abuse (5.1%), DSM-IV
N = 415
Age: 35.8 years old (mean age)

Sex: males 44.6%

Ethnicity: white 45%, African American 31.6%, Latino 12.9%

Marital status: married or cohabitant 23.59%, separated/divorced 32.56%, never married 43.82%

Education level: mean 11.8 years

Psychosocial interventions for stimulant use disorder (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

113

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Petry 2005a  (Continued)

Employment: unemployed 65.2%, employed full-time 19.5%, employed part-time 15.3%

Setting: outpatients in 8 community clinics

History:

• Route: not reported
• Psychostimulant use: 83% stimulants
• Other drugs: 42% alcohol; 21% marijuana; 9.4% opiates
• Psychiatric comorbidity: not reported

Interventions

1. CM + TAU (n = 223, analysed 209; 14 participants excluded after randomisation due to ineligibility)
2. TAU (n = 222, analysed 206; 16 participants excluded after randomisation due to ineligibility)

Outcomes

Duration of intervention: 3 months

Duration of follow-up: 6 months

• Mean time retention in treatment
• Use of the 2 primary study drugs

Notes

Funding source: not stated

Conflict of interest: not stated

Risk of bias

Bias

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Low risk

Quote: "Random assignment was conducted at each site independently using
a computer program and
a dynamic balanced randomization procedure."

Allocation concealment
(selection bias)

Low risk

Quote: "The randomization sequence was unknown to research staff, but
group assignment was not masked after randomization".

Blinding of participants
and personnel (perfor-
mance bias)
Subjective outcomes

Blinding of participants
and personnel (perfor-
mance bias)
Objective outcomes

Blinding of outcome as-
sessment (detection bias)
Subjective outcomes

High risk

Blinding of participants and personnel impossible for the types of intervention

Low risk

No blinding or incomplete blinding, but the review authors judge that the out-
come is unlikely to be influenced by lack of blinding

Unclear risk

No information reported

Blinding of outcome as-
sessment (detection bias)
Objective outcomes

Low risk

No blinding or incomplete blinding, but the review authors judge that the out-
come is unlikely to be influenced by lack of blinding

Incomplete outcome data
(attrition bias)
All outcomes except reten-
tion in treatment

Low risk

7% dropout

Psychosocial interventions for stimulant use disorder (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

114

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Unclear risk

Protocol of the study not available

Petry 2005a  (Continued)

Selective reporting (re-
porting bias)

Petry 2005b 

Study characteristics

Methods

Randomised controlled trial

Participants

Country: USA

Participants: cocaine dependence (DSM-IV) in methadone maintenance
N = 77
Age: 40 years old (mean age)

Sex: males 27%
Ethnicity: Latino 45%, African American 35%, white 19%
Marital status: never been married 68%
Education level: 10.7 years (mean)
Employment: employed full-time 25%
Setting: outpatients at a community clinic

History:

• Route: not reported
• Psychostimulant use: years of cocaine use: ~13
• Other drugs: years of heroin use: ~16.5. 100% in methadone maintenance
• Psychiatric comorbidity: exclusion criteria were severe dementia, uncontrolled psychosis, or bipolar

disorder

Interventions

1. CM + standard methadone group therapy (n = 40)
2. Standard methadone group therapy (n = 37)

Outcomes

Duration of intervention: 3 months

Duration of follow-up: 6 months

• Dropouts
• Duration of abstinence
• Use of cocaine

Notes

Funding source: "funding for this study and preparation of this report was provided by NIH"

Conflict of interest: not stated

Risk of bias

Bias

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Low risk

Quote: "minimum likelihood allocation was used to randomize patients to
conditions"

Allocation concealment
(selection bias)

Unclear risk

Information not reported

Psychosocial interventions for stimulant use disorder (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

115

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Petry 2005b  (Continued)

Blinding of participants
and personnel (perfor-
mance bias)
Subjective outcomes

Blinding of participants
and personnel (perfor-
mance bias)
Objective outcomes

Blinding of outcome as-
sessment (detection bias)
Subjective outcomes

High risk

Blinding of participants and personnel impossible for the types of intervention

Low risk

No blinding or incomplete blinding, but the review authors judge that the out-
come is unlikely to be influenced by lack of blinding

Unclear risk

No information reported

Blinding of outcome as-
sessment (detection bias)
Objective outcomes

Low risk

No blinding or incomplete blinding, but the review authors judge that the out-
come is unlikely to be influenced by lack of blinding

Low risk

8% dropout, balanced across groups

Unclear risk

Protocol of the study not available

Incomplete outcome data
(attrition bias)
All outcomes except reten-
tion in treatment

Selective reporting (re-
porting bias)

Petry 2007 

Study characteristics

Methods

Randomised controlled trial

Participants

Country: USA

Participants: cocaine dependent patients (DSM-IV) on methadone
N = 74
Age: 41.6 years old (mean age)
Sex: males 43.2%
Ethnicity: white 23%, African American 45%, Latino American 32%
Marital status: married 2.7%
Education level: 12 years (median)

Employment: employed 14.8%

Setting: outpatients

History:

• Route: information not reported
• Psychostimulant use: mean 18.1 years of consumption, mean 5.6 days of cocaine use in the past 30

days

• Other drugs: 100% on methadone maintenance; 9.4% past year alcohol dependence diagnosis
• Psychiatric comorbidity: not reported

Interventions

1. Standard treatment + daily methadone doses (n = 19)
2. Standard treatment + daily methadone doses + CM prize based: participants earned the opportunity

to draw a card out of an urn each time they submitted cocaine-negative specimens (n = 30)

Psychosocial interventions for stimulant use disorder (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

116

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Petry 2007  (Continued)

Cochrane Database of Systematic Reviews

3. Standard treatment + daily methadone doses + CM vouchers based: participants earned vouchers,
exchangeable for retail goods and services, for each cocaine-negative sample that they submitted (n
= 27)

Duration of intervention: 3 months

Duration of follow-up: 9 months

• Addiction Severity Index (ASI)
• Weeks of consecutive abstinence
• Retention
• Urine toxicology (cocaine and opioid)

Funding source: "This research was funded by National Institutes of Health Grants R01- DA13444, RO1-
DA016855, RO1-DA14618, R29-DA12056, R01- MH60417-Suppl, P50-DA09241, and P50-AA03510 and by
General Clinical Research Center Grant M01-RR06192."

Conflict of interest: not stated

Authors' judgement

Support for judgement

Outcomes

Notes

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Low risk

Quote: "Patients were randomly assigned to one of the three treatment condi-
tions using computerized urn randomisation procedure"

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias)
Subjective outcomes

Blinding of participants
and personnel (perfor-
mance bias)
Objective outcomes

Blinding of outcome as-
sessment (detection bias)
Subjective outcomes

Blinding of outcome as-
sessment (detection bias)
Objective outcomes

Incomplete outcome data
(attrition bias)
All outcomes except reten-
tion in treatment

Selective reporting (re-
porting bias)

Unclear risk

Information not reported

High risk

Blinding not possible for this type of trial

Low risk

No blinding or incomplete blinding, but the review authors judge that the out-
come is unlikely to be influenced by lack of blinding

Unclear risk

Information not reported

Low risk

Not likely to be influenced by lack of blinding

Low risk

ITT analysis

Unclear risk

Protocol of the study not available

Psychosocial interventions for stimulant use disorder (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

117

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Petry 2012a 

Study characteristics

Methods

Randomised controlled trial

Participants

Country: USA

Cochrane Database of Systematic Reviews

Participants: cocaine dependent patients (DSM-IV) on methadone
N = 130

Age: 36.7 years old (mean age)
Sex: males 53.4%
Ethnicity: white 71.5%, African American 7.6%, Latino 17.6%, other 3.3%
Marital status: currently married 17.1%
Education level: 11.5 years (mean)

Employment: employed full-time 52%

Setting: outpatients

History:

• Route: not reported
• Psychostimulant use: cocaine or alcohol positive at baseline: 50.7%
• Other drugs: 100% on methadone maintenance (mean dose 89.1 mg), 13.8 % alcohol dependence
• Psychiatric comorbidity: not reported

Interventions

Outcomes

1. Standard treatment (n = 59)
2. Standard treatment + CM (n = 71)

Duration of intervention: 3 months

Duration of follow-up: 9 months

• Weeks remained in study treatment
• Longest duration of abstinence for alcohol and cocaine
• Retention
• Urine toxicology

Notes

Funding source: "funding for this study and preparation of this report was provided by NIH Grants"

Conflict of interest: not stated

Risk of bias

Bias

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Low risk

Quote: "Patients were randomized to one of two conditions using a computer-
ized urn program"

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias)
Subjective outcomes

Unclear risk

Information not reported

High risk

Blinding not possible for this type of trial

Psychosocial interventions for stimulant use disorder (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

118

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Low risk

No blinding or incomplete blinding, but the review authors judge that the out-
come is unlikely to be influenced by lack of blinding

Low risk

No self-reported outcome was evaluated in this RCT

Low risk

Not likely to be influenced by lack of blinding

Low risk

ITT analysis

Unclear risk

Protocol of the study not available

Petry 2012a  (Continued)

Blinding of participants
and personnel (perfor-
mance bias)
Objective outcomes

Blinding of outcome as-
sessment (detection bias)
Subjective outcomes

Blinding of outcome as-
sessment (detection bias)
Objective outcomes

Incomplete outcome data
(attrition bias)
All outcomes except reten-
tion in treatment

Selective reporting (re-
porting bias)

Petry 2012b 

Study characteristics

Methods

Randomised controlled trial

Participants

Country: USA

Participants: cocaine dependent patients (DSM-IV)
N = 442

Age: 36.8 years old (mean age)
Sex: males 44.5%
Ethnicity: African American 34%, white 44.6%, Latino 18.4%, other 3%
Marital status: never been married 56.1%

Education level: 11.9 years (mean)

Employment: 33.4%

Setting: outpatients

History:

• Route: not reported
• Psychostimulant use: 4.7 mean days of use in past 30 days
• Other drugs: not reported
• Psychiatric comorbidity: not reported

Interventions

Cocaine-negative participants at baseline urine sample:

1. Standard treatment (n = 108)
2. Standard treatment + CM (n = 118)
3. Standard treatment + higher magnitude (CM n = 107)

Cocaine-positive participants at baseline urine sample:

Psychosocial interventions for stimulant use disorder (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

119

 
 
 
 
Cochrane Database of Systematic Reviews

Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Petry 2012b  (Continued)

1. Standard treatment (n = 34)
2. Standard treatment + CM (n = 35)
3. Standard treatment + higher magnitude (CM n = 40)

Duration of intervention: 3 months

Duration of follow-up: 9 months

• Longest duration of abstinence for cocaine
• Number of sessions attended
• Retention
• Urine toxicology

Outcomes

Notes

Funding source: "Funding for this study and preparation of this report was provided by NIH Grants"

Conflict of interest: not stated

Risk of bias

Bias

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Low risk

Quote: "Randomization occurred via two computerized urn randomisation
programs, one for each arm, at each clinic"

Unclear risk

Information not reported

High risk

Blinding not possible for this type of trial

Low risk

No blinding or incomplete blinding, but the review authors judge that the out-
come is unlikely to be influenced by lack of blinding

Low risk

No subjective outcomes were evaluated in this RCT

Low risk

Not likely to be influenced by lack of blinding

Low risk

ITT analysis

Unclear risk

Protocol of the study not available

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias)
Subjective outcomes

Blinding of participants
and personnel (perfor-
mance bias)
Objective outcomes

Blinding of outcome as-
sessment (detection bias)
Subjective outcomes

Blinding of outcome as-
sessment (detection bias)
Objective outcomes

Incomplete outcome data
(attrition bias)
All outcomes except reten-
tion in treatment

Selective reporting (re-
porting bias)

Petry 2013 

Study characteristics

Psychosocial interventions for stimulant use disorder (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

120

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Petry 2013  (Continued)

Methods

Randomised controlled trial

Participants

Country: USA

Cochrane Database of Systematic Reviews

Participants: cocaine-dependent patients (DSM-IV) with severe and persistent mental health disorder
N = 19

Age: 41.7 years old (mean age)
Sex: males 58%
Ethnicity: white 68.4%, Latino 26.3%, other 5.3%
Marital status: information not reported
Education level: 11.5 years (mean)

Employment: not reported

Setting: outpatients

History:

• Route: information not reported
• Psychostimulant use: 40% cocaine-positive at baseline urine sample
• Other drugs: 36.8 % alcohol dependent, 15.8% marijuana dependent, 57.9% opioid dependent (all of

whom were receiving methadone or buprenorphine/naloxone maintenance

• Psychiatric  comorbidity:  47.4%  major  recurrent  depression,  36.8%  bipolar  disorder,  15.8%  schizo-

Interventions

Outcomes

phrenia/ schizoaffective disorder

1. Standard treatment + CM (n = 10)
2. Standard treatment (n = 9)

Duration of intervention: 2 months

Duration of follow-up: 2 months

• Longest duration of abstinence for cocaine
• Retention
• Urine toxicology

Notes

Funding source: not stated

Conflict of interest: none declared

Risk of bias

Bias

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Low risk

Quote: "Patients were randomised to one of two 8-week treatments after
baseline evaluation. A computer program stratified patients on opioid depen-
dence and baseline urine sample result"

Allocation concealment
(selection bias)

Unclear risk

Quote: "Patients were randomised to one of two 8-week treatments after
baseline evaluation. A computer program stratified patients on opioid depen-
dence and baseline urine sample result"

Blinding of participants
and personnel (perfor-
mance bias)
Subjective outcomes

High risk

Blinding not possible for this type of trial

Psychosocial interventions for stimulant use disorder (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

121

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Petry 2013  (Continued)

Blinding of participants
and personnel (perfor-
mance bias)
Objective outcomes

Blinding of outcome as-
sessment (detection bias)
Subjective outcomes

Blinding of outcome as-
sessment (detection bias)
Objective outcomes

Low risk

No blinding or incomplete blinding, but the review authors judge that the out-
come is unlikely to be influenced by lack of blinding

Low risk

No self-reported outcome was evaluated in this RCT

Low risk

Not likely to be influenced by lack of blinding

Incomplete outcome data
(attrition bias)
All outcomes except reten-
tion in treatment

Low risk

10.5% dropout, balanced between groups (11% standard treatment, 10%
standard treatment + CM)

Selective reporting (re-
porting bias)

High risk

Secondary outcomes, as described in the protocol, were not reported in the
results.

Petry 2015 

Study characteristics

Methods

Randomised controlled trial

Participants

Country: USA

Participants: cocaine-dependent methadone patients

N= 240

Age: 40,3 years; 40.5 years (usual care), 41.0 years (300 prize CM), 40.6 years (900 prize CM), 39.1 years
(900 voucher CM)

Sex (Male %): 50.3%; 52.6% (usual care), 43.1% (300 prize CM), 43.5% (900 prize CM), 61.9% (900 vouch-
er CM)

Marital status (%, n): unmarried 47.4(27), 51.7 (30), 46.8 (29), 57.1 (36) for usual care, 300 prize CM, 900
prize CM, and 900 voucher CM, respectively

Education level (years (SD): 11.6 (1.8), 11.5 (1.6), 11.9 (2.0), 11.6 (2.3) for usual care, 300 prize CM, 900
prize CM, and 900 voucher CM, respectively

Employment: not reported

Setting: outpatients

History:

• Route: not reported
• Psychostimulant use: cocaine
• Other drugs: alcohol and heroin
• Psychiatric comorbidity: not reported

Psychosocial interventions for stimulant use disorder (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

122

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Petry 2015  (Continued)

Interventions

Outcomes

Notes

Risk of bias

Bias

1. Control condition (n = 57): usual care (UC, consisting of daily methadone doses, at least monthly in-
dividual counselling, and weekly group counselling focusing on relapse prevention, coping and life
skills training, and AIDS education).

2. Experimental conditions:

a. (n = 58) UC plus “standard” prize CM in which average expected prize earnings were about USD 300
b. (n = 62) UC plus high magnitude prize CM in which average expected prize earnings were about

USD 900

c. (n = 63) UC plus voucher CM with an expected maximum of about USD 900 in vouchers

Duration of intervention: 12 weeks

Duration of follow-up: 12 months

Primary outcomes: longest duration of continuous cocaine and alcohol negative samples (LDA) and
proportion of samples submitted negative for cocaine and alcohol

Funding source: "This study and preparation of this report was supported in part by NIH grants R01-
DA13444, P30-DA023918, R01-DA027615, P50-DA09241, P60-AA03510, and M01-RR06192."

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Low risk

Quote: "computerized program (Stout, Wirtz, Carbonari, & Del Boca, 1994) ran-
domized participants to a study treatment, balancing groups on whether par-
ticipants submitted a cocaine-negative sample during the 2-week baseline
phase, a variable consistently associated with response to CM"

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias)
Subjective outcomes

Blinding of participants
and personnel (perfor-
mance bias)
Objective outcomes

Blinding of outcome as-
sessment (detection bias)
Subjective outcomes

Blinding of outcome as-
sessment (detection bias)
Objective outcomes

Incomplete outcome data
(attrition bias)
All outcomes except reten-
tion in treatment

Selective reporting (re-
porting bias)

Unclear risk

No information

High risk

Blinding not possible for this type of trial

Low risk

Not likely to be influenced by lack of blinding

Unclear risk

Information not reported

Low risk

Not likely to be influenced by lack of blinding

Low risk

No dropout from the study

Unclear risk

No protocol available

Psychosocial interventions for stimulant use disorder (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

123

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Petry 2018 

Study characteristics

Methods

Sequential randomised controlled trial

Participants

Country: USA

Participants: patients with cocaine use disorders

N = 141

Age (years (SD)): total: 39; UC = 40.6 (9.8); CM = 37.4 (10.0)

Sex: males % (n): total: 45; 45% UC = 45.9 (28); CM = 45.0 (36)

Ethnicity: African American % (n): UC = 41.0 (25); CM = 23.8 (19). European American: UC = 47.5 (29); CM
= 62.5 (50)

Marital status: never married % (n): UC = 50.8 (31); CM = 58.8 (47)

Education level: years of education (SD) : UC = 11.5 (1.7); CM = 11.8 (1.8)

Employment: not reported

Setting: outpatients

History:

• Route: not reported
• Psychostimulant use: cocaine
• Other drugs: opioids, marijuana, alcohol
• Psychiatric comorbidity: not reported

Interventions

Outcomes

Notes

Risk of bias

In the primary study, participants with cocaine use disorders (N = 360) were randomised into 2 groups
(usual care (UC, group therapy sessions focusing on time management, life skills, motivational en-
hancement, relapse prevention, AIDS education, and 12-step) or usual care + contingency management
(CM)) for 6 weeks. At week 6, participants (n = 308) were re-randomised into 6 different groups. We in-
cluded only participants who received the same treatment in both the phases:

1. Control condition:(n = 61) usual care (UC, consisting of group therapy sessions focusing on time man-
agement, life skills, motivational enhancement, relapse prevention, AIDS education, and 12-step) for
12 weeks

2. Experimental condition (n = 80) CM + usual care for 12 weeks

Duration of intervention: 12 weeks

Duration of follow-up:3, 6 and 9 months

• Number of days participant attended groups
• Proportion of scheduled days participant attended groups
• Longest duration of time attended all scheduled groups
• Longest consecutive period of objectively determined abstinence (LDA)
• Proportion of negative samples

Funding source: "Funding for this study and preparation of this report was provided by the NIH,
awarded to Nancy Petry, P50- DA09241, P60-AA03510, R01-AA021446. We thank the patients and clini-
cians for participating in this study."

Psychosocial interventions for stimulant use disorder (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

124

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Petry 2018  (Continued)

Bias

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Low risk

Quote: "computerized program; The program (Stout, Wirtz, Carbonari, & Del
Boca, 1994) balanced assignment on baseline urine and breath sample results
(positive for alcohol or any drug tested vs. negative for all) and whether the pa-
tient had been in a controlled environment (e.g., jail, detoxification unit) in the
prior month (yes/no)."

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias)
Subjective outcomes

Blinding of participants
and personnel (perfor-
mance bias)
Objective outcomes

Blinding of outcome as-
sessment (detection bias)
Subjective outcomes

Blinding of outcome as-
sessment (detection bias)
Objective outcomes

Incomplete outcome data
(attrition bias)
All outcomes except reten-
tion in treatment

Selective reporting (re-
porting bias)

Unclear risk

No information

High risk

Blinding not possible for this type of trial

Low risk

Not likely to be influenced by lack of blinding

Unclear risk

Information not reported

Low risk

Not likely to be influenced by lack of blinding

Unclear risk

ITT analysis

Unclear risk

Protocol not available

Pirnia 2016 

Study characteristics

Methods

Randomised controlled trial

Participants

Country: Iran

Participants: male patients with history of cocaine use

N = 50

Age: 24.6 years (18 – 31)

Sex: 100% male

Ethnicity: 100% Iranian

Marital status: not reported

Education level: higher than high school diploma (CM: 64%, control: 72%).

Psychosocial interventions for stimulant use disorder (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

125

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Pirnia 2016  (Continued)

Employment: employed (52.5%)

Setting: outpatients

History:

Cochrane Database of Systematic Reviews

• Route: not reported
• Psychostimulant use: cocaine
• Other drugs: not reported
• Psychiatric comorbidity: patients with psychotic, bipolar or major depressive disorders were excluded

Interventions

1. Control condition (n = 25)
2. Experimental condition (n = 25): contingency management (CM)

Duration of intervention: 12 weeks

Duration of follow-up: 12 weeks

Outcomes

Primary: number of negative urine tests

Secondary: cocaine usage craving index over twelve weeks

Notes

Funding source: not reported

Trial registration: not reported

Conflict of interest: no conflicts of interest declared

Risk of bias

Bias

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Unclear risk

No information

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias)
Subjective outcomes

Blinding of participants
and personnel (perfor-
mance bias)
Objective outcomes

Blinding of outcome as-
sessment (detection bias)
Subjective outcomes

Blinding of outcome as-
sessment (detection bias)
Objective outcomes

Incomplete outcome data
(attrition bias)
All outcomes except reten-
tion in treatment

Unclear risk

No information

High risk

Blinding not possible for this type of trial

Low risk

Not likely to be influenced by lack of blinding

Unclear risk

Information not reported

Low risk

Not likely to be influenced by lack of blinding

Unclear risk

No information

Psychosocial interventions for stimulant use disorder (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

126

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Unclear risk

No protocol available

Pirnia 2016  (Continued)

Selective reporting (re-
porting bias)

Poling 2006 

Study characteristics

Methods

Randomised controlled trial

Participants

Country: USA

Participants: cocaine abuse and opiate dependence (DSM-IV)
N = 106

Age: 34.6 years old (mean age)
Sex: males 69.8%
Ethnicity: African American 10.4%, white 75.5%, Latino 13.2%
Marital status: not reported
Education level: not reported

Employment: not reported

Setting: outpatients

History:

• Route: not reported
• Psychostimulant use: mean 16.5 days of cocaine use in past 30
• Other drugs: mean 25.5 days of heroin use in past 30 days; no information on other current drugs
• Psychiatric  comorbidity:  31.2%  lifetime  alcohol  dependence;  89%  lifetime  cocaine  dependence;

28.7% major depressive disorder in past month

Interventions

The primary study had the following four arms:

1. CBT + CM + bupropion (CMB) n = 27
2. CBT + CM + placebo (CMP) n = 25
3. CBT + voucher control + bupropion (VCB) n = 30 (non-contingent)
4. CBT + voucher control + placebo (VCP) n = 24 (non-contingent)

In this review, we compared the combination of arms 1 and 2 (experimental group) versus the combi-
nation of arms 3 and 4 (control group)

Outcomes

Duration of intervention: 6 months

Duration of follow-up: 6 months

• Maximum consecutive weeks of opioid abstinence
• Maximum consecutive weeks of cocaine abstinence
• Retention
• Urine toxicology (opiate and cocaine)

Notes

Funding source: supported by grants from the National Institute on Drug Abuse, Bethesda, MD

Conflict of interest: not stated

Risk of bias

Psychosocial interventions for stimulant use disorder (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

127

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Poling 2006  (Continued)

Bias

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Low risk

Quote: "the data manager conducted the randomisation, which was comput-
erized using an urn randomisation technique stratifying for sex, race and age"

Allocation concealment
(selection bias)

Low risk

Quote: "the data manager conducted the randomisation, which was com-
puterized using an urn randomisation technique stratifying for sex, race and
age. Only the research pharmacist was aware of the medication condition. Re-
search staff were aware of which patients were assigned to CM".

High risk

Quote: "Only the research pharmacist was aware of the medication condition.
Research staff were aware of which patients were assigned to CM". Blinding
not possible for the psychological treatment

Low risk

No blinding or incomplete blinding, but the review authors judge that the out-
come is unlikely to be influenced by lack of blinding

Low risk

No subjective outcomes were evaluated in this RCT

Low risk

Not likely to be influenced by lack of blinding

High risk

41.4% dropout, balanced between groups (40% CMP, 44% CMB, 37% VCP, 44%
VCB)

Unclear risk

Protocol of the study not available

Blinding of participants
and personnel (perfor-
mance bias)
Subjective outcomes

Blinding of participants
and personnel (perfor-
mance bias)
Objective outcomes

Blinding of outcome as-
sessment (detection bias)
Subjective outcomes

Blinding of outcome as-
sessment (detection bias)
Objective outcomes

Incomplete outcome data
(attrition bias)
All outcomes except reten-
tion in treatment

Selective reporting (re-
porting bias)

Rawson 2002 arm 1 

Study characteristics

Methods

Randomised controlled trial

Participants

Country: USA

Participants: cocaine dependence (DSM-IV) in methadone maintenance

N = 108

Sex: males 55%

Age: 43.6 years old (mean age)

Ethnicity: white 39%, African American 32%, Latino 26%

Marital status: married ~24%

Education level: ~12 years of education (mean)

Psychosocial interventions for stimulant use disorder (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

128

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Rawson 2002 arm 1  (Continued)

Employment: unemployed ~36% (past 3 years)

Setting: methadone maintenance treatment programme (MMTP) clinic

History:

• Route: 72% freebase, 20% crack, 51% intranasal, 12% intravenous
• Psychostimulant use: days of use in year prior to enter study: 56.9 (SD 45.9) days; days abstinent 6

months prior to enter treatment: 12.63 (SD 20.27) days

• Other drugs: 73% also with alcohol dependence or abuse; 100% in methadone maintenance
• Psychiatric comorbidity: other SCID Axis 1 psychiatric disorders and antisocial personality disorder

Interventions

The primary study had the following four arms:

1. CBT + TAU (n = 28)
2. CM + TAU (n = 27)
3. CBT + CM + TAU (n = 26)
4. TAU (n = 27)

In this review:

• in Rawson 2002 arm 1, we compared group 1 versus group 4;
• in Rawson 2002 arm 2, we compared group 2 versus group 4;
• in Rawson 2002 arm 3, we compared group 3 versus group 4;
• in Rawson 2002 arm 4, we compared group 1 versus group 2.

Duration of intervention: 4 months

Duration of follow-up: 24 months

Outcomes

Use of cocaine

Notes

Funding source: supported by grants from the National Institute on Drug Abuse (NIDA) Bethesda, MD

Conflict of interest: not stated

USD 40 per month incentive

Risk of bias

Bias

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Unclear risk

Information not reported

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias)
Subjective outcomes

Blinding of participants
and personnel (perfor-
mance bias)
Objective outcomes

Blinding of outcome as-
sessment (detection bias)

Unclear risk

Information not reported

High risk

Blinding of participants and personnel impossible for the types of intervention

Low risk

No blinding or incomplete blinding, but the review authors judge that the out-
come is unlikely to be influenced by lack of blinding

Unclear risk

No information reported

Psychosocial interventions for stimulant use disorder (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

129

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Rawson 2002 arm 1  (Continued)

Subjective outcomes

Blinding of outcome as-
sessment (detection bias)
Objective outcomes

Low risk

Cochrane Database of Systematic Reviews

No blinding or incomplete blinding, but the review authors judge that the out-
come is unlikely to be influenced by lack of blinding

Low risk

20% dropout, balanced between groups

Unclear risk

Protocol not available

Incomplete outcome data
(attrition bias)
All outcomes except reten-
tion in treatment

Selective reporting (re-
porting bias)

Rawson 2002 arm 2 

Study characteristics

Methods

Randomised controlled trial

Participants

Country: USA

Participants: cocaine dependence (DSM-IV) in methadone maintenance

N = 108

Sex: males 55%

Age: 43.6 years old (mean age)

Ethnicity: white 39%, African American 32%, Latino 26%

Marital status: married ~24%

Education level: ~12 years of education (mean)

Employment: unemployed ~36% (past 3 years)

Setting: methadone maintenance treatment programme (MMTP) clinic

History:

• Route: 72% freebase, 20% crack, 51% intranasal, 12% intravenous
• Psychostimulant use: days of use in year prior to enter study: 56.9 (SD 45.9) days; days abstinent 6

months prior to enter treatment: 12.63 (SD 20.27) days

• Other drugs: 73% also with alcohol dependence or abuse; 100% in methadone maintenance
• Psychiatric comorbidity: other SCID Axis 1 psychiatric disorders and antisocial personality disorder

Interventions

The primary study had the following four arms:

1. CBT + TAU, (n = 28)
2. CM + TAU, (n = 27)
3. CBT + CM + TAU, (n = 26)
4. TAU, (n = 27)

In this review:

• in Rawson 2002 arm 1, we compared group 1 versus group 4;
• in Rawson 2002 arm 2, we compared group 2 versus group 4;

Psychosocial interventions for stimulant use disorder (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

130

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Rawson 2002 arm 2  (Continued)

• in Rawson 2002 arm 3, we compared group 3 versus group 4;
• in Rawson 2002 arm 4, we compared group 1 versus group 2.

Duration of intervention: 4 months

Duration of follow-up: 24 months

Cochrane Database of Systematic Reviews

Outcomes

Use of cocaine

Notes

Funding source: supported by grants from the National Institute on Drug Abuse (NIDA) Bethesda, MD

Conflict of interest: not stated

USD 40 per month incentive

Risk of bias

Bias

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Unclear risk

Information not reported

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias)
Subjective outcomes

Blinding of participants
and personnel (perfor-
mance bias)
Objective outcomes

Blinding of outcome as-
sessment (detection bias)
Subjective outcomes

Unclear risk

Information not reported

High risk

Blinding of participants and personnel impossible for the types of intervention

Low risk

No blinding or incomplete blinding, but the review authors judge that the out-
come is unlikely to be influenced by lack of blinding

Unclear risk

No information reported

Blinding of outcome as-
sessment (detection bias)
Objective outcomes

Low risk

No blinding or incomplete blinding, but the review authors judge that the out-
come is unlikely to be influenced by lack of blinding

Low risk

20% dropout, balanced between groups

Unclear risk

Protocol of the study not available

Incomplete outcome data
(attrition bias)
All outcomes except reten-
tion in treatment

Selective reporting (re-
porting bias)

Rawson 2002 arm 3 

Study characteristics

Methods

Randomised controlled trial

Psychosocial interventions for stimulant use disorder (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

131

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Rawson 2002 arm 3  (Continued)

Participants

Country: USA

Cochrane Database of Systematic Reviews

Participants: cocaine dependence (DSM-IV) in methadone maintenance

N = 108

Sex: males 55%

Age: 43.6 years old (mean age)

Ethnicity: white 39%, African American 32%, Latino 26%

Marital status: married ~24%

Education level: ~12 years of education (mean)

Employment: unemployed ~36% (past 3 years)

Setting: methadone maintenance treatment programme (MMTP) clinic

History:

• Route: 72% freebase, 20% crack, 51% intranasal, 12% intravenous
• Psychostimulant use: days of use in year prior to enter study: 56.9 (SD 45.9) days; days abstinent 6

months prior to enter treatment: 12.63 (SD 20.27) days

• Other drugs: 73% also with alcohol dependence or abuse; 100% in methadone maintenance
• Psychiatric comorbidity: other SCID Axis 1 psychiatric disorders and antisocial personality disorder

Interventions

The primary study had the following four arms:

1. CBT + TAU (n = 28)
2. CM + TAU (n = 27)
3. CBT + CM + TAU,(n = 26)
4. TAU (n = 27)

In this review:

• in Rawson 2002 arm 1, we compared group 1 versus group 4;
• in Rawson 2002 arm 2, we compared group 2 versus group 4;
• in Rawson 2002 arm 3, we compared group 3 versus group 4;
• in Rawson 2002 arm 4, we compared group 1 versus group 2.

Duration of intervention: 4 months

Duration of follow-up: 24 months

Outcomes

Use of cocaine

Notes

Funding source: supported by grants from the National Institute on Drug Abuse (NIDA) Bethesda, MD

Conflict of interest: not stated

USD 40 per month incentive

Risk of bias

Bias

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Unclear risk

Information not reported

Psychosocial interventions for stimulant use disorder (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

132

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Rawson 2002 arm 3  (Continued)

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias)
Subjective outcomes

Blinding of participants
and personnel (perfor-
mance bias)
Objective outcomes

Blinding of outcome as-
sessment (detection bias)
Subjective outcomes

Unclear risk

Information not reported

High risk

Blinding of participants and personnel impossible for the types of intervention

Low risk

No blinding or incomplete blinding, but the review authors judge that the out-
come is unlikely to be influenced by lack of blinding

Unclear risk

No information reported

Blinding of outcome as-
sessment (detection bias)
Objective outcomes

Low risk

No blinding or incomplete blinding, but the review authors judge that the out-
come is unlikely to be influenced by lack of blinding

Low risk

20% dropout, balanced between groups

Unclear risk

Protocol of the study not available

Incomplete outcome data
(attrition bias)
All outcomes except reten-
tion in treatment

Selective reporting (re-
porting bias)

Rawson 2002 arm 4 

Study characteristics

Methods

Randomised controlled trial

Participants

Country: USA

Participants: cocaine dependence (DSM-IV) in methadone maintenance

N = 108

Sex: males 55%

Age: 43.6 years old (mean age)

Ethnicity: white 39%, African American 32%, Latino 26%

Marital status: married ~24%

Education level: ~12 years of education (mean)

Employment: unemployed ~36% (past 3 years)

Setting: methadone maintenance treatment programme (MMTP) clinic

History:

• Route: 72% freebase, 20% crack, 51% intranasal, 12% intravenous

Psychosocial interventions for stimulant use disorder (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

133

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Rawson 2002 arm 4  (Continued)

Cochrane Database of Systematic Reviews

• Psychostimulant use: days of use in year prior to enter study: 56.9 (SD 45.9) days; days abstinent 6

months prior to enter treatment: 12.63 (SD 20.27) days

• Other drugs: 73% also with alcohol dependence or abuse; 100% in methadone maintenance
• Psychiatric comorbidity: other SCID Axis 1 psychiatric disorders and antisocial personality disorder

Interventions

The primary study had the following four arms:

1. CBT + TAU, (n = 28)
2. CM + TAU, (n = 27)
3. CBT + CM + TAU, (n = 26)
4. TAU, (n = 27)

In this review:

• in Rawson 2002 arm 1, we compared group 1 versus group 4;
• in Rawson 2002 arm 2, we compared group 2 versus group 4;
• in Rawson 2002 arm 3, we compared group 3 versus group 4;
• in Rawson 2002 arm 4, we compared group 1 versus group 2.

Duration of intervention: 4 months

Duration of follow-up: 24 months

Outcomes

Use of cocaine

Notes

Funding source: supported by grants from the National Institute on Drug Abuse (NIDA) Bethesda, MD

Conflict of interest: not stated

USD 40 per month incentive

Risk of bias

Bias

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Unclear risk

Information not reported

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias)
Subjective outcomes

Blinding of participants
and personnel (perfor-
mance bias)
Objective outcomes

Blinding of outcome as-
sessment (detection bias)
Subjective outcomes

Unclear risk

Information not reported

High risk

Blinding of participants and personnel impossible for the types of intervention

Low risk

No blinding or incomplete blinding, but the review authors judge that the out-
come is unlikely to be influenced by lack of blinding

Unclear risk

No information reported

Blinding of outcome as-
sessment (detection bias)
Objective outcomes

Low risk

No blinding or incomplete blinding, but the review authors judge that the out-
come is unlikely to be influenced by lack of blinding

Psychosocial interventions for stimulant use disorder (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

134

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Low risk

20% dropout, balanced between groups

Unclear risk

Protocol of the study not available

Rawson 2002 arm 4  (Continued)

Incomplete outcome data
(attrition bias)
All outcomes except reten-
tion in treatment

Selective reporting (re-
porting bias)

Roll 2013 

Study characteristics

Methods

Randomised controlled trial

Participants

Country: USA

Participants: methamphetamine dependence (DSM-IV)
N = 118

Age: 32 years old (mean age)
Sex: males 55%
Ethnicity: African American 2.5%, white 56.7%, Latino 36.4%, Asian 2.5%, other 1.8%
Marital status: married 14.3%,divorced 21.3%, separated 8.4%, never married/unmarried relationship
8.5%
Education level: grades 1 to 8 - 4.2%, grades 9 to 11 - 18.6%, high school graduate - 34.7%, some col-
lege - 39.8%, graduate school - 1.7%

Employment: employed 40.6%

Setting: outpatients

History:

• Route: not reported
• Psychostimulant use: not reported
• Other drugs: not reported
• Psychiatric comorbidity: not reported

Interventions

Outcomes

1. Standard psychosocial treatment (manualised model based on the Matrix model) (n = 29)
2. 1-month CM condition + standard treatment (n = 30)
3. 2-month CM condition + standard treatment (n = 30)
4. 4-month CM condition + standard treatment (n = 29)

Duration of intervention: 4 months

Duration of follow-up: 12 months

• Longest duration of continuous abstinence
• Addiction severity index (ASI)
• Retention
• Urine toxicology (methamphetamine)

Notes

We combined the results of the three experimental groups and compared these to the control group.

Funding source: not stated

Psychosocial interventions for stimulant use disorder (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

135

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Roll 2013  (Continued)

Cochrane Database of Systematic Reviews

Conflict of interest: authors reported "no real or potential conflict(s) of interest, including financial,
personal or other relationship with other organisation or pharmaceutical/biomedical companies that
may inappropriately influence or impact the research or the interpretation of the findings"

Authors' judgement

Support for judgement

Unclear risk

Quote: "Participants were randomised to one of four treatment conditions"

High risk

Quote: "Participants were randomised to one of four treatment conditions"

High risk

Blinding not possible for this type of trial

Low risk

No blinding or incomplete blinding, but the review authors judge that the out-
come is unlikely to be influenced by lack of blinding

Unclear risk

Information not reported

Low risk

Not likely to be influenced by lack of blinding

Low risk

ITT analysis. Missing urine tests imputed as positive

Unclear risk

Protocol not available

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias)
Subjective outcomes

Blinding of participants
and personnel (perfor-
mance bias)
Objective outcomes

Blinding of outcome as-
sessment (detection bias)
Subjective outcomes

Blinding of outcome as-
sessment (detection bias)
Objective outcomes

Incomplete outcome data
(attrition bias)
All outcomes except reten-
tion in treatment

Selective reporting (re-
porting bias)

Sanchez-Hervas 2010 

Study characteristics

Methods

Randomised controlled trial

Participants

Country: Spain

Participants: cocaine dependence (DSM-IV)
N = 82

Age: mean 31.4 years old (mean age)
Sex: males 86.3%
Ethnicity: not reported
Marital status: never married 44.4%

Education level: 9.6 years (mean)

Psychosocial interventions for stimulant use disorder (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

136

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Sanchez-Hervas 2010  (Continued)

Employment: employed full-time 77.2%

Setting: outpatients

History:

• Route: 91% intranasal
• Psychostimulant use: mean 10.2 years of regular use
• Other drugs: other abuses in lifetime: 52.7% alcohol, 28.1% cannabis
• Psychiatric comorbidity: not reported

Interventions

1. CRA (n = 47)
2. TAU (n = 35)

Outcomes

Duration of intervention: 6 months

Duration of follow-up: 12 months

• Cocaine abstinence (point-prevalence and continuous)
• Europe Addiction Severity Index (EuropASI)
• Compliance with post-treatment assessments
• Retention
• Urine toxicology (cocaine)

Notes

Funding source: Spanish National Plan on Drugs (Ministry of Health and Consumers (ref. MSC-06-01)

Conflict of interest: not stated

Risk of bias

Bias

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Low risk

Quote: "Computer-generated randomisation list". Randomisation process is
unclear and it is not explained why more people were allocated to CRA arm

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias)
Subjective outcomes

Blinding of participants
and personnel (perfor-
mance bias)
Objective outcomes

Blinding of outcome as-
sessment (detection bias)
Subjective outcomes

Blinding of outcome as-
sessment (detection bias)
Objective outcomes

Unclear risk

No mention of allocation concealment information

High risk

Blinding not possible for this type of trial

Low risk

No blinding or incomplete blinding, but the review authors judge that the out-
come is unlikely to be influenced by lack of blinding

Unclear risk

Information not reported

Low risk

Not likely to be influenced by lack of blinding

Incomplete outcome data
(attrition bias)

High risk

51.2% dropout at 6 months. Unbalanced between treatment arms (44.6% CRA;
56.7% TAU)

Psychosocial interventions for stimulant use disorder (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

137

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Sanchez-Hervas 2010  (Continued)

All outcomes except reten-
tion in treatment

Selective reporting (re-
porting bias)

Unclear risk

Protocol of the study not available

Cochrane Database of Systematic Reviews

Schottenfeld 2011 

Study characteristics

Methods

Randomised controlled trial

Participants

Country: USA

Participants: women meeting DSM-IV criteria for cocaine dependence who were either pregnant (n =
64) or had custody of a young child (n = 81)
N = 145

Age: 31.1 years old (mean age) (SD 5.7)
Sex: males 0%
Ethnicity: African American 78%
Marital status: never married 81%

Education level: high school education or its equivalent 57%

Employment: employed full-time 3%

Setting: outpatients

History:

• Route: cocaine use was overwhelmingly smoked (97%)
• Psychostimulant use: participants reported using cocaine on average 7.6 (SD 9) days during the pre-
ceding 30 days; women assigned to TSF reported more days of use (9.4 SD 10.2) than those assigned
to CRA (5.8 SD 7.3); P = 0.02)

• Other drugs: 47% had a lifetime history of alcohol dependence
• Psychiatric comorbidity: 24% met DSM-IV symptom criteria for current major depression based on

SCID

Interventions

The primary study had the following four arms:

1. Community Reinforcement Approach (CRA) + Contingency Management (CM) (n = 36)
2. Twelve-step facilitation (TSF) + CM (n = 37)
3. CRA + non-contingent, yoked voucher control (VC) (n = 35)
4. TSF + VC (n = 37)

In this review we compared the combination of arms 1 and 2 (experimental group) versus the combina-
tion of arms 3 and 4 (control group).

Duration of intervention: 6 months

Duration of follow-up: 12 months

Outcomes

• Treatment retention and participation
• Cocaine use

Psychosocial interventions for stimulant use disorder (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

138

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Schottenfeld 2011  (Continued)

Notes

Funding source: "This work was supported by the following NIDA Projects: K24 DA000445 and R01-
DA-06915. NIDA had no further role in study design; in the collection, analysis and interpretation of da-
ta; in the writing of the report; or in the decision to submit the paper for publication."

Conflict of interest: "RS Schottenfeld, BA Moore and MV Pantalon have no conflicts of interest"

Risk of bias

Bias

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Low risk

Quote: "computerized urn randomisation procedure to balance allocation of
the treatment groups on the basis of meeting symptom criteria for current ma-
jor depression or lifetime alcohol dependence"

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias)
Subjective outcomes

Blinding of participants
and personnel (perfor-
mance bias)
Objective outcomes

Blinding of outcome as-
sessment (detection bias)
Subjective outcomes

Unclear risk

Information not reported

High risk

Blinding of participants and personnel impossible for the types of intervention

Low risk

No blinding or incomplete blinding, but the review authors judge that the out-
come is unlikely to be influenced by lack of blinding

Unclear risk

Information not reported

Blinding of outcome as-
sessment (detection bias)
Objective outcomes

Low risk

Information not reported, but the review authors judge that the outcome is
unlikely to be influenced by lack of blinding

Incomplete outcome data
(attrition bias)
All outcomes except reten-
tion in treatment

High risk

About 50% of participants dropped out before the end of treatment; no infor-
mation reported about balance between groups and reasons for dropout

Selective reporting (re-
porting bias)

Low risk

All the declared outcomes in the protocol were reported in the results of the
study.

Secades Villa 2013 

Study characteristics

Methods

Randomised controlled trial

Participants

Country: Spain

Participants: cocaine dependence (DSM-IV)
N = 118

Age: 31.2 years old (mean age)
Sex: males 85.5%
Ethnicity: information not reported

Psychosocial interventions for stimulant use disorder (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

139

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Secades Villa 2013  (Continued)

Marital status: married 25.4%, divorced 20.3%, single 53.3%
Education level: 9.8 years (mean)

Employment: employed 65.2%

Setting: outpatients

History:

• Route: 94% intranasal
• Psychostimulant use: mean 8.4 years of regular use
• Other drugs: other abuses in lifetime: 68.6% alcohol, 42.3% cannabis
• Psychiatric comorbidity: not reported

1. CRA + CM vouchers (n = 50)
2. CRA (n = 68)

Duration of intervention: 6 months

Duration of follow-up: 6 months

• Continuous cocaine abstinence
• Europe Addiction Severity Index (EuropASI)
• Retention
• Urine toxicology (cocaine)

Funding source: "This project was funded by the Spanish National Plan on Drugs (PNsD) (Ref.
MINT-03-01 and Ref.MSC-06-01) and supported by a grant from the University of Oviedo (Ref. UN-
OV-08-BECDOC)"

Conflict of interest: not stated

Authors' judgement

Support for judgement

Low risk

Quote: "Computer-generated randomization list"

Unclear risk

Information not reported

High risk

Blinding not possible for this type of trial

Low risk

No blinding or incomplete blinding, but the review authors judge that the out-
come is unlikely to be influenced by lack of blinding

Unclear risk

Information not reported

Low risk

Not likely to be influenced by lack of blinding

Interventions

Outcomes

Notes

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias)
Subjective outcomes

Blinding of participants
and personnel (perfor-
mance bias)
Objective outcomes

Blinding of outcome as-
sessment (detection bias)
Subjective outcomes

Blinding of outcome as-
sessment (detection bias)
Objective outcomes

Psychosocial interventions for stimulant use disorder (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

140

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

High risk

No clear data on dropouts

Unclear risk

Protocol of the study not available

Secades Villa 2013  (Continued)

Incomplete outcome data
(attrition bias)
All outcomes except reten-
tion in treatment

Selective reporting (re-
porting bias)

Shoptaw 2005 arm 1 

Study characteristics

Methods

Randomised controlled trial

Participants

Country: USA

Participants: gay and bisexual with methamphetamine dependence (DSM-IV)

N = 162

Age: 37 years old (mean age)

Sex: only men (gay and bisexual)

Ethnicity: white 80%, Mexican Latino 12%, African American 3, American Indian 1%, Asian/Pacific Islan-
der 3%

Marital status: not reported

Education level: 15 years (i.e. college)

Employment: information not reported

Setting: outpatients

History:

• Route: not reported
• Psychostimulant use: not reported
• Other drugs: not reported
• Psychiatric comorbidity: participants were excluded on the basis of pre-existing medical or psychiatric

conditions

Interventions

The primary study had the following four arms:

1. CBT (n = 40)
2. CM (n = 42)
3. CBT + CM (n = 40)
4. Culturally tailored CBT (n = 40)

In this review:

• in Shoptaw 2005 arm 1, we compared group 1 versus group 2
• in Shoptaw 2005 arm 2, we compared group 3 versus group 2
• in Shoptaw 2005 arm 3, we compared group 3 versus group 1

We did not consider group 4.

Duration of intervention: 4 months

Psychosocial interventions for stimulant use disorder (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

141

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Shoptaw 2005 arm 1  (Continued)

Duration of follow-up: 12 months

Outcomes

• Methamphetamine use
• Depression symptoms
• Sexual risk behaviours

Notes

Funding source: NIDA Grants 1 R01 DA 11031 and 1 P50 DA 12755 for support

Conflict of interest: not reported

Risk of bias

Bias

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Low risk

Quote: "[P]articipants determined to meet all study criteria were assigned to
condition using an urn randomization procedure (Stout et al., 1994) that pro-
vided multivariate balance across conditions based on level of drug use (heavy
versus light) and ethnicity"

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias)
Subjective outcomes

Blinding of participants
and personnel (perfor-
mance bias)
Objective outcomes

Blinding of outcome as-
sessment (detection bias)
Subjective outcomes

Unclear risk

Information not reported

High risk

Blinding of participants and personnel impossible for the types of intervention

Low risk

No blinding or incomplete blinding, but the review authors judge that the out-
come is unlikely to be influenced by lack of blinding

Unclear risk

No information reported

Blinding of outcome as-
sessment (detection bias)
Objective outcomes

Low risk

No blinding or incomplete blinding, but the review authors judge that the out-
come is unlikely to be influenced

Low risk

ITT analysis

Unclear risk

Protocol of the study not available

Incomplete outcome data
(attrition bias)
All outcomes except reten-
tion in treatment

Selective reporting (re-
porting bias)

Shoptaw 2005 arm 2 

Study characteristics

Methods

Randomised controlled trial

Participants

Country: USA

Psychosocial interventions for stimulant use disorder (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

142

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Shoptaw 2005 arm 2  (Continued)

Participants: gay and bisexual with methamphetamine dependence (DSM-IV)

N = 162

Age: 37 years old (mean age)

Sex: only men (gay and bisexual)

Ethnicity: white 80%, Mexican Latino 12%, African American 3, American Indian 1%, Asian/Pacific Islan-
der 3%

Marital status: not reported

Education level: 15 years (i.e. college)

Employment: information not reported

Setting: outpatients

History:

• Route: not reported
• Psychostimulant use: not reported
• Other drugs: not reported
• Psychiatric comorbidity: participants were excluded on the basis of pre-existing medical or psychiatric

conditions

Interventions

The primary study had the following four arms:

1. CBT (n = 40)
2. CM (n = 42)
3. CBT + CM (n = 40)
4. Culturally tailored CBT (n = 40)

In this review:

• in Shoptaw 2005 arm 1, we compared group 1 versus group 2
• in Shoptaw 2005 arm 2, we compared group 3 versus group 2
• in Shoptaw 2005 arm 3, we compared group 3 versus group 1

Outcomes

We did not consider group 4.

Duration of intervention: 4 months

Duration of follow-up: 12 months

• Methamphetamine use
• Depression symptoms
• Sexual risk behaviours

Notes

Funding source: NIDA Grants 1 R01 DA 11031 and 1 P50 DA 12755 for support

Conflict of interest: not reported

Risk of bias

Bias

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Low risk

Quote: "[P]articipants determined to meet all study criteria were assigned to
condition using an urn randomization procedure (Stout et al., 1994) that pro-

Psychosocial interventions for stimulant use disorder (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

143

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Shoptaw 2005 arm 2  (Continued)

Cochrane Database of Systematic Reviews

vided multivariate balance across conditions based on level of drug use (heavy
versus light) and ethnicity"

Unclear risk

Information not reported

High risk

Blinding of participants and personnel impossible for the types of intervention

Low risk

No blinding or incomplete blinding, but the review authors judge that the out-
come is unlikely to be influenced by lack of blinding

Unclear risk

No information reported

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias)
Subjective outcomes

Blinding of participants
and personnel (perfor-
mance bias)
Objective outcomes

Blinding of outcome as-
sessment (detection bias)
Subjective outcomes

Blinding of outcome as-
sessment (detection bias)
Objective outcomes

Low risk

No blinding or incomplete blinding, but the review authors judge that the out-
come is unlikely to be influenced by lack of blinding

Low risk

ITT analysis

Unclear risk

Protocol of the study not available

Incomplete outcome data
(attrition bias)
All outcomes except reten-
tion in treatment

Selective reporting (re-
porting bias)

Shoptaw 2005 arm 3 

Study characteristics

Methods

Randomised controlled trial

Participants

Country: USA

Participants: gay and bisexual with methamphetamine dependence (DSM-IV)

N = 162

Age: 37 years old (mean age)

Sex: only men (gay and bisexual)

Ethnicity: white 80%, Mexican Latino 12%, African American 3, American Indian 1%, Asian/Pacific Islan-
der 3%

Marital status: not reported

Education level: 15 years (i.e. college)

Employment: information not reported

Setting: outpatients

Psychosocial interventions for stimulant use disorder (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

144

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Shoptaw 2005 arm 3  (Continued)

History:

Cochrane Database of Systematic Reviews

• Route: not reported
• Psychostimulant use: not reported
• Other drugs: not reported
• Psychiatric comorbidity: participants were excluded on the basis of pre-existing medical or psychiatric

conditions

Interventions

The primary study had the following four arms:

1. CBT (n = 40)
2. CM (n = 42)
3. CBT + CM (n = 40)
4. Culturally tailored CBT (n = 40)

In this review:

• in Shoptaw 2005 arm 1, we compared group 1 versus group 2
• in Shoptaw 2005 arm 2, we compared group 3 versus group 2
• in Shoptaw 2005 arm 3, we compared group 3 versus group 1

Outcomes

We did not consider group 4.

Duration of intervention: 4 months

Duration of follow-up: 12 months

• Methamphetamine use
• Depression symptoms
• Sexual risk behaviours

Notes

Funding source: NIDA Grants 1 R01 DA 11031 and 1 P50 DA 12755 for support

Conflict of interest: not reported

Risk of bias

Bias

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Low risk

Quote: "[P]articipants determined to meet all study criteria were assigned to
condition using an urn randomization procedure (Stout et al., 1994) that pro-
vided multivariate balance across conditions based on level of drug use (heavy
versus light) and ethnicity"

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias)
Subjective outcomes

Blinding of participants
and personnel (perfor-
mance bias)
Objective outcomes

Blinding of outcome as-
sessment (detection bias)

Unclear risk

Information not reported

High risk

Blinding of participants and personnel impossible for the types of intervention

Low risk

No blinding or incomplete blinding, but the review authors judge that the out-
come is unlikely to be influenced by lack of blinding

Unclear risk

No information reported

Psychosocial interventions for stimulant use disorder (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

145

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Shoptaw 2005 arm 3  (Continued)

Subjective outcomes

Blinding of outcome as-
sessment (detection bias)
Objective outcomes

Low risk

Cochrane Database of Systematic Reviews

No blinding or incomplete blinding, but the review authors judge that the out-
come is unlikely to be influenced by lack of blinding

Low risk

ITT analysis

Unclear risk

Protocol of the study not available

Incomplete outcome data
(attrition bias)
All outcomes except reten-
tion in treatment

Selective reporting (re-
porting bias)

Shoptaw 2008 

Study characteristics

Methods

Randomised controlled trial

Participants

Country: USA

Participants: gay or bisexual men with stimulant abuse, alcohol abuse, or both

N = 128

Age: 37 years old (mean age)

Sex: males: 100% (gay and bisexual)

Ethnicity: Latino 21.8%, white 64.8%, others 13.2%

Marital status: not reported

Education level: college-educated: 69.5%, less than college 30.5%

Employment: employed 31.2% (with an income of ≤ USD 14,999)

Setting: outpatients

History:

• Route: 12.5% injection drug use
• Psychostimulant use: cocaine abused for a mean of 11.3 days during the past 30 days; amphetamines

abused for a mean of 6.5 days during the past 30 days
• Other drugs: 7.8% alcohol abuse; 100% cannabis abuse
• Psychiatric comorbidity: not reported

Interventions

Outcomes

1. Gay cognitive behavioural therapy (n = 64)
2. Gay social support therapy (n = 64)

Duration of intervention: 12 weeks

Duration of follow-up: 17, 26, and 52 weeks

• Retention rate
• Days of self-reported substance use
• Urine toxicology

Psychosocial interventions for stimulant use disorder (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

146

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Shoptaw 2008  (Continued)

• Self-reported sexual risk behaviours

Notes

Funding source: "funding for this study was provided by Center for Substance Abuse Treatment
Knowledge Development and Application (Grant TI-12043) to Drs Shoptaw and Reback"

Conflict of interest: not reported

Risk of bias

Bias

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Unclear risk

Information not reported

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias)
Subjective outcomes

Blinding of participants
and personnel (perfor-
mance bias)
Objective outcomes

Blinding of outcome as-
sessment (detection bias)
Subjective outcomes

Blinding of outcome as-
sessment (detection bias)
Objective outcomes

Incomplete outcome data
(attrition bias)
All outcomes except reten-
tion in treatment

Selective reporting (re-
porting bias)

Unclear risk

Information not reported

High risk

Blinding not possible for this type of trial

Low risk

Not likely to be influenced by lack of blinding

Unclear risk

Information not reported

Low risk

Not likely to be influenced by lack of blinding

Low risk

ITT analysis

Unclear risk

Protocol not available

Silverman 1996 

Study characteristics

Methods

Randomised controlled trial

Participants

Country: USA

Participants: cocaine dependence and abuse (DSM-III-R) in methadone-maintenance patients
N = 37
Age: 36.05 (1.4) years old

Sex: not reported

Psychosocial interventions for stimulant use disorder (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

147

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Silverman 1996  (Continued)

Cochrane Database of Systematic Reviews

Ethnicity: black 46.5%, white 53.5

Marital status: married 13.5%

Education level: 2 years or more of education 67.5%

Employment: employed 43%

Setting: outpatient

History:

• Route: not reported
• Psychostimulant use: all patients reported injecting cocaine
• Other drugs: all participants reported injecting heroin; 100% of participants in methadone mainte-

nance

• Psychiatric comorbidity: 25% antisocial personality disorder

Interventions

1. CBT (CRA + CM) (n =19)
2. CBT (CRA + voucher independent to urine analysis results) (n =18)

Individual sessions for both conditions.

Duration of intervention: 3 months

Duration of follow-up: 3 months

Outcomes

• Dropouts
• Use of cocaine for at least 5 consecutive weeks

Notes

Funding source: National Institute on Drug Abuse, through intramural research, Baltimore, MD

Conflict of interest: not stated

Risk of bias

Bias

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Low risk

Quote: "[P]atients were randomly assigned to the abstinence reinforcement or
control group using minimum likelihood allocation. This procedure stratified
patients according to whether or no they were: heavy cocaine users, light co-
caine users, male, etc"

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias)
Subjective outcomes

Blinding of participants
and personnel (perfor-
mance bias)
Objective outcomes

Blinding of outcome as-
sessment (detection bias)
Subjective outcomes

Unclear risk

Information not reported

High risk

Blinding of participants and personnel impossible for the types of intervention

Low risk

No blinding or incomplete blinding, but the review authors judge that the out-
come is not likely to be influenced by lack of blinding

Unclear risk

No information reported

Psychosocial interventions for stimulant use disorder (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

148

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Low risk

No blinding or incomplete blinding, but the review authors judge that the out-
come is not likely to be influenced

Low risk

ITT analysis

Unclear risk

Protocol of the study not available

Silverman 1996  (Continued)

Blinding of outcome as-
sessment (detection bias)
Objective outcomes

Incomplete outcome data
(attrition bias)
All outcomes except reten-
tion in treatment

Selective reporting (re-
porting bias)

Silverman 1998 

Study characteristics

Methods

Randomised controlled trial

Participants

Country: USA

Participants: cocaine abuse (DSM-III) in methadone maintenance
N = 59
Age: 37.8 years old (mean age) (SD 5.2)

Sex: males 66%

Ethnicity: black 62.6%, white 37.4%

Marital status: married 10.3%

Education level: 12 years of education 66.3%

Employment: employed 13.3% (full-time)

Setting: outpatients

History:

• Route: 95% intravenous, 7% crack smokers
• Psychostimulant use: 98% cocaine
• Other drugs: 96% heroin, 61% alcohol, 28% marijuana, 100% of participants in methadone mainte-

nance

• Psychiatric  comorbidity:  nicotine  dependence,  general  anxiety  disorder,  phobia,  PTSD,  manic

episode, antisocial personality, bulimia, alcohol dependence, sedative dependence

Interventions

The primary study had the following three arms:

1. CM (n = 20)
2. CM + start-up bonus (n = 20)
3. Non-CM (n = 19)

In this review, we compared the combination of arms 1 and 2 (experimental group) versus arm 3 (con-
trol group).

Duration of intervention: 3 months

Duration of follow-up: 6 months

Outcomes

• Average duration of weeks in treatment

Psychosocial interventions for stimulant use disorder (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

149

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Silverman 1998  (Continued)

• Use of cocaine for at least 5 consecutive weeks

Notes

Cocaine-abusing methadone-maintenance patients. Individual sessions offered for all 3 treatment con-
ditions.

Funding source:National Institute on drug abuse, through intramural research fund and in part by Ex-
tramural research Grant from NIDA

Conflict of interest: not stated

Risk of bias

Bias

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Unclear risk

Information not reported

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias)
Subjective outcomes

Blinding of participants
and personnel (perfor-
mance bias)
Objective outcomes

Blinding of outcome as-
sessment (detection bias)
Subjective outcomes

Unclear risk

No information reported

High risk

Blinding of participants and personnel impossible for the types of intervention

Low risk

No blinding or incomplete blinding, but the review authors judge that the out-
come is not likely to be influenced by lack of blinding

Unclear risk

No information reported

Blinding of outcome as-
sessment (detection bias)
Objective outcomes

Low risk

No blinding or incomplete blinding, but the review authors judge that the out-
come is not likely to be influenced by lack of blinding

Unclear risk

Information on dropout is not reported

Unclear risk

Protocol of the study not available

Incomplete outcome data
(attrition bias)
All outcomes except reten-
tion in treatment

Selective reporting (re-
porting bias)

Smout 2010 

Study characteristics

Methods

Randomised controlled trial

Participants

Country: Australia

Participants: methamphetamine use or dependence (MINI)

N = 104

Psychosocial interventions for stimulant use disorder (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

150

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Smout 2010  (Continued)

Cochrane Database of Systematic Reviews

Age: 34.9 years old (mean age)

Sex: males 60%

Ethnicity: white 58%

Marital status: not reported

Education level: 11 to 13 years (mean)

Employment: unemployed 39%, employed 39%, student 12%, other 10%

Setting: outpatients

History:

• Route: 78% injection, 14% oral, 8% intranasal
• Psychostimulant use: 6.0 g in 16 days in the last month
• Other drugs: 29.8% participants positive for another, not specified, drug
• Psychiatric comorbidity: not reported

Interventions

1. CBT (n = 53)
2. ACT (acceptance and commitment therapy) (n = 51)

Duration of intervention: 3 months

Duration of follow-up: 6 months

Outcomes

• Reported average amount of methamphetamine used in the past month
• Objective methamphetamine and other drug use by hair analysis
• Dropout
• Severity of methamphetamine dependence (LDQ)
• Beck Depression Inventory
• SF-12: Short form (general mental and physical health)

Notes

Funding source: "This study was supported by the 2002 South Australian Premier's Drug Summit (Ini-
tiative R1.4 Young People and Amphetamines—Treatment)"

Conflict of interest: not stated

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Authors' judgement

Support for judgement

Low risk

Quote: "computer- generated random number sequence"

Allocation concealment
(selection bias)

High risk

Quote: "An allocation table was constructed by dividing the estimated sample
size into an equal number of clinician-therapy combinations. These were al-
located to client ID via a computer-generated random number sequence. The
second author then used this table to allocate participants; although the table
was not concealed from the person assigning, it was not consulted other than
at the time of randomization."

Blinding of participants
and personnel (perfor-
mance bias)
Subjective outcomes

High risk

Blinding not possible for the types of intervention

Psychosocial interventions for stimulant use disorder (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

151

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Low risk

Not likely to be influenced by lack of blinding

Unclear risk

Information not reported

Low risk

Not likely to be influenced by lack of blinding

Low risk

ITT analysis

Unclear risk

Protocol of the study not available

Smout 2010  (Continued)

Blinding of participants
and personnel (perfor-
mance bias)
Objective outcomes

Blinding of outcome as-
sessment (detection bias)
Subjective outcomes

Blinding of outcome as-
sessment (detection bias)
Objective outcomes

Incomplete outcome data
(attrition bias)
All outcomes except reten-
tion in treatment

Selective reporting (re-
porting bias)

Sorsdahl 2021 

Study characteristics

Methods

Randomised controlled trial

Participants

Country: South Africa

Participants: methamphetamine use disorders

N = 60

Age: 31 (6.5)

Sex: male 32 (53.3%), female (46.7%)

Ethnicity: black: 8.3%; "coloured" ('coloured' was a legally defined racial classification during
apartheid referring to anyone not white or not of the black Bantu tribes): 88.3%; white: 3.3%

Marital status: single (88.3%)

Education level: finished high school (51.7%), did not finish high school (48.3%)

Employment: unemployed (78.3%), employed (21.7%)

Setting: outpatients

History:

• Route: not reported
• Psychostimulant use: methamphetamine
• Other drugs: heroin (13%)
• Psychiatric  comorbidity:  patients  with  bipolar  disorder,  suicidality,  schizophrenia  (including  psy-

chosis) and antisocial personality disorder were excluded

Interventions

1. Control condition (n = 30): usual care (participants referred to a specialised, registered outpatient re-

habilitation centre)

Psychosocial interventions for stimulant use disorder (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

152

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Sorsdahl 2021  (Continued)

Cochrane Database of Systematic Reviews

2. Experimental condition (n = 30): 6 sessions of motivational interviewing (IDMI) intervention

Duration of intervention: the treatment group received the six-session treatment, while the control
group were referred to local substance use treatment centres for treatment. Follow-up interviews were
conducted at 6 weeks and 3 months following study enrolment, at which time the baseline question-
naire was re-administered.

Duration of follow-up: 3 months

Outcomes

Primary:frequency of methamphetamine use (measured using the timeline followback method (TLFB)

Secondary: Penn Alcohol Craving Scale (PACS) (modified for methamphetamine dependence), Clinical
Global Impression (Severity) scale (CGI), Hamilton Rating Scale for Depression (HAM-D), Hamilton Rat-
ing Scale for Anxiety (HAM-A), Sheehan Disability Scale (SDS)

Notes

Funding source: "This research was funded through departmental funds"

Trial registration: The trial is registered with the Pan African Clinical Trials Registry (Trial ID:
PACTR201310000589295)

Conflict of interest: "The authors declare that they have no competing interests."

Risk of bias

Bias

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Low risk

Quote: "The randomisation sequence was prepared by the data manager (us-
ing a computer programme) and allocation done by a trial manager."

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias)
Subjective outcomes

Blinding of participants
and personnel (perfor-
mance bias)
Objective outcomes

Blinding of outcome as-
sessment (detection bias)
Subjective outcomes

Blinding of outcome as-
sessment (detection bias)
Objective outcomes

Incomplete outcome data
(attrition bias)
All outcomes except reten-
tion in treatment

Selective reporting (re-
porting bias)

Unclear risk

Quote: "allocation done by a trial manager"

High risk

Blinding not possible for this type of trial

Low risk

Not likely to be influenced by lack of blinding

Low risk

Low risk

Low risk

Quote: "a research assistant who was not involved in the recruitment of the
participants and is not working at the hospital conducted the follow-up as-
sessment and was blinded to the treatment allocation."

Quote: "a research assistant who was not involved in the recruitment of the
participants and is not working at the hospital conducted the follow-up as-
sessment and was blinded to the treatment allocation."

Quote: "The primary regression analysis used an intention-to-treat approach
with last observation carried forward (LOCF) to impute scores for missing data
values."

Unclear risk

No protocol available

Psychosocial interventions for stimulant use disorder (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

153

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Stein 2009 

Study characteristics

Methods

Randomised controlled trial

Participants

Country: USA

Participants: cocaine abuse or dependence
N = 198

Age: 38.1 years (mean)
Sex: males 61.6%
Ethnicity: white 39.8%
Marital status: information not reported

Education level: information not reported

Employment: information not reported

Setting: outpatients and inpatients

History:

• Route: 10.5% snort, 81.2% smoke, 8.6% inject
• Psychostimulant use: mean 16.3 years using cocaine, mean 16.3 days used cocaine in past 30
• Other drugs: not reported
• Psychiatric comorbidity: not reported

Interventions

1. 4-session motivational interviewing (MI) (n = 97)
2. Control: written handout of treatment (n = 101)

Duration of intervention: 6 months

Duration of follow-up: 6 months

Outcomes

• Self-reported quality of life (SF-12)
• Days employed
• Any entry into drug detoxification programmes, inpatient drug treatment, outpatient drug treatment,

and attendance in self-help programmes

• Reduction in frequency of cocaine use
• Self-reported cocaine abstinence at 6 months

Notes

Funding source: grant from the National Institute on Drug Abuse (DA 13759)

Conflict of interest: not stated

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias)

Authors' judgement

Support for judgement

Unclear risk

No information reported

Unclear risk

No information reported

High risk

Blinding not possible for this type of trial

Psychosocial interventions for stimulant use disorder (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

154

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Stein 2009  (Continued)

Subjective outcomes

Blinding of participants
and personnel (perfor-
mance bias)
Objective outcomes

Blinding of outcome as-
sessment (detection bias)
Subjective outcomes

Blinding of outcome as-
sessment (detection bias)
Objective outcomes

Incomplete outcome data
(attrition bias)
All outcomes except reten-
tion in treatment

Selective reporting (re-
porting bias)

Low risk

No blinding or incomplete blinding, but the review authors judge that the out-
come is not likely to be influenced by lack of blinding

Unclear risk

Information not reported

Low risk

Not likely to be influenced by lack of blinding

Low risk

ITT analysis

Unclear risk

Protocol of the study not available

ACT:  acceptance  and  commitment  therapy;  APD:  antisocial  personality  disorder;  ASI:  Addiction  Severity  Index;  BDI:  Beck  Depression
Inventory; BSI: Brief Symptom Inventory; BT: behaviour therapy; CBRT: cash-based reinforcement therapy (i.e. cash-based contingency
management);  CBT:  cognitive  behavioural  therapy;  CM:  contingency  management;  CRA:  community  reinforcement  approach;  CT:
cognitive therapy; CST: coping skills training; ICMJE: International Committee of Medical Journal Editors; DAM: diacetylmorphine; D/O:
disorder; DSM: Diganostic and Statistical Manual of Mental Disorders; IDC: individual drug counselling; I&R: information and referral; IPT:
interpersonal therapy; IQR: interquartile range; ITT: intention-to-treat; LDQ: Leeds Dependence Questionnaire; MADRS: Montgomery–
Åsberg  Depression  Rating  Scale;  MET:  motivational  enhancement  techniques/therapy;  MINI:  Mini-International  Neuropsychiatric
Interview;  MMTP:  methadone  maintenance  treatment  programme;  MSM:  men  who  have  sex  with  men;  NIDA:  National  Institute  on
Drug Abuse; NIH: National Institutes of Health; OCD: obsessive compulsive disorder; OTI: Opiate Treatment Index; PTSD: post-traumatic
stress disorder; RBT: reinforcement-based therapy; RP: relapse prevention; SCID: Structured Clinical Interview for DSM-IV; SD: standard
deviation; SDU: standard drink units; SE: supportive-expressive psychotherapy; SOAR: service outreach and recovery; SUD: substance
use disorder; TAU: treatment as usual; TSF: 12-Step Facilitation; TW: therapeutic workplace; URICA: University of Rhode Island Change
Assessment; VBRT: voucher-based (reinforcement therapy (i.e. voucher-based contingency management); VL: viral load

Characteristics of excluded studies [ordered by study ID]

Study

Reason for exclusion

Aharonovich 2017

Ineligible population: non-injection drug use patients: 10% heroin users, 20% "meth"; unclear if
"meth" = methadone or methamphetamine

Alessi 2007

Alim 1995

Azrin 1994

Ineligible population: not all psychostimulant users

Ineligible intervention: diethylpropion treatment for craving

Ineligible population: RCT assessing the role of behaviour therapy for drug abuse; not specific to
cocaine use, most were marijuana users

Azrin 1996

Ineligible population: not all psychostimulant users

Bahrami 2017

Ineligible intervention: acceptance and commitment therapy

Barrowclough 2009

Ineligible population: people with psychosis and substance misuse

Psychosocial interventions for stimulant use disorder (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

155

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study

Bellack 2006

Bickel 2008

Brewer 2009

Reason for exclusion

Ineligible population: drug dependence (cocaine, heroin, or cannabis) and serious mental illness

Ineligible population: opioid-dependent participants

Ineligible population: alcohol or cocaine dependence: separate results for cocaine-dependent par-
ticipants not provided

Brooner 1998

Ineligible population: participants were not psychostimulant users

Burduli 2018

Ineligible population: 50.9% of all participants self-reported methamphetamine as their most used
drug; 36.8% self-reported cannabis as their most used drug; and 12.3% self-reported prescription
opiates as their most used drug.

Campbell 2014

Ineligible population: participants self-reporting use of any illicit substance in the 30 days prior to
study entry

Carrico 2018

Ineligible intervention: positive affect intervention

Chen 2013

Covi 2002

Ineligible intervention: mindfulness plus acupuncture

Ineligible comparison: compared the same intervention with two different intensities

Dansereau 1996

Ineligible population: only opioid abuse/dependence

Dees 1997

Ineligible population: heroin-addicted participants; 54% never used cocaine or any other psychos-
timulant

DeFulio 2009

Ineligible intervention: participants were already detoxified; intervention aimed to prevent relapse

Donovan 2013

Gawin 1984

Gawin 1989

Glasner 2022

Ineligible population: 38.9% of the sample reported stimulant abstinence in the 30 days pre-base-
line

Ineligible study design: open pilot study with desipramine and lithium carbonate

Ineligible intervention: comparison of desipramine hydrochloride, lithium carbonate, and placebo
treatments

Ineligible population: participants included 50% with opioid dependence, 50% with stimulant de-
pendence

Glasner-Edwards 2007

Ineligible population: veterans with co-occurring substance-use disorders and concomitant major
depressive disorder

Gonçalves 2014

Ineligible intervention: motivational interviewing combined with chess

Gottheil 1998

Ineligible comparison: compared the same intervention with two different intensities

Gross 2006

Ineligible population: opioid-dependent patients; only 25% with comorbid cocaine dependence.
Results for the subgroups with comorbid participants not reported

Hall 1994

Ineligible intervention: enhanced continuity of care and desipramine

Hawkins 1989

Ineligible population: any drug abusers

Hoffman 1994

Ineligible comparison: compared the same intervention with two different intensities

Psychosocial interventions for stimulant use disorder (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

156

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study

Holtyn 2020

Islam 2014

Jones 2005

Kalapatapu 2021

Kang 1991

Reason for exclusion

Ineligible population: opioid-dependent patients; not clear how many were also cocaine-depen-
dent (cocaine dependence not in the inclusion criteria)

Ineligible intervention: physical activity

Ineligible population: not all psychostimulant abusers

Ineligible intervention: counselling plus occupational therapy-based cognitive rehabilitation aimed
at improving cognitive impairment in mildly to moderately cognitively-impaired participants with
cocaine-use disorders

Ineligible study design: stated as randomised, but the number of participants randomised to each
of the three groups was not reported, and the results were provided for the whole sample together
as a pre-post uncontrolled design

Kelpin 2022

Ineligible population: only 1.6% of particicpants with stimulant use

Keoleian 2013

Ineligible intervention: text messaging intervention for use as an adjunct to cognitive behavioural
group therapy

Kidorf 2013

Kiluk 2010

Knight 1994

Kouri 1995

Magura 1994

Marcus 2009

Martino 2006

Martino 2016

McKay 1997

McKay 1998

McKay 2004

McKay 2005

McKay 2010

McKay 2013a

McKay 2013b

Ineligible population: opioid-dependent outpatients

Ineligible population: substance-abusing individuals

Ineligible population: methadone maintenance participants, 85% used heroin alone daily

Ineligible intervention: buprenorphine treatment in participants with concurrent opiate and co-
caine abuse/dependence

Ineligible comparison: compared the same intervention with two different intensities

Ineligible population: any substance dependence

Ineligible population: co-occurring psychotic and drug-related disorders

Ineligible population: clinical supervision for clinician providing motivational interviewing

Ineligible population: already-treated participants with intensive outpatient programme (IOP);
continuing aftercare intervention

Ineligible population: 48 (34.8%) participants had alcohol dependence only and separate data for
cocaine-dependent participants were not provided

Ineligible population: already-abstinent participants in relapse prevention intervention

Ineligible population: 74% of participants with cocaine dependence. No separate data available

Ineligible population: already-abstinent participants in relapse prevention intervention

Ineligible population: already-treated participants with intensive outpatient programme (IOP);
continuing aftercare intervention

Ineligible population: already-treated participants with intensive outpatient programme (IOP);
continuing aftercare intervention

Metsch 2018

Ineligible intervention: intervention aimed to increase treatment adherence in HIV patients

Psychosocial interventions for stimulant use disorder (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

157

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study

Miller 1983

Monti 1997

Mueser 2009

Najavits 2018

Reason for exclusion

Ineligible intervention: comparison of bupropion, dextroamphetamine, and placebo in mixed-sub-
stance abusers

Ineligible comparison: psychosocial intervention compared to relaxation and meditation

Ineligible population: participants with co-occurring substance use and severe psychiatric disor-
ders; family intervention

Ineligible population: participants included alcohol-use disorder (75%), any drug use disorder
(50%)

Norberg 2014

Ineligible population: occasional use of ecstasy

Ollo 1996

Petry 2010

Petry 2011

Pirnia 2017

Ineligible intervention: diethylpropion treatment

Ineligible population: participants with HIV and opioid or cocaine abuse or dependence; results for
the subgroup of participants with cocaine abuse or dependence not reported

Ineligible population: substance-abusing patients

Ineligible population: “cocaine-dependent males during abstinence”. Intervention aimed to pre-
vent relapse

Polcin 2014

Ineligible comparison: compared the same intervention with two different intensities

Preston 2008

Ineligible comparison: compared the same intervention with two different types of CM

Rash 2008

Ineligible design: sub-analysis of three RCTs

Rawson 2021

Ineligible comparison: compared two different intensities of the same treatment

Rogers 2008

Rosen 2009

Ineligible population: already-abstinent participants

Ineligible population: veterans with psychiatric disorder, a substance-use disorder, or co-occurring
psychiatric and substance-use disorders

Rosenblum 2005

Ineligible population: not all participants were cocaine abusers or dependent

Ruger 2012

Ineligible intervention: Well Woman Exam (WWE) and educational intervention

Santisteban 2011

Ineligible population: adolescents who met DSM-IV criteria for substance abuse disorder

Saxon 1996

Ineligible population: primary opiate abuse/dependence (89% of sample used heroin intravenous-
ly)

Schaub 2019

Ineligible intervention: non-standardised intervention

Schmitz 1997

Ineligible comparison: compared the same intervention with two different intensities

Silverman 2001

Ineligible population: not all participants were psychostimulant abusers or dependent

Stitzer 2010

Ineligible intervention: intervention aimed to increase hepatitis B vaccination amongst cocaine
abusers

Van Horn 2011

Ineligible intervention: telephone continuing care with and without voucher incentives

Psychosocial interventions for stimulant use disorder (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

158

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study

Reason for exclusion

Wardle 2015

Ineligible intervention: moderator effect of anhedonia on CM effect. Conference abstract

Wechsberg 2007

Ineligible intervention: personalised feedback about drug use and associated problems, informa-
tion about the treatment process

Weddington 1991

Ineligible intervention: comparison of desipramine and amantadine

Weiss 2007

Ineligible population: bipolar disorder and current substance dependence

Winters 2000

Ineligible population: any drug abusers; no discrimination for cocaine users

Xu 2021

Zhu 2018

Zlotnick 2009

Ineligible intervention: transcranial direct current stimulation over prefrontal cortex combined
with cognitive training

Ineligible intervention: mobile-based computerised cognitive addiction therapy app for the im-
provement of cognition impairments

Ineligible population: incarcerated women with substance use disorder and post-traumatic stress
disorder

CM: contingency management; RCT: randomised controlled trial

Characteristics of ongoing studies [ordered by study ID]

IRCT20221018056234N1 

Study name

Evaluation of the effects of motivational interviewing on beliefs related to substances, craving and
desire for treatment in methamphetamine-dependent psychotic patients

Methods

Randomised controlled trial

Participants

32 psychotic patients with methamphetamine dependence

Interventions

1. Intervention group: single 50-minute motivational interview session

2. Control group: nothing is done

Primary outcomes: "The score of beliefs related to substances in the Beck and Wright question-
naire, The score of the questionnaire measuring the craving to use substances after leaving Feder-
di, Bararfan and Ziyai, The score of Miller and Tunigan stages of preparation for change and enthu-
siasm for addiction treatment questionnaire"

Outcomes

Starting date

Contact information

Notes

Country: Iran

https://en.irct.ir/trial/66683

Mallorquí-Bagué 2023 

Study name

Psychosocial interventions for stimulant use disorder (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

159

 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Mallorquí-Bagué 2023  (Continued)

Methods

Randomised controlled trial

Participants

70 (estimated) inpatients with cocaine use disorder

Interventions

1. Treatment as usual (TAU) + web-based CBT (CBT4CBT)

2. TAU

Outcomes

Primary: treatment dropout and cocaine use (number of positive urine specimens submitted, per-
cent negative urine screens, percent days of abstinence, self-reported frequency of cocaine use).

Secondary: sociodemographic variables and anthropometric measures (weight and high), cocaine
craving, psychopathological symptoms and comorbidities, other addictive behaviors, personality
traits, emotion regulation skills and CBT4CBT usability as well as treatment satisfaction.

Starting date

Contact information

Notes

Country: Europe

Study completion: June 2024 (estimated)

clinicaltrials.gov/study/NCT05207228

NCT00292110 

Study name

Methods

Randomised double-blind clinical trial

Participants

300 participants with opiate and cocaine-related disorders in a methadone clinic

Interventions

1. Contingency management with incentives given for cocaine abstinence, flexible methadone dos-

ing to 190 mg/day daily orally

2. Contingency management with incentives given for cocaine abstinence and incentives given in-

dependent of drug use, methadone 100 mg/day orally
3. Flexible methadone dosing to 190 mg/day daily orally
4. Contingency management with incentives given independent of drug use, methadone 100 mg/

day orally

Abstinence from cocaine and heroin, time to relapse, psychological and psychosocial outcome, HIV
risk behaviours, QT interval (a measurement made on an electrocardiogram used to assess some
of the electrical properties of the heart), urine microalbuminuria, blood lipid profile, quality of life,
substance dependence, methadone plasma and saliva concentration, cortisol and prolactin levels

Outcomes

Starting date

Contact information

Notes

Country: USA

Principal Investigator: Kenzie Preston, PhD

The study was completed August 2013. Website accessed 8 March 2016.

Psychosocial interventions for stimulant use disorder (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

160

 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

NCT01401270 

Study name

Prize contingency management for cocaine-dependent methadone patients

Methods

Randomised controlled trial

Participants

300 cocaine-dependent methadone patients

Interventions

1. Control group
2. Contingency management condition that arranges a 100% probability of winning a prize with each

draw and has 3 prize categories

3. Contingency management condition that arranges a 31% probability of winning and has 3 prize

categories

4. Contingency management condition that arranges a 100% probability of winning and has 7 prize

categories

5. Contingency management condition that arranges a 31% probability of winning and has 7 prize

categories

6. Usual prize contingency management with a 50% probability of winning from 3 prize categories

Outcomes

Longest continuous period of cocaine abstinence

Starting date

November 2011

Contact information

Sheila M Alessi, PhD, University of Connecticut Health Center

Notes

Country: USA

NCT01899313 

Study name

A cognitive behavioral therapy-based text message intervention for methamphetamine depen-
dence

Methods

Randomised cross-over trial

Participants

50 patients with methamphetamine addiction

Interventions

Outcomes

1. CBT-based SMS text messaging intervention
2. Placebo texts as add-on to CBT group therapy

Proportion of MA-negative urine samples between the 2-week CBT text period and the 2-week con-
trol period

Starting date

May 2014

Contact information

Gantt Galloway, PharmD California Pacific Medical Center

Notes

Country: USA

NCT01926184 

Study name

RCT of an integrative intervention for non-treatment-seeking meth users (ARTEMIS)

Psychosocial interventions for stimulant use disorder (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

161

 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

NCT01926184  (Continued)

Methods

Randomised controlled trial

Participants

230 HIV-positive, methamphetamine-using men who have sex with men

Interventions

Outcomes

1. Affect Regulation Treatment to Enhance Meth Intervention Success (ARTEMIS)
2. Contingency management

HIV Viral Load, sustained HIV viral suppression, T-helper Count, methamphetamine and cocaine
use, psychological adjustment, potentially amplified transmission risk behaviour

Starting date

January 2013

Contact information

Walter Gomez MA, walter.gomez@ucsf.edu

Notes

Country: USA

NCT01986075 

Study name

A sequenced behavioral and medication intervention for cocaine dependence

Methods

Randomised controlled trial

Participants

155 treatment-seeking cocaine-dependent participants

Interventions

Outcomes

1. Computer-assisted therapy alone
2. Computer-assisted CBT + Adderall-XR
3. Computer-assisted CBT plus placebo

Cocaine abstinence after 3 weeks, dichotomous abstinence after 3 weeks: urine toxicology-con-
firmed self-reported abstinence, proportion of cocaine positive urine samples

Starting date

January 2014

Contact information

Frances R Levin, MD, Columbia University/New York State Psychiatric Institute

Notes

Country: USA

NCT04982796 

Study name

Methods

Participants

Interventions

Outcomes

Starting date

Randomised parallel-group controlled trial

30 participants with methamphetamine dependence

Psilocybin-enhanced psychotherapy

Acceptability, dropout, methamphetamine use, disability, craving, depression

7 July 2022

Contact information

Philip.Bouleh@va.gov

Psychosocial interventions for stimulant use disorder (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

162

 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

NCT04982796  (Continued)

Notes

NCT05207228 

Study name

Improvement of Cocaine Use Disorder Treatment Through Cognitive Behavioral Therapy Web-
based Treatment (CBT4CBT)

Methods

Randomised controlled trial

Participants

70 (estimated) adults with cocaine use disorder

Interventions

1. Web-delivered CBT (CBT4CBT) plus treatment as usual (TAU)

2. TAU

Outcomes

Primary: relapse, assessing presence of benzoylecgonine (metabolite of cocaine), treatment reten-
tion

Secondary: psychopathology, dependence and craving, anthropometric measures

Starting date

Contact information

Notes

Countries: Spain and Europe

Study completion (estimated): June 2024

classic.clinicaltrials.gov/show/NCT05207228

NCT05593796 

Study name

Cognitive Behavioral Therapy (CBT) in Treatment of Methamphetamine Use Disorder

Methods

Randomised controlled trial

Participants

50 (estimated) patients who meet the criteria for methamphetamine use disorder

Interventions

1. Clinician-delivered CBT plus treatment as usual (TAU)

2. TAU

Addiction severity index for methamphetamine use disorder

Outcomes

Starting date

Contact information

Notes

Country: Egypt

Study completion (estimated): March 2025

clinicaltrials.gov/study/NCT05593796

Psychosocial interventions for stimulant use disorder (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

163

 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

NCT05854667 

Study name

Clinical Trial of High Dose Lisdexamfetamine and Contingency Management in MA Users

Methods

Randomised controlled trial

Participants

400 (estimated) adults with moderate to severe methamphetamine (MA) use disorder

Interventions

1. Treatment as usual (TAU) plus placebo and contingency management (CM)

2. TAU plus placebo arm

3. TAU plus lisdexamfetamine (LDX-01) and CM

4. TAU plus lisdexamfetamine (LDX-01)

Outcomes

Primary: total number of days of methamphetamine use

Secondary: medication adherence, safety events, changes in quality of life, MA and other sub-
stance use (self-report and urine drug screening), indigenous wellness perspective, treatment sat-
isfaction

Starting date

December 2023

Contact information

Notes

Country: Canada

Study completion (estimated): November 2025

clinicaltrials.gov/study/NCT05854667

Shaub 2015 

Study name

Snow Control 2.0 - web-based interventions for the reduction of cocaine use

Methods

Randomised controlled trial

Participants

432 problematic cocaine users

Interventions

Outcomes

1. Guided chat-counselling and web-based self-help
2. Web-based self-help alone
3. Waiting-list control condition

Weekly quantity of cocaine used; number of cocaine use days in the past 30 days; severity of co-
caine dependence; use of alcohol, tobacco, or other illicit drugs; changes in mental health symp-
toms; treatment retention

Starting date

March 2015

Contact information

Dr Michael P Schaub, Konradstrasse 32, Zurich 8031, Switzerland

Notes

Country: Switzerland

CBT: cognitive behavioural therapy; MA: methamphetamines; RCT: randomised controlled trial

Psychosocial interventions for stimulant use disorder (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

164

 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

D A T A   A N D   A N A L Y S E S

Cochrane Database of Systematic Reviews

Comparison 1.   Any psychosocial treatment versus no intervention

Outcome or subgroup ti-
tle

No. of studies

No. of partici-
pants

Statistical method

Effect size

1.1 Dropouts

1.1.1 CBT

1.1.2 Contingency man-
agement

1.1.3 Motivational inter-
viewing

1.1.4 12-step facilitation

1.1.5 Psychodynamic ther-
apy

29

8

16

3

1

1

1.2 Point abstinence, end
of treatment

12

1.2.1 CBT

1.2.2 Contingency man-
agement

1.2.3 12-step facilitation

1.2.4 Psychodynamic ther-
apy

1.2.5 CBT + contingency
management

1.3 Point abstinence,
longest follow-up

1.3.1 CBT

1.3.2 Contingency man-
agement

1.3.3 Psychodynamic ther-
apy

1.3.4 CBT + contingency
management

1.3.5 Motivational inter-
viewing

4

5

1

1

1

9

4

2

1

1

1

1.4 Continuous absti-
nence, end of treatment

12

4049

851

2287

614

112

185

Risk Ratio (M-H, Random, 95% CI)

0.82 [0.74, 0.91]

Risk Ratio (M-H, Random, 95% CI)

0.89 [0.68, 1.17]

Risk Ratio (M-H, Random, 95% CI)

0.76 [0.67, 0.87]

Risk Ratio (M-H, Random, 95% CI)

0.92 [0.66, 1.29]

Risk Ratio (M-H, Random, 95% CI)

1.58 [0.85, 2.94]

Risk Ratio (M-H, Random, 95% CI)

0.87 [0.72, 1.04]

1293

Risk Ratio (M-H, Random, 95% CI)

1.15 [0.94, 1.41]

454

507

112

185

35

Risk Ratio (M-H, Random, 95% CI)

1.05 [0.88, 1.25]

Risk Ratio (M-H, Random, 95% CI)

1.75 [0.92, 3.34]

Risk Ratio (M-H, Random, 95% CI)

0.84 [0.48, 1.46]

Risk Ratio (M-H, Random, 95% CI)

1.05 [0.77, 1.44]

Risk Ratio (M-H, Random, 95% CI)

2.08 [0.57, 7.55]

1187

Risk Ratio (M-H, Random, 95% CI)

1.22 [0.91, 1.62]

484

141

185

35

342

Risk Ratio (M-H, Random, 95% CI)

1.78 [0.98, 3.24]

Risk Ratio (M-H, Random, 95% CI)

1.06 [0.28, 3.98]

Risk Ratio (M-H, Random, 95% CI)

0.95 [0.72, 1.27]

Risk Ratio (M-H, Random, 95% CI)

1.15 [0.41, 3.28]

Risk Ratio (M-H, Random, 95% CI)

1.17 [0.94, 1.46]

1770

Risk Ratio (M-H, Random, 95% CI)

1.89 [1.20, 2.97]

Psychosocial interventions for stimulant use disorder (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

165

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup ti-
tle

No. of studies

No. of partici-
pants

Statistical method

Effect size

1.4.1 CBT

1.4.2 Contingency man-
agement

1.4.4 Psychodynamic ther-
apy

1.5 Continuous absti-
nence, longest follow-up

1.5.1 CBT

1.5.2 Contingency man-
agement

1.6 Frequency of drug in-
take, end of treatment

1.6.1 CBT

1.6.2 Contingency man-
agement

1.6.3 Motivational inter-
viewing

1.7 Longest period of ab-
stinence

1.7.1 CBT

1.7.2 Contingency man-
agement

1.8 Craving

1.8.1 CBT

1.8.2 Contingency man-
agement

1.9 Severity of depen-
dence

1.9.1 Contingency man-
agement

1.10 Depression

2

9

1

3

1

2

9

3

5

1

17

5

12

3

1

2

4

4

2

282

1303

185

266

85

181

1186

133

711

342

2118

440

1678

272

30

242

223

223

78

Risk Ratio (M-H, Random, 95% CI)

1.30 [0.51, 3.34]

Risk Ratio (M-H, Random, 95% CI)

2.51 [1.43, 4.43]

Risk Ratio (M-H, Random, 95% CI)

0.68 [0.38, 1.19]

Risk Ratio (M-H, Random, 95% CI)

1.14 [0.85, 1.54]

Risk Ratio (M-H, Random, 95% CI)

1.16 [0.93, 1.46]

Risk Ratio (M-H, Random, 95% CI)

1.88 [0.33, 10.61]

Std. Mean Difference (IV, Random,
95% CI)

-0.35 [-0.51, -0.18]

Std. Mean Difference (IV, Random,
95% CI)

-0.49 [-1.06, 0.08]

Std. Mean Difference (IV, Random,
95% CI)

-0.39 [-0.56, -0.22]

Std. Mean Difference (IV, Random,
95% CI)

-0.15 [-0.37, 0.06]

Std. Mean Difference (IV, Random,
95% CI)

0.54 [0.41, 0.68]

Std. Mean Difference (IV, Random,
95% CI)

0.59 [0.23, 0.94]

Std. Mean Difference (IV, Random,
95% CI)

0.54 [0.39, 0.69]

Std. Mean Difference (IV, Random,
95% CI)

-0.85 [-1.67, -0.03]

Std. Mean Difference (IV, Random,
95% CI)

-1.63 [-2.47, -0.79]

Std. Mean Difference (IV, Random,
95% CI)

-0.52 [-1.26, 0.22]

Std. Mean Difference (IV, Random,
95% CI)

-0.83 [-1.96, 0.30]

Std. Mean Difference (IV, Random,
95% CI)

-0.83 [-1.96, 0.30]

Std. Mean Difference (IV, Random,
95% CI)

-0.41 [-0.86, 0.04]

Psychosocial interventions for stimulant use disorder (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

166

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup ti-
tle

No. of studies

No. of partici-
pants

Statistical method

Effect size

1.10.1 CBT

1.10.2 Contingency man-
agement

1

1

41

37

Std. Mean Difference (IV, Random,
95% CI)

-0.28 [-0.90, 0.34]

Std. Mean Difference (IV, Random,
95% CI)

-0.56 [-1.22, 0.10]

Psychosocial interventions for stimulant use disorder (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

167

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 1.1.   Comparison 1: Any psychosocial treatment versus no intervention, Outcome 1: Dropouts

Study or Subgroup

Events

Total

Any psychosocial intervention

No intervention
Total
Events

Risk Ratio
M-H, Random, 95% CI

Weight

Risk Ratio
M-H, Random, 95% CI

Risk of Bias

A

B

C

D

1.1.1 CBT
Baker 2001
Baker 2005
Carroll 2014
Carroll 2018
Crits-Christoph 1999 arm 1
Higgins 2003
Marsden 2018
Mimiaga 2019
Subtotal (95% CI)
Total events:
Heterogeneity: Tau² = 0.05; Chi² = 12.27, df = 7 (P = 0.09); I² = 43%
Test for overall effect: Z = 0.84 (P = 0.40)

8
39
13
19
79
17
1
2

178

32
140
47
66
119
49
16
21
490

1.1.2 Contingency management
Blanken 2016
Carroll 2016
Garcia-Fernandez 2011
Hagedorn 2013
Higgins 1994
Kirby 1998
Menza 2010
Miguel 2017
Peirce 2006
Petitjean 2014
Petry 2005a
Petry 2005b
Petry 2007
Petry 2015
Roll 2013
Secades Villa 2013
Subtotal (95% CI)
Total events:
Heterogeneity: Tau² = 0.01; Chi² = 16.69, df = 14 (P = 0.27); I² = 16%
Test for overall effect: Z = 4.08 (P < 0.0001)

17
8
9
25
2
10
14
16
65
10
107
5
6
0
31
21

107
45
29
71
20
44
70
32
198
29
209
40
57
183
89
47
1270

346

1.1.3 Motivational interviewing
Marsden 2006
McKee 2007
Stein 2009
Subtotal (95% CI)
Total events:
Heterogeneity: Tau² = 0.00; Chi² = 0.69, df = 2 (P = 0.71); I² = 0%
Test for overall effect: Z = 0.47 (P = 0.64)

22
12
17

51

1.1.4 12-step facilitation
Carroll 2012
Subtotal (95% CI)
Total events:
Heterogeneity: Not applicable
Test for overall effect: Z = 1.45 (P = 0.15)

1.1.5 Psychodynamic therapy
Crits-Christoph 1999 arm 2
Subtotal (95% CI)
Total events:
Heterogeneity: Not applicable
Test for overall effect: Z = 1.49 (P = 0.14)

19

19

83

83

166
38
97
301

56
56

124
124

Total (95% CI)
Total events:
Heterogeneity: Tau² = 0.02; Chi² = 36.75, df = 27 (P = 0.10); I² = 27%
Test for overall effect: Z = 3.64 (P = 0.0003)
Test for subgroup differences: Chi² = 6.72, df = 4 (P = 0.15), I² = 40.5%

2241

677

32
74
54
54
62
51
14
20
361

0.9%
3.9%
2.7%
1.9%
11.1%
4.4%
0.1%
0.4%
25.4%

2.00 [0.67 , 5.98]
1.03 [0.65 , 1.63]
0.79 [0.44 , 1.41]
1.73 [0.85 , 3.50]
0.86 [0.71 , 1.03]
0.52 [0.34 , 0.80]
0.88 [0.06 , 12.73]
0.63 [0.12 , 3.41]
0.89 [0.68 , 1.17]

107
54
29
68
20
46
57
32
190
31
206
37
19
57
29
35
1017

2.7%
1.1%
2.0%
4.8%
0.5%
1.4%
1.9%
6.0%
7.7%
2.1%
12.0%
0.8%
0.6%

4.8%
4.6%
53.0%

0.81 [0.45 , 1.45]
1.60 [0.60 , 4.27]
0.75 [0.37 , 1.50]
0.75 [0.50 , 1.12]
0.29 [0.07 , 1.21]
1.31 [0.57 , 3.01]
1.04 [0.51 , 2.10]
0.51 [0.36 , 0.72]
0.93 [0.71 , 1.23]
0.89 [0.46 , 1.74]
0.79 [0.67 , 0.93]
0.77 [0.26 , 2.31]
0.67 [0.18 , 2.41]
Not estimable
0.56 [0.38 , 0.84]
0.74 [0.49 , 1.13]
0.76 [0.67 , 0.87]

176
36
101
313

2.9%
2.4%
2.7%
8.0%

1.11 [0.64 , 1.94]
0.81 [0.44 , 1.51]
0.84 [0.47 , 1.50]
0.92 [0.66 , 1.29]

?
+
+
+
+
+
+
?

+
+
+
+
?
+
+
+
+
+
+
+
+
+
?
+

+
?
?

?
+
?
?
+
?
−

?

?
?
+
?
?
?
+
?
+
+
+
?
?
?
−

?

+
+
?

+
+
+
+
+
−

+
+

+
+
−
−
+
+
+
+
−
+
+
+
+
+
+
−

+
−

+

?
?
+
+
+
?
?
?

+
+
?
?
?
?
+
−

?
+
?
?
?
?
?
?

?
?
?

56
56

2.4%
2.4%

1.58 [0.85 , 2.94]
1.58 [0.85 , 2.94]

+

?

+

?

61
61

11.2%
11.2%

0.87 [0.72 , 1.04]
0.87 [0.72 , 1.04]

+

+

+

+

1808

100.0%

0.82 [0.74 , 0.91]

4
20
19
9
48
34
1
3

138

21
6
12
32
7
8
11
32
67
12
134
6
3
0
18
21

390

21
14
21

56

12

12

47

47

643

0.1

0.5
Favours psychosocial

0.2

1

2

5

10

Favours no intervention

Risk of bias legend
(A) Random sequence generation (selection bias)
(B) Allocation concealment (selection bias)
(C) Incomplete outcome data (attrition bias)

Psychosocial interventions for stimulant use disorder (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

168

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Analysis 1.1.   (Continued)

(A) Random sequence generation (selection bias)
(B) Allocation concealment (selection bias)
(C) Incomplete outcome data (attrition bias)
(D) Selective reporting (reporting bias)

Cochrane Database of Systematic Reviews

Analysis 1.2.   Comparison 1: Any psychosocial treatment versus
no intervention, Outcome 2: Point abstinence, end of treatment

Study or Subgroup

Events

Total

Any psychosocial intervention

No intervention
Total
Events

Risk Ratio
M-H, Random, 95% CI

Weight

Risk Ratio
M-H, Random, 95% CI

Risk of Bias

A

B

C

D

1.2.1 CBT
Crits-Christoph 1999 arm 1
Marsden 2018
Milby 2008
Rawson 2002 arm 1
Subtotal (95% CI)
Total events:
Heterogeneity: Tau² = 0.00; Chi² = 2.75, df = 3 (P = 0.43); I² = 0%
Test for overall effect: Z = 0.52 (P = 0.60)

50
6
67
11

134

119
16
103
28
266

1.2.2 Contingency management
Blanken 2016
Carroll 2016
Garcia-Fernandez 2011
Menza 2010
Rawson 2002 arm 2
Subtotal (95% CI)
Total events:
Heterogeneity: Tau² = 0.35; Chi² = 18.33, df = 4 (P = 0.001); I² = 78%
Test for overall effect: Z = 1.70 (P = 0.09)

13
15
19
35
16

107
45
29
55
27
263

98

1.2.3 12-step facilitation
Carroll 2012
Subtotal (95% CI)
Total events:
Heterogeneity: Not applicable
Test for overall effect: Z = 0.61 (P = 0.54)

1.2.4 Psychodynamic therapy
Crits-Christoph 1999 arm 2
Subtotal (95% CI)
Total events:
Heterogeneity: Not applicable
Test for overall effect: Z = 0.31 (P = 0.76)

1.2.5 CBT + contingency management
Rawson 2002 arm 3
Subtotal (95% CI)
Total events:
Heterogeneity: Not applicable
Test for overall effect: Z = 1.11 (P = 0.27)

16

16

62

62

12

12

56
56

124
124

26
26

Total (95% CI)
Total events:
Heterogeneity: Tau² = 0.04; Chi² = 19.98, df = 11 (P = 0.05); I² = 45%
Test for overall effect: Z = 1.37 (P = 0.17)
Test for subgroup differences: Chi² = 4.02, df = 4 (P = 0.40), I² = 0.6%

322

735

62
14
103
9
188

14.5%
2.6%
18.9%
2.2%
38.2%

0.87 [0.62 , 1.21]
1.75 [0.53 , 5.73]
1.10 [0.89 , 1.36]
1.77 [0.48 , 6.53]
1.05 [0.88 , 1.25]

107
54
29
45
9
244

1.0%
5.8%
10.1%
16.7%
2.3%
35.9%

13.00 [1.73 , 97.63]
2.00 [0.97 , 4.13]
1.46 [0.90 , 2.37]
0.89 [0.68 , 1.18]
2.67 [0.76 , 9.42]
1.75 [0.92 , 3.34]

+
+
?
?

+
+
+
+
?

+
−

?
?

?
?
+
+
?

+
+
+
+

+
+
−
+
+

+
?
?
?

+
+
?
+
?

56
56

8.6%
8.6%

0.84 [0.48 , 1.46]
0.84 [0.48 , 1.46]

+

?

+

?

61
61

15.1%
15.1%

1.05 [0.77 , 1.44]
1.05 [0.77 , 1.44]

+

+

+

+

9
9

2.2%
2.2%

2.08 [0.57 , 7.55]
2.08 [0.57 , 7.55]

?

?

+

?

30
3
61
2

96

1
9
13
32
2

57

19

19

29

29

2

2

558

100.0%

1.15 [0.94 , 1.41]

203

0.1

0.5
Favours no intervention

0.2

1

2

5

10

Favours psychosocial

Risk of bias legend
(A) Random sequence generation (selection bias)
(B) Allocation concealment (selection bias)
(C) Incomplete outcome data (attrition bias)
(D) Selective reporting (reporting bias)

Psychosocial interventions for stimulant use disorder (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

169

 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 1.3.   Comparison 1: Any psychosocial treatment versus
no intervention, Outcome 3: Point abstinence, longest follow-up

Study or Subgroup

Events

Total

Any psychosocial intervention

No intervention
Total
Events

Risk Ratio
M-H, Random, 95% CI

Weight

Risk Ratio
M-H, Random, 95% CI

Risk of Bias

A

B

C

D

1.3.1 CBT
Baker 2001
Baker 2005
Crits-Christoph 1999 arm 1
Rawson 2002 arm 1
Subtotal (95% CI)
Total events:
Heterogeneity: Tau² = 0.25; Chi² = 11.30, df = 3 (P = 0.01); I² = 73%
Test for overall effect: Z = 1.89 (P = 0.06)

14
50
64
17

145

24
140
119
28
311

1.3.2 Contingency management
Menza 2010
Rawson 2002 arm 2
Subtotal (95% CI)
Total events:
Heterogeneity: Tau² = 0.73; Chi² = 4.26, df = 1 (P = 0.04); I² = 77%
Test for overall effect: Z = 0.09 (P = 0.93)

29
14

43

1.3.3 Psychodynamic therapy
Crits-Christoph 1999 arm 2
Subtotal (95% CI)
Total events:
Heterogeneity: Not applicable
Test for overall effect: Z = 0.32 (P = 0.75)

1.3.4 CBT + contingency management
Rawson 2002 arm 3
Subtotal (95% CI)
Total events:
Heterogeneity: Not applicable
Test for overall effect: Z = 0.27 (P = 0.79)

1.3.5 Motivational interviewing
Marsden 2006
Subtotal (95% CI)
Total events:
Heterogeneity: Not applicable
Test for overall effect: Z = 1.38 (P = 0.17)

64

64

10

10

86

86

58
27
85

124
124

26
26

166
166

Total (95% CI)
Total events:
Heterogeneity: Tau² = 0.11; Chi² = 29.28, df = 8 (P = 0.0003); I² = 73%
Test for overall effect: Z = 1.32 (P = 0.19)
Test for subgroup differences: Chi² = 3.65, df = 4 (P = 0.46), I² = 0%

348

712

28
74
62
9
173

8.0%
11.6%
16.4%
4.2%
40.2%

2.72 [1.24 , 5.97]
2.03 [1.18 , 3.49]
1.01 [0.76 , 1.35]
2.73 [0.78 , 9.61]
1.78 [0.98 , 3.24]

47
9
56

16.2%
4.1%
20.3%

0.64 [0.47 , 0.85]
2.33 [0.65 , 8.35]
1.06 [0.28 , 3.98]

?
+
+
?

?
+
+
?

+
+
+
+

?
?
+
?

+
?

+
?

+
+

+
?

61
61

16.4%
16.4%

0.95 [0.72 , 1.27]
0.95 [0.72 , 1.27]

+

+

+

+

9
9

5.5%
5.5%

1.15 [0.41 , 3.28]
1.15 [0.41 , 3.28]

?

?

+

?

176
176

17.6%
17.6%

1.17 [0.94 , 1.46]
1.17 [0.94 , 1.46]

+

+

+

?

6
13
33
2

54

37
2

39

33

33

3

3

78

78

475

100.0%

1.22 [0.91 , 1.62]

207

0.5 0.7
Favours no intervention

1

1.5 2
Favours psychosocial

Risk of bias legend
(A) Random sequence generation (selection bias)
(B) Allocation concealment (selection bias)
(C) Incomplete outcome data (attrition bias)
(D) Selective reporting (reporting bias)

Psychosocial interventions for stimulant use disorder (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

170

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 1.4.   Comparison 1: Any psychosocial treatment versus no
intervention, Outcome 4: Continuous abstinence, end of treatment

Study or Subgroup

Events

Total

Any psychosocial intervention

No intervention
Total
Events

Risk Ratio
M-H, Random, 95% CI

Weight

Risk Ratio
M-H, Random, 95% CI

Risk of Bias

A

B

C

D

1.4.1 CBT
Carroll 2014
Crits-Christoph 1999 arm 1
Subtotal (95% CI)
Total events:
Heterogeneity: Tau² = 0.37; Chi² = 4.63, df = 1 (P = 0.03); I² = 78%
Test for overall effect: Z = 0.54 (P = 0.59)

17
27

44

47
119
166

1.4.2 Contingency management
Garcia-Fernandez 2011
Hagedorn 2013
Higgins 1994
Miguel 2017
Miguel 2022
Peirce 2006
Petitjean 2014
Petry 2005a
Petry 2007
Subtotal (95% CI)
Total events:
Heterogeneity: Tau² = 0.44; Chi² = 29.96, df = 8 (P = 0.0002); I² = 73%
Test for overall effect: Z = 3.19 (P = 0.001)

29
52
20
33
50
198
29
209
57
677

11
27
11
7
26
11
15
39
16

163

1.4.4 Psychodynamic therapy
Crits-Christoph 1999 arm 2
Subtotal (95% CI)
Total events:
Heterogeneity: Not applicable
Test for overall effect: Z = 1.35 (P = 0.18)

22

22

124
124

Total (95% CI)
Total events:
Heterogeneity: Tau² = 0.41; Chi² = 45.33, df = 11 (P < 0.00001); I² = 76%
Test for overall effect: Z = 2.73 (P = 0.006)
Test for subgroup differences: Chi² = 10.32, df = 2 (P = 0.006), I² = 80.6%

967

229

9
17

26

10
15
3
0
7
1
17
10
0

63

16

16

105

54
62
116

9.9%
11.1%
21.1%

2.17 [1.07 , 4.40]
0.83 [0.49 , 1.40]
1.30 [0.51 , 3.34]

29
51
20
32
48
190
31
206
19
626

10.1%
11.3%
7.3%
2.2%
9.7%
3.6%
11.4%
10.2%
2.2%
68.1%

1.10 [0.55 , 2.18]
1.77 [1.07 , 2.91]
3.67 [1.20 , 11.19]
14.56 [0.87 , 244.83]
3.57 [1.71 , 7.43]
10.56 [1.38 , 80.97]
0.94 [0.59 , 1.52]
3.84 [1.97 , 7.49]
11.38 [0.72 , 181.09]
2.51 [1.43 , 4.43]

+
+

?
+

+
+

+
+

+
+
?
+
+
+
+
+
+

+
?
?
?
+
+
+
+
?

−
−

+
+
+
−

+
+
+

?
?
?
−
−

?
+
?
?

61
61

10.9%
10.9%

0.68 [0.38 , 1.19]
0.68 [0.38 , 1.19]

+

+

+

+

803

100.0%

1.89 [1.20 , 2.97]

0.1

0.5
Favours no intervention

0.2

1

2

5

10

Favours psychosocial

Risk of bias legend
(A) Random sequence generation (selection bias)
(B) Allocation concealment (selection bias)
(C) Incomplete outcome data (attrition bias)
(D) Selective reporting (reporting bias)

Psychosocial interventions for stimulant use disorder (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

171

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 1.5.   Comparison 1: Any psychosocial treatment versus no
intervention, Outcome 5: Continuous abstinence, longest follow-up

Study or Subgroup

Events

Total

Any psychosocial intervention

No intervention
Total
Events

Risk Ratio
M-H, Random, 95% CI

Weight

Risk Ratio
M-H, Random, 95% CI

Risk of Bias

A

B

C

D

1.5.1 CBT
Higgins 2003
Subtotal (95% CI)
Total events:
Heterogeneity: Not applicable
Test for overall effect: Z = 1.31 (P = 0.19)

38

38

45
45

1.5.2 Contingency management
Higgins 1994
Petry 2018
Subtotal (95% CI)
Total events:
Heterogeneity: Tau² = 1.17; Chi² = 3.12, df = 1 (P = 0.08); I² = 68%
Test for overall effect: Z = 0.71 (P = 0.47)

20
80
100

6
37

43

Total (95% CI)
Total events:
Heterogeneity: Tau² = 0.03; Chi² = 3.13, df = 2 (P = 0.21); I² = 36%
Test for overall effect: Z = 0.86 (P = 0.39)
Test for subgroup differences: Chi² = 0.29, df = 1 (P = 0.59), I² = 0%

145

81

40
40

58.9%
58.9%

1.16 [0.93 , 1.46]
1.16 [0.93 , 1.46]

+

?

−

?

20
61
81

2.1%
38.9%
41.1%

6.00 [0.79 , 45.42]
1.01 [0.70 , 1.45]
1.88 [0.33 , 10.61]

?
+

?
?

+
?

?
?

121

100.0%

1.14 [0.85 , 1.54]

29

29

1
28

29

58

0.1

0.5
Favours no intervention

0.2

1

2

5

10

Favours psychosocial

Risk of bias legend
(A) Random sequence generation (selection bias)
(B) Allocation concealment (selection bias)
(C) Incomplete outcome data (attrition bias)
(D) Selective reporting (reporting bias)

Psychosocial interventions for stimulant use disorder (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

172

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 1.6.   Comparison 1: Any psychosocial treatment versus no
intervention, Outcome 6: Frequency of drug intake, end of treatment

No intervention
SD

Total

Mean

Weight

Std. Mean Difference
IV, Random, 95% CI

Std. Mean Difference
IV, Random, 95% CI

Risk of Bias

A

B

C

D

Study or Subgroup

Any psychosocial intervention
Total
SD
Mean

1.6.1 CBT
Marsden 2018
Mimiaga 2019
Shoptaw 2005 arm 2
Subtotal (95% CI)
Heterogeneity: Tau² = 0.15; Chi² = 4.80, df = 2 (P = 0.09); I² = 58%
Test for overall effect: Z = 1.67 (P = 0.09)

18.96
5.6
5.1

14.6
3.1
1.7

16
21
20
57

1.6.2 Contingency management
Blanken 2016
Carroll 2016
Miguel 2022
Petry 2015
Shoptaw 2005 arm 3
Subtotal (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 4.58, df = 4 (P = 0.33); I² = 13%
Test for overall effect: Z = 4.53 (P < 0.00001)

19.75
19.88
7.65
8.6
1.7

8.24
24.57
4.7
3.9
5.1

107
45
50
183
20
405

45.41
4.5
2.7

30.29
6.5
4.6

14
20
42
76

3.9%
5.9%
7.4%
17.1%

-1.21 [-1.99 , -0.42]
-0.23 [-0.84 , 0.39]
-0.21 [-0.74 , 0.33]
-0.49 [-1.06 , 0.08]

22.38
24.17
10.5
10.3
2.2

4.57
22.99
3.4
2.7
6

107
54
48
57
40
306

17.2%
11.2%
10.8%
15.5%
7.3%
62.0%

-0.39 [-0.66 , -0.12]
-0.18 [-0.58 , 0.22]
-0.69 [-1.10 , -0.28]
-0.46 [-0.76 , -0.16]
-0.09 [-0.62 , 0.45]
-0.39 [-0.56 , -0.22]

1.6.3 Motivational interviewing
Marsden 2006
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 1.42 (P = 0.16)

5.54

11.5

166
166

7.4

12.6

176
176

20.9%
20.9%

-0.15 [-0.37 , 0.06]
-0.15 [-0.37 , 0.06]

+
?
+

+
+
+
+
+

−

?
?

?
?
+
?
?

+
+
+

+
+
+
+
+

?
?
?

+
+
−

?
?

+

+

+

?

Total (95% CI)
Heterogeneity: Tau² = 0.02; Chi² = 12.94, df = 8 (P = 0.11); I² = 38%
Test for overall effect: Z = 4.12 (P < 0.0001)
Test for subgroup differences: Chi² = 3.38, df = 2 (P = 0.18), I² = 40.9%

628

Risk of bias legend
(A) Random sequence generation (selection bias)
(B) Allocation concealment (selection bias)
(C) Incomplete outcome data (attrition bias)
(D) Selective reporting (reporting bias)

558

100.0%

-0.35 [-0.51 , -0.18]

-1 -0.5
Favours psychosocial

0

1

0.5
Favours no intervention

Psychosocial interventions for stimulant use disorder (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

173

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 1.7.   Comparison 1: Any psychosocial treatment versus
no intervention, Outcome 7: Longest period of abstinence

Study or Subgroup

Any psychosocial intervention
Total
SD
Mean

No intervention
SD

Total

Mean

Weight

Std. Mean Difference
IV, Random, 95% CI

Std. Mean Difference
IV, Random, 95% CI

Risk of Bias

A

B

C

D

1.7.1 CBT
Carroll 2014
Marsden 2018
Milby 2008
Mimiaga 2019
Shoptaw 2005 arm 2
Subtotal (95% CI)
Heterogeneity: Tau² = 0.09; Chi² = 10.43, df = 4 (P = 0.03); I² = 62%
Test for overall effect: Z = 3.27 (P = 0.001)

65.3
15.69
19.18
40.6
7

47
16
103
21
20
207

29.4
10.1
16
1.5
5.2

1.7.2 Contingency management
Blanken 2016
Kirby 1998
Miguel 2022
Petitjean 2014
Petry 2005b
Petry 2012a
Petry 2012b
Petry 2013
Petry 2015
Petry 2018
Secades Villa 2013
Shoptaw 2005 arm 3
Subtotal (95% CI)
Heterogeneity: Tau² = 0.03; Chi² = 20.04, df = 11 (P = 0.04); I² = 45%
Test for overall effect: Z = 7.18 (P < 0.00001)

5.84
2.8
4.7
9.6
3.7947
4.7
4.39
1.7
3.9
28.9
2.4
5.2

3.72
2.7
4.35
11.54
2.9
4.7
4.95
2.9
3.4
33.6
3.1
7

107
44
50
25
40
71
300
10
183
80
50
20
980

56.6
6
13.89
38.5
5.1

32.6
7.34
12.6
1.5
4.9

1.59
2.4
1.5
7.83
0.8
1.7
3.22
0.6
1.7
23.2
1.9
2.1

2.17
3.2
3.4
8.97
1.8248
2.7
3.43
1.7
2.7
27.8
2.5
2

54
14
103
20
42
233

107
46
48
24
37
59
142
9
57
61
68
40
698

6.3%
2.5%
8.7%
3.0%
4.3%
24.8%

8.8%
6.0%
6.1%
4.0%
5.3%
7.0%
10.5%
1.6%
8.2%
7.4%
6.7%
3.7%
75.2%

0.28 [-0.12 , 0.67]
1.06 [0.28 , 1.83]
0.37 [0.09 , 0.64]
1.37 [0.69 , 2.06]
0.38 [-0.16 , 0.91]
0.59 [0.23 , 0.94]

0.48 [0.21 , 0.75]
0.10 [-0.31 , 0.51]
0.69 [0.28 , 1.10]
0.39 [-0.17 , 0.96]
0.69 [0.23 , 1.15]
0.76 [0.40 , 1.12]
0.42 [0.22 , 0.62]
1.29 [0.28 , 2.30]
0.46 [0.16 , 0.76]
0.36 [0.03 , 0.70]
0.48 [0.11 , 0.86]
1.42 [0.83 , 2.02]
0.54 [0.39 , 0.69]

+
+
?
?
+

+
+
+
+
+
+
+
+
+
+
+
+

?
−

?
?
?

?
?
+
+
?
?
?
?
?
?
?
?

+
+
+
+
+

+
+
+
+
+
+
+
+
+
?
−

+

+
?
?
?
?

+
?
−

+
?
?
?
−

?
?
?
?

Total (95% CI)
Heterogeneity: Tau² = 0.03; Chi² = 30.60, df = 16 (P = 0.02); I² = 48%
Test for overall effect: Z = 7.92 (P < 0.00001)
Test for subgroup differences: Chi² = 0.05, df = 1 (P = 0.82), I² = 0%

1187

Risk of bias legend
(A) Random sequence generation (selection bias)
(B) Allocation concealment (selection bias)
(C) Incomplete outcome data (attrition bias)
(D) Selective reporting (reporting bias)

931

100.0%

0.54 [0.41 , 0.68]

-0.5
Favours no intervention

-1

0

0.5

1

Favours psychosocial

Analysis 1.8.   Comparison 1: Any psychosocial treatment versus no intervention, Outcome 8: Craving

Study or Subgroup

Any psychosocial intervention
Total
SD
Mean

No intervention
SD

Total

Mean

Weight

Std. Mean Difference
IV, Random, 95% CI

Std. Mean Difference
IV, Random, 95% CI

1.8.1 CBT
Marsden 2018
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 3.79 (P = 0.0001)

14.77

21.47

16
16

51.75

22.72

14
14

28.3%
28.3%

-1.63 [-2.47 , -0.79]
-1.63 [-2.47 , -0.79]

1.8.2 Contingency management
Festinger 2014
Pirnia 2016
Subtotal (95% CI)
Heterogeneity: Tau² = 0.23; Chi² = 5.19, df = 1 (P = 0.02); I² = 81%
Test for overall effect: Z = 1.38 (P = 0.17)

114
25
139

16.11
14.79

5.71
2.29

17.26
17.24

6.72
2.78

78
25
103

38.3%
33.4%
71.7%

-0.19 [-0.48 , 0.10]
-0.95 [-1.53 , -0.36]
-0.52 [-1.26 , 0.22]

Total (95% CI)
Heterogeneity: Tau² = 0.44; Chi² = 13.49, df = 2 (P = 0.001); I² = 85%
Test for overall effect: Z = 2.02 (P = 0.04)
Test for subgroup differences: Chi² = 3.76, df = 1 (P = 0.05), I² = 73.4%

155

117

100.0%

-0.85 [-1.67 , -0.03]

-2
Favours psychosocial

-1

0

1

2

Favours no intervention

Psychosocial interventions for stimulant use disorder (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

174

 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 1.9.   Comparison 1: Any psychosocial treatment
versus no intervention, Outcome 9: Severity of dependence

Study or Subgroup

Any psychosocial intervention
Total
SD
Mean

No intervention
SD

Total

Mean

Weight

Std. Mean Difference
IV, Random, 95% CI

Std. Mean Difference
IV, Random, 95% CI

1.9.1 Contingency management
Garcia-Fernandez 2011
Higgins 1994
Petry 2005b
Roll 2013
Subtotal (95% CI)
Heterogeneity: Tau² = 1.21; Chi² = 37.47, df = 3 (P < 0.00001); I² = 92%
Test for overall effect: Z = 1.43 (P = 0.15)

0.07
0.05
0.46
0.048

20
20
40
58
138

0.04
0.01
0.31
0.08

0.1
0.1
0.42
0.057

0.08
0.02
0.3
0.1

17
20
37
11
85

25.2%
23.1%
26.4%
25.3%
100.0%

-0.48 [-1.13 , 0.18]
-3.10 [-4.05 , -2.15]
0.13 [-0.32 , 0.58]
-0.11 [-0.75 , 0.54]
-0.83 [-1.96 , 0.30]

Total (95% CI)
Heterogeneity: Tau² = 1.21; Chi² = 37.47, df = 3 (P < 0.00001); I² = 92%
Test for overall effect: Z = 1.43 (P = 0.15)
Test for subgroup differences: Not applicable

138

85

100.0%

-0.83 [-1.96 , 0.30]

-4

-2

0

2

4

Favours psychosocial

Favours no intervention

Analysis 1.10.   Comparison 1: Any psychosocial treatment versus no intervention, Outcome 10: Depression

Study or Subgroup

Any psychosocial intervention
Total
SD
Mean

1.10.1 CBT
Mimiaga 2019
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 0.89 (P = 0.37)

14.8

1.10.2 Contingency management
Garcia-Fernandez 2011
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 1.66 (P = 0.10)

5.58

2.4

4.6

21
21

20
20

Total (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 0.37, df = 1 (P = 0.54); I² = 0%
Test for overall effect: Z = 1.78 (P = 0.07)
Test for subgroup differences: Chi² = 0.37, df = 1 (P = 0.54), I² = 0%

41

No intervention
SD

Total

Mean

Weight

Std. Mean Difference
IV, Random, 95% CI

Std. Mean Difference
IV, Random, 95% CI

15.5

2.5

20
20

53.5%
53.5%

-0.28 [-0.90 , 0.34]
-0.28 [-0.90 , 0.34]

10.33

11.22

17
17

46.5%
46.5%

-0.56 [-1.22 , 0.10]
-0.56 [-1.22 , 0.10]

37

100.0%

-0.41 [-0.86 , 0.04]

-2
Favours psychosocial

-1

0

1

2
Favours no intervention

Comparison 2.   Any psychosocial treatment versus treatment as usual (TAU)

Outcome or subgroup ti-
tle

No. of studies

No. of partici-
pants

Statistical method

Effect size

2.1 Dropouts

2.1.1 CBT

2.1.2 Contingency man-
agement

2.1.3 Motivational inter-
viewing

2.2 Point abstinence, end
of treatment

2.2.1 CBT

9

6

1

2

1

1

735

540

82

113

128

128

Risk Ratio (M-H, Random, 95% CI)

0.79 [0.65, 0.97]

Risk Ratio (M-H, Random, 95% CI)

0.76 [0.61, 0.95]

Risk Ratio (M-H, Random, 95% CI)

0.74 [0.49, 1.13]

Risk Ratio (M-H, Random, 95% CI)

1.46 [0.73, 2.91]

Risk Ratio (M-H, Random, 95% CI)

1.67 [0.64, 4.31]

Risk Ratio (M-H, Random, 95% CI)

1.67 [0.64, 4.31]

Psychosocial interventions for stimulant use disorder (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

175

 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup ti-
tle

No. of studies

No. of partici-
pants

Statistical method

Effect size

2.3 Point abstinence,
longest follow up

2.3.1 CBT

2.3.2 Motivational inter-
viewing

2.4 Continuous absti-
nence, end of treatment

2.4.1 CBT

2.5 Frequency of drug in-
take, end of treatment

2.5.1 CBT

2.5.2 Motivational inter-
viewing

2.5.3 Motivational inter-
viewing + CBT

2.5.4 Interpersonal thera-
py

2.6 Longest period of ab-
stinence

2.6.1 CBT

2.7 Craving

2.7.2 Motivational inter-
viewing

2.8 Severity of depen-
dence (ASI)

2.8.1 CBT

2.8.2 Motivational inter-
viewing

2.8.3 Contingency man-
agement

2.9 Depression

2

1

1

1

1

4

1

1

1

1

1

1

1

1

6

3

2

1

1

124

82

42

128

128

479

120

39

210

110

110

110

39

39

509

312

79

118

39

Risk Ratio (M-H, Random, 95% CI)

1.31 [0.86, 1.99]

Risk Ratio (M-H, Random, 95% CI)

1.65 [0.86, 3.18]

Risk Ratio (M-H, Random, 95% CI)

1.11 [0.64, 1.92]

Risk Ratio (M-H, Random, 95% CI)

1.18 [0.92, 1.53]

Risk Ratio (M-H, Random, 95% CI)

1.18 [0.92, 1.53]

Std. Mean Difference (IV, Random,
95% CI)

-1.17 [-2.81, 0.47]

Std. Mean Difference (IV, Random,
95% CI)

-4.76 [-5.47, -4.05]

Std. Mean Difference (IV, Random,
95% CI)

-0.25 [-0.89, 0.38]

Std. Mean Difference (IV, Random,
95% CI)

0.07 [-0.20, 0.34]

Std. Mean Difference (IV, Random,
95% CI)

0.15 [-0.22, 0.53]

Std. Mean Difference (IV, Random,
95% CI)

-0.16 [-0.54, 0.21]

Std. Mean Difference (IV, Random,
95% CI)

-0.16 [-0.54, 0.21]

Std. Mean Difference (IV, Random,
95% CI)

-0.18 [-0.81, 0.46]

Std. Mean Difference (IV, Random,
95% CI)

-0.18 [-0.81, 0.46]

Std. Mean Difference (IV, Random,
95% CI)

-0.42 [-1.15, 0.32]

Std. Mean Difference (IV, Random,
95% CI)

-0.89 [-2.10, 0.32]

Std. Mean Difference (IV, Random,
95% CI)

0.02 [-0.63, 0.67]

Std. Mean Difference (IV, Random,
95% CI)

0.18 [-0.24, 0.60]

Std. Mean Difference (IV, Fixed, 95%
CI)

-0.16 [-0.80, 0.47]

Psychosocial interventions for stimulant use disorder (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

176

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup ti-
tle

No. of studies

No. of partici-
pants

Statistical method

Effect size

2.9.1 Motivational inter-
viewing

1

39

Std. Mean Difference (IV, Fixed, 95%
CI)

-0.16 [-0.80, 0.47]

Analysis 2.1.   Comparison 2: Any psychosocial treatment versus treatment as usual (TAU), Outcome 1: Dropouts

Study or Subgroup

Events

Total

Events

Total

Weight

Any psychosocial intervention

TAU

Risk Ratio
M-H, Random, 95% CI

Risk Ratio
M-H, Random, 95% CI

Risk of Bias

A

B

C

D

2.1.1 CBT
Alammehrjerdi 2019
Carroll 1994
Dursteler-MacFarland 2013
Higgins 1993
Sanchez-Hervas 2010
Shoptaw 2008
Subtotal (95% CI)
Total events:
Heterogeneity: Tau² = 0.01; Chi² = 5.01, df = 4 (P = 0.29); I² = 20%
Test for overall effect: Z = 2.42 (P = 0.02)

0
34
8
8
21
24

95

2.1.2 Contingency management
Secades Villa 2013
Subtotal (95% CI)
Total events:
Heterogeneity: Not applicable
Test for overall effect: Z = 1.38 (P = 0.17)

21

21

2.1.3 Motivational interviewing
Ingersoll 2011
Sorsdahl 2021
Subtotal (95% CI)
Total events:
Heterogeneity: Tau² = 0.00; Chi² = 0.97, df = 1 (P = 0.33); I² = 0%
Test for overall effect: Z = 1.08 (P = 0.28)

1
13

14

60
58
32
19
47
64
280

47
47

27
30
57

Total (95% CI)
Total events:
Heterogeneity: Tau² = 0.02; Chi² = 9.09, df = 7 (P = 0.25); I² = 23%
Test for overall effect: Z = 2.24 (P = 0.02)
Test for subgroup differences: Chi² = 3.25, df = 2 (P = 0.20), I² = 38.4%

130

384

0
32
10
17
21
32

112

21

21

2
8

10

143

60
52
30
19
35
64
260

24.7%
5.9%
10.9%
16.6%
17.6%
75.8%

Not estimable
0.95 [0.70 , 1.29]
0.75 [0.34 , 1.64]
0.47 [0.27 , 0.82]
0.74 [0.49 , 1.13]
0.75 [0.50 , 1.12]
0.76 [0.61 , 0.95]

+
?
?
+
+
?

+
?
?
?
?
?

+
−

+
+
−

+

?
?
?
−

?
?

35
35

16.6%
16.6%

0.74 [0.49 , 1.13]
0.74 [0.49 , 1.13]

+

?

−

?

26
30
56

0.7%
6.9%
7.7%

0.48 [0.05 , 4.99]
1.63 [0.79 , 3.34]
1.46 [0.73 , 2.91]

?
+

?
?

−

+

?
?

351

100.0%

0.79 [0.65 , 0.97]

0.5
0.2
Favours psychosocial

1

2

5

Favours TAU

Risk of bias legend
(A) Random sequence generation (selection bias)
(B) Allocation concealment (selection bias)
(C) Incomplete outcome data (attrition bias)
(D) Selective reporting (reporting bias)

Psychosocial interventions for stimulant use disorder (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

177

 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 2.2.   Comparison 2: Any psychosocial treatment versus
treatment as usual (TAU), Outcome 2: Point abstinence, end of treatment

Study or Subgroup

Events

Total

Events

Total

Weight

Any psychosocial intervention

TAU

Risk Ratio
M-H, Random, 95% CI

Risk Ratio
M-H, Random, 95% CI

Risk of Bias

A

B

C

D

64
64

64

6

6

6

64
64

100.0%
100.0%

1.67 [0.64 , 4.31]
1.67 [0.64 , 4.31]

?

?

+

?

64

100.0%

1.67 [0.64 , 4.31]

0.01

0.1
Favours TAU

1

10

100

Favours psychosocial

2.2.1 CBT
Shoptaw 2008
Subtotal (95% CI)
Total events:
Heterogeneity: Not applicable
Test for overall effect: Z = 1.05 (P = 0.29)

10

10

Total (95% CI)
Total events:
Heterogeneity: Not applicable
Test for overall effect: Z = 1.05 (P = 0.29)
Test for subgroup differences: Not applicable

10

Risk of bias legend
(A) Random sequence generation (selection bias)
(B) Allocation concealment (selection bias)
(C) Incomplete outcome data (attrition bias)
(D) Selective reporting (reporting bias)

Analysis 2.3.   Comparison 2: Any psychosocial treatment versus
treatment as usual (TAU), Outcome 3: Point abstinence, longest follow up

Study or Subgroup

Events

Total

Events

Total

Weight

Any psychosocial intervention

TAU

Risk Ratio
M-H, Random, 95% CI

Risk Ratio
M-H, Random, 95% CI

Risk of Bias

A

B

C

D

2.3.1 CBT
Sanchez-Hervas 2010
Subtotal (95% CI)
Total events:
Heterogeneity: Not applicable
Test for overall effect: Z = 1.51 (P = 0.13)

2.3.2 Motivational interviewing
Ingersoll 2011
Subtotal (95% CI)
Total events:
Heterogeneity: Not applicable
Test for overall effect: Z = 0.37 (P = 0.71)

20

20

11

11

47
47

19
19

Total (95% CI)
Total events:
Heterogeneity: Tau² = 0.00; Chi² = 0.90, df = 1 (P = 0.34); I² = 0%
Test for overall effect: Z = 1.26 (P = 0.21)
Test for subgroup differences: Chi² = 0.84, df = 1 (P = 0.36), I² = 0%

66

31

9

9

12

12

21

35
35

41.3%
41.3%

1.65 [0.86 , 3.18]
1.65 [0.86 , 3.18]

+

?

−

?

23
23

58.7%
58.7%

1.11 [0.64 , 1.92]
1.11 [0.64 , 1.92]

?

?

−

?

58

100.0%

1.31 [0.86 , 1.99]

0.1

0.5
Favours psychosocial

0.2

1

2

5

10

Favours TAU

Risk of bias legend
(A) Random sequence generation (selection bias)
(B) Allocation concealment (selection bias)
(C) Incomplete outcome data (attrition bias)
(D) Selective reporting (reporting bias)

Psychosocial interventions for stimulant use disorder (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

178

 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 2.4.   Comparison 2: Any psychosocial treatment versus treatment
as usual (TAU), Outcome 4: Continuous abstinence, end of treatment

Study or Subgroup

Events

Total

Events

Total

Weight

Any psychosocial intervention

TAU

Risk Ratio
M-H, Random, 95% CI

Risk Ratio
M-H, Random, 95% CI

Risk of Bias

A

B

C

D

64
64

64

38

38

38

64
64

100.0%
100.0%

1.18 [0.92 , 1.53]
1.18 [0.92 , 1.53]

?

?

+

?

64

100.0%

1.18 [0.92 , 1.53]

0.1

0.2

0.5
Favours TAU

1

2

5

10

Favours psychosocial

2.4.1 CBT
Shoptaw 2008
Subtotal (95% CI)
Total events:
Heterogeneity: Not applicable
Test for overall effect: Z = 1.29 (P = 0.20)

45

45

Total (95% CI)
Total events:
Heterogeneity: Not applicable
Test for overall effect: Z = 1.29 (P = 0.20)
Test for subgroup differences: Not applicable

45

Risk of bias legend
(A) Random sequence generation (selection bias)
(B) Allocation concealment (selection bias)
(C) Incomplete outcome data (attrition bias)
(D) Selective reporting (reporting bias)

Analysis 2.5.   Comparison 2: Any psychosocial treatment versus treatment
as usual (TAU), Outcome 5: Frequency of drug intake, end of treatment

Study or Subgroup

Any psychosocial intervention
Total
SD
Mean

Mean

TAU
SD

Total

Weight

Std. Mean Difference
IV, Random, 95% CI

Std. Mean Difference
IV, Random, 95% CI

Risk of Bias

A

B

C

D

2.5.1 CBT
Alammehrjerdi 2019
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 13.15 (P < 0.00001)

5.2

3.77

2.5.2 Motivational interviewing
Sorsdahl 2021
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 0.78 (P = 0.44)

4.83

2.5.3 Motivational interviewing + CBT
Parsons 2018
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 0.52 (P = 0.60)

2.21

2.5.4 Interpersonal therapy
Carroll 1991
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 0.80 (P = 0.42)

0.27

7.86

4.49

0.19

60
60

17
17

105
105

58
58

18.8

1.39

60
60

24.5%
24.5%

-4.76 [-5.47 , -4.05]
-4.76 [-5.47 , -4.05]

6.43

4.62

22
22

24.7%
24.7%

-0.25 [-0.89 , 0.38]
-0.25 [-0.89 , 0.38]

1.93

3.18

105
105

25.5%
25.5%

0.07 [-0.20 , 0.34]
0.07 [-0.20 , 0.34]

0.24

0.2

52
52

25.3%
25.3%

0.15 [-0.22 , 0.53]
0.15 [-0.22 , 0.53]

+

+

+

?

+

?

+

?

+

?

+

?

?

?

−

?

Total (95% CI)
Heterogeneity: Tau² = 2.73; Chi² = 164.68, df = 3 (P < 0.00001); I² = 98%
Test for overall effect: Z = 1.40 (P = 0.16)
Test for subgroup differences: Chi² = 164.68, df = 3 (P < 0.00001), I² = 98.2%

240

239

100.0%

-1.17 [-2.81 , 0.47]

-2

-1

0

Any psychosocial intervention

1
TAU

2

Risk of bias legend
(A) Random sequence generation (selection bias)
(B) Allocation concealment (selection bias)
(C) Incomplete outcome data (attrition bias)
(D) Selective reporting (reporting bias)

Psychosocial interventions for stimulant use disorder (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

179

 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 2.6.   Comparison 2: Any psychosocial treatment versus
treatment as usual (TAU), Outcome 6: Longest period of abstinence

Study or Subgroup

Any psychosocial intervention
Total
SD
Mean

Mean

TAU
SD

Total

Weight

Std. Mean Difference
IV, Random, 95% CI

Std. Mean Difference
IV, Random, 95% CI

Risk of Bias

A

B

C

D

58
58

58

2.6.1 CBT
Carroll 1994
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 0.86 (P = 0.39)

19.25

16.5

Total (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 0.86 (P = 0.39)
Test for subgroup differences: Not applicable

Risk of bias legend
(A) Random sequence generation (selection bias)
(B) Allocation concealment (selection bias)
(C) Incomplete outcome data (attrition bias)
(D) Selective reporting (reporting bias)

22.4

21.4

52
52

100.0%
100.0%

-0.16 [-0.54 , 0.21]
-0.16 [-0.54 , 0.21]

?

?

−

?

52

100.0%

-0.16 [-0.54 , 0.21]

-1

-0.5
Favours TAU

0

0.5
Favours psychosocial

1

Analysis 2.7.   Comparison 2: Any psychosocial treatment versus treatment as usual (TAU), Outcome 7: Craving

Study or Subgroup

Any psychosocial intervention
Total
SD
Mean

Mean

TAU
SD

Total

Weight

Std. Mean Difference
IV, Random, 95% CI

Std. Mean Difference
IV, Random, 95% CI

2.7.2 Motivational interviewing
Sorsdahl 2021
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 0.55 (P = 0.58)

15.97

7.61

Total (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 0.55 (P = 0.58)
Test for subgroup differences: Not applicable

17
17

17

17.43

8.35

22
22

100.0%
100.0%

-0.18 [-0.81 , 0.46]
-0.18 [-0.81 , 0.46]

22

100.0%

-0.18 [-0.81 , 0.46]

-2
Any psychosocial intervention

-4

0

4

2
TAU

Psychosocial interventions for stimulant use disorder (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

180

 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 2.8.   Comparison 2: Any psychosocial treatment versus
treatment as usual (TAU), Outcome 8: Severity of dependence (ASI)

Study or Subgroup

Any psychosocial intervention
Total
SD
Mean

Mean

TAU
SD

Total

Weight

Std. Mean Difference
IV, Random, 95% CI

Std. Mean Difference
IV, Random, 95% CI

2.8.1 CBT
Alammehrjerdi 2019
Carroll 1994
Sanchez-Hervas 2010
Subtotal (95% CI)
Heterogeneity: Tau² = 1.10; Chi² = 49.39, df = 2 (P < 0.00001); I² = 96%
Test for overall effect: Z = 1.44 (P = 0.15)

2.9
0.24
0.098

60
58
47
165

3.8
0.38
0.03

2.8.2 Motivational interviewing
Ingersoll 2011
18
17
Sorsdahl 2021
35
Subtotal (95% CI)
Heterogeneity: Tau² = 0.11; Chi² = 2.09, df = 1 (P = 0.15); I² = 52%
Test for overall effect: Z = 0.06 (P = 0.95)

0.11
4.03

0.09
1.65

9.8
0.43
0.06

2.59
0.22
0.107

60
52
35
147

16.9%
17.2%
17.0%
51.1%

-2.17 [-2.62 , -1.71]
-0.22 [-0.59 , 0.16]
-0.29 [-0.73 , 0.15]
-0.89 [-2.10 , 0.32]

0.08
4.57

0.08
1.72

22
22
44

15.9%
15.9%
31.8%

0.35 [-0.28 , 0.98]
-0.31 [-0.95 , 0.32]
0.02 [-0.63 , 0.67]

2.8.3 Contingency management
Roll 2013
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 0.82 (P = 0.41)

0.0396

0.0766

0.027

0.05

89
89

29
29

17.1%
17.1%

0.18 [-0.24 , 0.60]
0.18 [-0.24 , 0.60]

Total (95% CI)
Heterogeneity: Tau² = 0.77; Chi² = 72.02, df = 5 (P < 0.00001); I² = 93%
Test for overall effect: Z = 1.12 (P = 0.26)
Test for subgroup differences: Chi² = 2.66, df = 2 (P = 0.26), I² = 24.8%

289

220

100.0%

-0.42 [-1.15 , 0.32]

-4

-2
Favours TAU

0

2

4

Favours psychosocial

Analysis 2.9.   Comparison 2: Any psychosocial treatment versus treatment as usual (TAU), Outcome 9: Depression

Study or Subgroup

Any psychosocial interven
Total
SD
Mean

Mean

TAU
SD

Total

Weight

Std. Mean Difference
IV, Fixed, 95% CI

Std. Mean Difference
IV, Fixed, 95% CI

2.9.1 Motivational interviewing
Sorsdahl 2021
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 0.51 (P = 0.61)

10.2

6.5

Total (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 0.51 (P = 0.61)
Test for subgroup differences: Not applicable

17
17

17

11.23

5.83

22
22

100.0%
100.0%

-0.16 [-0.80 , 0.47]
-0.16 [-0.80 , 0.47]

22

100.0%

-0.16 [-0.80 , 0.47]

-2
Any psychosocial intervention

-1

0

1

TAU

2

Comparison 3.   Contingency management (CM) reinforcement versus non-contingency management (non-CM)
reinforcement

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

3.1 Dropouts

3.2 Point abstinence, longest fol-
low-up

3.3 Continuous abstinence, end
of treatment

6

2

2

704

246

96

Risk Ratio (M-H, Random, 95%
CI)

0.86 [0.56, 1.32]

Risk Ratio (M-H, Fixed, 95% CI)

1.43 [1.00, 2.04]

Risk Ratio (M-H, Random, 95%
CI)

8.11 [1.62, 40.55]

Psychosocial interventions for stimulant use disorder (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

181

 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

3.4 Frequency of drug intake,
end of treatment

3.5 Severity of dependence

1

1

176

70

Std. Mean Difference (IV, Fixed,
95% CI)

-0.67 [-0.97, -0.36]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

0.16 [-0.30, 0.63]

Analysis 3.1.   Comparison 3: Contingency management (CM) reinforcement versus
non-contingency management (non-CM) reinforcement, Outcome 1: Dropouts

Study or Subgroup

CM reinforcement
Total
Events

Non-CM reinforcement

Events

Total

Weight

Risk Ratio
M-H, Random, 95% CI

Risk Ratio
M-H, Random, 95% CI

Higgins 2000
Landovitz 2015
McDonell 2013
Poling 2006
Schottenfeld 2011
Silverman 1996

16
14
53
22
27
2

36
70
91
52
73
19

16
44
30
22
41
3

Total (95% CI)
134
Total events:
Heterogeneity: Tau² = 0.20; Chi² = 22.92, df = 5 (P = 0.0004); I² = 78%
Test for overall effect: Z = 0.68 (P = 0.50)
Test for subgroup differences: Not applicable

156

341

34
100
85
54
72
18

17.7%
17.6%
20.6%
18.7%
20.2%
5.2%

0.94 [0.57 , 1.57]
0.45 [0.27 , 0.76]
1.65 [1.18 , 2.31]
1.04 [0.66 , 1.63]
0.65 [0.45 , 0.93]
0.63 [0.12 , 3.35]

363

100.0%

0.86 [0.56 , 1.32]

0.5
Favours CM reinforcement

0.1

0.2

1

2

10
Favours non-CM reinforcement

5

Analysis 3.2.   Comparison 3: Contingency management (CM) reinforcement versus non-
contingency management (non-CM) reinforcement, Outcome 2: Point abstinence, longest follow-up

Study or Subgroup

CM reinforcement
Total
Events

Non-CM reinforcement

Events

Total

Weight

Risk Ratio
M-H, Fixed, 95% CI

Risk Ratio
M-H, Fixed, 95% CI

Higgins 2000
McDonell 2013

7
42

36
91

Total (95% CI)
Total events:
Heterogeneity: Chi² = 1.43, df = 1 (P = 0.23); I² = 30%
Test for overall effect: Z = 1.98 (P = 0.05)
Test for subgroup differences: Not applicable

127

49

2
30

32

34
85

6.2%
93.8%

3.31 [0.74 , 14.81]
1.31 [0.91 , 1.88]

119

100.0%

1.43 [1.00 , 2.04]

0.5
0.1
Favours non-CM reinforcement

0.2

1

2

5

10

Favours CM reinforcement

Analysis 3.3.   Comparison 3: Contingency management (CM) reinforcement versus non-contingency
management (non-CM) reinforcement, Outcome 3: Continuous abstinence, end of treatment

Study or Subgroup

CM reinforcement
Total
Events

Non-CM reinforcement

Events

Total

Weight

Risk Ratio
M-H, Random, 95% CI

Risk Ratio
M-H, Random, 95% CI

Silverman 1996
Silverman 1998

9
7

19
40

1
0

18
19

67.2%
32.8%

8.53 [1.20 , 60.70]
7.32 [0.44 , 121.82]

Total (95% CI)
Total events:
Heterogeneity: Tau² = 0.00; Chi² = 0.01, df = 1 (P = 0.93); I² = 0%
Test for overall effect: Z = 2.55 (P = 0.01)
Test for subgroup differences: Not applicable

16

59

1

37

100.0%

8.11 [1.62 , 40.55]

0.01
Favours non-CM reinforcement

0.1

1

10

100

Favours CM reinforcement

Psychosocial interventions for stimulant use disorder (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

182

 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 3.4.   Comparison 3: Contingency management (CM) reinforcement versus non-contingency
management (non-CM) reinforcement, Outcome 4: Frequency of drug intake, end of treatment

Study or Subgroup

CM reinforcement
SD

Total

Mean

McDonell 2013

0.91

2.4

Total (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 4.30 (P < 0.0001)
Test for subgroup differences: Not applicable

91

91

Non-CM reinforcement
Total
SD

Mean

Weight

Std. Mean Difference
IV, Fixed, 95% CI

Std. Mean Difference
IV, Fixed, 95% CI

4.67

7.69

85

100.0%

-0.67 [-0.97 , -0.36]

85

100.0%

-0.67 [-0.97 , -0.36]

-2

-1

Favours CM reinforcement

0

1

2
Favours non-CM reinforcement

Analysis 3.5.   Comparison 3: Contingency management (CM) reinforcement versus non-
contingency management (non-CM) reinforcement, Outcome 5: Severity of dependence

Study or Subgroup

CM reinforcement
SD

Total

Mean

Higgins 2000

0.14

0.06

Total (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 0.69 (P = 0.49)
Test for subgroup differences: Not applicable

36

36

Non-CM reinforcement
Total
SD

Mean

Weight

Std. Mean Difference
IV, Random, 95% CI

Std. Mean Difference
IV, Random, 95% CI

0.13

0.06

34

100.0%

0.16 [-0.30 , 0.63]

34

100.0%

0.16 [-0.30 , 0.63]

-2
Favours CM reinforcement

-1

0

1

2

Favours non-CM reinforcement

Comparison 4.   Cognitive behavioural therapy (CBT) versus other psychosocial interventions

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

4.1 Dropouts

4.1.1 Interpersonal therapy

4.1.2 Psychodynamic therapy

4.1.3 12-step facilitation

4.1.4 Acceptance and commit-
ment therapy

4.2 Point abstinence, end of
treatment

4.2.1 Interpersonal therapy

4.2.2 Psychodynamic therapy

4.2.3 Contingency management

4.2.4 Acceptance and commit-
ment therapy

4.3 Point abstinence, longest
follow-up

4

1

1

1

1

4

1

1

1

1

3

42

243

145

104

42

243

55

26

Risk Ratio (M-H, Random, 95% CI)

Subtotals only

Risk Ratio (M-H, Random, 95% CI)

0.54 [0.27, 1.08]

Risk Ratio (M-H, Random, 95% CI)

0.99 [0.83, 1.18]

Risk Ratio (M-H, Random, 95% CI)

0.87 [0.62, 1.24]

Risk Ratio (M-H, Random, 95% CI)

0.94 [0.73, 1.20]

Risk Ratio (M-H, Random, 95% CI)

Subtotals only

Risk Ratio (M-H, Random, 95% CI)

1.71 [0.84, 3.48]

Risk Ratio (M-H, Random, 95% CI)

0.87 [0.66, 1.15]

Risk Ratio (M-H, Random, 95% CI)

0.66 [0.38, 1.16]

Risk Ratio (M-H, Random, 95% CI)

1.29 [0.47, 3.51]

Risk Ratio (M-H, Fixed, 95% CI)

Subtotals only

Psychosocial interventions for stimulant use disorder (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

183

 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

4.3.1 Psychodynamic therapy

4.3.2 Contingency management

4.3.3 Acceptance and commit-
ment therapy

4.4 Continuous abstinence, end
of treatment

4.4.1 Interpersonal therapy

4.4.2 12-step facilitation

4.5 Continuous abstinence,
longest follow-up

4.5.1 12-step facilitation

4.6 Frequency of drug intake,
end of treatment

4.6.1 Contingency management

4.7 Longest period of absti-
nence

4.8 Severity of dependence

4.8.2 Acceptance and commit-
ment therapy

4.9 Depression

4.9.1 Acceptance and commit-
ment therapy

1

1

1

3

1

2

1

1

1

1

1

1

1

1

1

243

55

19

42

225

51

82

104

104

104

Risk Ratio (M-H, Fixed, 95% CI)

1.04 [0.82, 1.32]

Risk Ratio (M-H, Fixed, 95% CI)

1.17 [0.73, 1.87]

Risk Ratio (M-H, Fixed, 95% CI)

0.73 [0.26, 2.07]

Risk Ratio (M-H, Fixed, 95% CI)

Subtotals only

Risk Ratio (M-H, Fixed, 95% CI)

2.25 [0.82, 6.18]

Risk Ratio (M-H, Fixed, 95% CI)

1.23 [0.89, 1.70]

Risk Ratio (M-H, Fixed, 95% CI)

Subtotals only

Risk Ratio (M-H, Fixed, 95% CI)

1.97 [1.00, 3.86]

Std. Mean Difference (IV, Fixed,
95% CI)

Subtotals only

Std. Mean Difference (IV, Fixed,
95% CI)

-0.09 [-0.53, 0.34]

Std. Mean Difference (IV, Fixed,
95% CI)

Subtotals only

Std. Mean Difference (IV, Random,
95% CI)

Subtotals only

Std. Mean Difference (IV, Random,
95% CI)

-0.02 [-0.40, 0.37]

Std. Mean Difference (IV, Random,
95% CI)

0.18 [-0.21, 0.56]

Std. Mean Difference (IV, Random,
95% CI)

0.18 [-0.21, 0.56]

Psychosocial interventions for stimulant use disorder (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

184

 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 4.1.   Comparison 4: Cognitive behavioural therapy (CBT)
versus other psychosocial interventions, Outcome 1: Dropouts

Study or Subgroup

Events

Total

Events

Total

Weight

CBT

Other psychosocial intervention

Risk Ratio
M-H, Random, 95% CI

Risk Ratio
M-H, Random, 95% CI

4.1.1 Interpersonal therapy
Carroll 1991
Subtotal (95% CI)
Total events:
Heterogeneity: Not applicable
Test for overall effect: Z = 1.75 (P = 0.08)

7

7

4.1.2 Psychodynamic therapy
Crits-Christoph 1999 arm 1
Subtotal (95% CI)
Total events:
Heterogeneity: Not applicable
Test for overall effect: Z = 0.09 (P = 0.93)

79

79

4.1.3 12-step facilitation
Schottenfeld 2011
Subtotal (95% CI)
Total events:
Heterogeneity: Not applicable
Test for overall effect: Z = 0.76 (P = 0.45)

31

31

4.1.4 Acceptance and commitment therapy
Smout 2010
Subtotal (95% CI)
Total events:
Heterogeneity: Not applicable
Test for overall effect: Z = 0.52 (P = 0.61)

36

36

21
21

119
119

71
71

53
53

13

13

83

83

37

37

37

37

21
21

100.0%
100.0%

0.54 [0.27 , 1.08]
0.54 [0.27 , 1.08]

124
124

100.0%
100.0%

0.99 [0.83 , 1.18]
0.99 [0.83 , 1.18]

74
74

100.0%
100.0%

0.87 [0.62 , 1.24]
0.87 [0.62 , 1.24]

51
51

100.0%
100.0%

0.94 [0.73 , 1.20]
0.94 [0.73 , 1.20]

Test for subgroup differences: Chi² = 3.01, df = 3 (P = 0.39), I² = 0.4%

0.5
Favours other psychosocial

0.2

1

2

5

Favours CBT

Psychosocial interventions for stimulant use disorder (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

185

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 4.2.   Comparison 4: Cognitive behavioural therapy (CBT) versus other
psychosocial interventions, Outcome 2: Point abstinence, end of treatment

Study or Subgroup

Events

Total

Events

Total

Weight

CBT

Other psychosocial intervention

Risk Ratio
M-H, Random, 95% CI

Risk Ratio
M-H, Random, 95% CI

4.2.1 Interpersonal therapy
Carroll 1991
Subtotal (95% CI)
Total events:
Heterogeneity: Not applicable
Test for overall effect: Z = 1.49 (P = 0.14)

12

12

4.2.2 Psychodynamic therapy
Crits-Christoph 1999 arm 1
Subtotal (95% CI)
Total events:
Heterogeneity: Not applicable
Test for overall effect: Z = 0.99 (P = 0.32)

50

50

4.2.3 Contingency management
Rawson 2002 arm 4
Subtotal (95% CI)
Total events:
Heterogeneity: Not applicable
Test for overall effect: Z = 1.45 (P = 0.15)

11

11

4.2.4 Acceptance and commitment therapy
Smout 2010
Subtotal (95% CI)
Total events:
Heterogeneity: Not applicable
Test for overall effect: Z = 0.49 (P = 0.62)

6

6

21
21

119
119

28
28

14
14

7

7

60

60

16

16

4

4

21
21

100.0%
100.0%

1.71 [0.84 , 3.48]
1.71 [0.84 , 3.48]

124
124

100.0%
100.0%

0.87 [0.66 , 1.15]
0.87 [0.66 , 1.15]

27
27

100.0%
100.0%

0.66 [0.38 , 1.16]
0.66 [0.38 , 1.16]

12
12

100.0%
100.0%

1.29 [0.47 , 3.51]
1.29 [0.47 , 3.51]

Test for subgroup differences: Chi² = 4.87, df = 3 (P = 0.18), I² = 38.4%

0.2
Favours other psychosocial

0.5

1

2

5
Favours CBT

Analysis 4.3.   Comparison 4: Cognitive behavioural therapy (CBT) versus other
psychosocial interventions, Outcome 3: Point abstinence, longest follow-up

Study or Subgroup

Events

Total

Events

Total

Weight

CBT

Other psychosocial intervention

Risk Ratio
M-H, Fixed, 95% CI

Risk Ratio
M-H, Fixed, 95% CI

4.3.1 Psychodynamic therapy
Crits-Christoph 1999 arm 1
Subtotal (95% CI)
Total events:
Heterogeneity: Not applicable
Test for overall effect: Z = 0.34 (P = 0.73)

64

64

4.3.2 Contingency management
Rawson 2002 arm 4
Subtotal (95% CI)
Total events:
Heterogeneity: Not applicable
Test for overall effect: Z = 0.66 (P = 0.51)

17

17

4.3.3 Acceptance and commitment therapy
Smout 2010
Subtotal (95% CI)
Total events:
Heterogeneity: Not applicable
Test for overall effect: Z = 0.60 (P = 0.55)

4

4

119
119

28
28

11
11

64

64

14

14

4

4

124
124

100.0%
100.0%

1.04 [0.82 , 1.32]
1.04 [0.82 , 1.32]

27
27

100.0%
100.0%

1.17 [0.73 , 1.87]
1.17 [0.73 , 1.87]

8
8

100.0%
100.0%

0.73 [0.26 , 2.07]
0.73 [0.26 , 2.07]

Test for subgroup differences: Chi² = 0.69, df = 2 (P = 0.71), I² = 0%

Psychosocial interventions for stimulant use disorder (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

0.5
Favours other psychosocial

0.1

0.2

1

2

5

10

Favours CBT

186

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 4.4.   Comparison 4: Cognitive behavioural therapy (CBT) versus other
psychosocial interventions, Outcome 4: Continuous abstinence, end of treatment

Study or Subgroup

Events

Total

Events

Total

Weight

CBT

Other psychosocial interventions

Risk Ratio
M-H, Fixed, 95% CI

Risk Ratio
M-H, Fixed, 95% CI

4.4.1 Interpersonal therapy
Carroll 1991
Subtotal (95% CI)
Total events:
Heterogeneity: Not applicable
Test for overall effect: Z = 1.57 (P = 0.12)

9

9

21
21

4.4.2 12-step facilitation
Carroll 1998
Maude-Griffin 1998
Subtotal (95% CI)
Total events:
Heterogeneity: Chi² = 0.62, df = 1 (P = 0.43); I² = 0%
Test for overall effect: Z = 1.23 (P = 0.22)

47
59
106

20
26

46

4

4

20
22

42

21
21

100.0%
100.0%

2.25 [0.82 , 6.18]
2.25 [0.82 , 6.18]

50
69
119

48.9%
51.1%
100.0%

1.06 [0.66 , 1.71]
1.38 [0.88 , 2.17]
1.23 [0.89 , 1.70]

Test for subgroup differences: Chi² = 1.25, df = 1 (P = 0.26), I² = 20.3%

0.5
Favours other psychosocial

0.2

0.1

1

2

5

10

Favours CBT

Analysis 4.5.   Comparison 4: Cognitive behavioural therapy (CBT) versus other
psychosocial interventions, Outcome 5: Continuous abstinence, longest follow-up

Study or Subgroup

Events

Total

Events

Total

Weight

CBT

Other psychosocial interventions

Risk Ratio
M-H, Fixed, 95% CI

Risk Ratio
M-H, Fixed, 95% CI

4.5.1 12-step facilitation
Carroll 1998
Subtotal (95% CI)
Total events:
Heterogeneity: Not applicable
Test for overall effect: Z = 1.97 (P = 0.05)

14

14

24
24

8

8

27
27

100.0%
100.0%

1.97 [1.00 , 3.86]
1.97 [1.00 , 3.86]

Test for subgroup differences: Not applicable

0.5
Favours other psychosocial

0.2

0.1

1

2

5

10

Favours CBT

Analysis 4.6.   Comparison 4: Cognitive behavioural therapy (CBT) versus other
psychosocial interventions, Outcome 6: Frequency of drug intake, end of treatment

Study or Subgroup

Mean

CBT
SD

Total

Other psychosocial intervention
Total
SD
Mean

Weight

Std. Mean Difference
IV, Fixed, 95% CI

Std. Mean Difference
IV, Fixed, 95% CI

4.6.1 Contingency management
Shoptaw 2005 arm 1
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 0.42 (P = 0.67)

2.2

Test for subgroup differences: Not applicable

6

40
40

2.7

4.6

42
42

100.0%
100.0%

-0.09 [-0.53 , 0.34]
-0.09 [-0.53 , 0.34]

-2

-1
Favours CBT

0

1

2

Favours other psychosocial

Psychosocial interventions for stimulant use disorder (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

187

 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 4.7.   Comparison 4: Cognitive behavioural therapy (CBT) versus
other psychosocial interventions, Outcome 7: Longest period of abstinence

Study or Subgroup

Mean

CBT
SD

Total

Other psychosocial interventions
Total
SD
Mean

Std. Mean Difference
IV, Fixed, 95% CI

Std. Mean Difference
IV, Fixed, 95% CI

Shoptaw 2005 arm 1

2.1

2

40

5.1

4.9

42

-0.79 [-1.24 , -0.34]

Test for subgroup differences: Not applicable

-2

-1

Favours other psychosocial

0

1
Favours CBT

2

Analysis 4.8.   Comparison 4: Cognitive behavioural therapy (CBT) versus
other psychosocial interventions, Outcome 8: Severity of dependence

Study or Subgroup

Mean

CBT
SD

Total

Other psychosocial interventions
Total
SD
Mean

Weight

Std. Mean Difference
IV, Random, 95% CI

Std. Mean Difference
IV, Random, 95% CI

4.8.2 Acceptance and commitment therapy
55
Smout 2010
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 0.08 (P = 0.94)

18.2

Test for subgroup differences: Not applicable

53
53

19

49

51
51

100.0%
100.0%

-0.02 [-0.40 , 0.37]
-0.02 [-0.40 , 0.37]

-2

-1
Favours CBT

0

1

2

Favours other psychosocial

Analysis 4.9.   Comparison 4: Cognitive behavioural therapy (CBT)
versus other psychosocial interventions, Outcome 9: Depression

Study or Subgroup

Mean

CBT
SD

Total

Other psychosocial intervention
Total
SD
Mean

Weight

Std. Mean Difference
IV, Random, 95% CI

Std. Mean Difference
IV, Random, 95% CI

4.9.1 Acceptance and commitment therapy
12.2
Smout 2010
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 0.90 (P = 0.37)

17.7

Total (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 0.90 (P = 0.37)
Test for subgroup differences: Not applicable

53
53

53

15.4

13.6

51
51

100.0%
100.0%

0.18 [-0.21 , 0.56]
0.18 [-0.21 , 0.56]

51

100.0%

0.18 [-0.21 , 0.56]

-2

-1
Favours CBT

0

1

2

Favours other psychosocial

A P P E N D I C E S

Appendix 1. Cochrane Drug and Alcohol Group Specialised Register search strategy

CDAG Specialised register (via CRSLive)

from 2015 to 26 September 2023 (43 hits)

#1 (amphetamine* OR cocaine OR diethylpropion OR ephedrine OR methylphenidate OR pemoline OR phenmetrazine OR phendimetrazine
OR phenylpropanolamine OR phenilpropanolamine OR psychostimulant*):ti,xdi AND INREGISTER

#2 (counsel* OR psychoeducat* OR educat*):ti,ab,xin AND INREGISTER

#3 (psychological NEAR2 (therap* OR treatment*)):ti,ab,xin AND INREGISTER

#4 ((social OR peer OR group) NEAR2 support) OR (self NEXT help) OR (cognitive NEAR2 (therap* OR behav*)):ti,ab,xin AND REGISTER

#5 CBT:ti,xin AND INREGISTER

Psychosocial interventions for stimulant use disorder (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

188

 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

#6 (mindfulness OR relax* OR (family OR couple) NEAR2 therap*):ti,ab,xin AND INREGISTER

#7 "Contingency Management" AND INREGISTER

#8 CM:ti,ab,xin AND INREGISTER

#9  incentive*  OR  voucher  OR  psychotherap*  OR  psychosocial*  OR  reinforcement  OR  motivation*  OR  contingent*  OR  advice  AND
INREGISTER

#10 #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9

#11 #1 AND #10

#12 >2014:YR AND INREGISTER

#13 #11 AND #12

Appendix 2. CENTRAL search strategy

CENTRAL (via onlinelibrary.wiley.com)

Cochrane Library issue 9, 2023 (468 hits)

1. MeSH descriptor: [Substance-Related Disorders] explode all trees
2. ((psychostimulant* or polydrug* or drug* or substance) near/3 (abuse* or abusing or depend* or addict* or disorder*)):ti,ab
3. #1 or #2
4. MeSH descriptor: [Psychotherapy] explode all trees
5. psychotherap* or psychosocial or voucher or reinforcement or motivation* or contingent* or biofeedback or community or stimulation

or education* or counsel*:ti,ab,kw

6. (social near/2 skill*):ti,ab
7. (coping near/2 skill):ti,ab
8. MeSH descriptor: [Counseling] explode all trees
9. (behavi* near/2 therap*):ti,ab
10.MeSH descriptor: [Reinforcement (Psychology)] explode all trees
11.(brief near intervention):ti,ab
12.(early near intervention):ti,ab
13.(minimal near intervention):ti,ab
14.(cognitive near therapy):ti,ab
15.(family near therapy):ti,ab
16.(stress near management near training):ti,ab
17.(supportive near expressive near therapy):ti,ab
18.MeSH descriptor: [Social Support] explode all trees
19.MeSH descriptor: [Case Management] explode all trees
20.(self near control near training):ti,ab
21.neurobehavioral*:ab,ti
22.#4 or #5 or #6 or #7 or #8 or #9 or #10 or #11 or #12 or #13 or #14 or #15 or #16 or #17 or #18 or #19 or #20 or #21
23.amphetamine:ti,ab,kw (Word variations have been searched)
24.diethylpropion:ti,ab,kw (Word variations have been searched)
25.methylphenidate:ti,ab,kw (Word variations have been searched)
26.pemoline:ti,ab,kw (Word variations have been searched)
27.phenmetrazine:ti,ab,kw (Word variations have been searched)
28.phendimetrazine:ti,ab,kw (Word variations have been searched)
29.phenylpropanolamine:ti,ab,kw (Word variations have been searched)
30.Phenylpropanolamine:ti,ab,kw (Word variations have been searched)
31.ephedrine:ti,ab,kw (Word variations have been searched)
32.cocaine:ti,ab,kw (Word variations have been searched)
33.#23 or #24 or #25 or #26 or #27 or #28 or #29 or #30 or #31 or #32
34.#3 and #22 and #33 with Publication Year from 2015 to present, in Trials

Psychosocial interventions for stimulant use disorder (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

189

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Appendix 3. MEDLINE search strategy

Ovid MEDLINE

From 2015 to 26 September 2023 (580 hits)

Cochrane Database of Systematic Reviews

1. ((stimulant* or psychostimulant* or psycho-stimulant*) adj5 (abstain* or abstinence or abstinent or abuse* or addict* or chronic* or
detox* or disorder* or depend* or habitual* or misuse* or overuse or reduce* or reducing or reduction or retain* or retention or users
or withdrawal)).tw,hw,id.

2. Cocaine-Related Disorders/ or ((cocaine* or crack-cocaine*) adj5 (abuse* or addict* or chronic* or disorder* or depend* or habitual* or

misuse* or overuse or users)).tw,kf.

3. Amphetamine-Related Disorders/ or (methamphetamine* adj5 (abuse* or addict* or chronic* or disorder* or depend* or habitual* or

misuse* or overuse or users)).tw,kf.

4. 1 or 2 or 3
5. ((drug  or  polydrug*  or  substance  or  stimulant*  or  psychostimulant*  or  psycho-stimulant*)  and  (abuse*  or  addict*  or  disorder*  or

depend* or misuse* or overuse or users)).tw,kf.

6. substance-related disorders/ or drug overdose/ or substance abuse, intravenous/ or substance withdrawal syndrome/
7. 5 or 6
8. Amphetamine/  or  Diethylpropion/  or  Methylphenidate/  or  Pemoline/  or  Phenmetrazine/  or  Phenylpropanolamine/  or  Ephedrine/
or  Cocaine/  or  Crack  Cocaine/  or  (amphetamine*  or  diethylpropion*or  methylphenidate  or  methilphenidate  or  pemoline  or
phenmetrazine or phendimetrazine or phenilpropanolamine or phenylpropanolamine or ephedrine or cocaine or crack).tw.

9. 7 and 8
10.4 or 9
11.exp Psychotherapy/
12.(psychotherap* or psychosocial or voucher or reinforcement or motivation* or contingent* or biofeedback or community or stimulation

or education* or counsel*).tw.

13.(social adj2 skill*).tw.
14.(coping adj2 skill).tw.
15.exp Counseling/
16.(behavi* adj2 therap*).tw.
17.exp Reinforcement, Psychology/
18.((brief or minimal or early or motivat$) adj3 (intervention$ or therap$ or interview$ or advice)).tw.
19.(cognitive adj3 therapy).tw.
20.(family adj2 therapy).tw.
21.stress management training.tw.
22.supportive expressive therapy.tw.
23.exp Social Support/
24.exp Case Management/
25.self control training.tw.
26.(behavio* adj2 (change or modification)).tw.
27.CBT.tw.
28.psychodynamic*.tw.
29.talking therap*.tw.
30.((self adj2 help adj2 group$) or (twelve adj2 step) or 12-step).ti,ab.
31.or/11-30
32.10 and 31
33.randomized controlled trial.pt.
34.controlled clinical trial.pt.
35.random*.ab.
36.placebo.ab.
37.clinical trials as topic.sh.
38.39 random allocation.sh.
39.trial.ti.
40.33 or 34 or 35 or 36 or 37 or 38 or 39
41.exp animals/ not humans.sh.

Psychosocial interventions for stimulant use disorder (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

190

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

42.40 not 41
43.32 and 42
44.limit 43 to yr="2015 -Current"

Appendix 4. Embase search strategy

Ovid Embase

From 2015 to 26 September 2023 (1100 hits)

Cochrane Database of Systematic Reviews

1. ((stimulant* or psychostimulant* or psycho-stimulant*) adj5 (abstain* or abstinence or abstinent or abuse* or addict* or chronic* or
detox* or disorder* or depend* or habitual* or misuse* or overuse or reduce* or reducing or reduction or retain* or retention or users
or withdrawal)).tw,kf.

2. cocaine dependence/ or ((cocaine* or crack-cocaine*) adj5 (abuse* or addict* or chronic* or disorder* or depend* or habitual* or misuse*

or overuse or users)).tw,kf.

3. amphetamine dependence/ or (methamphetamine* adj5 (abuse* or addict* or chronic* or disorder* or depend* or habitual* or misuse*

or overuse or users)).tw,kf.

4. 1 or 2 or 3
5. ((drug  or  polydrug*  or  substance  or  stimulant*  or  psychostimulant*  or  psycho-stimulant*)  and  (abuse*  or  addict*  or  disorder*  or

depend* or misuse* or overuse or users)).tw,kf.

6. drug dependence/ or amphetamine dependence/ or cocaine dependence/ or drug abuse pattern/ or drug craving/ or drug misuse/ or

drug seeking behavior/ or methamphetamine dependence/ or multiple drug abuse/

7. 5 or 6
8. Amphetamine/  or  Diethylpropion/  or  Methylphenidate/  or  Pemoline/  or  Phenmetrazine/  or  Phenylpropanolamine/  or  Ephedrine/
or  Cocaine/  or  Crack  Cocaine/  or  (amphetamine*  or  diethylpropion*or  methylphenidate  or  methilphenidate  or  pemoline  or
phenmetrazine or phendimetrazine or phenilpropanolamine or phenylpropanolamine or ephedrine or cocaine or crack).tw.

9. 7 and 8
10.4 or 9
11.exp psychotherapy/
12.(psychotherap* or psychosocial or voucher or reinforcement or motivation* or contingent* or biofeedback or community or stimulation

or education* or counsel*).tw.

13.(social adj2 skill*).tw.
14.(coping adj2 skill).tw.
15.exp counseling/
16.(behavi* adj2 therap*).tw.
17.exp "reinforcement (psychology)"/
18.((brief or minimal or early or motivat$) adj3 (intervention$ or therap$ or interview$ or advice)).tw.
19.(cognitive adj3 therapy).tw.
20.(family adj2 therapy).tw.
21.stress management training.tw.
22.supportive expressive therapy.tw.
23.exp social support/
24.exp case management/
25.self control training.tw.
26.(behavio* adj2 (change or modification)).tw.
27.(behavio* adj2 (change or modification)).tw. (40445)
28.CBT.tw. (18921)
29.psychodynamic*.tw. (9606)
30.talking therap*.tw. (236)
31.((self adj2 help adj2 group$) or (twelve adj2 step) or 12-step).ti,ab. (4122)
32.contingency management.mp. (1598)
33.financial incentives.mp. (5548)
34.11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28 or 29 or 30 or 31 or 32 or 33
35.10 and 34
36.Clinical-Trial/  or  Randomized-Controlled-Trial/  or  Randomization/  or  Single-Blind-Procedure/  or  Double-Blind-Procedure/  or

Crossover-Procedure/ or Prospective-Study/ or Placebo/

Psychosocial interventions for stimulant use disorder (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

191

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

37.(((clinical or control or controlled) adj (study or trial)) or ((single or double or triple) adj (blind$3 or mask$3)) or (random$ adj (assign
$ or allocat$ or group or grouped or patients or study or trial or distribut$)) or (crossover adj (design or study or trial)) or placebo or
placebos).ti,ab.

38.36 or 37
39.35 and 38
40.limit 39 to yr="2015 -Current"

Appendix 5. CINAHL search strategy

CINAHL (via EBSCO HOST)

from 2015 to 26 September 2023 (354 hits)

1. (MH "Substance Use Disorders+")
2. TX(drug N3 addict*) or TX(drug N3 dependen*) or TX(drug N3 abuse*) or TX(drug N3 misus*)
3. TX(substance N3 addict*) or TX(substance N3 dependen*) or TX(substance N3 abuse*) or TX(substance N3 misus*)
4. TX(addict* OR overdos* OR intoxicat* OR abstin* OR abstain OR withdraw* OR abus* OR misus* OR disorder* OR dependen*)
5. TX(use* N2 drug) or TX(use* N2 disorder) or TX(use* N2 illicit)
6. S1 OR S2 OR S3 OR S4 OR S5
7. (MH "Amphetamines+")
8. TI amphetamine* OR AB amphetamine*
9. TI Diethylpropion OR AB Diethylpropion
10.(MH "Methylphenidate") OR TX methylphenidate OR TX methilphenidate
11.TX pemoline
12.TI Phenmetrazine OR AB Phenmetrazine
13.MH  Phenylpropanolamine  OR  TI  phenilpropanolamine  OR  AB  phenilpropanolamine  OR  TI  phenylpropanolamine  OR  AB

phenylpropanolamine

14.TX Ephedrine
15.MH Cocaine OR TI Cocaine OR AB Cocaine
16.S7 OR S8 OR S9 OR S10 OR S11 OR S12 OR S13 OR S14 OR S15
17.S6 AND S16
18.TX((psychostimulant* ) N3 (abuse* OR dependence* OR disorder* OR addict*))
19.S17 OR S18
20.(MM "Counseling")
21.(MH "Motivational Interviewing")
22.(MH "Psychotherapy+")
23.TI incentive* OR voucher OR psychotherap* OR psychosocial* OR reinforcement OR motivation* OR contingent* OR advice
24.AB incentive* OR voucher OR psychotherap* OR psychosocial* OR reinforcement OR motivation* OR contingent* OR advice
25.TI (contingency N1 management) OR AB (contingency N1 management)
26.TI (behaviour* N2 therapy) OR AB (behaviour* N2 therapy)
27.(MH "Reinforcement (Psychology)+")
28.TI(CBT or CM)
29.S20 OR S21 OR S22 OR S23 OR S24 OR S25 OR S26 OR S27 OR S28
30.MH "Clinical Trials+"
31.PT Clinical trial
32.TI clinic* N1 trial* or AB clinic* N1 trial*
33.TI ( singl* or doubl* or trebl* or tripl* ) and TI ( blind* or mask* )
34.AB ( singl* or doubl* or trebl* or tripl* ) and AB ( blind* or mask* )
35.TI randomi?ed control* trial* or AB randomi?ed control* trial*
36.MH "Random Assignment"
37.TI random* allocat* or AB random* allocat*
38.MH "Placebos"
39.TI placebo* or AB placebo*
40.MH "Quantitative Studies"
41.S30 OR S31 OR S32 OR S33 OR S34 OR S35 OR S36 OR S37 OR S38 OR S39 OR S40

Psychosocial interventions for stimulant use disorder (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

192

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

42.S19 AND S29 AND S41

Appendix 6. Web of Science search strategy

WOS (via THOMSON REUTERS)

from 2015 to 26 September 2023 (293 hits)

Cochrane Database of Systematic Reviews

((TS=(counsel* OR psychoeducat* OR educat* OR (psychological NEAR/2 (therap* OR treatment*)) OR psychotherap* OR psychosocial*
OR  psychoanalytic  OR  ((social  OR  peer  OR  group)  NEAR/2  support)  OR  (self  NEXT  help)  OR  (cognitive  NEAR/2  (therap*  OR  behav*))
OR  mindfulness  OR  relax*  OR  ((family  OR  couple)  NEAR/2  therap*)))  AND  TS=(((amphetamine*  OR  cocaine  OR  diethylpropion  OR
ephedrine OR methylphenidate OR pemoline OR phenmetrazine OR phenmetrazine OR phenylpropanolamine OR phenylpropanolamine
OR psychostimulant*) NEAR/3 (abuse* OR depend* OR use* OR disorder* OR addict*)))) AND TS=(“ clinical trial” OR “comparative study”
OR “evaluation study” OR “controlled trial” OR “prospective stud” OR random* OR placebo* OR “single blind” OR “double blind”) and 2023
or 2022 or 2021 or 2020 or 2019 or 2018 or 2017 or 2016 or 2015 (Publication Years)

Appendix 7. PsycINFO search strategy

APA PsycINFO

From 2015 to September Week 3 2023 (407 hits)

1. ((stimulant* or psychostimulant* or psycho-stimulant*) adj5 (abstain* or abstinence or abstinent or abuse* or addict* or chronic* or
detox* or disorder* or depend* or habitual* or misuse* or overuse or reduce* or reducing or reduction or retain* or retention or users
or withdrawal)).mp.

2. ((cocaine*  or  crack-cocaine*)  adj5  (abuse*  or  addict*  or  chronic*  or  disorder*  or  depend*  or  habitual*  or  misuse*  or  overuse  or

users)).mp.

3. (methamphetamine* adj5 (abuse* or addict* or chronic* or disorder* or depend* or habitual* or misuse* or overuse or users)).mp.
4. 1 or 2 or 3
5. ((drug  or  polydrug*  or  substance  or  stimulant*  or  psychostimulant*  or  psycho-stimulant*)  and  (abuse*  or  addict*  or  disorder*  or

depend* or misuse* or overuse or users)).tw.

6. exp "substance use disorder"/ or addiction treatment/ or craving/ or drug addiction/ or drug seeking/ or "substance use treatment"/
7. 5 or 6
8. Amphetamine/  or  Diethylpropion/  or  Methylphenidate/  or  Pemoline/  or  Phenmetrazine/  or  Phenylpropanolamine/  or  Ephedrine/
or  Cocaine/  or  Crack  Cocaine/  or  (amphetamine*  or  diethylpropion*or  methylphenidate  or  methilphenidate  or  pemoline  or
phenmetrazine or phendimetrazine or phenilpropanolamine or phenylpropanolamine or ephedrine or cocaine or crack).tw.

9. 7 and 8
10.4 or 9
11.exp psychotherapy/
12.(psychotherap* or psychosocial or voucher or reinforcement or motivation* or contingent* or biofeedback or community or stimulation

or education* or counsel*).tw.

13.(social adj2 skill*).tw.
14.(coping adj2 skill).tw.
15.exp counseling/
16.(behavi* adj2 therap*).tw.
17.exp Reinforcement/
18.(cognitive adj3 therapy).tw.
19.(family adj2 therapy).tw.
20.stress management training.tw.
21.supportive expressive therapy.tw.
22.exp Social Support/
23.exp Case Management/
24.self control training.tw.
25.(behavio* adj2 (change or modification)).tw.
26.(behavio* adj2 (change or modification)).tw.
27.CBT.tw.
28.psychodynamic*.tw.
29.talking therap*.tw.

Psychosocial interventions for stimulant use disorder (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

193

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

30.((self adj2 help adj2 group$) or (twelve adj2 step) or 12-step).ti,ab.
31.contingency management.mp.
32.financial incentives.mp.
33.or/11-32
34.10 and 33
35.exp Clinical Trials/
36.(random* or (clinical adj3 trial*) or (reserch adj3 design*) or (evaluat adj3 stud*) or (prospective* adj3 stud*)).tw.
37.((singl* or doubl* or trebl* or tripl*) adj3 (blind* or mask*)).tw.
38.35 or 36 or 37
39.34 and 38
40.limit 39 to yr="2015 -Current"

Appendix 8. Clinical trials registers search strategy

Database: ClinicalTrials.gov

Search Date: 28 September 2023

55 Studies found for:

Condition or disease: amphetamine OR methamphetamine OR cocaine OR psychostimulant

Intervention/treatment: "Cognitive Behavioral Therapy" OR CBT OR “cognitive therapy” OR reinforcement OR “coping skills” OR “relapse
prevention”  OR  Contingency  OR  CM  OR  motivational  OR  MI  OR  "Interpersonal  therapy  approach"  OR  psychodynamic  OR  “supportive
expressive” OR “self help” OR “twelve-steps” OR “12-steps”

Other terms: randomized

First posted on or after 01/01/2015

Database: WHO International Clinical Trials Registry Platform (ICTRP)

Search Date: 28 September 2023

Date registration from 2015

69 Studies found for:

amphetamine AND Cognitive Behavioral Therapy OR amphetamine AND CBT OR amphetamine AND cognitive therapy OR amphetamine
AND reinforcement OR amphetamine AND coping skills OR amphetamine AND relapse prevention OR amphetamine AND Contingency
OR  amphetamine  AND  CM  OR  amphetamine  AND  motivational  OR  amphetamine  AND  MI  OR  amphetamine  AND  Interpersonal
therapy  approach  OR  amphetamine  AND  psychodynamic  OR  amphetamine  AND  supportive  expressive  OR  amphetamine  AND  self
help  OR  amphetamine  AND  twelve-steps  OR  amphetamine  AND  12-steps  OR  methamphetamine  AND  Cognitive  Behavioral  Therapy
OR  methamphetamine  AND  CBT  OR  methamphetamine  AND  cognitive  therapy  OR  methamphetamine  AND  reinforcement  OR
methamphetamine  AND  coping  skills  OR  methamphetamine  AND  relapse  prevention  OR  methamphetamine  AND  Contingency  OR
methamphetamine  AND  CM  OR  methamphetamine  AND  motivational  OR  methamphetamine  AND  MI  OR  methamphetamine  AND
Interpersonal  therapy  approach  OR  methamphetamine  AND  psychodynamic  OR  methamphetamine  AND  supportive  expressive  OR
methamphetamine AND self help OR methamphetamine AND twelve-steps OR methamphetamine AND 12-steps OR cocaine AND Cognitive
Behavioral Therapy OR cocaine AND CBT OR cocaine AND cognitive therapy OR cocaine AND reinforcement OR cocaine AND coping skills
OR cocaine AND relapse prevention OR cocaine AND Contingency OR cocaine AND CM OR cocaine AND motivational OR cocaine AND MI OR
cocaine AND Interpersonal therapy approach OR cocaine AND psychodynamic OR cocaine AND supportive expressive OR cocaine AND self
help OR cocaine AND twelve-steps OR cocaine AND 12-steps OR psychostimulant AND Cognitive Behavioral Therapy OR psychostimulant
AND  CBT  OR  psychostimulant  AND  cognitive  therapy  OR  psychostimulant  AND  reinforcement  OR  psychostimulant  AND  coping  skills
OR  psychostimulant  AND  relapse  prevention  OR  psychostimulant  AND  Contingency  OR  psychostimulant  AND  CM  OR  psychostimulant
AND  motivational  OR  psychostimulant  AND  MI  OR  psychostimulant  AND  Interpersonal  therapy  approach  OR  psychostimulant  AND
psychodynamic OR psychostimulant AND supportive expressive OR psychostimulant AND self help OR psychostimulant AND twelve-steps
OR psychostimulant AND 12-steps

Appendix 9. Criteria for risk of bias assessment

Psychosocial interventions for stimulant use disorder (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

194

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Item

Judgement

Description

1. Random sequence
generation (selection
bias)

Low risk

The investigators describe a random component in the sequence generation
process such as: random number table; computer random number generator;
coin tossing; shuffling cards or envelopes; throwing dice; drawing of lots; min-
imisation

High risk

The investigators describe a non-random component in the sequence genera-
tion process such as: odd or even date of birth; date (or day) of admission; hos-
pital or clinic record number; alternation; judgement of the clinician; results of
a laboratory test or a series of tests; availability of the intervention

Unclear risk

Insufficient information about the sequence generation process to permit
judgement of low or high risk

2. Allocation conceal-
ment (selection bias)

Low risk

High risk

Unclear risk

Low risk

3. Blinding of partic-
ipants and providers
(performance bias)

Objective outcomes

Investigators enroling participants could not foresee assignment because one
of the following, or an equivalent method, was used to conceal allocation: cen-
tral allocation (including telephone, web-based, and pharmacy-controlled,
randomisation); sequentially numbered drug containers of identical appear-
ance; sequentially numbered, opaque, sealed envelopes

Investigators enroling participants could possibly foresee assignments be-
cause one of the following method was used: open random allocation sched-
ule (e.g. a list of random numbers); assignment envelopes without appropriate
safeguards (e.g. if envelopes were unsealed or non-opaque or not sequentially
numbered); alternation or rotation; date of birth; case record number; any oth-
er explicitly unconcealed procedure

Insufficient information to permit judgement of low or high risk. This is usually
the case if the method of concealment is not described or not described in suf-
ficient detail to allow a definite judgement.

No blinding or incomplete blinding, but the review authors judge that the out-
come is not likely to be influenced by lack of blinding.

Blinding of participants and key study personnel ensured, and unlikely that
the blinding could have been broken

High risk

No blinding or incomplete blinding, and the outcome is likely to be influenced
by lack of blinding.

Blinding of key study participants and personnel attempted, but likely that the
blinding could have been broken, and the outcome is likely to be influenced by
lack of blinding

Unclear risk

Insufficient information to permit judgement of low or high risk

4. Blinding of partic-
ipants and providers
(performance bias)

Subjective outcomes

Low risk

High risk

Blinding of participants and providers ensured and unlikely that the blinding
could have been broken.

No blinding or incomplete blinding, and the outcome is likely to be influenced
by lack of blinding

Blinding of key study participants and personnel attempted, but likely that the
blinding could have been broken, and the outcome is likely to be influenced by
lack of blinding

Unclear risk

Insufficient information to permit judgement of low or high risk

Psychosocial interventions for stimulant use disorder (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

195

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

  (Continued)

5. Blinding of outcome
assessor (detection
bias)

Objective outcomes

Low risk

No blinding of outcome assessment, but the review authors judge that the out-
come measurement is not likely to be influenced by lack of blinding

Blinding of outcome assessment ensured, and unlikely that the blinding could
have been broken

High risk

No blinding of outcome assessment, and the outcome measurement is likely
to be influenced by lack of blinding

Blinding of outcome assessment, but likely that the blinding could have been
broken, and the outcome measurement is likely to be influenced by lack of
blinding

Unclear risk

Insufficient information to permit judgement of low or high risk

6. Blinding of outcome
assessor (detection
bias)

Subjective outcomes

Low risk

High risk

Blinding of outcome assessment ensured, and unlikely that the blinding could
have been broken

No blinding of outcome assessment, and the outcome measurement is likely
to be influenced by lack of blinding

Blinding of outcome assessment, but likely that the blinding could have been
broken, and the outcome measurement is likely to be influenced by lack of
blinding

Unclear risk

Insufficient information to permit judgement of low or high risk

7. Incomplete outcome
data (attrition bias)

Low risk

For all outcomes except
retention in treatment
or dropout

No missing outcome data

Reasons for missing outcome data unlikely to be related to true outcome (for
survival data, censoring unlikely to be introducing bias)

Missing outcome data balanced in numbers across intervention groups, with
similar reasons for missing data across groups

For dichotomous outcome data, the proportion of missing outcomes com-
pared with observed event risk not enough to have a clinically relevant impact
on the intervention effect estimate

For continuous outcome data, plausible effect size (difference in means or
standardized difference in means) among missing outcomes not enough to
have a clinically relevant impact on observed effect size

Missing data have been imputed using appropriate methods

All randomised patients are reported/analysed in the group they were allocat-
ed to by randomisation irrespective of non-compliance and co-interventions
(intention-to-treat)

High risk

Reason for missing outcome data likely to be related to true outcome, with
either imbalance in numbers or reasons for missing data across intervention
groups

For dichotomous outcome data, the proportion of missing outcomes com-
pared with observed event risk enough to induce clinically relevant bias in in-
tervention effect estimate

For continuous outcome data, plausible effect size (difference in means or
standardized difference in means) among missing outcomes enough to induce
clinically relevant bias in observed effect size

Psychosocial interventions for stimulant use disorder (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

196

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

  (Continued)

Cochrane Database of Systematic Reviews

'As-treated' analysis done with substantial departure of the intervention re-
ceived from that assigned at randomisation

Unclear risk

Insufficient information to permit judgement of low or high risk (e.g. num-
ber randomised not stated, no reasons for missing data provided; number of
dropouts not reported for each group)

8. Selective reporting
(reporting bias)

Low risk

The study protocol is available and all the study’s pre-specified (primary and
secondary) outcomes that are of interest in the review have been reported in
the pre-specified way

The study protocol is not available but it is clear that the published reports in-
clude all expected outcomes, including those that were pre-specified (convinc-
ing text of this nature may be uncommon)

High risk

Not all of the study's pre-specified primary outcomes have been reported

One or more primary outcomes is reported using measurements, analysis
methods or subsets of the data (e.g. subscales) that were not pre-specified

One or more reported primary outcomes were not pre-specified (unless clear
justification for their reporting is provided, such as an unexpected adverse ef-
fect)

One or more outcomes of interest in the review are reported incompletely so
that they cannot be entered in a meta-analysis

The study report fails to include results for a key outcome that would be ex-
pected to have been reported for such a study

Unclear risk

Insufficient information to permit judgement of low or high risk

W H A T ' S   N E W

Date

Event

Description

15 February 2024

New search has been performed

Search updated, conclusions not changed

15 February 2024

New citation required but conclusions
have not changed

New authors. Conclusions have not changed.

H I S T O R Y

Protocol first published: Issue 11, 2015
Review first published: Issue 9, 2016

C O N T R I B U T I O N S   O F   A U T H O R S

Minozzi, Saulle, and Agabio screened abstracts and full texts for inclusion.

Minozzi, Saulle, Agabio, and Traccis extracted data; Minozzi, Traccis, and Saulle assessed risk of bias of the included studies. Minozzi and
Agabio performed the meta-analysis and wrote the results.

Minozzi, Agabio, and Saulle assessed the certainty of the evidence.

Agabio and Minozzi update the background.

Psychosocial interventions for stimulant use disorder (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

197

 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Minozzi and Amato wrote the discussion and the conclusions.

All review authors contributed to writing the discussion and conclusion sections and revised the final report.

D E C L A R A T I O N S   O F   I N T E R E S T

Silvia Minozzi: is the Joint-Coordinating Editor of Cochrane Drugs and Alcohol Group. She was not involved in the editorial process of the
present review.

Rosella Saulle: none known.

Laura Amato: is an editor of Cochrane Drugs and Alcohol Group. She was not involved in the editorial process of the present review.

Roberta Agabio: is an editor of Cochrane Drugs and Alcohol Group. She was not involved in the editorial process of the present review.

Francesco Traccis: none known

S O U R C E S   O F   S U P P O R T

Internal sources

• Department of Epidemiology, Lazio Regional Health Service, ASL Rome 1, Italy

source of support

External sources

• No sources of support provided

D I F F E R E N C E S   B E T W E E N   P R O T O C O L   A N D   R E V I E W

Title. The title of the previous version of the review was "Psychosocial interventions for psychostimulant misuse". We changed the title
to "Psychosocial interventions for stimulant use disorder" to adopt current non-stigmatising language conventions. We used the term
"stimulant use disorder" throughout the review text instead of "misuse" or "abuse".

Measures of treatment effect. We measured point abstinence and continuous abstinence at two different times: at the end of treatment
and at the longest available follow-up after the end of treatment. We combined self-reported measures and measures assessed by urine
analyses as the studies very often did not provide separate results for self-reported results and results verified by urine analysis results.

Risk of bias. For the domain "selective reporting of the results", in the previous version, we judged a study at low risk of bias if all the
outcomes listed in the methods section of the studies were also reported in the results section. In this update, we searched for protocols of
all the included studies; we judged a study at unclear risk of bias if the protocol was unavailable, and at low risk of bias if all the outcomes
listed in the protocol were also reported in the results section of the study.

Data synthesis. In the previous version of the review, we analysed continuous outcomes by calculating the mean difference (MD) with
95% CI when the studies used the same instrument for assessing the outcome. We used the standardised mean difference (SMD) when the
studies used different instruments. In this update, as the studies used different instruments or ways to measure continuous outcomes, we
used SMDs for all the continuous outcomes, as well as for the very few comparisons where only one study was included, to increase the
comparability of outcomes across comparisons.

Unit of analysis issues. For multi-arm studies that compared different treatments with the same control group, we divided the number
of events and the number of participants of the control group by the number of experimental arms to avoid double-counting participants
in the control groups when different arms of the same study were included in the same meta-analysis.

We  added  a  sentence  explaining  that  we  analysed  cluster-randomised  studies  according  to  guidance  in  the  Cochrane  Handbook  for
Systematic  Reviews  of  Interventions  (Higgins  2023).  If  results  did  not  control  for  clustering,  we  imputed  the  intracluster  correlation
coefficient (ICC) from similar studies. We divided the effective sample size of each arm by the "design effect" quantity (1+(M-1) x ICC), where
M is the average cluster size. However, as the Mitcheson 2007 study did not report the number of clusters and their size, we could not adjust
the data for the design effect, and we excluded the study from meta-analyses. This was reported in the results section.

Subgroup  analyses.  In  the  previous  version  of  the  review,  we  performed  subgroup  analyses  for  studies  including  more  than  30%  of
participants  with  opiate  dependence  or  in  methadone  treatment.  In  this  update,  we  performed  subgroup  analyses  for  the  primary
outcomes  reported  by  at  least  10  studies.  We  created  three  subgroups:  all  participants  with  comorbid  opiate  dependence  and  in
methadone  treatment;  variable  percentages  of  participants  with  comorbid  opiate  dependence  and  in  methadone  treatment;  no
participants with opiate dependence and in methadone treatment.

Psychosocial interventions for stimulant use disorder (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

198

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

In the previous version of the review, we planned to divide studies into two groups: studies with low-complexity TAU (counselling, case
management,  clinical  management)  and  studies  with  high-complexity  TAU  (cognitive  behavioural  therapy,  contingency  management,
interpersonal therapy, psychodynamic therapy, 12- step facilitation), and to perform subgroup analyses to assess the effect of adding on
another psychosocial intervention to low-complexity TAU or high-complexity TAU. We did not perform this analysis in the previous version
because we didn't find important differences in TAU complexity in the included studies. For this update, we did not plan to undertake this
subgroup analysis.

I N D E X   T E R M S

Medical Subject Headings (MeSH)

*Cognitive Behavioral Therapy  [methods];  Counseling;  *Motivational Interviewing  [methods];  Psychosocial Intervention;  *Substance-
Related Disorders  [therapy]

MeSH check words

Adult; Humans

Psychosocial interventions for stimulant use disorder (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

199
